

Live from the studio: Welcome to the EAU21 Virtual Congress

Thursday 8 July 07:45 - 08:00	Location	Virtual room 1
	P. Albers, Düsseldorf (DE)	
	C.R. Chapple, Sheffield (GB)	
	A. Stenzl, Tübingen (DE)	

Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

Urology beyond Europe

Thursday 8 July
08:00 - 10:00

Location Virtual Room 3

Chairs J.W.F. Catto, Sheffield (GB)
S. Mark, Christchurch (NZ)

Learning objectives

In this joint session of the EAU and the Urological Society of Australia and New Zealand we will discuss patterns of practice in the different regions of the world. We start with a safe and efficient follow regimen for men with prostate cancer, which reduces face to face clinic visits and help compliance. We review the vexed issue of adjuvant radiation following prostatectomy, plus the causes of post-prostatectomy incontinence.

Mesh issues are rarely out of the press, and we discuss assessment and treatment modalities for mesh complications. Haematuria is a common condition, so rationalising patient assessment is vital. We will review a controversial presentation suggesting a further role for MRI, and present an overview of retroperitoneal fibrosis, often a conundrum in patient care. The session is rounded off by looking at the complex issue of implementation of the widely lauded EAU treatment guidelines into practice.

08:00 - 08:05

Introduction

08:05 - 08:15

Can prostate cancer databases safely reduce clinic numbers
S. Mark, Christchurch (NZ)

08:15 - 08:20

Discussion

08:20 - 08:30

When and how to investigate haematuria?
J.D. Kelly, London (GB)

08:30 - 08:35

Discussion

08:35 - 08:45

A meshy business: Current status of transvaginal/pelvic mesh use in Australia
J. Cheng, Melbourne (AU)

08:45 - 08:50

Discussion

08:50 - 09:00

Prostate cancer in 2020 and beyond: Re-imagining survivorship
S. Chambers, NSW (AU)

09:00 - 09:05

Discussion

09:05 - 09:15

The role of adjuvant radiotherapy following radical prostatectomy in men with high risk disease
P.J. Boström, Turku (FI)

09:15 - 09:20

Discussion

09:20 - 09:30

Current understanding on the mechanism of post prostatectomy incontinence
M. Patel, Westmead (AU)

Scientific Programme - EAU21 Virtual

09:30 - 09:35

Discussion

09:35 - 09:45

Retroperitoneal fibrosis: Management for 2020 and beyond
T.S. O'Brien, London (GB)

09:45 - 09:50

Discussion

09:50 - 10:00

Closing remarks

Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

Urology beyond Europe

Thursday 8 July
08:00 - 10:00

Location Virtual Room 5

Chairs K.A. Mohd Ghani, Kuala Lumpur (MY)
J.P.M. Sedelaar, Nijmegen (NL)

Learning objectives

This session provides an excellent platform for collaboration between the major countries of ASEAN and Europe. Focusing on four important themes in urology, experts from the FAUA and the EAU will present and discuss new developments that are relevant to their region.

08:00 - 08:02

Welcome and introduction

08:02 - 08:36

Urological training and education

08:02 - 08:12

Simulation training in endourology
D. Veneziano, Reggio Calabria (IT)

08:12 - 08:22

Current state of training and evaluation of open and laparoscopic surgical skills in urology – Simultaneous training through regional collaboration?
S.V. Yrastorza, Quezon City (PH)

08:22 - 08:32

UROCADEMY: An e-assessment module for urological training
S. Kuppusamy, Kuala Lumpur (MY)

08:32 - 08:36

Discussion

08:36 - 09:10

Renal transplantation

08:36 - 08:46

Laparoscopic donor nephrectomy
F. D'Ancona, Nijmegen (NL)

08:46 - 08:56

Robot-assisted kidney transplantation – Is it the way forward?
A. Breda, Barcelona (ES)

08:56 - 09:06

Outcomes of renal transplant in patients on long-term haemodialysis: A Malaysian perspective
V. Manogran, Kuala Lumpur (MY)

09:06 - 09:10

Discussion

09:10 - 09:34

Prostate cancer – Current status and updates in ASEAN

09:10 - 09:20

Prostate cancer management in developing country
J.P. Agatep Jr., Quezon City (PH)

09:20 - 09:30

Look first, then biopsy – Will 'manography' become the future routine?
G. Gandaglia, Milan (IT)

09:30 - 09:34

Discussion

09:34 - 09:58

Reconstructive urology

09:34 - 09:44

Staged versus one-stage urethroplasty in routine practice
P. Satyagraha, Malang (ID)

09:44 - 09:54

Hypospadias repair in developing countries
To be confirmed

Scientific Programme - EAU21 Virtual

09:54 - 09:58

Discussion

09:58 - 10:00

Closing remarks

Joint Session of the European Association of Urology (EAU) and the Russian Society of Urology (RSU)

Urology beyond Europe

Thursday 8 July
08:00 - 10:00

Location Virtual Room 2

Chairs C.R. Chapple, Sheffield (GB)
I. Korneyev, St. Petersburg (RU)

Learning objectives

The aim of this session is to continue active discussion between Russian urologists and EAU opinion leaders on prostate cancer and kidney cancer. Attendees will be able to learn updates on robot assisted radical prostatectomy, locally advanced and metastatic prostate cancer, kidney cancer surgical and medical treatment. Both sides will also present interactive discussion of clinical cases and approaches to solve the patients' problems. The session will serve as an outstanding opportunity to improve the education in urology and exchange opinions.

08:00 - 08:02

Welcome and introduction

08:02 - 08:41

Prostate cancer surgery

Moderators V. Matveev, Moscow (RU)
M. Wirth, Dresden (DE)

08:02 - 08:12

Actualising new models of healthcare service delivery in prostate cancer

V. Sangar, Manchester (GB)

08:12 - 08:22

RARP: Index patient in Russia in 2021

K. Kolontarev, Moscow (RU)

08:22 - 08:32

Case presentations

A. Khachatryan, Moscow (RU)
V. Sangar, Manchester (GB)

08:32 - 08:41

Discussion

08:41 - 09:20

Locally advanced and metastatic prostate cancer

Moderators S. Petrov, Saint Petersburg (RU)
H. Van Poppel, Leuven (BE)

08:41 - 08:51

What is new in pharmacotherapy?

M. Wirth, Dresden (DE)

08:51 - 09:01

Metastatic prostate cancer update

S. Reva, Saint-Petersburg (RU)

09:01 - 09:11

Case presentations

K.M. Nyushko, Moscow (RU)
L. Moris, Leuven (BE)

09:11 - 09:20

Discussion

09:20 - 09:58

Kidney cancer surgery

Moderators M.S. Gazimiev, Moscow (RU)
H. Van Poppel, Leuven (BE)

09:20 - 09:30

Latest developments in medical management

A. Bex, London (GB)

09:30 - 09:40

Kidney cancer surgical treatment update

A. Proskura, Moscow (RU)

Scientific Programme - EAU21 Virtual

09:40 - 09:50

Case presentations

G. Palaguta, Krasnodar (RU)
S.K. Pathak, Sheffield (GB)

09:50 - 09:58

Discussion

09:58 - 10:00

Closing remarks

Basic research and clinical developments in chronic pelvic pain, OAB and neurogenic bladder

Poster Session 01

Thursday 8 July
08:00 - 09:00

Location Virtual Room 8

Chairs D.J.M.K. De Ridder, Leuven (BE)
D. Vrijens, Maastricht (NL)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

To appreciate the progress that is made in the fields of basic research and clinical developments for the various disease groups. This includes unraveling the pathophysiologic mechanisms, new pharmacological targets, epidemiological insight and evaluation of new therapeutic approaches.

08:00 - 08:01

Introduction

P0001	Electric stimulation combination with hyperthermia ameliorates pain through inhibition of NLRP3 inflammasome in chronic prostatitis/chronic pelvic pain syndrome D. Shin, Seoul (KR)
P0002	Mast cells in the urinary bladders of interstitial cystitis/bladder pain syndrome patients express the Mast cell Related G-Protein coupled Receptor X2 (MRGPRX2): Potential role in the pathogenesis of neurogenic inflammation O.K. Abdelwahab, Southampton (GB)
P0003	The importance of neurophysiological study and computed tomography-guided perineural injection in the characterization of pudendal neuropathy A. Artiles Medina, Madrid (ES)
P0004	Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: Multicenter randomized controlled double-blind trial L. Pivazyan, Moscow (RU)
P0005	Laparoscopic transperitoneal pudendal nerve and artery release for pudendal entrapment syndrome G. Mjaess, Beirut (LB)
P0006	Resilience in patients affected by urologic chronic pelvic pain A.G. Giannantoni, Siena (IT)

08:07 - 08:15

Discussion

08:15 - 08:18

Expert summary
A.G. Giannantoni, Siena (IT)

P0007	Mesenchymal stem cells injection attenuates spinal cord injury-induced neurogenic bladder via modulation of myogenesis, angiogenesis, trophic factors and apoptosis in female rats H. Salehi-Pourmehr, Tabriz (IR)
P0008	MicroRNAs miR-491-5p and miR-592 in urine with potential diagnostic value for female patients with overactive bladder L. Campeau, Montreal (CA)
P0009	Sprouting of bladder afferents following spinal cord injury is independent from the lumbosacral cord highly repulsive environment T. Antunes Lopes, Porto (PT)
P0010	Therapeutic potential of cell-type selective optogenetics for a mouse model with urinary frequency H. Shimura, Chuo-City (JP)
P0011	A study of DNA methylation of bladder cancer markers in urine and bladder tissue of patients with Neurogenic Lower Urinary Tract Dysfunction (NLUTD) P. Koukourikis, Chalastra (GR)
P0012	Uncovering a role of β3-adrenoceptors in control of bladder size M.C. Michel, Mainz (DE)
08:24 - 08:31	Discussion
P0013	The prevalence of nocturnal polyuria in the US: Results from the Epidemiology of Nocturnal Polyuria (EpiNP) study K.S. Coyne, Bethesda (US)
P0014	Serum serotonin level as an independent factor for overactive bladder: Results from the community based cross-sectional study in Japan T. Okamoto, Hirosaki (JP)
P0017	Adverse events related to different antimuscarinics and beta-3-agonist: Analysis of real-life data from Eudra-Vigilance R. Lombardo, Rome (IT)
P0018	Does mirabegron improve sexual health in patients with Overactive Bladder (OAB) and sexual dysfunction? A systematic review and meta-analysis V. Sakalis, Nea Moudania (GR)
P0019	Efficacy of fesoterodine fumarate in Neurogenic Detrusor Overactivity (NDO) due to Spinal Cord Lesion (SCL) or Multiple Sclerosis (MS) – A prospective study C. Konstantinidis, Piraeus (GR)
P0020	Variations of urodynamic parameters and bladder contractility in women with idiopathic OAB undergoing Onabotulinum Toxin A injection. A prospective multi-institutional study G.D. De Rienzo, Bari (IT)
P0021	The safety and efficacy of botulinum toxin type A treatment in neurogenic detrusor overactivity and idiopathic overactive bladder: A systematic review and meta-analysis of prospective, randomized, double-blinded, placebo-controlled clinical trials A. Bijmens, Vosselaar (BE)

P0022	5-year continuation rate of intra-vesical BoNTA injections in multiple sclerosis patients with lower urinary tract dysfunction: A retrospective study from the French Committee of Neuro-Urology P.L. Dequierez, Lille (FR)
P0023	IncobotulinumtoxinA is not inferior to OnabotulinumtoxinA intradetrusor injections in the treatment of neurogenic detrusor overactivity incontinence: A multicentre, randomized, double-blind, clinical trial A.G. Giannantoni, Siena (IT)
P0024	Significant reduction of urinary incontinence episodes in patients with neurogenic detrusor overactivity treated with abobotulinumtoxinA (aboBoNT-A): Pooled results of the phase III CONTENT program A.G. Giannantoni, Siena (IT)
P0025	Sacral neuromodulation with the InterStim™ system for lower urinary tract dysfunctions (SOUNDS): 3-Year results of clinical effectiveness, quality of life, patient-reported outcomes and safety in a French multicenter observational study E. Chartier-Kastler, Paris (FR)
P0026	Sacral Neuromodulation (SNM) in patients with neurogenic Lower Urinary Tract Dysfunction (nLUTD): A systematic literature review and meta-analysis covering over two decades A. Van Ophoven, Herne (DE)
P0027	Long term continence rates in patients undergoing augmentation cystoplasty with 30 year follow up A. Frost, London (GB)
P0028	Robot-assisted cystectomy and ileal conduit for neurogenic bladder: Comparison of extracorporeal vs intracorporeal urinary diversion B. Peyronnet, Rennes (FR)
P0029	Symptoms suggestive of urinary tract infection rates among intermittent urinary catheter users: Real-world evidence research based on a longitudinal patient database in the UK E. Chartier-Kastler, Paris (FR)
P0030	Urinary catheterization from 1997 to 2018: A Dutch population-based cohort S.A. Berendsen, Rotterdam (NL)
08:49 - 08:57	Discussion
08:57 - 09:00	Expert summary L. Campeau, Montreal (CA)

Surgical management of prolapse and urinary incontinence/female pelvic floor disorders

ESU Course 01

Thursday 8 July
08:00 - 10:00

Location Zoom 1

Chair H. Hashim, Bristol (GB)

Learning objectives

This course will explore the management of various female pelvic floor disorders. This will include discussion of the various surgical techniques for stress urinary incontinence, pelvic organ prolapse, urethro/vesico vaginal fistula and urethral diverticula. It will also cover the treatment of complex pelvic floor problems including urethral loss, vaginal shortening and mesh complications. Interesting and challenging cases will be presented to facilitate the decision making process of surgeons at any stage of their career.

08:00 - 10:00

Introduction

H. Hashim, Bristol (GB)

08:00 - 10:00

Stress urinary incontinence treatment - bulking agents/meshes/colposuspension/ autologous fascial sling/artificial urinary sphincter

H. Hashim, Bristol (GB)

08:00 - 10:00

Pelvic organ prolapse treatment - vaginal and abdominal approaches

D. Pushkar, Moscow (RU)

08:00 - 10:00

Vesicovaginal fistula (vaginal and abdominal approaches) /Urethral diverticulum

T.J. Greenwell, London (GB)

08:00 - 10:00

Urethral loss/ Urethrovaginal fistula repair/vaginal shortening complications management

D. Pushkar, Moscow (RU)

08:00 - 10:00

Mesh erosion/urethral stricture complications management

T.J. Greenwell, London (GB)

Step by step management LUTS/BPO: From drug treatment to minimally invasive therapies

Poster Session 02

Thursday 8 July
09:00 - 10:00

Location Virtual Room 9

Chairs
F. Fusco, Naples (IT)
S. Malde, Epsom (GB)
N. Barber, Camberley (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session deals with LUTS/BPO in men, from medical treatment to minimally invasive therapies

09:00 - 09:01

Introduction

09:01 - 09:12

Drug treatment

P0031 **Mirabegron inhibits neurogenic and α 1-adrenergic human prostate smooth muscle contractions, with similar pharmacologic patterns as α 1-blockers**
R. Huang, Munich (DE)

P0032 **The monomeric GTPase ARF6 is required for smooth muscle contraction and stromal proliferation in the prostate, and is specifically inhibited by NAV2729**
R. Wang, Munich (DE)

P0033 **Sexual adverse events-related to dutasteride e finasteride: Analysis of real-life data from EudraVigilance database**
A. Nacchia, Prata Sannita (IT)

P0034 **Alpha-blockers adverse events: Analysis of real-life data from Eudra-Vigilance**
C. De Nunzio, Rome (IT)

P0035 **A meta-analysis of the effect of urological and non-urological medication on morphometric parameters of the prostate**
V. Sakalis, Nea Moudania (GR)

P0036 **A new risk calculator to predict changes in IPSS score and risk of AUR / BPH-related surgery in BPH patients with moderate-severe symptoms at risk of disease progression receiving placebo, dutasteride, tamsulosin, or combination therapy**
S. Gravas, Larissa (GR)

P0037 **Healthcare Resource Utilization (HCRU) and treatment patterns in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-associated Lower Urinary Tract Symptoms (BPH-LUTS) in the United States: A retrospective database study**
T. Hassan, New York (US)

09:07 - 09:12

Discussion

09:12 - 09:24

Break the dogmas of evaluation and indications

P0038	Assessing burden of benign prostatic hyperplasia in a National Health Service: A real-world data analysis R. Dasgupta, London (GB)
P0039	Feasibility of a deep learning-based diagnostic platform to evaluate lower urinary tract disorders in men using simple uroflowmetry S. Bang, Seoul (KR)
P0040	First qualitative study into comprehensibility of IPSS and 2 visual alternatives for men with adequate and men with limited health literacy skills, leading to a new, better understood alternative: Dutch Reduced Illustrated Prostate Symptom Score (DRIPSS) F.W.M. Schlatmann, Groningen (NL)
P0041	Nocturnal polyuria is associated with worst functional outcomes after trans-urethral resection of prostate: A frequency volume chart study C. De Nunzio, Rome (IT)
P0042	Do men ≥ 40 yrs with bladder stones require surgery for Benign Prostatic Obstruction (BPO): Does the evidence support the dogma? G. Maresca, Aberdeen (GB)
P0043	Effect of routinely preoperative urethral dilation to prevent urethral stricture after transurethral resection of the prostate for benign prostatic hyperplasia Y.U. Kim, Daegu (KR)
P0044	Evaluation of a novel technique of bladder neck and supramontanal sparing ejaculatory preserving transurethral prostatectomy F. Zanaty, Shibin El Kom (EG)
09:19 - 09:24	Discussion
09:24 - 09:33	Innovations in minimally invasive techniques
P0045	The Butterfly: A novel minimally invasive transurethral retraction device for BPH R. Katz, Zefat (IL)
P0046	The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A multicenter, randomized, controlled trial D. Elterman, Toronto (CA)
P0047	MRI-guided transurethral ultrasound ablation for treatment of benign prostatic obstruction M.H.J. Anttinen, Turku (FI)
P0048	Transperineal laser ablation for benign prostatic hyperplasia: Ejaculation sparing technique A. Ruffo, San Giorgio a cremano (IT)
09:28 - 09:33	Discussion
09:33 - 09:46	Minimally invasive surgical treatments: LIFT, Rezum or PAE
P0049	Prostatic Urethral Lift (PUL) in retention patients: 12-month outcomes from Real-World and PULSAR studies M. Rochester, Norwich (GB)
P0050	Prostatic Urethral Lift (PUL) effectiveness in real-world subjects with obstructive median lobes N. Barber, Camberley (GB)
P0051	Real-world predictors of durability after Prostatic Urethral Lift (PUL) O. Kayes, Leeds (GB)

P0052	Functional and sexual symptoms improvement after Rezum water vapor therapy for the treatment of LUTS/BPE: 3-year results from the first European observational study A. Cocci, Florence (IT)
P0053	Rezum water vapour therapy: Understanding retreatment D. Whiting, Ash Vale (GB)
P0054	Holmium laser enucleation and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: A cost analysis M. Baboudjian, Marseille (FR)
P0055	Prostatic Artery Embolisation (PAE) versus Transurethral Resection of the Prostate (TURP) for benign prostatic hyperplasia: Two-year outcomes of a randomised, open-label, single-centre trial D. Abt, St. Gallen (CH)
P0056	Prostatic artery embolization: Results from a large multi-institutional Italian series S. Secco, Milan (IT)
09:41 - 09:46	Discussion

09:46 - 09:55	Aquablation: Bridging MiST and ablative BPO relief
P0057	WATER vs WATER II: Three year comparison of aquablation therapy for benign prostatic hyperplasia P.J. Gilling, Tauranga (NZ)
P0058	Aquablation for benign prostatic hyperplasia in large prostates (80-150cc): 3-year results K. Zorn, Montreal (CA)
P0059	The surgical learning curve of aquablation: An international multicenter prospective study A.A. Nasrallah, Riad El Solh - Beirut (LB)
P0060	Three-year outcomes after Aquablation compared to TURP: Efficacy and ejaculatory improvements sustained N. Barber, Camberley (GB)
09:50 - 09:55	Discussion

09:55 - 09:59	Expert summary C. Roehrborn, Dallas (US)
---------------	--

Joint Session of the European Association of Urology (EAU) and the Taiwan Urological Association (TUA)

Urology beyond Europe

Thursday 8 July 10:00 - 12:00	Location	Virtual Room 4
	Chairs	J. Palou, Barcelona (ES) W-J. Wu, Kaohsiung (TW)
10:00 - 10:02	Welcome and introduction	
10:02 - 10:27	Functional urology	
	<i>Moderators</i>	C-H. Liao, New Taipei City (TW) C. Errando-Smet, Barcelona (ES)
10:02 - 10:12	Biomarkers in interstitial cystitis / Bladder pain syndrome	
	Y-H. Jiang, Hualien (TW)	
10:12 - 10:22	Trouble shooting in artificial urinary sphincter surgery	
	C. Errando-Smet, Barcelona (ES)	
10:22 - 10:27	Discussion	
10:27 - 10:47	Andrology	
	<i>Moderator</i>	S-D. Chung, Taipei (TW)
10:27 - 10:32	Corporoplasty plication for managing penile curvature	
	S-D. Yeh, Taipei (TW)	
10:32 - 10:42	Erectile dysfunction: Live style and medical treatment	
	S. Minhas, London (GB)	
10:42 - 10:47	Discussion	
10:47 - 11:07	Robotic and laparoscopic urology	
	<i>Moderator</i>	E.Y-H. Huang, Taipei (TW)
10:47 - 10:52	Intraoperative 3-dimensional mapping during robotic partial nephrectomy	
	C.K. Yang, Taichung (TW)	
10:52 - 11:02	Retroperitoneal approach in kidney tumors. When and why?	
	J.M. Gaya Sopena, Barcelona (ES)	
11:02 - 11:07	Discussion	
11:07 - 11:32	Oncology	
	<i>Moderators</i>	C-P. Huang, Tiachung (TW) A.S. Merseburger, Lübeck (DE)
11:07 - 11:17	Urinary biomarkers to identify urothelial carcinoma in Taiwan	
	C. Chen, Taipei (TW)	
11:27 - 11:32	Discussion	
11:17 - 11:27	Molecular classification in bladder cancer: Where are we?	
	A.S. Merseburger, Lübeck (DE)	
11:32 - 11:52	Urolithiasis	
	<i>Moderators</i>	V.C-H. Lin, Kaohsiung City (TW) D.A. Pérez Fentes, Santiago de Compostela (ES)

Scientific Programme - EAU21 Virtual

11:32 - 11:37	How to remove stone fragments after retrograde intrarenal surgery study C-C. Lin, Keelung City (TW)
11:37 - 11:47	Fluoreless ureterorenoscopy: Fact or fiction? D.A. Pérez Fentes, Santiago de Compostela (ES)
11:47 - 11:52	Discussion
11:52 - 12:00	Conclusion

Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Urology beyond Europe

Thursday 8 July
10:00 - 12:00

Location Virtual Room 6

Chairs S.K. Hong, Seongnam (KR)
J. N'Dow, Aberdeen (GB)

Learning objectives

This session will address a variety of hot urology topics with the help of specialists and key opinion leaders from South Korea and Europe. Delegates can expect detailed and up-to-date coverage of topics like andrology, voiding difficulty, endourology, and urological cancers including renal cell carcinoma and prostate cancer.

In this session some of the regional similarities and differences in approaches will be explored.

10:00 - 10:01

Welcome

10:01 - 10:05

Introduction

S-D. Lee, Busan (KR)
J.O.R. Sønksen, Herlev (DK)

10:05 - 10:30

Andrology and voiding difficulty

Moderators A. Salonia, Milan (IT)
D.Y. Yang, Seoul (KR)

10:05 - 10:10

Metabolic syndrome and male fertility

A. Salonia, Milan (IT)

10:10 - 10:15

Recovery of spermatogenesis following cancer treatment with cytotoxic chemotherapy and radiotherapy

S.H. Song, Seoul (KR)

10:15 - 10:20

Management of BPH with detrusor underactivity

K.J. Ko, Seoul (KR)

10:20 - 10:30

Discussion

Panel S.H. Song, Seoul (KR)
H. Son, Seoul (KR)

10:30 - 10:55

Endourology

Moderators S. Gravas, Larissa (GR)
I.Y. Seo, Iksan (KR)

10:30 - 10:35

BPH enucleation technique according to each energy device

S. Gravas, Larissa (GR)

10:35 - 10:40

Current status of use of flexible ureteroscopy in endoluminal endourology

S.Y. Cho, Seoul (KR)

10:40 - 10:45

Radiation-free PCNL: A step-by-step approach

B.S. Kim, Daegu (KR)

10:45 - 10:55

Discussion

Panel S.Y. Cho, Seoul (KR)
D-H. Han, Seoul (KR)

10:55 - 11:15

Renal cell carcinoma

Scientific Programme - EAU21 Virtual

	<i>Moderator</i>	B. Ljungberg, Umeå (SE)
10:55 - 11:00	The potential of 3D organoids derived from patients with RCC	
	R. Giles, Duivendrecht (NL)	
11:00 - 11:05	Minimally invasive radical nephrectomy with IVC thrombectomy	
	S-H. Hong, Seoul (KR)	
11:05 - 11:15	Discussion	
	<i>Panel</i>	S-H. Hong, Seoul (KR) E.C. Hwang, Gwangju (KR)
11:15 - 11:50	Prostate cancer	
	<i>Moderators</i>	P. Cornford, Liverpool (GB) J.H. Hong, Seoul (KR)
11:15 - 11:20	EAU's structured population-based PSA screening for prostate cancer	
	G. Gandaglia, Milan (IT)	
11:20 - 11:25	Clinical role of prostate cancer risk calculator	
	J.Y. Park, Ansan (KR)	
11:25 - 11:50	Oligometastatic Pca	
	<i>Case presenter</i>	S.H. Lee, Seoul (KR)
	<i>Panel</i>	G. Gandaglia, Milan (IT) J.Y. Park, Ansan (KR)
11:50 - 11:55	Closing remarks	
	S.K. Hong, Seongnam (KR)	

Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Urology beyond Europe

Thursday 8 July
10:00 - 12:00

Location Virtual Room 7

Chairs M. Eto, Fukuoka (JP)
J. Rassweiler, Heilbronn (DE)

Learning objectives

The aim of this session is to provide the audience an insight in specific topics of current clinical practice in urology. The selected themes this year are Overactive Bladder (OAB), Upper Tract Urothelial Cancer (UTUC), and non-muscle invasive bladder cancer. For each topic, the discussion will follow two pathways: on one hand a synthesis of the most recent scientific evidence will be examined, on the other hand, complex scenarios will be discussed by top-class experts. The audience will learn how to face complex clinical decision-making in case of refractory OAB, recurrent non-muscle invasive bladder cancer, und upper tract urothelial cancer based on the actual EAU-Guidelines.

10:00 - 10:05

Welcome and introduction

10:05 - 10:25

Overactive Bladder (OAB)

Moderators F. Cruz, Porto (PT)
H. Kakizaki, Asahikawa (JP)

10:05 - 10:15

Treatment challenges to refractory OAB

K. Takezawa, Suita (JP)

10:15 - 10:25

Are there any new drugs for functional urology

F. Cruz, Porto (PT)

10:25 - 10:50

Panel discussion Refractory OAB: How do you treat this patient?

Case presenter H. Kakizaki, Asahikawa (JP)
Panel H. Akaihashi, Fukushima (JP)
M. Oelke, Gronau (DE)
F. Cruz, Porto (PT)
Y. Miyauchi, Kida-gun (JP)

10:50 - 11:35

Urothelial cancer

Moderators H. Matsuyama, Ube (JP)
M. Rouprêt, Paris (FR)

11:15 - 11:25

Treatment challenges to BCG unresponsive NMIBC

K. Shigeta, Tokyo (JP)

11:25 - 11:35

Update on EAU-Guidelines on management of Upper Tract Urothelial Cancer (UTUC)

M. Rouprêt, Paris (FR)

10:50 - 11:15

Panel discussion Urothelial cancer: How to manage this situation?

Panel M. Kato, Osaka (JP)
Y. Nagata, Kitakyushu (JP)
M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)

11:35 - 11:55

Questions and answers

Moderators M. Eto, Fukuoka (JP)
J. Rassweiler, Heilbronn (DE)

11:55 - 12:00

Conclusion

N. Nonomura, Osaka (JP)

Ablative BPO surgery - The world of lasers

Poster Session 03

Thursday 8 July
10:00 - 11:00

Location Virtual Room 8
Chairs G.I. Russo, Catania (IT)
To be confirmed

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session will focus on surgical issues in BPO relief. The following items will be discussed:

Technical issues and intra-operative challenges during HoLEP
Predictive factors of post-operative outcomes after HoLEP
Recent advances in the use of Thulium laser
Long term performance of Greenlight laser surgery
Potential of minimally invasive simple prostatectomy

10:00 - 10:01

Introduction

10:01 - 10:15

Technical issues and intra-operative challenges during HoLEP

P0061

Surgical efficiency of “one-lobe” technique vs. “three-lobe” technique for Holmium Laser Enucleation of the Prostate (HoLEP)
T. Westhofen, München (DE)

P0062

Preliminary results of a randomised controlled trial to assess the benefit to apply MOSES™ technology: HoLEP vs. m-HoLEP
A. Pinero Zomeno, Barcelona (ES)

P0063

En-Bloc MoLEP (Moses Laser Enucleation of Prostate) vs. En-Bloc HoLEP: Comparing intra and post-operative outcomes for En-Bloc enucleation technique with early apical release, to treat patients affected by Benign Prostatic Enlargement (BPE)
M.E. Rodríguez Socarrás, Madrid (ES)

P0064

En bloc laser enucleation technique using holmium pulse modulation (virtual basket and bubble blast effects), for the treatment of Benign Prostatic Enlargement (BPE)
M.E. Rodríguez Socarrás, Madrid (ES)

P0065

Prostate vascularity and surgical blood loss during Holmium Laser Enucleation of the Prostate (HoLEP): Short-term pretreatment with dutasteride
G.M. Busetto, Rome (IT)

P0066

Risk factors for transurethral coagulation for hemostasis during Holmium Laser Enucleation of the Prostate (HoLEP): A prospective study

P0067

Holmium laser enucleation of the prostate with virtual basket tool: Faster and better control on bleeding
M. Maltagliati, Modena (IT)

P0068	Risk factors for salvage procedure for refractory morcellation during HoLEP surgery
P0069	Post-enucleation morcellation procedure: Lights and shadows M. Maltagliati, Modena (IT)
10:10 - 10:15	Discussion
10:15 - 10:28	Predictive factors of post-operative outcomes after HoLEP
P0070	Does prostate volume affect early continence recovery after holmium laser enucleation of the prostate? Results from a prospective trial (ExpHo) P. Capogrosso, Milano (IT)
P0071	Unfavourable outcomes after Holmium Laser Enucleation of the Prostate (HoLEP) are common also in the hands of a very experienced surgeon – Results from a prospective trial (ExpHo) P. Capogrosso, Milano (IT)
P0072	Preoperative drivers of persistent/recurrent Lower Urinary Tract Syndroms (LUTS) after Holmium Laser Enucleation of the Prostate (HoLEP) - report from a single center cohort of 902 patients with long-term follow-up P. Gild, Hamburg (DE)
P0073	Impact of early release of apical adenoma during Holmium Laser Enucleation of the Prostate (HoLEP) on early postoperative functional outcome M. Deuker, Frankfurt (DE)
P0074	What is the most significant factor predicting persistent storage symptoms after HoLEP?
P0075	Short time delay between prostate biopsy for prostate cancer assessment and Holmium laser enucleation of the prostate (HoLEP) correlates with worse perioperative outcomes P. Piazza, Bologna (IT)
P0076	Evaluation of Retrograde Ejaculation (RE) and overall satisfaction with sexual function before and after Holmium Laser Enucleation of the Prostate (HoLEP) M-N. Welte, Frankfurt / Main (DE)
P0077	Comparison of two techniques for Holmium Laser Enucleation of Prostate (HoLEP): Long-term outcomes and predictive model for symptoms recurrence L. Bianchi, Bologna (IT)
10:23 - 10:28	Discussion
10:28 - 10:38	Recent advances in the use of Thulium laser
P0078	Holmium laser versus thulium laser versus bipolar enucleation of the prostate for treatment of large sized benign prostatic enlargement. Preliminary report of a randomized controlled trial F.K. Ghobrial, Mansoura (EG)
P0079	Thulium Laser Enucleation (ThuLEP) versus Transurethral Bipolar Prostate Resection (TURP): Prospective randomized study: Early intra- and postoperative results M.L. Zanoni, Milan (IT)
P0080	ThuLEP vs. open simple prostatectomy for the treatment of prostates larger than 150 cc L. Berti, Busto Arsizio (IT)
P0081	Educational value of YouTube surgical videos of thulium laser enucleation of the prostate (ThuLEP): The quality assessment K. Yang, Beijing (CN)

P0082	Thulium vaporization of the prostate: Postoperative bleeding risk in new vs. old generation anticoagulant therapy C. Signorini, Milan (IT)
10:33 - 10:38	Discussion
10:38 - 10:49	Performance of Greenlight laser surgery
P0083	Outpatient 180 W XPS GreenLight™ Laser photoselective vaporization of the prostate: Seven year experience J. Chavarriaga , Bogota (CO)
P0084	Comparison of vaporization and enucleation techniques based on the functional outcomes and complications of patients with benign prostatic hyperplasia: Systematic review and meta-analysis A.O. Morozov, Moscow (RU)
P0085	Long-term functional outcomes in large prostates (>80cc): A comparative study between Greenlight laser photoselective vaporization and open simple prostatectomy P. Lainé Caroff, Tours (FR)
P0086	GreenLight laser prostatectomy: Are outcomes sustainable after a decade of surgery? A single center experience with up to 15 years' follow-up A. Ibrahim, Montreal (CA)
P0087	Ejaculation preserving photoselective vaporization versus plasma kinetic vaporization versus transurethral resection of the prostate for management of benign prostatic enlargement: An objective evaluation through a prospective randomized trial E. Abouelenein, mansoura (EG)
P0088	Greenlight (532nm) laser transurethral prostatectomy for treatment of benign prostate obstruction using XPS-180Watt system, does it pass the test of time? F.K. Ghobrial, Mansoura (EG)
10:44 - 10:49	Discussion
10:49 - 10:56	Potential of minimally invasive simple prostatectomy
P0089	Assessing comprehensive surgical outcomes of Freyer, Millin and Madigan robot assisted simple prostatectomy: Trifecta and pentafecta outcomes A.M. Bove, Cirella Di Diamante (IT)
P0090	Robot-assisted simple prostatectomy versus HOLEP, multicenter comparative outcomes A.M. Bove, Cirella Di Diamante (IT)
P0091	Holmium laser enucleation of prostate versus minimally invasive simple prostatectomy for large volume (≥ 120 ml) prostate glands: A prospective multicenter randomized study A.L. Pastore, Rome (IT)
10:52 - 10:56	Discussion
10:56 - 11:00	Expert summary To be confirmed

Technology development never ends!

Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS)

Thursday 8 July
10:15 - 19:00

Location Virtual room 1

Learning objectives

The ESUT session in collaboration with EULIS and ERUS will inform the participants about the newest surgical technology in urology. All these new technological developments will be explained as technical, practical and scientific aspects and presented in semi-live cases by the experts.

The different opinions will be discussed with the experts and questions from the audience will be answered. With this programme we aim to update the urologists about all the latest developments in their field and how they can apply all the latest technology in their daily practice in order to keep the healthcare of the patients at the highest level.

10:15 - 10:20

Welcome and introduction

A.S. Gözen, Heilbronn (DE)

10:20 - 10:30

Ethics of live and semi-live surgery

B. Somani, Southampton (GB)

10:30 - 10:40

Cases from the last EAU live surgery session

A. Breda, Barcelona (ES)

10:40 - 12:00

Semi-live surgery part I

Chairs

A.S. Gözen, Heilbronn (DE)

A. Mottrie, Aalst (BE)

K. Sarica, Istanbul (TR)

Moderators

F. Dal Moro, Padova (IT)

T. Knoll, Sindelfingen (DE)

A. Skolarikos, Athens (GR)

10:40 - 10:50

Flexible ureteroscopy with TFL

G.M. Kamphuis, Amsterdam (NL)

10:50 - 11:00

Mini-PCNL with MOSES technology 2.0

M.D. Duvdevani, Mevaseret-Zion (IL)

11:00 - 11:10

Hugo RAS system

R. Olivares, Santiago (CL)

11:10 - 11:20

Anatomical enucleation of prostate with Thulium fiber laser

L. Tunc, Ankara (TR)

11:20 - 11:30

FURS

L. Ajayi, London (GB)

11:30 - 11:40

Bipolar anatomic enucleation of prostate

T.R.W. Herrmann, Frauenfeld (CH)

11:40 - 11:50

JFil, an innovative ureteral stent

A. Bosio, Torino (IT)

11:50 - 12:00

Discussion

12:00 - 13:00

Break

13:00 - 13:40

Semi-live surgery part II

Chairs

A.S. Gözen, Heilbronn (DE)

A. Mottrie, Aalst (BE)

K. Sarica, Istanbul (TR)

Moderators

O.R. Durutovic, Belgrade (RS)

D. Enikeev, Moscow (RU)

J.B. Roche, Bordeaux (FR)

13:00 - 13:10

Endoscopic combined intrarenal surgery (ECIRS)

O. Angerri Feu, Barcelona (ES)

E. Emiliani, Barcelona (ES)

13:10 - 13:20

Robotic assisted cystectomy with intracorporeal diversion

C.J. Wijburg, Arnhem (NL)

13:20 - 13:30

Thulium Laser Enucleation of the Prostate (ThuLEP)

G. Bozzini, Busto Arsizio (IT)

13:30 - 13:40

Discussion

13:40 - 15:00

Semi-live surgery part III

Chairs

A.S. Gözen, Heilbronn (DE)

A. Mottrie, Aalst (BE)

K. Sarica, Istanbul (TR)

Moderators

E. Barret, Paris (FR)

A. Bujons Tur, Barcelona (ES)

S. Micali, Baggiovara (IT)

13:40 - 13:50

Plasma En-Bloc resection NMIBC

B. Malavaud, Toulouse (FR)

13:50 - 14:00

Aquablation therapy reimagining BPH surgery

N. Barber, Camberley (GB)

14:00 - 14:10

Robot-assisted endoscopic extraperitoneal radical prostatectomy with the Senhance digital platform

T. Kuliš, Zagreb (HR)

14:10 - 14:20

Laparoscopic partial nephrectomy (Tachosil)

A.S. Gözen, Heilbronn (DE)

14:20 - 14:30

Flexible single use ureteroscopic lithotripsy

G. Giusti, Milan (IT)

14:30 - 14:40

Flexible single use ureteroscopy with LithoVue™

S. Proietti, Milan (IT)

14:40 - 14:50

Endoscopic combined intrarenal surgery (ECIRS)

C.M. Scoffone, Turin (IT)

C.M. Cracco, Turin (IT)

14:50 - 15:00

Retrograde intra renal surgery for UTUC

J. Baard, Amsterdam (NL)

15:00 - 15:10

Break

15:10 - 17:30

Semi-live surgery part IV

Chairs

A. Breda, Barcelona (ES)

E. Liatsikos, Patras (GR)

C.C. Seitz, Vienna (AT)

Moderators

M. Cepeda, Valladolid (ES)

C. Fiori, Orbassano (IT)

A.J. Gross, Hamburg (DE)

15:10 - 15:20	Laparoscopic lymphadenectomy with Rubina system M. Ramírez-Backhaus, Valencia (ES)
15:20 - 15:30	FURS with MOSES technology B. Somani, Southampton (GB)
15:30 - 15:40	Extended RARP + ePLND with SynchroSeal A. Mottrie, Aalst (BE)
15:40 - 15:50	PCNL with Swiss LithoClast® Trilogy D.A. Pérez Fentes, Santiago de Compostela (ES)
15:50 - 16:00	Edoscopic combined intrarenal surgery (ECIRS) with Swiss LithoClast® Trilogy + LaserClast 35 O. Wiseman, Cambridge (GB)
16:00 - 16:10	Retrograde intra renal surgery (RIRS) for stones O. Traxer, Paris (FR)
16:10 - 16:20	Laser endoscopic enucleation of the prostate for BPH C. Netsch, Hamburg (DE)
16:20 - 16:30	Endoscopic stone management with RevoLix HTL I. Kartalas-Goumas, Vigevano (IT)
16:30 - 16:40	Endoscopic combined intrarenal surgery (ECIRS) with LithoVue™ Flexible Ureteroscope and Swiss LithoClast® Trilogy T. Kunit, Salzburg (AT) M. Drerup, Salzburg (AT)
16:40 - 16:50	Holmium Laser Enucleation of the Prostate (HoLEP) using the two-lobe technique C.R. Brunken, Reinbek (DE)
16:50 - 17:00	Rezüm™ for prostate treatment R.G. Hindley, London (GB)
17:00 - 17:10	Techniques in robotic assisted ultrasound for partial nephrectomy O. Karim, London (GB)
17:10 - 17:20	A stone case on flexible ureteroscopy To be confirmed
17:20 - 17:30	Discussion
17:30 - 18:50	Semi-live surgery part V <i>Chairs</i> A. Breda, Barcelona (ES) E. Liatsikos, Patras (GR) C.C. Seitz, Vienna (AT) <i>Moderators</i> P. Nyirády, Budapest (HU) F. Porpiglia, Turin (IT) B. Petrut, Cluj Napoca (RO)
17:30 - 17:40	HoLEP procedure using special emission mode (Virtual Basket) F. Gomez Sancha, Madrid (ES)
17:40 - 17:50	HoLEP with MOSES technology to improve outcomes T. Aho, Cambridge (GB)
17:50 - 18:00	Robotic assisted retroperitoneal partial nephrectomy RAPN (da Vinci Xi) A. Breda, Barcelona (ES)
18:00 - 18:10	Robotic pelvic lymphadenectomy J. Rassweiler, Heilbronn (DE)
18:10 - 18:20	En-bloc TURB L. Lusuardi, Salzburg (AT)

18:20 - 18:30

Combined holmium procedures

E. Liatsikos, Patras (GR)

18:30 - 18:40

Enbloc laser enucleation of the prostate (HoLEP)

P. Kallidonis, Patras (GR)

18:40 - 18:50

Closing remarks

A.S. Gözen, Heilbronn (DE)

Male and female stress urinary incontinence - Evaluation and surgical solutions

Poster Session 04

Thursday 8 July
11:00 - 12:00

Location Virtual Room 9

Chairs R. Bauer, Munich (DE)
A. Kretschmer, Munich (DE)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session covers new relevant data about female and male stress incontinence, focusing on patient profiles, surgical options (balloons, injections, slings and sphincters)

11:00 - 11:01

Introduction

11:01 - 11:11

Epidemiology, symptoms and evaluation of SUI in women

P0092

Prevalence of urinary incontinence in portuguese women, associated comorbidities and use of healthcare resources - a population-based study
P. Ramos, Porto (PT)

P0093

The impact of female urinary incontinence on mental health disease - a population-based study
P. Ramos, Porto (PT)

P0094

Development and validation of the international female coital incontinence questionnaire (IFCI-Q)
M. Gubbiotti, Assisi (IT)

P0095

Voiding symptoms and pressure-flow study patterns in female mixed urinary incontinence
A.G. Giannantoni, Siena (IT)

P0096

Detrusor contraction shortening velocity of patients is affected by outflow obstruction and aging and varies by gender
P.F.W.M. Rosier, Nijmegen (NL)

11:06 - 11:11

Discussion

11:11 - 11:22

PFMT and slings in women; Results and complications

P0097

Factors contributing to long-term adherence to pelvic floor muscle training in women suffering from stress urinary incontinence
A. Zachariou, Volos (GR)

P0098

Long-term efficacy and safety of Altis® single-incision sling procedure for stress urinary incontinence
A. Gromicho, Figueira da Foz (PT)

P0099	Sexual function outcomes in patients and patients' spouses after midurethral sling procedure for stress urinary incontinence: Data from a minimum of 7 years of follow-up To be confirmed
P0100	Complications, revision and perceived health after surgery for stress urinary incontinence by mid urethra sling in the VIGI-MESH register: Description and medium-term incidence for 1814 women T. Charles, Poitiers (FR)
P0101	Comparison of early loosening vs. delayed section of mid-urethral slings for suspected bladder outlet obstruction A. Gasmi, Rennes (FR)
P0102	Transobturator adjustable sling for the treatment stress urinary incontinence in morbidly obese female patients A. Tursunkulov, Tashkent (UZ)
11:17 - 11:22	Discussion
11:22 - 11:32	Management of female SUI with fixed urethra/sphincter deficiency
P0103	Long-term outcomes from the REMEEX System® in female patients with intrinsic sphincteric deficiency and recurrent urinary incontinence: Data from a minimum of 12 years of follow-up To be confirmed
P0104	Long-term outcomes of polyacrylamide hydrogel (Bulkamid®) treatment in women with stress urinary incontinence V. Hoe, Melbourne (AU)
P0105	Adjustable Continence Therapy (ACT®) balloons: A comparison between neurogenic female urinary incontinence and non-neurogenic A. Demeestere, Mouvax (FR)
P0106	New technique of robot-assisted laparoscopic artificial urinary sphincter implantation in female by a posterior approach with intraoperative cystoscopic monitoring L. Broudeur, Nantes (FR)
P0107	Long-term functional outcomes of artificial urinary sphincter implantation for the treatment of female stress urinary incontinence: A high-volume single center experience F. Cancrini, Rome (IT)
11:27 - 11:32	Discussion
11:32 - 11:34	Conclusion on female SUI
11:34 - 11:42	Male SUI : Patients characteristics and peri-operative evaluation
P0108	Prospective multi centre registry for patients undergoing surgery for male stress urinary incontinence. An update of the EAU Registry 'SATURN' F.M.J. Martens, Nijmegen (NL)
P0109	Who gets what in male incontinence surgery? A retrospective comparison of male sling and artificial urinary sphincter patient characteristics in a tertiary referral center Y. Deruyver, Mechelen (BE)
P0110	Membranous urethral length (MUL) in patients who have had male sling or artificial urinary sphincter surgery for bothersome post prostatectomy stress incontinence N.A. Faure Walker, London (GB)

P0111	Perioperative use of anticholinergic medication in patients undergoing surgery for male urinary stress incontinence M.T. Grabbert, Freiburg (DE)
11:38 - 11:42	Discussion
11:42 - 11:56	Male SUI, surgical issues: Slings and sphincters
P0112	Long-term patient-reported outcomes after AdVance and AdVance XP male sling surgery for stress urinary incontinence Y. Deruyver, Mechelen (BE)
P0113	Long-term evaluation of the adjustable bulbourethral Argus® sling: Single center experience with a mean follow-up of 10 years G. Ameli, Vienna (AT)
P0114	The Artificial Urinary Sphincter (AUS) in male non-neurogenic incontinence: Long-term analysis of the functional and subjective outcomes and potential risk factors for failure C. Schillebeeckx, Vosselaar (BE)
P0115	Impact of the center volume activity on the results of artificial urinary sphincter in non-neurological male patients I. Bentellis, Nice (FR)
P0116	Prevalence and risk factors of artificial urinary sphincter revision in non-neurological male patients I. Bentellis, Nice (FR)
P0117	Outcomes of artificial urinary sphincter implantation in irradiated patients: A multicenter study J. Mamane, Reins (FR)
P0118	Outcomes and complication rates of cuff-downsizing in the treatment of increasing or persisting incontinence after artificial urinary sphincter implantation: A retrospective analysis of a prospective database S. Weis, Hamburg (DE)
P0119	Functional outcomes of robot-assisted laparoscopic artificial urinary sphincter implantation for the treatment of adult male neurogenic stress urinary incontinence C. Guillot-Tantay, Paris (FR)
P0120	Adjustable artificial urinary sphincter (VICTO): Experience after 104 cases G. Ameli, Vienna (AT)
11:51 - 11:56	Discussion
11:56 - 11:58	Conclusion on male SUI
11:58 - 12:00	Expert summary C. Harding, Newcastle upon Tyne (GB)

Practical aspects of cancer pathology for urologists. The 2021 WHO novelties

ESU Course 02

Thursday 8 July
11:00 - 13:00

Location Zoom 1

Chair E. Compérat, Paris (FR)

Learning objectives

During the pathology course we will focus on specific aspects of prostate, bladder, kidney and testicular pathology:

Prostate: Recent developments in Gleason grading, contemporary reporting issues (i.e. Gleason Grade 4).

Bladder: Overlap between histopathology and molecular pathology; recent recommendations for T1 staging.

Kidney: Urological impact of major changes in the upcoming WHO classification of renal carcinomas (i.e. new entities or categories and their relevance).

Testicle: current classification of testicular germ cell tumours; value of histological tumour type in predicting post-chemotherapy residual metastasis.

11:00 - 13:00

Prostate cancer: Contemporary reporting of Gleason grades, meaning for the patient's management, integration of the white paper of GUPS (Genitourinary Society of Pathology 32589068)
E. Compérat, Paris (FR)

11:00 - 13:00

Bladder cancer: Correlationship between histological and molecular aspects of bladder cancer, PD-L1 and its meaning, how to substage a pT1 urothelial carcinoma?
E. Compérat, Paris (FR)

11:00 - 13:00

Kidney cancer: Urological impact of the upcoming WHO classification of renal carcinomas
F. Algaba, Barcelona (ES)

11:00 - 13:00

Testicular cancer: Current classification of testicular germ cell tumours and histological prediction of post-chemotherapy residual metastatic tumour according to testicular tumour
F. Algaba, Barcelona (ES)

Urinary tract infections: Screening and diagnosis

Poster Session 05

Thursday 8 July
12:00 - 13:00

Location Virtual Room 8

Chairs T.E. Bjerklund Johansen, Oslo (NO)
Z. Tandoğdu, London (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

The impact of COVID-19 pandemic on urologists' daily practice, novel therapies for prevention of urinary tract infections and development of validated symptom scores for various types of urinary tract infections will be discussed with the audience.

12:00 - 12:01

Introduction

P0121	Urological surgery remained safe during the second wave of SARS-CoV-2 pandemic in a high incidence area A. González Díaz, Madrid (ES)
P0122	Morbidity and mortality in urological emergency patients during COVID-19 A. Ahmad, Wales (GB)
P0123	The potential role of COVID-19 hygienic measures in reducing infective complications during hospitalization D. Baiamonte, Palermo (IT)
P0124	The impact Of COVID-19 on acute obstructive pyelonephritis severity – 2020 and its unforeseen presentations A.Bilé Silva, Lisboa (PT)
P0125	Post-operative infections, a silver lining from the COVID-19 pandemic. A retrospective cohort study from urology departments B.L. Teixeira, Aveiro (PT)
P0126	Does the urine microbiota of healthy women fluctuate during the daytime? Y.L. Naboka, Rostov-on-Don (RU)
P0127	The bacterial-viral microbiota of urine in healthy people Y.L. Naboka, Rostov-on-Don (RU)
P0128	Relapses of urogenital tract tuberculosis E. Kulchavenya, Novosibirsk (RU)
P0129	Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) 3a is a classic Chronic Bacterial Prostatitis (CBP) R.S. Ismailov, Rostov-on-Don (RU)

12:10 - 12:18	Discussion
P0130	Efficacy and safety of the sublingual bacterial vaccine MV140 in women with recurrent urinary tract infections: An European phase III, multicentre, randomized, double-blind, placebo-controlled trial M.F. Lorenzo Gomez, Salamanca (ES)
P0131	Immunomodulatory roles of antimicrobial peptide LL-37 in urinary bladder bacterial infection K. Wongsakorn, London, Ontario (CA)
P0132	Catheterised urine is not superior to mid-stream samples in the study of male urinary microbiota J. Hrbacek, Praha (CZ)
P0133	Urinary tract infection diagnosis and antimicrobial susceptibility testing within <90 minutes S. Shprits, Haifa (IL)
P0134	Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly M.F. Lorenzo Gomez, Salamanca (ES)
P0135	Lactobacillus vaginal suppositories for recurrent cystitis: A phase 2 clinical trial T. Sadahira, Okayama (JP)
P0136	Do bacteriophages really prevent urinary tract infections? A. Govorov, Moscow (RU)
P0137	Internal and external metal-based coatings to prevent uropathogen adhesion on stents B. Domingues, Barco GMR (PT)
P0138	Novel antimicrobial strategies for catheter infection prevention in muscle invasive bladder cancer patients after radical cystectomy and ureterocutaneostomy E. Illiano, Bacoli (IT)
P0139	Bioluminescence imaging enables the study of bladder hyperreflexia during urinary tract infections in mice N. Luyts, Leuven (BE)
12:28 - 12:36	Discussion
P0140	Bacteraemia and bacteria spread into the irrigation fluid during percutaneous nephrolithotomy: A prospective study E. De Lorenzis, Milan (IT)
P0141	Development of a novel clinical and radiological risk score to predict septic complications in patients with obstructive uropathy C. Bebi, Milan (IT)
P0142	Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19 C. Zaccaro, Florence (IT)

P0143	Is there a relationship between the severity of inflammatory changes in the prostate and microbial load of its tissues (an experimental study)? R.S. Ismailov, Rostov-on-Don (RU)
P0144	Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis D. Schlager, Freiburg (DE)
P0145	Prevalence of traumatic sexual events in patients with recurrent UTI M. Grootemaat, Hoofddorp (NL)
P0146	Linguistic and clinical validation of the Greek Acute Cystitis Symptom Score questionnaire K. Stamatiou, Pireaus (GR)
P0147	Re-evaluation of the acute cystitis symptom score in multinational settings J.F. Alidjanov, Giessen (DE)
P0148	Linguistic and clinical validation of the Spanish Acute Cystitis Symptoms Score (ACSS) questionnaire in females with acute cystitis J. Medina-Polo, Madrid (ES)
12:45 - 12:53	Discussion
12:53 - 12:58	Expert summary K. Bausch, Liestal (CH)

Joint Session of the European Association of Urology (EAU) and the Pakistan Association of Urological Surgeons (PAUS)

Urology beyond Europe

Thursday 8 July
13:00 - 15:00

Location Virtual Room 4

Chairs D. Pushkar, Moscow (RU)
M. Sheriff, Gillingham (GB)

Learning objectives

This session will collaboratively endeavour to provide an overview of the latest developments in the management urinary tract infections and provide an update on current challenges in urological training which have historically received inadequate attention in Pakistan.

13:00 - 13:10

Welcome and introduction

M. Ahmad, Rawalpindi (PK)
D. Pushkar, Moscow (RU)
M. Sheriff, Gillingham (GB)

13:10 - 14:00

Urinary tract infections

Moderators R. Hamid, London (GB)
M.S. Khan, London (GB)

13:10 - 13:25

Catheter associated infections and their management: Interesting observations in developing countries

N. Damani, Geneva (CH)

13:25 - 13:40

Management algorithm for recurrent urinary tract infections in the light of recent advancements

G.R. Kasyan, Moscow (RU)

13:40 - 14:00

Questions and answers

14:00 - 14:50

Urological training

Moderators A. Govorov, Moscow (RU)
A. Rahman, Peshawar (PK)

14:00 - 14:15

How to achieve best outcomes in urological training

A.J. Figueiredo, Coimbra (PT)

14:15 - 14:30

Overview of urological training in Pakistan: Our vision for the future

S. Shah, Lahore (PK)

14:30 - 14:50

Questions and answers

14:50 - 15:00

Closing remarks

D. Pushkar, Moscow (RU)
M. Sheriff, Gillingham (GB)

Joint Session of the European Association of Urology (EAU) and the Iranian Urological Association (IUA)

Urology beyond Europe

Thursday 8 July
13:00 - 15:00

Location Virtual Room 6

Chairs A. Basiri, Tehran (IR)
J.O.R. Sønksen, Herlev (DK)

Learning objectives

This year's joint session between the Iranian Urological Association (IUA) and the EAU consists of a larger variety of difficult case presentations, arranged around the topics of renal cyst masses, adrenal masses and Wilms' tumour. Further talks cover complex urethral strictures and post-prostatectomy incontinence. Participants can expect practical take-home messages and an interesting exchange of thoughts and experiences between Iranian and European urologists.

13:00 - 13:02

Welcome and introduction

13:02 - 13:35

Renal cyst mass

13:10 - 13:20

Management of renal cyst mass – An update 2021

M. Ayati, Tehran (IR)

13:20 - 13:25

Difficult case presentation 1

To be confirmed

13:25 - 13:30

Difficult case presentation 2

A.S. Gözen, Heilbronn (DE)

13:30 - 13:35

Difficult case presentation 3

M. Kardoust Parizi, Tehran (IR)

13:02 - 13:10

Discussion of difficult cases

Panel

J. Bedke, Tübingen (DE)

To be confirmed

13:35 - 14:08

Adrenal mass

13:35 - 13:45

Management of adrenal mass – An update 2021

A. Alcaraz, Barcelona (ES)

13:45 - 13:50

Difficult case presentation 1

G. Pourmand, Tehran (IR)

13:50 - 13:55

Difficult case presentation 2

L. Lund, Odense (DK)

13:55 - 14:00

Difficult case presentation 3

M.R. Nowroozi, Tehran (IR)

14:00 - 14:08

Discussion of difficult cases

Panel

L. Lund, Odense (DK)

To be confirmed

14:08 - 14:34

Wilms' tumour

14:08 - 14:18

Management of Wilms' tumour – An update 2021

S. Tekgül, Ankara (TR)

14:18 - 14:23

Difficult case presentation 1

S.M. Ghahestani, Tehran (IR)

Scientific Programme - EAU21 Virtual

14:23 - 14:28

Difficult case presentation 2

N. Smeulders, London (GB)

14:28 - 14:34

Discussion of difficult cases

Panel

A. Basiri, Tehran (IR)

S. Tekgül, Ankara (TR)

14:34 - 14:46

Last decision in complex urethral strictures

Moderators

A. Basiri, Tehran (IR)

A. Mundy, London (GB)

14:34 - 14:42

Last decision in complex urethral strictures

S.J. Hosseini, Tehran (IR)

14:42 - 14:46

Discussion

14:46 - 14:58

Post-prostatectomy incontinence: Evaluation and management

Moderators

A. Basiri, Tehran (IR)

J.O.R. Sønksen, Herlev (DK)

14:46 - 14:54

Post-prostatectomy incontinence: Evaluation and management

M.M. Fode, Herlev (DK)

14:54 - 14:58

Discussion

14:58 - 15:00

Conclusion

Joint Session of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

Urology beyond Europe

Thursday 8 July
13:00 - 15:00

Location Virtual Room 7

Chairs D. Nikoleishvili, Tbilisi (GE)
H. Van Poppel, Leuven (BE)

Learning objectives

This session serves to exchange knowledge between the EAU and neighboring regions in the Caucasus and Central Asia. It offers a medium for discussions on the unique experiences that these countries face. Presentations will address laparoscopic, oncological and endourological topics and feature expert speakers from across continents.

13:00 - 13:03

Welcome and introduction

H. Van Poppel, Leuven (BE)

13:03 - 13:50

Laparoscopy

Moderators R. Badalyan, Yerevan (AM)
A. Chkhotua, Tbilisi (GE)
J.F. Langenhuijsen, Nijmegen (NL)

13:03 - 13:10

Is pure (non-robot assisted) laparoscopy ready to vanish?

A.S. Gözen, Heilbronn (DE)

13:10 - 13:17

How to avoid complications in laparoscopy in urologic practice? Our experience

B. Ayubov, Tashkent (UZ)

13:17 - 13:24

Laparoscopic surgery in the management of urolithiasis

S. Kussymzhanov, Almaty (KZ)

13:24 - 13:31

Urological laparoscopy surgery in Turkmenistan – Our initial experience

B. Gadamov, Ashgabat (TM)

13:31 - 13:38

Urolithiasis and laparoscopy: From the unheard of to the distinctive niche

R. Hovhannisyan, Yerevan (AM)

13:38 - 13:50

Discussion

13:50 - 14:23

Oncology

Moderators N. Monolov, Bishkek (KG)
T. Muratov, Nur-Sultan (KZ)
H. Van Poppel, Leuven (BE)

13:50 - 13:57

PCa early detection: A priority?

H. Van Poppel, Leuven (BE)

13:57 - 14:04

Early oncological and functional results of prostate-capsule sparing cystectomy comparison with standard extraperitoneal radical cystectomy: Experiences of the National Center of Urology

A. Pertia, Tbilisi (GE)

14:04 - 14:11

The role of lymphadenectomy in locally advanced prostate cancer

F. Guliyev, Baku (AZ)

14:11 - 14:23

Discussion

14:23 - 14:56

Endourology

Moderators

E. Liatsikos, Patras (GR)
S. Mukhtarov, Tashkent (UZ)
T. Musayev, Baku (AZ)

14:23 - 14:30

Will expert/modern URS make PCNL superfluous?

E. Liatsikos, Patras (GR)

14:30 - 14:37

PCNL is a good option for the treatment of renal stones

A. Abduvokhidov, Dushanbe (TJ)

14:37 - 14:44

Comparative study of efficacy and safety between the holmium laser and pulse shock in nephrolithotomy (PNL)

A. Toktonaliev, Bishkek (KG)

14:44 - 14:56

Discussion

14:56 - 15:00

Conclusion

D. Nikoleishvili, Tbilisi (GE)
H. Van Poppel, Leuven (BE)

Urinary tract infections: Treatment and follow-up

Poster Session 06

Thursday 8 July
13:00 - 14:00

Location Virtual Room 9

Chairs H.M. Çek, Edirne (TR)
N. Stepanova, Kyiv (UA)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Novel treatment models for treating urinary tract infections, increasing antibiotic resistance and side effects as well as prophylaxis will be discussed with the participants

13:00 - 13:01

Introduction

P0149	Adverse events in patients treated with quinolones and fluoroquinolones before and after European Medicines Agency warning A.F.M. Cicione, Lamezia Terme - CZ (IT)
P0150	The efficacy and tolerability of pollen extract in combination with hyaluronic acid and vitamins in the management of patients affected by CP/CPPS: A 26 weeks, randomized, controlled, single-blinded, phase III study T. Cai, Trento (IT)
P0151	Effects of preoperative immunonutrition on surgical site infections for bladder cancer patients undergoing cystectomy and ileal conduit H. Takeuchi, Sakai city (JP)
P0152	Using machine learning models to predict antimicrobial resistance and assist urologists in decision-making regarding empirical antibiotic treatment L. Tzelves, Athens (GR)
P0153	Is adjuvant amikacin to oral levofloxacin effective for prevention of febrile complications following transrectal prostate biopsy in patients with fluoroquinolone-resistant E.coli in the rectal flora? Y. Nasu, Okayama (JP)
P0154	Relationship between the clinical profile of women with recurrent urinary tract infections and the prophylactic treatment chosen M.F. Lorenzo Gomez, Salamanca (ES)
P0155	The results of treatment of patients with urolithiasis by Renotinx® in early postoperative period A. Nemenov, Moscow (RU)

P0156	The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: Results from a phase IV study T. Cai, Trento (IT)
P0157	Antimicrobial prophylaxis (AMP) in transurethral resection of the prostate (TURP): results of a randomized trial E. Baten, Leuven (BE)
P0158	Predictive factors of failure of conservative management in patients with emphysematous pyelonephritis M.H. Saadi, Rades (TN)
13:11 - 13:19	Discussion
P0159	Photothermal treatment of ESBL E. coli via iron oxide nanoparticles T-W. Chang, Taipei (TW)
P0160	Value of condom based vaginal intercourse while treating chronic prostatitis: A randomized trial M.K.M. Omar, Shibin El Kom (EG)
P0161	Effect of standard antibiotic prophylaxis versus enhanced prophylactic measures on rate of urinary tract infection after flexible ureteroscopy T. Ali Abouelgreed, Cairo (EG)
P0162	Variability in expenses in the treatment of recurrent urinary infection due to the costs of concomitant medication according to the prophylaxis protocol received M.F. Lorenzo Gomez, Salamanca (ES)
P0163	Evaluation of the evolution of antibiotic prescription in the treatment of Healthcare-Associated Infections (HAIs) in a urology ward after implementing a treatment optimisation programme J. Medina-Polo, Madrid (ES)
P0164	Novel scoring system and advanced management algorithm for emphysematous pyelonephritis
P0165	Would increase daily water intake/ I.V saline administration help in prevention of urinary tract infections in female patients with advanced Parkinson disease M.K.M. Omar, Shibin El Kom (EG)
P0166	Contemporary practice patterns in the treatment of Fournier's gangrene – Implications for planning a Fournier's gangrene registry L. Schneidewind, Greifswald (DE)
P0167	Sexually transmitted infections remain under-diagnosed and under-treated in young men presenting with acute scrotal pain M.J.R. Thomas, Stoke-on-trent (GB)
P0168	Urosepsis in malignant ureteral obstruction or obstructing stones: Is the treatment the same? A. Nogara, Macerata (IT)
13:29 - 13:37	Discussion

P0169	Antibiotic prophylaxis for prevention of infectious complications after shockwave lithotripsy: A systematic review and meta-analysis B. Tadayon Najafabadi, Hamilton (CA)
P0170	Minimally Invasive Surgery (MIS) in simple nephrectomy – differences in perioperative outcomes based on infectious or noninfectious aetiology A. Papadopoulou, London (GB)
P0171	A multicenter, propensity score-matched retrospective study of preventing postoperative infection in robotic and laparoscopic minimally invasive surgeries; double- versus single-gloving T. Nagai, Nagoya (JP)
P0172	Febrile urinary tract infection as a cause for 90-day readmission after radical cystectomy for bladder cancer: Microbiology and risk factors A. Artilles Medina, Madrid (ES)
P0173	Interest of FGSI and LRINEC prognostic scores in the management of Fournier gangrene S. Zaghib, Ariana (TN)
P0174	Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study K-J. Lundström, Östersund (SE)
P0175	Risk factors for sepsis and mortality in patients with emphysematous pyelonephritis M.H. Saadi, Rades (TN)
P0176	Prophylaxis for recurrent urinary tract infections in women with StroVac – Efficacy and patient's compliance in a 2-year follow-up S. Nestler, Mainz (DE)
P0177	The role of the booster injection in prophylaxis for recurrent urinary tract infections with StroVac S. Nestler, Mainz (DE)
13:46 - 13:54	Discussion
13:54 - 13:59	Expert summary F.M.E. Wagenlehner, Giessen (DE)

Andrology and infertility update

ESU Course 03

Thursday 8 July
14:00 - 16:00

Location	Zoom 1
Chair	W. Aulitzky, Vienna (AT)
Moderator	W. Aulitzky, Vienna (AT)

14:00 - 14:05

Welcome and Introduction
W. Aulitzky, Vienna (AT)

14:05 - 14:05

Male Infertility

14:05 - 14:35

Overview
A. Salonia, Milan (IT)

14:35 - 14:45

Varicocele
W. Aulitzky, Vienna (AT)

14:45 - 14:50

Microsurgery
W. Aulitzky, Vienna (AT)

14:50 - 15:10

Questions and answers
W. Aulitzky, Vienna (AT)

15:10 - 15:10

Erectile dysfunction

15:10 - 15:15

Introduction
A. Salonia, Milan (IT)

15:15 - 15:35

Overview
J.I. Martínez Salamanca, Majadahonda (ES)

15:35 - 15:55

Questions and answers
A. Salonia, Milan (IT)

15:55 - 16:00

Wrap-up slide with contacts
W. Aulitzky, Vienna (AT)

Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Urology beyond Europe

Thursday 8 July
15:00 - 17:00

Location Virtual Room 3

Chairs C. Mallikarjuna, Hyderabad (IN)
J.M. Nijman, Groningen (NL)

Learning objectives

This session brings together urologists from India and Europe on behalf of the Urological Society of India and the EAU. Participants can look forward to a variety of kidney-related topics, including surgical and non-surgical treatment options. The session concludes with a live panel discussion of complex cases.

15:00 - 15:03

Welcome and introduction
J.M. Nijman, Groningen (NL)

15:03 - 15:08

Snapshot of kidney cancer demographics and outcome from a Indian tertiary cancer center
R.S. Mavuduru, Chandigarh (IN)

15:08 - 15:22

Laparoscopic procedures including partial nephrectomy: When to do what
A.S. Merseburger, Lübeck (DE)

15:22 - 15:31

Robotic management of complex endophytic & hilar tumours
A. Kumar, New Delhi (IN)

15:31 - 15:40

Role of lymphadenectomy in RCC
S. Kumar, Vellore (IN)

15:40 - 15:49

Role of excision of single metastatic RCC
H. Tongaonkar, Mumbai (IN)

15:49 - 15:54

Discussion
Moderators R. Keshavamurthy, Bangalore (IN)
H. Van Poppel, Leuven (BE)

15:54 - 16:03

IVC thrombectomy
A. Seth, New Delhi (IN)

16:03 - 16:12

Open surgical procedures, IVC thrombectomy and metastasectomy
A. Bex, London (GB)

16:12 - 16:26

Evolving role of chemotherapy and immunotherapy in metastatic RCC
P.F.A. Mulders, Nijmegen (NL)

16:26 - 16:31

Managing metastatic RCC – Cytoreductive surgery vs. TKI
R K Dey, Kolkata (IN)

16:31 - 16:36

Discussion
Moderators C. Mallikarjuna, Hyderabad (IN)
H. Van Poppel, Leuven (BE)

16:36 - 16:56

Complex cases

Case presenters

B. Ljungberg, Umeå (SE)

Panel

R.S. Mavuduru, Chandigarh (IN)

R. Keshavamurthy, Bangalore (IN)

S. Rawal, Delhi (IN)

H. Van Poppel, Leuven (BE)

16:56 - 17:00

Conclusion

C. Mallikarjuna, Hyderabad (IN)

J.M. Nijman, Groningen (NL)

Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

Urology beyond Europe

Thursday 8 July
15:00 - 17:00

Location Virtual Room 5

Chairs H. Abol-Enein, Mansoura (EG)
M. Wirth, Dresden (DE)

Learning objectives

In this session, Arabic and European speakers will address the up-to-date topics in urology. The attending participants will learn a lot from the discussion. The topics include uro-oncology, urolithiasis, paediatric urology and how-I-do-it videos.

By the end of the session, the audience will have many tips and tricks which will be of great help in decision-making and improving the clinical urological practice.

15:00 - 15:05

Welcome and introduction

15:05 - 15:32

Urolithiasis and endourology

Moderators N. Al-Hamdani, Baghdad (IQ)
A.R. Hammady, Sohag (EG)
Y. Farahat, Dubai (AE)

15:05 - 15:15

Did laser use change stone treatment?

K. Thomas, London (GB)

15:15 - 15:25

Tricks and innovations in endourologic procedure

M. Lezrek, Meknes (MA)

15:25 - 15:32

Discussion

15:32 - 15:59

Uro-oncology

Moderators A.A. Al-Zarooni, Sharjah (AE)
M. Eissa, Cairo (EG)
N. Ramadan, Amdurman (SD)

15:32 - 15:42

Upper urothelial cancer: Established treatment and guidelines

A. Stenzl, Tübingen (DE)

15:42 - 15:52

Neo-adjuvant chemotherapy in upper urothelial cancer

M. Abufaraj, Amman (JO)

15:52 - 15:59

Discussion

15:59 - 16:26

Paediatric urology

15:59 - 16:09

Optimal time to interfere in urologic disorders

A. Abdelhalim, Mansoura (EG)

16:09 - 16:19

Late problems after urinary diversion in children

M. Fisch, Hamburg (DE)

16:19 - 16:26

Discussion

16:26 - 16:53

How I do it:

16:26 - 16:36

Open radical prostatectomy

O. Hakenberg, Rostock (DE)

16:36 - 16:46

Ileal loop conduit

H. Abol-Enein, Mansoura (EG)

Scientific Programme - EAU21 Virtual

16:46 - 16:53

Discussion

16:53 - 16:58

Closing remarks

Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

Urology beyond Europe

Thursday 8 July
15:00 - 17:00

Location Virtual Room 2

Chairs V.G. Mirone, Naples (IT)
S. Kulkarni, Pune (IN)

Learning objectives

As two international urological bodies, the Société Internationale d'Urologie (SIU) and the EAU share a mission and enjoy longstanding ties. Many urologists are affiliated to both bodies and this session brings together big names from around the world to discuss a wide variety of hot topics in urology, mainly surgical in nature. Two debates are included, covering transection vs non-transection of bulbar urethra, and grafts vs flaps, respectively.

15:00 - 15:05

Welcome and introduction
C.R. Chapple, Sheffield (GB)

Urethral reconstruction

15:05 - 15:15

Female urethral stricture and diverticulum
C.R. Chapple, Sheffield (GB)

15:15 - 15:33

Debate Transection vs. non-transection of bulbar urethra

15:15 - 15:20

Non-transection bulbar urethroplasty
A. Mundy, London (GB)

15:20 - 15:25

Anastomotic urethroplasty
F. Morey, Dallas (US)

15:25 - 15:33

Discussion

15:33 - 15:51

Debate Grafts vs. Flaps

15:33 - 15:38

Grafts
F. Campos Juanatey, Santander (ES)

15:38 - 15:43

Flaps
R. Gomez, Santiago (CL)

15:43 - 15:51

Discussion

15:51 - 16:01

Complex posterior urethroplasty
S. Kulkarni, Pune (IN)

16:01 - 16:11

Failed hypospadias repair
P. Anderson, Dudley (GB)

16:11 - 16:21

Pan urethroplasty
P. Joshi, Pune (IN)

16:21 - 16:31

Urethral problems after prostate cancer treatment
A. De La Taille, Créteil (FR)

16:31 - 16:46

Ureteric reconstruction

Scientific Programme - EAU21 Virtual

Moderators

M. Gallucci, Rome (IT)

S. Tanguay, Montreal (CA)

16:31 - 16:41

Management of upper ureteric stricture (post-radiation, post-laser lithotripsy)

R. Olanas, Luneburg (DE)

16:41 - 16:46

Discussion

16:46 - 17:00

Questions, answers and closing remarks

V.G. Mirone, Naples (IT)

S. Kulkarni, Pune (IN)

Joint Session of the European Association of Urology (EAU) and the Maghreb Union countries

Urology beyond Europe

Thursday 8 July
15:00 - 17:00

Location Virtual Room 8

Chairs M. Alami, Meknes (MA)
B. Malavaud, Toulouse (FR)

Learning objectives

This session features key opinions leaders from both sides of the Mediterranean Sea. Thanks to the strong personal relationships established along the years between the members of the National Associations of Urology of the Maghreb and of the EAU, this joint session has become essential for those interested in state-of-the-art lectures and practice-oriented discussions.

Participants can expect an update on the most recent advances on timely topics, such as the challenges of getting optimal prostate biopsies, the management of complex stones and the current breakthroughs in the care of non-muscle and muscle invasive bladder cancers. The session will also feature a debate on ureteral stenting after uncomplicated ureteroscopy.

15:00 - 15:05

Welcome and introduction, in memoriam of Professor Saadeddine Zmerli
M. Alami, Meknes (MA)

15:05 - 15:35

The challenges of prostate biopsies

Moderators M. Alami, Meknes (MA)
B. Malavaud, Toulouse (FR)
M. Harouni, Oran (DZ)

15:05 - 15:13

Imaging for prostate biopsies

S. Sallami, Nabeul (TN)

15:13 - 15:21

Image-guided biopsies, a review of techniques

A. Chouakria, Annaba (DZ)

15:21 - 15:29

Controlling the risk of infection

F. Bruyere, Tours (FR)

15:29 - 15:35

Discussion

15:35 - 16:00

Burning questions in bladder cancer

Moderators M. Burger, Regensburg (DE)
M. Elmcherqui, Casablanca (MA)
R. El Kamel, Kairouan (TN)

15:35 - 15:40

Will MRI transform the management of MIBC?

V. Panebianco, Rome (IT)

15:40 - 15:45

How do I prepare my patients for cystectomy?

I. Ziouziou, Agadir (MA)

15:45 - 15:50

How relevant are advances in optics in the visualisation of NMIBC?

M. Tetou, Rabat (MA)

15:50 - 15:55

What are the main steps to optimal TURBT?

M. Burger, Regensburg (DE)

15:55 - 16:00

Discussion

16:59 - 17:58

Advances in stone management

	<i>Moderators</i>	S. Kerroumi, Oran (DZ) M. Lezrek, Meknes (MA) C.M. Scoffone, Turin (IT)
16:59 - 17:07	Imaging of the stone patient: The stone	To be confirmed
17:07 - 17:15	Imaging of the stone patient: The patient, anatomy and surgical access	S. Naouar, Kairouan (TN)
17:15 - 17:23	Retrograde flexible ureteroscopy during PNL	C.M. Scoffone, Turin (IT)
17:23 - 17:33	Pros and cons of ureteral stenting after uncomplicated ureteroscopy	<i>Pro</i> K. Youness, Rabat (MA) <i>Con</i> W. Zakhama, Mahdia (TN)
17:33 - 17:48	Unusual operative strategies adapted to the characteristics of ureteral stones, three case-presentations	<i>Case presenters</i> M. Azli, Annaba (DZ) M. Mrabti, Rabat (MA) A. Saadi, Tunis (TN)
17:48 - 17:58	Discussion	
17:58 - 17:59	Conclusion	B. Malavaud, Toulouse (FR)

Joint Session of the European Association of Urology (EAU) and the Pan-African Urological Surgeons Association (PAUSA)

Urology beyond Europe

Thursday 8 July
17:00 - 19:00

Location Virtual Room 4

Chairs S.M. Gueye, Dakar (SN)
P. Van Kerrebroeck, Berchem- Antwerp (BE)

Learning objectives

In this session members of the PAUSA and the EAU will discuss a variety of topics with clinical relevance in the specific African setting. The timing will allow for maximal interaction and discussion.

17:00 - 17:05	Welcome and introduction
17:05 - 17:20	Place of endoscopy in vesical pain syndrome / interstitial cystitis: Experience of the University Hospital of Annaba and review of the literature N. Laskri, Annaba (DZ)
17:20 - 17:25	Discussion
17:25 - 17:40	Imaging predictive tools and renal mass management A. Boulatrous, Annaba (DZ)
17:40 - 17:45	Discussion
17:45 - 18:00	Treatment of VVF: An update E. Chartier-Kastler, Paris (FR)
18:00 - 18:05	Discussion
18:05 - 18:20	The cost of prostate cancer care in Sub-Saharan Africa: Can we afford not to change the treatment landscape S. Mutambirwa, Pretoria (ZA)
18:20 - 18:25	Discussion
18:25 - 18:40	Tropical urology G. Bonkat, Basel (CH)
18:40 - 18:45	Discussion
18:45 - 18:55	Group discussion: What can we learn from each other? <i>Moderators</i> S.M. Gueye, Dakar (SN) P. Van Kerrebroeck, Berchem- Antwerp (BE)
18:55 - 19:00	Closing remarks

Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

Urology beyond Europe

Thursday 8 July
17:00 - 19:00

Location Virtual Room 6

Chairs P. Albers, Düsseldorf (DE)
A.R. Rodriguez, Rochester (US)

Learning objectives

The aim of this session is to facilitate an educational channel between urology in Europe and Latin-America. A deep insight in selected topics of current clinical practice in urology will be presented by a group of recognized experts from different countries' members of the EAU and CAU. Attendees will be able to learn updates on the diagnosis and management of prostate cancer, as well as, the contemporary approaches to treat related erectile dysfunction and incontinence due to prostate cancer therapies, from world-wide known experts in the field. This session will serve as an outstanding opportunity to exchange concepts and to improve the education of urology.

17:00 - 17:05

Welcome and introduction

17:05 - 17:30

Case-based debate Prostate biopsy

17:05 - 17:10

Case presentation
A.M. Alva Pinto, Lima (PE)

17:10 - 17:15

Always transrectal
J.G. Campos Salcedo, Mexico City (MX)

17:15 - 17:20

Always perineal
F. Bianco, Miami Lakes (US)

17:20 - 17:25

Are systematic biopsies still needed?
J. Walz, Marseille (FR)

17:25 - 17:30

Discussion

17:30 - 17:55

Case-based debate Focal treatment

17:30 - 17:35

Case presentation
H. Zampolli, São Paulo (BR)

17:35 - 17:40

Imaging and staging in localized prostate cancer (mpMRI, PSMA PET)
D. Murphy, Melbourne (AU)

17:40 - 17:45

Better HIFU
R. Sanchez-Salas, Paris (FR)

17:45 - 17:50

Better radical prostatectomy
R. Coelho, Sao Paulo (BR)

17:50 - 17:55

Discussion

17:55 - 18:05

Lymphadenectomy for prostate cancer: When and how?
A. Heidenreich, Cologne (DE)

18:05 - 18:15

Perioperative treatment of erectile dysfunction after radical prostatectomy
F. Montorsi, Milan (IT)

18:15 - 18:25

Management of urinary stress incontinence after prostate cancer therapy
M.A. Averbeck, Porto Alegre (BR)

Scientific Programme - EAU21 Virtual

18:25 - 18:30	Discussion
18:30 - 18:50	Surgical treatment of lymph node recurrences after radical prostatectomy – Pro vs. con
18:30 - 18:40	Pro surgery N. Fossati, Milan (IT)
18:40 - 18:50	Pro radiotherapy P. Ost, Ghent (BE)
18:50 - 18:55	Discussion
18:55 - 19:00	Closing remarks P. Albers, Düsseldorf (DE) A.R. Rodriguez, Rochester (US)

Joint Session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA)

Urology beyond Europe

Thursday 8 July
17:00 - 19:00

Location Virtual Room 7

Chairs R.A. Rendon, Halifax (CA)
A. Stenzl, Tübingen (DE)

Learning objectives

This session marks the first time that the Canadian Urological Association (CUA) is joining the Urology Beyond Europe sessions at the Annual EAU Congress! The session is organised in three parts, covering PSA and imaging, the role of nuclear medicine in treatment of metastatic PCa and what to consider with BCG treatment.

Canadian and European expert speakers will be covering a variety of topics in pre-recorded lectures and live discussions. After this session, participants will have had a good update on a variety of urological cancer screening and treatment options, taking into account both efficacy and patient safety.

17:00 - 17:05

Welcome

H. Razvi, London, Ontario (CA)
A. Stenzl, Tübingen (DE)

17:05 - 17:45

PSA, imaging and beyond

Moderator J. Walz, Marseille (FR)

17:05 - 17:15

Introduction

J. Walz, Marseille (FR)

17:15 - 17:25

Make indications for biopsy as precise as possible

A. Finelli, Toronto (CA)

17:25 - 17:35

Keep it simple

N. Mottet, Saint-Étienne (FR)

17:35 - 17:45

Discussion

17:45 - 18:20

Is nuclear medicine taking over the treatment of metastatic prostate cancer?

Moderator J. Chin, London-Ontario (CA)

17:45 - 17:50

Introduction

J. Chin, London-Ontario (CA)

17:50 - 18:00

PRLT could do much more if applied earlier and repetitive

C. La Fougère, Tübingen (DE)

18:00 - 18:10

PRLT is only a tessera in the treatment of CRPC

F. Pouliot, Quebec City (CA)

18:10 - 18:20

Discussion

18:20 - 18:55

BCG, maintenance, or else?

Moderator Y. Fradet, Quebec (CA)

18:20 - 18:25

Introduction

Y. Fradet, Quebec (CA)

18:25 - 18:35

We shouldn't deviate from the guidelines for the sake of patients' safety

W. Kassouf, Montreal (CA)

Scientific Programme - EAU21 Virtual

18:35 - 18:45

There are data for shorter maintenance due to different therapies, side effects and patients' compliance
J.A. Witjes, Nijmegen (NL)

18:45 - 18:55

Discussion

18:55 - 19:00

Closing remarks
R.A. Rendon, Halifax (CA)

Ultrasound in urology

ESU Course 04

Thursday 8 July
17:00 - 19:00

Location Zoom 1

Chair T. Loch, Flensburg (DE)

Learning objectives

Ultrasound is the basic imaging tool of the urologist. Almost all urologists are using ultrasound in daily practice. Despite this, training and teaching of urological ultrasound is not usually provided in a satisfactory manner. The aim of the course is to provide the technical basics and standards for the use of ultrasound in urology by image and video examples. After the course the delegate should know the ideal settings for reliable and informative urological ultrasound as well as the normal and pathological findings.

Image and video demonstrations:

- Covering urological organs: kidney, ureter, bladder, testis and penis
- Standard patient positioning
- Best choice of transducers and settings
- Standard operating procedures (SOP)
- Normal, benign and malignant pathologic findings
- Interventional and intraoperative ultrasound
- New technologies

17:00 - 19:00

Technical basics, tuning and reporting of ultrasound exams
M. Ritter, Bonn (DE)

17:00 - 19:00

Ultrasound of the bladder
T. Loch, Flensburg (DE)

17:00 - 19:00

Ultrasound of the testis
A.B. Galosi, Ancona (IT)

17:00 - 19:00

Ultrasound of the kidney and ureter
M. Ritter, Bonn (DE)

17:00 - 19:00

Ultrasound of the penis
A.B. Galosi, Ancona (IT)

17:00 - 19:00

New technologies
T. Loch, Flensburg (DE)

Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications

ESU Course 05

Friday 9 July
08:00 - 10:00

Location Zoom 1

Chair F.J. Burgos Revilla, Madrid (ES)

Learning objectives

Kidney transplantation (KT) is an essential part of urology. The aim of the course is to show a complete vision of KT from organ procurement to the resolution of postoperative and late potential complications developed after kidney implantation.

The content of this travel along transplantation process includes:

- Medical and surgical recipient evaluation
- Deceased donor procurement techniques depending on different scenarios: Brain death or non-heart-beating donor
- Approaches to live donor nephrectomy: Laparoscopic (conventional, mini-lap, single-port, robotic, transvaginal) or open
- Renal implantation options: Open or robot-assisted laparoscopy
- Diagnosis and treatment of complications associated to KT

Interaction between assistants and faculty is established in basis to clinical cases open to discussion. The focus will be on tips and tricks and surgical details after video sessions.

The faculty is comprised of Prof Burgos-Revilla, Prof Figueiredo (both past chairman of ESTU) and Prof Breda (elected chairman of ERUS). All of them are working in EAU certificated Host Center for Fellowship in KT.

08:00 - 10:00

Presentation of the course: Relevance of kidney transplant related techniques in different fields of urology

F.J. Burgos Revilla, Madrid (ES)

08:00 - 10:00

Surgical aspects of deceased donor nephrectomy in different scenarios: Brain-death / non heart beating donor

A.J. Figueiredo, Coimbra (PT)

08:00 - 10:00

Living donor nephrectomy: Technical alternatives

A. Breda, Barcelona (ES)

08:00 - 10:00

Tips, tricks, controversies and clinical cases for open discussion

F.J. Burgos Revilla, Madrid (ES)

08:00 - 10:00

Renal transplantation: Surgical options:

08:00 - 10:00

Conventional open approach

A.J. Figueiredo, Coimbra (PT)

08:00 - 10:00

Laparoscopic robotic-assisted:

A. Breda, Barcelona (ES)

08:00 - 10:00

Tips, tricks, controversies and difficult cases for open discussion

F.J. Burgos Revilla, Madrid (ES)

08:00 - 10:00

How to diagnose and manage complications following renal transplantation

F.J. Burgos Revilla, Madrid (ES)

08:00 - 10:00

Clinical cases for open discussion

F.J. Burgos Revilla, Madrid (ES)

Game changing session 1

Live from the studio: Game changing session

Friday 9 July 10:15 - 10:30	Location Chairs	Virtual room 1 C.H. Bangma, Rotterdam (NL) J. Walz, Marseille (FR)
10:15 - 10:30	Abiraterone acetate plus prednisone added to androgen deprivation therapy and docetaxel in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): detailed analysis of radiographic progression-free survival in the PEACE-1 phase 3 trial	
10:15 - 10:23	Presenter K. Fizazi, Villejuif (FR)	
10:23 - 10:30	Discussant A. Heidenreich, Cologne (DE)	

Game changing session 2

Live from the studio: Game changing session

Friday 9 July 10:00 - 10:30	Location	Virtual Room 3
	Chairs	C.R. Chapple, Sheffield (GB) J-N.L. Cornu, Rouen (FR) F. Cruz, Porto (PT)
10:00 - 10:15	Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): A randomised, double-blind, placebo-controlled, 2-year, phase 3b trial	
10:00 - 10:08	Presenter	G. Wittert, Adelaide (AU)
10:08 - 10:15	Discussant	M. Albersen, Leuven (BE)
10:15 - 10:30	Analysis of Real-World Healthcare data of outcomes of interventional procedures in BPH	
10:15 - 10:23	Presenter	S.A. Kaplan, New York (US)
10:23 - 10:30	Discussant	C. Gratzke, Freiburg (DE)

Patient engagement

Poster Session 07

Friday 9 July
10:00 - 11:00

Location Virtual Room 8

Chairs P. Cornford, Liverpool (GB)
F. Hervé, Bruxelles (BE)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

In this session clinician have the opportunity to learn from patients involved in their own care and for patient groups to learn from each other
Covering patient issues, patient reported outcomes and the effects of the Covid-19 pandemic this session will help clinicians understand the patient experience and design better clinical care pathways plus research trial using this knowledge

10:00 - 10:01

Introduction

10:01 - 10:09

Catheter, neobladder

P0178

I should catheterise myself, I'll never manage it - Specialised nursing proves the opposite
To be confirmed

P0179

Catheterisable pouch: A new and better life for those affected
To be confirmed

P0180

Quality of life in patients with orthotopic neobladder
L. Magenta, Milan (IT)

10:04 - 10:09

Discussion

10:09 - 10:23

COVID-19

P0181

Cancer care during COVID-19: Data from 157 patient organisations
A. Filicevas, Brussels (BE)

P0182

Lessons learned with remote research among older adults during COVID-19, a qualitative reflection
R.E. Gutschon, Hamilton (CA)

P0183

Impact of the COVID-19 pandemic on urologic care delivery in the United States
M.R. Cooperberg, San Francisco (US)

P0184

Developing a video information resource to inform and reassure patients through the COVID-19 pandemic
J. Withington, London (GB)

P0185

Are patients' fears of catching COVID-19 during an emergency hospital admission with an acute urological problem justified? A UK epicentre experience
O. Gbolahan, Harrow (GB)

P0186	Characteristics and 30-day outcomes for urological cancer patients operated on during the COVID-19 pandemic C. Gao, Ashford (GB)
P0187	Adapting the haematuria clinic during the Covid-19 pandemic M. Moghul, St. Albans (GB)
P0188	Urology diseases in times of the COVID-19 pandemic: Loss of chance of recovery in patients in Tunisian tertiary hospital S. Sallami, Nabeul (TN)
P0189	Influence of COVID-19 pandemic on mental health of urologic patients G. Maiolino, Perugia (IT)
10:18 - 10:23	Discussion
10:23 - 10:33	Engagement/communication, frailty, awareness
P0190	Patient engagement interventions not only improve health but survival in patients with cancer: A scoping review S. Barello, Rome (IT)
P0191	Physician–patient communication: Examples of best practice to improve patient experience JTN Nowak, Brooklyn (US)
P0192	Optimising emergency urological care in the older patient – impact of a dedicated Perioperative care for Older People undergoing Surgery (POPS) platform M.W. Yao, London (GB)
P0193	Geriatric assessment using G8 in patients who underwent major uro-oncologic surgery to predict postoperative complication: Comparison with Charlson comorbidity index To be confirmed
P0194	What's about doctors' awareness of genital lichen sclerosis? A national survey L. Di Marco, Trieste (IT)
10:28 - 10:33	Discussion
10:33 - 10:44	Major surgery, cancer
P0195	Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures L. Haeuser, Herne (DE)
P0196	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 41 countries R. Giles, Duivendrecht (NL)
P0197	Are reported sexual and urinary functioning in clinical studies an accurate representation of the burden after prostate cancer treatment: Results from the EUPROMS study S. Remmers, Rotterdam (NL)
P0198	Accrual of African American men into prostate cancer clinical trials: Collaborations to incorporate patient perspectives T. Farrington, Quincy (US)
P0199	Patient perspective on serving on the steering committee of the AURORAX-0087A trial for non-metastatic clear cell renal cell carcinoma R. Giles, Duivendrecht (NL)
P0200	Ten years' experience of peer support by specifically trained prostate cancer patients V. Griesser, Châtel-st-denis (CH)

P0201	Establishment of a national cancer specific outcomes registry and initial data D.J. Galvin, Dublin 4 (IE)
10:39 - 10:44	Discussion
10:44 - 10:54	Care pathway
P0202	Our initial experience with running a urological-oncology Multi-Disciplinary Team (MDT) clinic - A new model of care A. Lee, Singapore (SG)
P0203	Safety and efficacy of a well organised one-stop prostate investigation clinic A. Laoye, Doncaster (GB)
P0204	Patient quality criteria for a multidisciplinary integrated care pathway for von Hippel-Lindau syndrome R. Giles, Duivendrecht (NL)
P0205	Experience-Based Co-Design (EBCD): Designing the haematuria service of the future J. Withington, London (GB)
P0206	Remote consultations: Experiences of patients with prostate cancer R. Leszczynski, London (GB)
10:49 - 10:54	Discussion
10:54 - 10:59	Conclusion

Nightmare session: PCa early detection

Live from the studio: Plenary Session 01

Friday 9 July
10:30 - 12:00

Location Virtual room 1

Chairs C.H. Bangma, Rotterdam (NL)
B. Leigh, London (GB)
J. Walz, Marseille (FR)

Learning objectives

This special "nightmare" session features three challenging case presentations on the subject of the early detection of PCa. The cases are then discussed and furthermore cross-examined by a medical lawyer. Audience members can weigh in with their questions and proposed solutions. Participants will be challenged to think of the ethical and legal ramifications of their choices, in addition to the medical consequences of treatment.

10:30 - 11:00

Can we completely rely on MRI?

Moderator S. Joniau, Leuven (BE)

10:30 - 10:35

Case presentation

R.C.N. Van Den Bergh, Nieuwegein (NL)

10:35 - 10:40

Case discussion

H.U. Ahmed, London (GB)

10:40 - 10:55

Lawyer Cross-examination

B. Leigh, London (GB)

10:55 - 11:00

Case solution and audience questions

S. Joniau, Leuven (BE)

11:00 - 11:30

What are the best precautions for a safe biopsy?

Moderator A. Pilatz, Giessen (DE)

11:00 - 11:05

Case presentation

I. Heidegger, Innsbruck (AT)

11:05 - 11:10

Case discussion

C. Stief, Munich (DE)

11:10 - 11:25

Lawyer Cross-examination

B. Leigh, London (GB)

11:25 - 11:30

Case solution and audience questions

A. Pilatz, Giessen (DE)

11:30 - 12:00

How to deal with low-grade cancers?

Moderator A. Villers, Lille (FR)

11:30 - 11:35

Case presentation

A. Stabile, Milan (IT)

11:35 - 11:40

Case discussion

A. De La Taille, Créteil (FR)

11:40 - 11:55

Lawyer Cross-examination

B. Leigh, London (GB)

11:55 - 12:00

Case solution and audience questions

A. Villers, Lille (FR)

Optimal management of incontinence in the elderly patient

Live from the studio: Plenary Session 02

Friday 9 July
10:30 - 12:00

Location Virtual Room 3

Chairs C.R. Chapple, Sheffield (GB)
J-N.L. Cornu, Rouen (FR)
F. Cruz, Porto (PT)

Learning objectives

With ageing populations in Europe, special attention should be given to elderly urology patients. This session uses state-of-the-art lectures and case-based debates to highlight some of the challenges functional urologists face with elderly patients, and what their experiences were with challenging cases. Also featured is a statement on the latest EAU Guidelines on mesh use.

10:30 - 10:40

Société Internationale d'Urologie (SIU) Urgency urinary incontinence (UUI): Improving adherence to medication in elderly
R. Kumar, New Delhi (IN)

10:40 - 10:45

Drug interactions to be aware of when using pharmacotherapy for UUI
M.C. Michel, Mainz (DE)

10:45 - 10:50

Discussion

10:50 - 11:15

Case-based debate The artificial urinary sphincter (AUS) in my elderly patient is not working anymore

10:50 - 10:55

Case presentation
E. Chartier-Kastler, Paris (FR)

10:55 - 11:00

Replace the cuff of the AUS
A. Kretschmer, Munich (DE)

11:00 - 11:05

Remove the cuff of the AUS and place a sling
J.P.F.A. Heesakkers, Maastricht (NL)

11:05 - 11:15

Discussion

11:15 - 11:22

Guideline statement Is mesh for incontinence the same as mesh for prolapse?
C.R. Chapple, Sheffield (GB)

11:22 - 11:25

Discussion

11:25 - 11:50

Case-based debate Stress urinary incontinence (SUI) in elderly female patients

11:25 - 11:30

Case presentation
T. Hüscher, Mainz (DE)

11:30 - 11:35

Mid-urethral sling
N. Thiruchelvam, Cambridge (GB)

11:35 - 11:40

Injection of bulking agent
A. Kuhn, Bern (CH)

11:40 - 11:50

Discussion

11:50 - 12:00

Treatment goals and evaluation tools: The patient perspective
M.L. Van Poelgeest-Pomfret, Oegstgeest (NL)

Urolithiasis: Research, new technology and stents

Poster Session 08

Friday 9 July
11:00 - 12:00

Location Virtual Room 7

Chairs J. Halbritter, Leipzig (DE)
A. Papatsoris, Athens (GR)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

What's coming up in urolithiasis: new aspects on basic research, new technology and stents

11:00 - 11:01

Introduction

P0207	Examining the impact of different properties of ureteral access sheaths in reducing insertion force during retrograde intrarenal surgery: An in vitro study S. Fukui, Hirakata (JP)
P0208	Assessment of intrarenal pressures in a porcine kidney model to guide equipment selection for retrograde intrarenal surgery E. MacCraith, Dublin (IE)
P0209	Computational fluid dynamic modeling of renal stones in the renal calyx M. Komeya, Yokohama (JP)
P0210	Novel biocompatible adhesive to remove stone dust: Usability trial in a kidney model C.M. Rosenbaum, Hamburg (DE)
P0211	In vitro evaluation of a prototype Holmium laser with pulse modulation B. Yang, Oxford (GB)
P0212	An in vitro analysis of holmium: YAG and thulium fiber laser ablation rates M. Basulto-Martínez, Merida (MX)
P0213	SuperPulsed Thulium-fiber laser lithotripsy: An in vitro comparison of 200 µm and 150 µm laser fibers M. Taratkin, Moscow (RU)
11:08 - 11:14	Discussion
P0214	Preference and perception of treatment choices between radiologists and urologists for treatment for urgent urinary obstruction – nephrostomy versus retrograde ureteric stent: European survey from YAU and ESUT Endourology groups A. Pietropaolo, Southampton (GB)

P0215	Randomized, prospective study to compare the efficacy and safety of complete intraureteral stent placement versus conventional stent placement in relieving ureteral stent related symptoms A.K. Chawla, Manipal (IN)
P0216	Preoperative independent risk factors in predicting ureteral stent placement failure of obstructed ureterolithiasis patients H. Zhang, Shanghai (CN)
P0217	An innovative suture stent significantly reduces stent-related symptoms compared to conventional double J. A prospective randomized trial A. Bosio, Torino (IT)
P0218	The efficacy and the safety of the J Fil Stent in the post operative endoscopic procedures: The experience on 237 cases F. De Marco, Rocca di Papa (IT)
P0219	Prospective single-centre randomised control trial of magnetic ureteric stents versus conventional ureteric stents R. Lyons, Cork (IE)
11:20 - 11:26	Discussion
P0220	Proteomic analysis of stone matrix: A window to the pathogenesis of urolithiasis Y. Yang, Wuhan (CN)
P0221	CD4+, CD8+ T lymphocytes is related to OPN, THP expression in the kidney during the formation of kidney stones caused by nanobacteria
P0222	Fatty acid binding protein 4 attenuates macrophage and tubular cells crystal phagocytosis to drive renal calcium oxalate stone development K. Taguchi, Nagoya (JP)
P0223	Metformin elicits dual therapeutic effects on renal inflammatory and oxidative injury in calcium oxalate nephrocalcinosis C. Duan, Wuhan (CN)
P0224	Identification of aberrant glycosylation of osteopontin on urinary stone formation G. Anan, Hirosaki (JP)
P0225	AhR activation attenuates calcium oxalate nephrocalcinosis-mediated kidney injury and crystals deposition by promoting M2 macrophage polarization L. Haoran, Wuhan (CN)
P0226	Ceftriaxone-induced disruption of oxalate homeostasis is associated with total fecal microbiota oxalate-degrading activity but not with the numbers of oxalate-degrading bacteria in the experimental rats N. Stepanova, Kyiv (UA)
P0228	Urolithiasis and renal endothelial dysfunction. Experimental hyperoxaluria rat model J. Saenz Medina, Madrid (ES)
P0229	Sulforaphane elicits a dual therapeutic effects on renal inflammatory injury and crystal deposition in calcium oxalate nephrocalcinosis L. Haoran, Wuhan (CN)

Scientific Programme - EAU21 Virtual

P0230	Biased calcium-sensing receptor signalling in the pathogenesis of kidney stone disease S. Howles, High Wycombe (GB)
P0231	The activation of ROS/NFκB/MMP-9 pathway promotes calcium induced kidney crystal deposition Y. Wu, Wuhan (CN)
P0232	1,25-(OH)₂D₃ induces renal fibroblasts osteogenic-like transformation and contributes to Randall's plaque initiation P. Zhou, Wuhan (CN)
P0233	The effect of hypertension on the recovery of renal dysfunction following reversal of unilateral ureteric obstruction F. Hammad, Amman (JO)
11:40 - 11:46	Discussion
P0234	Automatic recognition of urinary stones: First results from per-operative endoscopic digital images of pure and mixed stones in-situ V. Estrade, Angoulême Cedex 9 (FR)
P0235	Application of deep learning convolutional neural network in prediction of stone location, skin to stone distance and composition in renal lithiasis: A single center pilot study S. Reddy, ()
P0236	Routine urinary biochemistry does not accurately predict stone type nor recurrence in kidney stone formers: A multi-centre, multi-model, externally validated machine-learning study R. Geraghty, Newcastle-upon-Tyne (GB)
P0237	The correlation between plasma ucMGP level and recurrence of kidney stones Q. Wang, Wuhan (CN)
11:50 - 11:56	Discussion
11:56 - 12:00	Summary

Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications

ESU Course 06

Friday 9 July
11:00 - 13:00

Location Zoom 1

Chair O. Traxer, Paris (FR)

Learning objectives

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium:YAG/TmFiber lasers.

At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions.

- To learn about equipment: disposable, Endoscopes and Laser.
- To learn about technique and indications..
- To learn about Laser and Strictures
- To learn how to use an Holmium and/or TmFiber Laser.
- To learn tips and tricks for special circumstances.
- To learn about complications of RIRS and how to prevent/solve them

11:00 - 13:00

Introduction

O. Traxer, Paris (FR)

11:00 - 13:00

Indications of RIRS in 2021

P.J.S. Osther, Fredericia (DK)

11:00 - 13:00

RIRS and endoscopes, reusable and single use

E. Emiliani, Barcelona (ES)

11:00 - 13:00

RIRS and disposable equipment: When and why

S. Doizi, Paris (FR)

11:00 - 13:00

RIRS and Lasers: Holmium: YAG vs TmFiber

O. Traxer, Paris (FR)

11:00 - 13:00

RIRS and irrigation

P.J.S. Osther, Fredericia (DK)

11:00 - 13:00

RIRS and special situations

E. Emiliani, Barcelona (ES)

11:00 - 13:00

Conclusions

O. Traxer, Paris (FR)

Prostate cancer

Patient information Session

Friday 9 July
11:30 - 12:30

Location Virtual Room 10

Chair E-G. Carl, Tornesch (DE)

Learning objectives

- Learn about the impact of PCa treatment through self-reported PRO data of fellow patients collected outside a clinical trial setting
- Learn about the programme specifically designed to support patient on Androgen Deprivation Therapy
- Learn why Early Detection and Active Surveillance matter
- Learn how individualised information about the risk of incontinence after prostatectomy could help patients in shared decision-making

11:30 - 11:42	Predictive individual risks of urinary incontinence after prostatectomy and impact on shared decision making C.N. Tillier, Amsterdam (NL)
11:42 - 11:45	Discussion
11:45 - 11:57	EUPROMS Study A. Deschamps, Antwerp (BE)
11:57 - 12:00	Discussion
12:00 - 12:12	ADT Educational Programme Canada/Europe R. Wassersug, Vancouver (CA)
12:12 - 12:15	Discussion L. Fleure, London (GB)
12:15 - 12:27	The Implications of Early Detection and AS E. Briers, Hasselt (BE)
12:27 - 12:30	Discussion

Techniques to evolve radical prostatectomy

Video Session 01

Friday 9 July
12:00 - 12:45

Location Virtual Room 2

Chairs J.W. Collins, London (GB)

D. Tilki, Hamburg (DE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

12:00 - 12:02

Introduction

V01

Modified apical dissection and lateral prostatic fascia preservation: Preliminary analysis of the reproducibility of the novel technique

B.M.C. Rocco, Modena (IT)

V02

Robot-assisted single knot-single running suture vesico-urethral anastomosis with posterior musculofascial reconstruction

C. Gerolimetto, tezze sul brenta (IT)

V03

Retzius-sparing robot assisted radical prostatectomy (rs-rarp) made easy: A step-by-step guide

P. Umari, Duino-Aurisina (TS) (IT)

12:34 - 12:37

Conclusion

Progress in sacrocolpopexy

Video Session 02

Friday 9 July
12:00 - 12:45

Location Virtual Room 4

Chairs M. Blaganje, Ljubljana (SI)
E. Costantini, Perugia (IT)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

12:00 - 12:02

Introduction

V04

Day hospital laparoscopic sacrocolpopexy. A case series

O. Blezien, Nice (FR)

V05

Laparoscopic colposacropepy: Technical considerations

M.C. Conde Redondo, Valladolid (ES)

V06

Treatment of bladder prolaps by sacrocolpopexy with jaimy robotic system

J. Lakssir, Rabat (MA)

12:35 - 12:38

Conclusion

Innovative training and novel technologies

Video Session 03

Friday 9 July
12:00 - 12:45

Location Virtual Room 5

Chairs M. Taratkin, Moscow (RU)
D. Veneziano, Reggio Calabria (IT)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

12:00 - 12:02

Introduction

V07

The tomato model: The cheapest and craziest way of learning how to puncture a kidney

G. Mantica, Genoa (IT)

V08

Development of novel transurethral surgery system to facilitate two-arm operation-preclinical study

Y. Komai, Tokyo (JP)

V09

Is real-time detection based on probability map of bladder tumor possible in clinic cystoscopy using deep learning?

A. Ikeda, Tsukuba (JP)

12:33 - 12:36

Conclusion

Urolithiasis: Epidemiology, imaging and conservative management

Poster Session 09

Friday 9 July
12:00 - 13:00

Location Virtual Room 8

Chairs L.B. Dragoş, Timișoara (RO)
G. Giusti, Milan (IT)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

New aspects on epidemiology, imaging, active and conservative management of urinary stones in the time of covid-19 pandemic

12:00 - 12:01

Introduction

P0238 Association between Dietary Inflammatory Index and kidney stones in US adults: Data from the NHANES 2007-2016
C. Zhang, ChengDu (CN)

P0239 Risk of metabolic syndrome in kidney stone formers: A comparative cohort study
R. Geraghty, Newcastle-upon-Tyne (GB)

P0240 Evidence for the genetic influence of waist-hip ratio on risk of kidney stone disease
C. Lovegrove, Oxfordshire (GB)

P0241 Urolithiasis prevalence in the Russian Federation: Analysis of trends over a 15-year period
M. Prosyannikov, Zhukovskiy (RU)

P0242 The new chronic lithiasic disease management and risk classification model, based on a Kaiser Permanente Pyramid (KPP) design. The 3-year results
F. Gómez Palomo, Valencia (ES)

12:06 - 12:12

Discussion

P0243 Lockdown is associated with a higher complication rate from ureteric stone disease: Outcomes from four acute hospitals in Northern Ireland
C. McCann, Craigavon (GB)

P0244 “Pseudo-renal colic” – A neglected common entity with significant impact on health service providers’ resources during both pre- and peri COVID-19 pandemic
S. Mukherjee, London (GB)

P0245 The real impact of the delay in presenting to the emergency department with acute renal colic: which patients are at risk?
S. Tappero, Genoa (IT)

P0246	Influence of the COVID-19 outbreak on urgent and elective surgical management of urolithiasis: A global perspective A. Artiles Medina, Madrid (ES)
P0247	Management of acute ureteric colic in a large tertiary centre during the initial COVID-19 pandemic - How did our practice change? I.G. Rizvi, Newcastle upon Tyne (GB)
P0248	Emergency Ureteroscopy (URS) in the COVID-era: Consequences and challenges C.T. Berridge, Leicester (GB)
P0249	The buscopan study; A randomized controlled non-inferiority trial of a continuous butylscopolamine infusion versus placebo in patients with a renal colic insufficiently responding to oral non-steroidal anti-inflammatory drugs K.T. Buddingh, Den Haag (NL)
12:19 - 12:25	Discussion
P0250	An efficiency decision-tree for treating urolithiasis up to 3 cm based on a cost-effective analysis A. Bernal Gomez, Valencia (ES)
P0251	Optimising pre-operative imaging-surgery intervals for stones I.N.C Chibuzo, Ibadan (NG)
P0252	Defining the optimal window setting of non-contrast computerized tomography for colon identification prior percutaneous nephrolithotomy Z. Savin, Tela Aviv (IL)
P0253	Predicting stone composition by dual energy computed tomography before extra corporeal shock wave lithotripsy and comparing it with stone analysis V. Sharma, New Delhi (IN)
P0254	Does operator-controlled imaging reduce fluoroscopy time during flexible ureterorenoscopy? M.M.E.L. Henderickx, Wilrijk (BE)
P0255	Correlation between exposure of endourologists and patient exposure during fluoroscopy-guided endourological procedures L. Tzelves, Athens (GR)
P0256	An analysis on the predictors of stone related events in asymptomatic untreated intra-renal calculi K. Daly, Malahide (IE)
P0257	Mirabegron, tamsulosin monotherapy versus combination in treatment of distal ureteric stone. A randomized controlled clinical trial M.M. Seleem, Zagazig (EG)
P0258	Spontaneous upper urinary tract rupture caused by ureteric stones: clinical characteristics and external validation of a radiological classification system L. Boeri, Milan (IT)
P0259	Predictive factors and the role of pre-operative imaging in reducing the rate of negative ureteroscopy L. Hemsworth, Longstanton (GB)

P0260	Evaluation and comparison of scoring systems for predicting stone-free status after flexible ureteroscopy for renal and ureteral stones M.H. Saadi, Rades (TN)
P0261	Clinically insignificant residual fragment perception among endourologists after percutaneous nephrolithotomy: A world-wide survey by EAU- YAU Endourology and Urolithiasis Working Group T. Tailly, Ghent (BE)
12:37 - 12:43	Discussion
P0262	Variations in the mineral content of bottled still water across Europe: Comparison of 182 brands across 10 countries S.J.M. Stoots, Amsterdam (NL)
P0263	Safety of Dutch tap water for kidney stone patients: Comparison of the 179 National production sites S.J.M. Stoots, Amsterdam (NL)
P0266	Over-the-counter alkali agents to raise urine ph and citrate excretion: A randomized crossover study in healthy adults G.M. Kamphuis, Amsterdam (NL)
12:49 - 12:55	Discussion
12:55 - 13:00	Expert summary N. Bernardo, Buenos Aires (AR)

Bladder cancer

Patient Information Session

Friday 9 July
12:30 - 13:30

Location Virtual Room 9

Chairs S. Demkiw, Melbourne (AU)
L. Makaroff, Chinnor (GB)

Learning objectives

- To learn how to have meaningful patient involvement in guideline development and implementation
- To understand the main challenges that patients experience in the bladder cancer care pathway
- To understand how a multi-disciplinary team can improve cancer care
- To learn how to decrease pain perception and anxiety during cystoscopy
- To learn how to be involved in a worldwide study on the bladder cancer patient experience

12:30 - 12:40

EVOLVE - agreeing priority areas for patient involvement within guideline development

J. Bjorkqvist, Aberdeen (GB)
L. Makaroff, Chinnor (GB)

12:40 - 12:42

Discussion

12:42 - 12:52

Exemplar: Striving for exceptional services for people affected by bladder cancer

A. Randall, Chinnor (GB)

12:52 - 12:54

Discussion

12:54 - 13:04

Piloting multi-disciplinary team (MDT) clinics for urothelial cancer

L.S. Lee, Singapore (SG)

13:04 - 13:06

Discussion

13:06 - 13:16

Does listening to music improve pain perception and anxiety in patients undergoing cystoscopy: A meta-analysis

F. Dechao, Chengdu (CN)

13:16 - 13:18

Discussion

13:18 - 13:28

Understanding bladder cancer patient experiences study

A. Filicevas, Brussels (BE)

13:28 - 13:30

Discussion

Urolithiasis: Endourology and ESWL

Poster Session 10

Friday 9 July
13:00 - 14:00

Location Virtual Room 7

Chairs D. Enikeev, Moscow (RU)
O. Wiseman, Cambridge (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

From ESWL, URS and PCNL to laser application: News on clinical management of urinary stones

13:00 - 13:01

Introduction

P0268 **Using artificial intelligence to identify stones on SWL intra-operative fluoroscopic images**
R.G.N. Seltzer, Tucson (US)

P0269 **Efficiency analysis of an increase of focal shock wave energy through an expanded number of shockwaves per session for treating urinary stones up to 2 cm with extracorporeal shockwave lithotripsy**
A. Budía Alba, Valencia (ES)

P0270 **A randomized study to investigate the effect of focal zone size on treatment outcomes in patients undergoing extracorporeal shockwave lithotripsy to renal calculi**
C.F.A. Ng, Hong Kong (HK)

P0271 **Is the increase in the number of shock waves per session more effective than standard treatment in extracorporeal shockwave lithotripsy? A prospective and comparative study**
A. Budía Alba, Valencia (ES)

P0272 **ESWL for lower calyx stones. Results, complications and analysis of the factors associated with treatment success. Development of a predictive model**
M. Mata Alcaraz, Madrid (ES)

13:06 - 13:12

Discussion

P0273 **A comparison among RIRS and MiniPerc for renal stones between 1-2 cm: A randomized controlled trial**
L. Berti, Busto Arsizio (IT)

P0274 **TISU (Therapeutic Intervention for Stones in the Ureter): ESWL versus Ureteroscopy, a multicentre RCT**
R. Dasgupta, London (GB)

P0275	3D virtual renal modeling to improve the learning curve of percutaneous nephrolithotripsy M.G. Giampaoli, Bologna (IT)
P0276	Flank free modified supine versus prone ultra-mini-percutaneous nephrolithotomy in treatment of medium-sized renal pelvic stone a randomized clinical trial M.M. Seleem, Zagazig (EG)
P0277	Xray and US free calix puncture before PCNL (XUF PCNL). Comparison with standard Xray/US guided puncture M. Maltagliati, Modena (IT)
P0278	Does skeletal muscle quality impact the outcomes of percutaneous nephrolithotomy? Y. Wu, Wuhan (CN)
P0279	Stone clearance using the EMS Swiss LithoClast® Trilogy: Results of the European multicentre prospective study in comparison to the BAUS national PCNL outcomes on behalf of European Society of UroTechnology N. Thakare, Cambridge (GB)
P0280	Mini percutaneous nephrolithotomy versus standard percutaneous nephrolithotomy in the management of 10-30mm renal stones. A randomized clinical trial M. Elgamal, Mansoura (EG)
P0281	Cost analysis and perioperative outcomes between mini-percutaneous nephrolithotomy with vacuum cleaner effect or with a vacuum-assisted access sheath L. Boeri, Milan (IT)
P0282	Mini PCNL versus standard PCNL in the treatment of renal stones ≥ 20 mm: Safety and advantages A. Sakly, Monastir (TN)
13:22 - 13:28	Discussion
P0283	Morbidity and mortality after Percutaneous Nephrolithotomy (PCNL) in patients with urolithiasis: Analysis of 16,201 patients from a nationwide German health insurance database B. Becker, Hamburg (DE)
P0284	Preoperative percutaneous nephrostomy before flexible ureteroscopy for impacted ureteral stone is effective on stone-free rate and ureteral injury G. Anan, Hirosaki (JP)
P0285	The use of ureteral access sheath does not reduce the rate of infectious complications after flexible ureteroscopy and Ho:YAG laser lithotripsy for renal stones E. Ventimiglia, Milan (IT)
P0286	Multi-aspect analysis of ureteral access sheath usage in retrograde intrarenal surgery: Results of propensity score matching study O. Ozman, Istanbul (TR)

P0287	A multicentre based critical analysis of laser settings during intrarenal laser lithotripsy S. Guven, Konya (TR)
P0288	Minimally invasive percutaneous nephrolithotomy with SuperPulsed Thulium-fiber laser A. Shpikina, Moscow (RU)
P0289	60watt superpulse thulium fiber laser in retrograde intrarenal surgery-aiming towards faster dust G. Soundarya , Hyderabad (IN)
P0290	Simultaneous Bilateral Endoscopic Surgery (SBES): Is it ready for prime time? M.P. Pavia, Milan (IT)
P0291	Uteroscopy-assisted versus conventional ultrasound-guided renal access for miniaturised endoscopic combined intrarenal surgery: A multicentre comparative study K. Taguchi, Nagoya (JP)
P0292	Large ureterolithiasis: Ureteroscopic lithotripsy or robotic ureterolithotomy? W-S. Hu, Taichung (TW)
13:38 - 13:44	Discussion
P0293	Uteroscopy (URS) video consensus: A simple and effective way to improve awareness of patients undergoing URS F. Tedesco, ()
P0294	Infective complications following ureteroscopy for stone disease: An analysis of nhs hospital episode statistics in England R. Veeratterapillay, Newcastle upon Tyne (GB)
P0295	Sepsis after ureteroscopy: Development of a predictive model and prospective validation D.E. Díaz Pérez, Madrid (ES)
P0296	Post-ureteroscopy febrile urinary tract infections are linked to pre-operative stent dwell time: Results from three European endourology centres R. Geraghty, Newcastle-upon-Tyne (GB)
P0297	Percutaneous nephrolithotomy can reduce the incidence of sepsis compared with flexible ureteroscopy in treating solitary proximal ureteral stone patients with positive urine culture Q-D. Xia, Wuhan (CN)
13:49 - 13:55	Discussion
13:55 - 14:00	Expert summary M. Sofer, Tel-Aviv (IL)

Kidney cancer

Patient Information Session

Friday 9 July
13:30 - 14:30

Location Virtual Room 10

Chairs S. MacLennan, Aberdeen (GB)
A. Alexandridou, ()

Learning objectives

The objective of this session is to explore obstacles experienced by kidney cancer patients: financial toxicity, psychosocial distress, and lack of disease awareness. Furthermore, does research reflect the needs of actual kidney cancer patients? Two examples of patient-driven research will explore that area, and the final talk will answer the question of how to balance quality of life with kidney cancer disease management.

13:30 - 13:35

Welcome and introduction

13:35 - 13:45

COVID-19 and financial toxicity in patients with renal cell carcinoma
D. Battle, Alexandria (US)

13:45 - 13:47

Discussion

13:47 - 13:57

World Kidney Cancer Day 2021: Initial results
A. Wilson, Duivendrecht (NL)

13:57 - 13:59

Discussion

13:59 - 14:04

Recipient of the Cecile and Ken Youner IKCC Scholarship for 2020: Working with RCC xenografts
A. Bessera, Sao Paulo (BR)

14:04 - 14:06

Discussion

14:06 - 14:16

RCC Brain Metastasis interdisciplinary consensus management survey
E. Hasanov, Houston (US)

14:16 - 14:18

Discussion

14:18 - 14:28

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
J. Aragon-Ching, Fairfax (US)

14:28 - 14:30

Discussion

Update on prostate cancer screening 2021

Live from the studio: Special Session

Friday 9 July
13:45 - 14:45

Location Virtual Room 2

Chairs
P. Albers, Düsseldorf (DE)
S. Carlsson, New York (US)
M.J. Roobol, Rotterdam (NL)

Learning objectives

Population-based screening for prostate cancer is in debate in spite of undisputable and significant reduction in cancer-specific mortality. In order to minimize harms of screening by overdiagnosis and overtreatment, risk-adapted screening strategies have been suggested already in many national guidelines. However, level I evidence is missing and, hence, this special session will present the current and ongoing randomized trials in this setting. Every trial tests a different risk-adapted strategy and experts in the field will discuss design and early results of these studies.

13:45 - 13:50

Welcome and introduction

P. Albers, Düsseldorf (DE)
S. Carlsson, New York (US)
M.J. Roobol, Rotterdam (NL)

13:50 - 13:55

2021 algorithm

M.J. Roobol, Rotterdam (NL)

13:55 - 14:00

Risk-adapted screening with age and baseline-PSA: PROBASE trial

C. Arsov, Düsseldorf (DE)

14:00 - 14:05

Risk-adapted screening with 4K and MRI: PROSCREEN Trial

A.P. Auvinen, Tampere (FI)

14:05 - 14:10

Risk-adapted screening with genomics and MRI: STHLM3 MR Phase 2 Trial

T. Nordström, Stockholm (SE)

14:10 - 14:15

Risk-adapted screening with SNPs: PROCARIS Trial

J. Fredsoe, Aarhus (DK)

14:15 - 14:20

Risk-adapted screening with MRI only: MVP trial

R. Nam, Toronto (CA)

14:20 - 14:40

Panel discussion

Panel

C. Arsov, Düsseldorf (DE)
A.P. Auvinen, Tampere (FI)
J. Fredsoe, Aarhus (DK)
R. Nam, Toronto (CA)
T. Nordström, Stockholm (SE)

14:40 - 14:45

Expert Summary and conclusion

S. Carlsson, New York (US)

Guideline Session I: Urethral strictures and female UI

Thematic Session 01

Friday 9 July
13:45 - 14:45

Location Virtual Room 4

Chairs
T.J. Greenwell, London (GB)
C. Harding, Newcastle upon Tyne (GB)
J. N'Dow, Aberdeen (GB)

Learning objectives

Following the Management of Short Bulbar Strictures session you should be able to fully counsel patients regarding the benefits and harms of endoscopic and open treatment. You should be able to determine which treatment is best for which stricture and which patient. You should also be able to understand the basics of these procedures.

13:45 - 14:06

Debate Short bulbar stricture: What are we talking about?

Moderators
K. Dimitropoulos, Aberdeen (GB)
N.I. Osman, Sheffield (GB)

13:45 - 13:46

Introduction

K. Dimitropoulos, Aberdeen (GB)

13:46 - 13:50

Flash presentation Endoluminal treatment is the way to go!

M. Waterloos, Ghent (BE)

13:50 - 13:54

Flash presentation Anastomotic repair is the way to go!

F. Campos Juanatey, Santander (ES)

13:54 - 13:58

Flash presentation Free graft urethroplasty is the way to go!

S. Riechardt, Hamburg (DE)

13:58 - 14:06

Discussion

N.I. Osman, Sheffield (GB)

14:06 - 14:22

Debate Mixed urinary incontinence: What to treat first?

Moderator
G.R. Kasyan, Moscow (RU)

14:06 - 14:10

Flash presentation Stress urinary incontinence

T. Tarcan, Istanbul (TR)

14:10 - 14:14

Flash presentation Urge urinary incontinence

T. Antunes Lopes, Porto (PT)

14:14 - 14:22

Discussion

14:22 - 14:29

Underactive bladder

S.A. Arlandis, Valencia (ES)

14:29 - 14:40

Debate Pelvic floor muscle training for stress urinary incontinence: A long term solution?

Moderator
M.C. Lapitan, Manila (PH)

14:29 - 14:31

Flash presentation Pro

K. Bø, Oslo (NO)

14:31 - 14:33

Flash presentation Con

C.H. Van der Vaart, Utrecht (NL)

14:33 - 14:40

Discussion

14:40 - 14:45

Mesh removal surgery
H. Hashim, Bristol (GB)

Semi-live I: Penile surgery

Thematic Session 02

Friday 9 July
13:45 - 14:45

Location Virtual Room 5

Chairs G. Bogaert, Leuven (BE)
D.J. Ralph, London (GB)

Learning objectives

This is a surgical session on behalf of ESGURS and EWPU. Four pre-recorded videos on penile surgery will be live commented by experts in the field and interactively discussed with the audience.

13:45 - 13:55

Video: Implantation of an inflatable penile prosthesis
A. Kadioglu, Istanbul (TR)

13:55 - 14:00

Discussion

14:00 - 14:10

Video: Phalloplasty
R. Djinoovic, Belgrade (RS)

14:10 - 14:15

Discussion

14:15 - 14:25

Video: Repair of distal hypospadias
M. Fisch, Hamburg (DE)

14:25 - 14:30

Discussion

14:30 - 14:40

Video: Management of buried penis
Y.T. Soygür, Ankara (TR)

14:40 - 14:45

Discussion

Guidelines

Poster Session 11

Friday 9 July
14:00 - 15:00

Location Virtual Room 8

Chairs G. Hatzichristodoulou, Nuremberg (DE)
K. Thomas, London (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Evidence-based medicine: Guidelines and real life assessment
In this session, the current EAU-Guidelines, covering several topics, will be presented in a brief and informative format. The Guidelines session will include Oncology- and Non-Oncology topics in Urology. The presenters, who are members of the respective Guidelines panels, will focus on new developments and research findings on each topic. In summary, the audience will get an up-to-date comprehensive overview of novel developments and recommendations on various topics of the current EAU Guidelines.

14:00 - 14:01

Introduction

P0298	Evaluation of oncological outcomes and data quality in studies assessing nerve sparing versus non-nerve sparing radical prostatectomy in non-metastatic prostate cancer: A systematic review L. Moris, Leuven (BE)
P0299	Diagnostic and prognostic factors in patients with prostate cancer K. Beyer, London (GB)
P0300	Evaluating Patient-Reported Outcomes Measures (PROMs) for localised prostate cancer: A systematic review using the Consensus-based Standard for the selection of health Measurement Instruments (COSMIN) methodology M.M. Ratti, Milan (IT)
P0301	Testicular tumors in prepubertal boys: A new chapter in 2021 EAU/ESPU Paediatric Urology guidelines J.S.L.T. Quaedackers, Groningen (NL)
P0302	Which ultrasound or MRI characteristics demonstrate the highest diagnostic accuracy in identifying malignancy in males with indeterminate lesions of the testis? A systematic review M. Ager, London (GB)
P0303	What are the different diagnostic tests for female Bladder Outlet Obstruction (fBOO)? A systematic review from the European Association of Urology non-neurogenic female LUTS Guidelines Panel R. Campi, Florence (IT)

P0304	Benefits and harms of conservative, pharmacological, and surgical management options for women with bladder outlet obstruction: A systematic review from the European Association of Urology non-neurogenic female LUTS guidelines panel B. Peyronnet, Rennes (FR)
P0305	Management of women with overactive bladder syndrome: A systematic review with meta-analysis of benefits and potential harms of surgical and non-surgical treatment options by the EAU non-neurogenic female LUTS Guidelines panel F. Farag, Norwich (GB)
P0306	A systematic review of patients' values, preferences and expectations for the diagnosis and treatment of male Lower Urinary Tract Symptoms (LUTS) S. Malde, Epsom (GB)
P0307	Efficacy and safety of surgical treatments for neurogenic stress urinary incontinence in adults: A systematic review S. Musco, Florence (IT)
P0308	Benefits and harms of Botulinum Toxin-A in the treatment of chronic pelvic pain syndromes: Systematic review by the EAU Chronic Pelvic Pain Panel B. Parsons, Exeter (GB)
P0309	Update of the EAU/ESPU guidelines on urinary tract infections in children L.A. 't Hoen, Rotterdam (NL)
P0310	EAU recommendations for the diagnosis and treatment of human papillomavirus infections in men T. Cai, Trento (IT)
14:14 - 14:26	Discussion
P0311	Treatment outcomes of bladder stones in children: A systematic review of >1000 cases on behalf of the European Association of Urology Urolithiasis Guideline Panel N.D. Davis, Dublin (IE)
P0312	Rare conditions in paediatric patients: New chapter in 2021 EAU Paediatric Urology guidelines N.R. Bhatt, cambridge (GB)
P0313	Are there any benefits of using an inlay graft in the treatment of primary hypospadias in children? A systematic review and metanalysis M.S. Silay, Istanbul (TR)
P0314	Re-Tur + BCG vs. upfront BCG in high-risk non-muscle invasive bladder cancer: Rationale for a feasibility phase of a randomized controlled study P. Gontero, Turin (IT)
P0315	Free graft augmentation urethroplasty for bulbar urethral strictures – Which technique is best? A systematic review R. Barratt, Halton (GB)
P0316	Surgical treatment of male Lichen Sclerosus-related urethral strictures disease: State of the art F. Esperto, Rome (IT)

P0317	What is the relationship between penile cancer and the microbiome? A scoping review V. Granados-Duque, Cali (CO)
P0318	Effectiveness of non-surgical therapies in the treatment of non-sickle cell disease-related ischemic priapism - findings from a systematic review P. Capogrosso, Milano (IT)
P0319	What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review M. Gül, Konya (TR)
P0320	The association between the partial thrombosis of the corpus cavernosum, partial priapism and hard flaccid syndrome. A scoping review G.M. Ocampo Florez, ()
P0321	Effectiveness of interventions in patients who develop graft nephrolithiasis after kidney transplantation: A systematic review R. Boissier, Marseille (FR)
P0322	Impact of the implementation of the EAU Guidelines recommendation on reporting and grading of complications in patients undergoing robot assisted radical cystectomy: A systematic review P. Dell'Oglio, Milan (IT)
P0323	Reducing the risk of postoperative complications after robot-assisted radical prostatectomy in prostate cancer patients: results of a prospective audit and feedback intervention following the implementation of prospective data collection G. Rosiello, Bacoli (IT)
P0324	A systematic review on the impact of surgeon and hospital caseload volume on oncological and non-oncological outcomes after radical prostatectomy for non-metastatic prostate cancer T. Van Den Broeck, Leuven (BE)
P0325	Development of a classification system for reporting postoperative complications in prostate cancer patients treated with robot-assisted radical prostatectomy: A comprehensive analysis based on the EAU guidelines recommendations G. Rosiello, Bacoli (IT)
P0326	Real-life implementation and survival outcomes of geriatric-assessment-based guidelines for treatment decision in older patients with prostate cancer: The ELCAPA-26 cohort study A. González Serrano, Verneuil-sur-Seine (FR)
14:42 - 14:54	Discussion
14:54 - 14:59	Expert summary N. Lawrentschuk, Collingwood Victoria (AU)

Management of lower urinary tract dysfunction and BPO: From urodynamics to medical and surgical treatment

ESU course 07

Friday 9 July
14:00 - 16:00

Location

Zoom 1

Chair

P. Abrams, Bristol (GB)

Learning objectives

- To justify the move from a prostate centric focus to a holistic view of MLUTS
- To describe the multifactorial nature of MLUTS aetiology
- To debate the correct use of terminology
- To examine the care pathways for drug therapy
- To review the evidence for combination drug therapy
- To examine the indications for urodynamics
- To define the requirements for delivering a high quality urodynamic service
- To define the principles needed to define surgical alternatives to TURP
- To consider the new techniques with clinical efficacy that can be offered to men

14:00 - 16:00

Do men need Holistic care for bothersome LUTS?

P. Abrams, Bristol (GB)

14:00 - 16:00

Individualised drug therapy in Male LUTS?

C. Gratzke, Freiburg (DE)

14:00 - 16:00

Why are pressure-flow studies not mandated for all men before BPO surgery?

J.L.H.R. Bosch, Rotterdam (NL)

14:00 - 16:00

When should a new surgical procedure for BPO be regarded as established?

T.R.W. Herrmann, Frauenfeld (CH)

Life After Cancer Treatment

Patient Information Session

Friday 9 July
14:30 - 15:30

Location

Virtual Room 9

Chair

L. Fleure, London (GB)

14:30 - 14:40

Remote follow-up programme

P. Cornford, Liverpool (GB)

14:40 - 14:42

Q&A

14:42 - 14:52

Educational sessions for remote surveillance

To be confirmed

14:52 - 14:54

Q&A

14:54 - 15:04

We wish we knew then what we know now

J. Daly, Galway (IE)

15:04 - 15:06

Q&A

15:06 - 15:16

Cancer-related complications and comorbidities as an EU health priority. The case of urological cancer survivors in older ages

K. Mastris, Clayhall Ilford (GB)

15:16 - 15:18

Q&A

15:18 - 15:28

Implications of incontinence at work

A. Deschamps, Antwerp (BE)

15:28 - 15:30

Q&A

Basic research in prostate cancer and potential clinical impact

Live from the studio: Thematic Session 03

Friday 9 July
15:00 - 16:00

Location Virtual room 1

Chairs
Z. Culig, Innsbruck (AT)
J. De Bono, London (GB)
N. Mottet, Saint-Étienne (FR)
J.A. Schalken, Nijmegen (NL)

Learning objectives

Molecular tests and classifiers for early detection and risk stratification of localised and advanced prostate cancer are rapidly emerging. This session will focus on current and future liquid- and tissue biomarkers, and will include a debate on potential clinical impact, and discussion of genomic drivers of resistance to therapy.

15:00 - 15:20	Early detection and localised disease
15:00 - 15:05	Current and future liquid biopsy markers for early detection H.G. Lilja, New York (US)
15:05 - 15:10	Molecular advances in risk stratification of localised prostate cancer G. Palapattu, Ann Arbor (US)
15:10 - 15:20	Discussion
15:20 - 15:40	Debate Genomic classifiers in prostate cancer: The holy grail or a waste of money
15:20 - 15:25	Yes, this is the holy grail M.R. Cooperberg, San Francisco (US)
15:25 - 15:30	No, this is a waste of money N. Mottet, Saint-Étienne (FR)
15:30 - 15:40	Discussion
15:40 - 16:00	Advanced prostate cancer
15:40 - 15:45	Current and future tissue markers M.A. Rubin, Berne (CH)
15:45 - 15:50	Genomic drivers of resistance to AR therapies M. Gleave, Vancouver (CA)
15:50 - 16:00	Discussion

Seminal discoveries in male infertility: From diagnosis to treatment

Live from the studio: Thematic Session 04

Friday 9 July
15:15 - 16:15

Location Virtual Room 3

Chairs M. Dinkelman-Smit, Rotterdam (NL)
U.N. Joensen, Copenhagen (DK)
J.O.R. Sønksen, Herlev (DK)

Learning objectives

The thematic session on infertility is all about controversies in the approach of the infertile male. The aim of the session is to gain an insight into new diagnostic developments, the treatment of varicocele in azoospermia, and to learn how to optimise your assisted reproduction techniques (ART). The session starts off with diagnostic controversies, including non-conventional semen analysis, human papilloma virus testing in infertility, and asking the question whether we test for Y chromosome microdeletions too often. A debate is held on the management of non-obstructive azoospermia, and a state of the art is given on improving outcomes in fertilisation and implantation in ART for male factor infertility.

15:15 - 15:22

Beyond the WHO: Non-conventional sperm analyses
A. Salonia, Milan (IT)

15:22 - 15:24

Discussion

15:24 - 15:31

Guidelines snapshot Challenging the guidelines: When and why should we test for Y?
P. Sangster, London (GB)

15:31 - 15:33

Discussion

15:33 - 15:40

Guidelines snapshot Challenging the guidelines: Shouldn't we routinely test for HPV?
N. Sofikitis, Ioannina (GR)

15:40 - 15:42

Discussion

15:42 - 16:08

Case-based debate Non-obstructive azospermia with varicocele

15:42 - 15:43

Case presentation
G.I. Russo, Catania (IT)

15:43 - 15:48

Always treat the varicocele first!
S. Çayan, Mersin (TR)

15:48 - 15:53

mTESE is always the approach of choice!
S. Minhas, London (GB)

15:53 - 15:58

We can do better in selecting patients for surgical sperm retrieval
C.F.S. Jensen, Herlev (DK)

15:58 - 16:08

Discussion

16:08 - 16:13

Improving outcomes in fertilization and implantation in ART for male factor infertility
M. Shabbir, London (GB)

16:13 - 16:15

Discussion

Urological trauma: What's new, what's controversial?

Thematic session 05

Friday 9 July
15:00 - 16:00

Location Virtual Room 6

Chairs M. Djordjevic, Belgrade (RS)
N. Kitrey, Ramat Gan (IL)

Learning objectives

Trauma is a leading cause of morbidity and death. Most urologists are involved in the management of trauma patients, therefore need to understand and follow basic principles. The aim of this thematic session is to provide state of the art update on the management of renal, urethral, and external genitalia trauma. A clinically-oriented debate will discuss the controversies and dilemmas in the management of blunt bulbar trauma.

15:00 - 15:07 **Operative vs. non-operative management of high-grade renal trauma**
D.M. Sharma, London (GB)

15:07 - 15:10 **Discussion**

15:10 - 15:17 **Explosive injuries to the external genitalia**
R. Viney, Birmingham (GB)

15:17 - 15:20 **Discussion**

15:20 - 15:40 **Early vs. delayed urethroplasty for bulbar urethral trauma**

15:20 - 15:25 **Early**
O. Shenfeld, Jerusalem (IL)

15:25 - 15:30 **Delayed**
L. Martínez Piñeiro, Madrid (ES)

15:30 - 15:40 **Discussion**

15:40 - 15:47 **Iatrogenic urethral injury**
D.M. Sharma, London (GB)

15:47 - 15:50 **Discussion**

15:50 - 15:57 **Treatment of penile amputation**
M. Djordjevic, Belgrade (RS)

15:57 - 16:00 **Discussion**

Renal transplantation: Expanding donors' indications, optimising recipients' outcomes

Poster Session 12

Friday 9 July
15:00 - 16:00

Location

Virtual Room 7

Chairs

M. Musquera Felip, Barcelona (ES)
J.D. Olsburgh, London (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

To provide the latest updates on hot-topics in renal transplantation: living donation, donor criteria expansion, graft function optimisation, surgical innovation and long-term recipients' outcomes

15:00 - 15:01

Introduction

15:01 - 15:16

Basic science and donor nephrectomy

P0327

Draining effect on maturation of the transplanted embryonic kidney

P0328

The effect of neprilysin inhibition and the combination of neprilysin and renin inhibitions in renal ischemia-reperfusion injury

F. Hammad, Amman (JO)

P0329

Protective effect of dapagliflozin against cyclosporine a-induced nephrotoxicity

N. Akdoğan, Sarıçam - Adana (TR)

P0330

Clinical implication of tertiary lymphoid tissue in the renal graft

M. Saito, Akita (JP)

P0331

Use of CT-angiography to determine preoperative renal volume as a predictor of residual renal function in living donors

P. Rodriguez-Marcos, Sevilla (ES)

P0332

Complexities in annotating surgical videos for building supervised deep learning models for critical steps of laparoscopic live donor nephrectomy

M. Bhandari, Novi (US)

P0333

The learning curve for pure retroperitoneoscopic donor nephrectomy by using CUSUM analysis

M.N. Mercimek, Samsun (TR)

15:08 - 15:16

Discussion

15:16 - 15:32

Expanding donors' pool and graft preservation

P0334

Kidney transplantation from Donation after Cardiocirculatory Death (DCD) after Extracorporeal Membrane Oxygenation (ECMO) – What can we say after 5 years of experience?

T. Pina Vaz, Matosinhos (PT)

P0335	Analysis of primary non-function, delayed graft function and overall graft survival for expanded criteria donors' kidneys M.R. Peradejordi Font, Barcelona (ES)
P0336	Efficacy and safety of marginal grafts from Expanded Criteria Donor (ECD) and Donation after Circulatory Death (DCD) in elderly recipients A. Dominguez, Pozuelo de Alarcón (ES)
P0337	Predictors of development and duration of Delayed Graft Function (DGF) in marginal kidneys preserved with Hypothermic Pulsatile Machine Perfusion (HPMP) A. Dominguez, Pozuelo de Alarcón (ES)
P0338	Small Renal Masses (SRM) in deceased donor kidneys – expanding the donor pool through improved organ utilisation P. Kotecha, London (GB)
P0339	Well controlled patients with diabetes mellitus has the potential to expand the kidney donor pool K. Yoshinaga, Okayama (JP)
P0340	Obesity in receptors. How does it affect kidney transplant outcomes? C. Munoz Calahorra, Sevilla (ES)
P0341	Normothermic machine perfusion of porcine kidneys with whole blood - Evaluation of an assistance system for donor kidneys in transplant medicine J. Putz, Dresden (DE)
P0342	Normothermic regional perfusion vs. super-rapid retrieval in controlled donation after circulatory death: Different outcomes in kidney transplantation? R. Chaves Marcos, Seville (ES)
P0343	Step-by-step development of a cold ischemia device for open and robot-assisted renal transplantation A. Territo, Barcelona (ES)
15:24 - 15:32	Discussion
15:32 - 15:48	Surgical techniques and outcomes
P0346	Four-year experience with robotic kidney transplantation from deceased donors: Overcoming logistical and technical challenges to broaden the indications of robotic kidney transplantation R. Campi, Florence (IT)
P0344	Arterial embolization of polycystic kidneys as current alternative to nephrectomy before kidney transplant F. Gómez Palomo, Valencia (ES)
P0349	Dual kidney transplantation: Which technic to use? C. Girard, Nice (FR)
P0351	Long-term survival benefit with dual kidney transplantation: analysis of French cohort between 2002 and 2014 and strategies to optimize the allocation of very extended criteria donor kidneys E. Savoye, Saint-Denis (FR)
P0347	History of urological malignancies before kidney transplantation, oncological outcome on the long term R. Boissier, Marseille (FR)
P0345	Prostate cancer in renal transplant recipients: Results from a large multicentre contemporary cohort G. Marra, Turin (IT)
P0348	Survival rates in re-transplantation. Are 3rd and 4th grafts a good option? M. Fiol Riera, L'Hospitalet de Llobregat (ES)

P0350

Progressive improvement in long-term graft survival in kidney transplantation patients in a single Spanish center. A retrospective study
M. Ramos-Cebrián, Valencia (ES)

15:40 - 15:48

Discussion

15:48 - 15:53

Expert summary
R. Boissier, Marseille (FR)

Functional urology

Patient Information Session

Friday 9 July
15:30 - 16:30

Location Virtual Room 10

Moderator M.L. Van Poelgeest-Pomfret, Oegstgeest (NL)

Learning objectives

The objective of the session is to cover a number of topics as presented by the speakers to see how we can enhance the collaboration between the hcps and the patient. By way of illustration a brief introduction to the Digital Platform 'Support in Continence'.

15:30 - 15:40

Information is key: How to reach and teach the incontinent patient
M.R. Van Balken, Arnhem (NL)

15:40 - 15:42

Discussion

15:42 - 15:52

You need the Brain to treat the Pain
E.J. Messelink, Leeuwarden (NL)

15:52 - 15:54

Discussion

15:54 - 16:04

Patient experience around testing: Understanding the patient perspective
L. Brett, London (GB)

16:04 - 16:06

Discussion

16:06 - 16:16

The role of scientific societies in relation to the patient pathway
M. Cervigni, Rome (IT)

16:16 - 16:18

Discussion

16:18 - 16:28

Introduction to WFIPP Digital Platform ' Support in Continence'
To be confirmed

16:28 - 16:30

Discussion

Urinary tract reconstruction, including pelvic organ prolapse and fistula repair

Poster Session 13

Friday 9 July
16:00 - 17:00

Location Virtual Room 8

Chairs K-D. Sievert, Detmold (DE)
L. Martínez Piñeiro, Madrid (ES)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

The objective is to gain more insight in the technical and surgical reconstructive aspects of urinary tract reconstruction in modern urology practice, except urethral strictures which is a topic on its own.

16:00 - 16:01

Introduction

P0352	The results of open ureterocalicostomy for reconstruction of the upper urinary tract D. Shchukin, Kharkiv (UA)
P0353	Retrosigmoid ileal conduit without transposition of the left ureter after open radical cystectomy: Results of a prospective two-centre study G. Giannarini, Udine (IT)
P0354	Ureteral substitution with intestinal segments
P0355	Replacement of the ureter with appendix
P0356	Endoscopic and fluorescence guided robot-assisted treatment of ureteral strictures: A single center experience D. Perri, Robecco sul naviglio (IT)
P0357	Robot-assisted laparoscopic ureteral reimplantation: Very often successful, which type of failures? T. Liernur, Genève (CH)
P0358	Results of intrauretroplasty in surgical treatment of primary megaureter O. Kononenko, Kyiv (UA)
P0359	Predictors of functional success and outcomes post pyeloplasty in different solitary kidney models. A single center experience
P0360	Right iliac fossa or umbilical stoma for a mitrofanoff – which is the best site? R. Nobrega, London (GB)

P0362	Perioperative safety and postoperative health-related quality of life in patients receiving salvage cystectomy and urinary diversion as a last-line option for benign diseases Y. Volz, München (DE)
P0363	Remnant bladder pyocystis -incidence, aetiology and management H.G. Kocadag, London (GB)
P0364	Open salvage reconstruction of recalcitrant bladder neck stenoses: Long-term follow-up and functional outcomes of the T plasty F. König, Hamburg (DE)
P0365	Robotic YV plasty for bladder neck contracture or vesico-urethral anastomosis stenosis in a French university hospital: Preliminary results L. Freton, Rennes (FR)
P0366	Influence of bladder neck preservation and the urethro-urethroanastomosis implementation technique during retropubic radical prostatectomy on urinary continence R.S. Ismailov, Rostov-on-Don (RU)
16:16 - 16:24	Discussion
P0367	Management strategies and outcome of ureterovaginal fistula: A systematic review and meta-analysis G. Singh, Hoshiarpur (IN)
P0368	Robot-assisted vesico-vaginal fistula cure: Preliminary results of a multicenter series P. Lecoanet, Nancy (FR)
P0369	Epidemiology and care pathway of vesicovaginal fistulas managed in France between 2010 and 2018 F. Michel, Marseille Cedex 20 (FR)
P0370	Prospective non-randomized comparison of transperitoneal transvesical versus extravesical laparoscopic supratrigonal vesico-vaginal fistula repair: A single center experience V. Singh, Lucknow (IN)
P0371	Predictive pre-operative nomogram of relapse-free survival rate in patients with urogenital fistula B. Grigoryan, Moscow (RU)
P0372	What is the clinical significance of a radiological leak after Urorectal Fistula (URF) repair? S. Bugeja, Msida (MT)
P0373	Rectourethral fistula induced by localized prostate cancer treatment: Surgical and functional outcomes of transperineal repair with gracilis muscle flap interposition M. Sbizzera, Lyon (FR)
P0374	The presentation, management and outcome of female urethral diverticulum surgery – A 2 centre 2 continent study F. Reeves, Essex (GB)
16:32 - 16:40	Discussion

P0375	Sexual and functional outcomes after prolapse surgery: Trocarless Transvaginal Mesh (TTMs) versus Pelvic Organ Prolapse Suspension (POPS) A. Martoccia, Latina (IT)
P0376	Efficacy and safety of an ultralight, six-point, polypropylene vaginal mesh in the treatment of urogenital prolapse A.G. Giannantoni, Siena (IT)
P0377	Advantages of using jaimy robotic system in sacrocolpopexy for bladder prolaps J. Lakssir, Rabat (MA)
P0378	Urodynamic profile of voiding in prolapse pelvic organ patients after surgery: A systematic review H.O.D. Santos, São Paulo (BR)
P0379	Serious complications and recurrences after pelvic organ prolapse surgery for 2,309 women in the VIGI-MESH registry T. Charles, Poitiers (FR)
P0380	Lower bowel tract symptoms before and after mesh robotic sacro (Hystero) colpopexy V. Li Marzi, Florence (IT)
P0381	A comparative study of perioperative outcomes and pain management after laparoscopic vs. vaginal approach for genital prolapse repair T. Taha, Durham (US)
16:47 - 16:55	Discussion
16:55 - 17:00	Expert summary G.R. Kasyan, Moscow (RU)

Active Surveillance for intermediate risk prostate cancer: What urologist and patients should know

Live from the studio: Special Session

Friday 9 July
16:30 - 17:30

Location Virtual Room 2

Chairs H. Van Poppel, Leuven (BE)
A. Villers, Lille (FR)
J. Walz, Marseille (FR)

Learning objectives

This session will address the current issues urologists might encounter when doing active surveillance in contemporary prostate cancer patients, especially: How to deal with small amounts of Gleason pattern 4 on biopsy? How to deal with MRI visible lesions? How to use new biomarkers and genomics in active surveillance? Finally shared decision making and patient involvement is key in active surveillance and a case discussion will highlight this aspect.

16:30 - 16:35	Patient statement Active surveillance C. Pieri, Milan (IT)
16:35 - 16:40	How to quantify biopsy Gleason grade 4 for active surveillance? G. Van Leenders, Rotterdam (NL)
16:40 - 16:55	Point-counterpoint session Should we do active surveillance in ISUP GG 2?
16:40 - 16:45	Pro S. Carlsson, New York (US)
16:45 - 16:50	Con G.Y. Robert, Bordeaux (FR)
16:50 - 16:55	Discussion
16:55 - 17:10	The MRI-visible lesions: Does it change the patient monitoring and outcome?
16:55 - 17:00	5 years outcome of MRI-visible vs. non-visible lesion under active surveillance: GAP3-results J. Olivier, Lille (FR)
17:00 - 17:05	Characteristics of MRI lesions allowing active surveillance and how to monitor F. Giganti, London (GB)
17:05 - 17:10	Discussion
17:10 - 17:15	Are PSA kinetics and other biomarkers able to replace per protocol biopsies? A.S. Rannikko, Helsinki (FI)
17:15 - 17:20	Discussion
17:20 - 17:30	Panel discussion Shared decision making with patients <i>Panel</i> S. Carlsson, New York (US) L.H. Klotz, Toronto (CA) C. Pieri, Milan (IT) A.S. Rannikko, Helsinki (FI) V. Stavrinos, London (GB)

Semi-Live II: Benign female surgery

Thematic Session 06

Friday 9 July
16:15 - 17:15

Location Virtual Room 4

Chairs F. Van Der Aa, Leuven (BE)
M.A. Cerruto, Verona (IT)

Learning objectives

This session is an unique opportunity to see surgical treatments for various rare conditions such as urethral diverticulum, severe incontinence and vesicovaginal fistula. Also prolaps repair will be covered. Attendees will learn technical aspects for these different benign female surgical conditions. We will discuss both technical aspects and surgical indications.

16:15 - 16:20

Welcome and introduction

16:20 - 16:30

Video: Dissection of urethral diverticula
N.I. Osman, Sheffield (GB)

16:30 - 16:35

Discussion

16:35 - 16:45

Video: Robotic sacrocolpopexy
E. Costantini, Perugia (IT)

16:45 - 16:50

Discussion

16:50 - 17:00

Video: Robotic female artificial urinary sphincter implantation
B. Peyronnet, Rennes (FR)

17:00 - 17:05

Discussion

17:05 - 17:15

Summary and closing remarks
To be confirmed

Treating Peyronie's disease and erectile dysfunction: It's not that hard!

Thematic Session 07

Friday 9 July
16:15 - 17:15

Location Virtual Room 5

Chairs C. Bettocchi, Bari (IT)
G. Hatzichristodoulou, Nuremberg (DE)

Learning objectives

In this thematic session colleagues will learn about the latest recommendations, data, news and trends on treating Peyronie's disease and erectile dysfunction. Renowned experts in the field will present state-of-the art lectures and report on the latest data of the international literature. Moreover, they will report on their own experience and give personal tips and tricks. The current EAU Guidelines on these topics will also be discussed. In addition, one highlight will be a case-based debate on Peyronie's with 60° dorsal curvature and simultaneous hourglass deformity. The faculty will debate about the best and optimal approach for this special condition.

16:15 - 16:20

A pill for every patient? PDE5i profiles and the optimization of their effects in patients with ED

M.M. Fode, Herlev (DK)

16:20 - 16:25

Inflatable penile prosthesis implantation: Are we training our future surgeons enough?

K. Van Renterghem, Hasselt (BE)

16:25 - 16:30

Is there still a role for malleable penile implants in 2021?

G. Blecher, Edgecliff (AU)

16:30 - 16:40

Discussion

16:40 - 17:10

Case-based debate 60° dorsal curvature with hourglass deformity

16:40 - 16:45

Case presentation

M. Nicolai, Leiden (NL)

16:45 - 16:50

Traction or vacuum are the least invasive and should be offered

I. Moncada Iribarren, Madrid (ES)

16:50 - 16:55

Perfect case for collagenase?

A. Cocci, Florence (IT)

16:55 - 17:00

Surgery is the only option

A. Muneer, London (GB)

17:00 - 17:10

Discussion

17:10 - 17:15

Surgical treatment options for ischemic and refractory priapism

J. Romero Otero, Madrid (ES)

Patient poster presentations

Patient Information Session

Friday 9 July
16:30 - 17:40

Location Virtual Room 9

Chairs L. Makaroff, Chinnor (GB)
E. Rogers, Renmore, Galway (IE)

Learning objectives

This session centres around the patient's perspective, experience and needs before and during their care pathway. It aims to create awareness of the disconnect that sometimes exists between patient and physician with the ultimate goal to improve patient care.

16:30 - 16:32

Introduction

16:32 - 16:44

Bladder cancer

16:35 - 16:38

Quality of life in patients with orthotopic neobladder

L. Magenta, Milan (IT)

16:38 - 16:41

Experience-based co-design (EBCD): Designing the haematuria service of the future

J. Withington, London (GB)

16:41 - 16:44

Discussion

16:44 - 16:52

Kidney cancer

16:44 - 16:47

Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 41 countries

R. Giles, Duivendrecht (NL)

16:47 - 16:50

Patient quality criteria for a multidisciplinary integrated care pathway for von Hippel-Lindau syndrome

R. Giles, Duivendrecht (NL)

16:50 - 16:52

Discussion

16:52 - 17:08

Prostate cancer

16:52 - 16:55

Sexual function of men undergoing invasive prostate cancer treatment vs active surveillance – results of the EUPROMS study

L.D.F. Venderbos, Rotterdam (NL)

16:55 - 16:58

Remote consultations: Experiences of patients with prostate cancer

R. Leszczynski, London (GB)

16:58 - 17:01

Ten years' experience of peer support by specifically trained prostate cancer patients

V. Griesser, Châtel-st-denis (CH)

17:01 - 17:04

Accrual of African American men into prostate cancer clinical trials: Collaborations to incorporate patient perspectives

T. Farrington, Quincy (US)

17:04 - 17:08

Discussion

17:08 - 17:16

General oncology

17:08 - 17:11

Patient engagement interventions not only improve health but survival in patients with cancer: A scoping review

R. Giles, Duivendrecht (NL)

Scientific Programme - EAU21 Virtual

17:11 - 17:14	Physician–patient communication: Examples of best practice to improve patient experience JTN Nowak, Brooklyn (US)
17:14 - 17:16	Discussion
17:16 - 17:21	Functional urology
17:16 - 17:19	Are reported sexual and urinary functioning in clinical studies an accurate representation of the burden after prostate cancer treatment: Results from the EUPROMS study S. Remmers, Rotterdam (NL)
17:19 - 17:21	Discussion
17:21 - 17:29	COVID-19
17:21 - 17:24	Cancer care during COVID-19: Data from 104 patient organisations A. Filicevas, Brussels (BE)
17:24 - 17:27	Developing a video information resource to inform and reassure patients through the COVID-19 pandemic J. Withington, London (GB)
17:27 - 17:29	Discussion
17:29 - 17:30	Closing remarks
17:30 - 17:40	Announcement of the top 5 presentations <i>Moderators</i> L. Makaroff, Chinnor (GB) E. Rogers, Renmore, Galway (IE)

Striking features of urethral strictures

Poster Session 14

Friday 9 July
17:00 - 18:00

Location Virtual Room 7

Chairs P. De Graaf, Utrecht (NL)
M. Fisch, Hamburg (DE)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Sound urethral stricture treatment is one of the most challenging activities in urology practice. The objective of this session is to have the latest insights in basic science and tissue engineering. Moreover the ongoing struggle with clinical diagnostics and results of urethral stricture management is discussed.

17:00 - 17:01

Introduction

P0382	Contemporary management of male anterior urethral strictures by reconstructive urology experts. Results from EAU-YAU survey among ESGURS members F. Campos Juanatey, Santander (ES)
P0383	Ectopic germinal centres with B and T cells and follicular dendritic cell networks in urethral stricture tissue: Possible avenue for immunological treatments A.T. Olsen Ekerhult, Gothenburg (SE)
P0384	Histomorphological analysis of the regenerative potential of platelet-rich plasma during urethroplasty (in an experimental model) M.M. Iritsyan, Moscow (RU)
P0385	New matrix for reconstruction and regeneration of urethral strictures in a minipig model S. Aufderklamm, Tübingen (DE)
P0386	Urethral reconstructive surgery: First results of a Bioreactor engineered human urethral implant in a minipig model S. Aufderklamm, Tübingen (DE)
P0387	Could intraurethral dexpantenol be used as a scar-modulating agent post urethroplasty? An experimental study A. Elkashef, Mansoura (EG)
P0388	Comparative analysis of the results of treatment of patients with recurrent urethral stricture using platelet-rich plasma M.M. Iritsyan, Moscow (RU)

P0389	Study on the influence of urine and balanopreputial swab microbiota in the pathogenesis of male genital lichen sclerosis W. Zeyu, Shanghai (CN)
P0390	Female stricture characterisation O.N.A. Naser, London (GB)
P0391	ROBUST III: Interim results of a randomized trial of the optilume drug coated balloon for anterior urethral strictures J DeLong, Norfolk (US)
P0392	The optilume drug coated balloon for recurrent anterior urethral strictures: 3-year results for the ROBUST I study J DeLong, Norfolk (US)
P0393	One-stage urethroplasty for lichen sclerosis related urethral stricture disease: A meta-analysis and systematic review J. Kurtzman, New York (US)
P0394	Incidence of post-micturition dribble after bulbar urethroplasty using transecting and non-transecting approaches N. Jeffery, London (GB)
P0395	Mucomucosal Anastomotic Non-Transecting Augmentation (MANTA) urethroplasty: Patient-reported outcomes and mid-term success rates of a surgical modification for obliterative bulbar strictures P. Marks, Hamburg (DE)
P0396	Anterior urethroplasty for the management of urethral strictures in males: A systematic review A. Bochinski, London (GB)
P0397	Long-term follow-up and patient-reported outcomes following staged split-thickness skin graft urethroplasty in men with complex urethral strictures L. Kühnke, Hamburg (DE)
P0398	Medium term outcomes of ventral onlay buccal mucosal graft female urethroplasty H. Gresty, London (GB)
P0399	Non-transecting dorsal mucosal anastomosis plus ventral oral graft for the treatment of bulbar strictures M. Preto, Turin (IT)
P0400	The efficacy of non-transecting urethroplasty for bulbar urethral stricture - A retrospective study from a urethral referral center Q. Fu, Shanghai (CN)
P0401	Female urethral reconstruction: Ventral onlay buccal mucosa graft urethroplasty E. Berdondini, Torino (IT)
P0402	Long-term follow-up of two-sided dorsal plus ventral oral graft bulbar urethroplasty: Single center experience on 216 patients M. Preto, Turin (IT)
P0403	Feasibility and outcomes of dorsolateral inner preputial graft urethroplasty for anterior urethral strictures: Follow-up of 60 months from a tertiary care center S. Tyagi, Hapur (IN)

P0404	Assessing in-hospital morbidity after urethroplasty using the EAU quality criteria for standardized reporting M. Bandini, Milan (IT)
P0406	Impact of catheter dwell time, type and diameter on recurrence rate after direct vision internal uretrotomy S. Zouari, Tunis (TN)
P0407	Risk factors for urethrostomy stenosis development in urethral strictures M.I. Kogan, Rostov On Don (RU)
P0408	The correlation between Peeling's voiding picture and uroflowmetry parameters S.S. Cohen, Jerusalem (IL)
P0409	Impact of perioperative complications on length of hospitalizations, readmission rate and treatment failure after urethroplasty M. Bandini, Milan (IT)
P0410	Direct visual internal urethrotomy versus non-transecting urethroplasty for short segment non traumatic bulbar urethral strictures – a non-randomised prospective observational study from university teaching institution A.K. Chawla, Manipal (IN)
P0411	Hormonal profile in patients with anterior urethral stricture. A case-control study A. Sabio-Bonilla, Granada (ES)
17:31 - 17:55	Discussion
17:55 - 18:00	Expert summary S. Kulkarni, Pune (IN)

Metabolic workup and non-surgical management of urinary stone disease

ESU Course 08

Friday 9 July
17:00 - 19:00

Location Zoom 1
Chair T. Tailly, Ghent (BE)

Learning objectives

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to:

- Identify patients that would benefit from metabolic workup
- Interpret standard metabolic workup, including dietary and medical history and biochemical analyses
- Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease
- Understand the influence of dietary changes on metabolic urinary values and provide dietary counseling

17:00 - 19:00

Who needs a metabolic evaluation, and why should this be done

A. Skolarikos, Athens (GR)

17:00 - 19:00

How to do a metabolic evaluation, step by step

O. Wiseman, Cambridge (GB)

17:00 - 19:00

Common stone types: What abnormalities might we find on investigation?

T. Tailly, Ghent (BE)

17:00 - 19:00

Stone and diet: What advice should we give?

A. Skolarikos, Athens (GR)

17:00 - 19:00

Medical treatment for stones: What works?

T. Tailly, Ghent (BE)

17:00 - 19:00

Case discussions

T. Tailly, Ghent (BE)
O. Wiseman, Cambridge (GB)
A. Skolarikos, Athens (GR)

Avoiding and managing complications

Video Session 04

Friday 9 July
17:15 - 18:00

Location Virtual room 1

Chairs A. Carbone, Latina (IT)
K.W. D'Hauwers, Nijmegen (NL)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:15 - 17:17

Introduction

V10

Management of inflatable penile prosthesis related urethral erosion
M. Saber Khalaf, Sohag (EG)

V11

How to successfully manage bladder neck injury during robotic artificial urinary sphincter implantation in women?
B. Peyronnet, Rennes (FR)

V12

The risk of symptomatic postoperative lymphocele following pelvic lymph node dissection during robotic radical prostatectomy, does the type of energy matter? A single center analysis
A. Mellouki, Nice (FR)

17:51 - 17:54

Conclusion

Alternative approaches to bladder outlet obstruction

Video Session 05

Friday 9 July
17:15 - 18:00

Location Virtual Room 3

Chairs F. Gomez Sancha, Madrid (ES)
F.E. Martins, Lisbon (PT)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:15 - 17:17

Introduction

V13

Acute or chronic urine retention in males: A new temporary prostatic stent as an alternative to Foley catheter. A prospective non randomized study: 84 cases in 3 centers

M. Devonec, Lyon (FR)

V14

Laparoscopic simple prostatectomy: Description of the surgical steps and results of a single-center 8-year experience

R. Zeder, Graz (AT)

V15

Combined surgical approach for treatment of refractory bladder neck contracture after TURP

I. Mamaev, Moscow (RU)

17:52 - 17:55

Conclusion

Challenges in genital cancer surgery

Video Session 06

Friday 9 July
17:15 - 18:00

Location Virtual Room 6

Chairs M. Albersen, Leuven (BE)
A. Parnham, Manchester (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:15 - 17:17

Introduction

V16

Radical hemiscrotectomy and en-bloc orchidectomy: Surgical technique, perioperative and oncologic outcomes of a supra-regional UK referral centre
C.D. Fankhauser, Lucerne (CH)

V17

Surgical outcomes of glansectomy and split thickness skin graft reconstruction for localized penile cancer
M. Falcone, Torino (IT)

V18

Robot assisted video endoscopic inguinal lymph node dissection in carcinoma penis with palpable inguinal lymphadenopathy: Our technique and long term functional and oncological outcomes
A. Khanna, New delhi (IN)

17:51 - 17:54

Conclusion

Cell biology, biomarkers and novel therapies in prostate cancer

Poster Session 15

Friday 9 July
18:00 - 19:00

Location Virtual Room 8

Chairs C.H. Bangma, Rotterdam (NL)
C. Jeronimo, Porto (PT)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

18:00 - 18:01

Introduction

18:01 - 18:24

Cell biology

- P0412** **Chromatin texture remodeling underlying the epigenomic dysfunction in prostate cancer**
G. Albo, Milan (IT)
- P0413** **First identification and validation of prostate cancer specific tumor endothelial cell markers by multi-omic profiling**
I. Heidegger, Innsbruck (AT)
- P0414** **Synergic AR and dual-mTOR blockade delays advanced prostate cancer growth and alters tumor heterogeneity**
F. La Manna, Bern (CH)
- P0415** **Lard diet accelerates prostate cancer development with modulation of systematic and local inflammation and gut microbiota alteration in a Pten-deficient mouse model**
H. Sato, Akita (JP)
- P0416** **The adipose tissue that surrounds the prostate gland exhibits traits of hypoxic state that could contribute to its role in prostate cancer progression**
M. Roumiguie, Auradé (FR)
- P0417** **miRNA-expression in prostate cancer-associated fibroblasts and their extracellular vesicles**
J. Linxweiler, Homburg/saar (DE)
- P0418** **Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer**
To be confirmed
- P0419** **The role of CRIPTO signaling in lethal prostate cancer**
E. Rodrigues Sousa, Bern (CH)
- P0420** **CDCP1 overexpression is associated with a specific immune-infiltrate driving prostate cancer progression**
M. Saponaro, Bonn (DE)
- P0421** **Untargeted metabolomics of prostate cancer zwitterionic and positively charged compound in urine**
M. Maggi, Rome (IT)

P0422	Patient-derived xenografts and organoids model therapy response in prostate cancer S. Karkampouna, Bern (CH)
P0423	Patient-derived preclinical models of castration resistant prostate cancer: Xenografts and PDX-derived organoids to recapitulate patients' disease profiles A. Van Hemelryk, Dendermonde (BE)
P0424	Effects of cytoreductive primary tumor resection in an orthotopic mouse model of metastatic prostate cancer J. Linxweiler, Homburg/saar (DE)
18:14 - 18:24	Discussion
18:24 - 18:43	Imaging and novel biomarkers
P0425	An opportunity for men with positive prostate mpMRI studies to safely avoid biopsy – Results from the INNOVATE Study S. Singh, London (GB)
P0426	Intraoperative resection margins assessment with confocal laser endomicroscopy during robot-assisted radical prostatectomy E. Compérat, Paris (FR)
P0427	Localised activation of the EMT switch by peri-neural invading epithelial cells in prostate cancer A. Sachdeva, Newcastle upon Tyne (GB)
P0428	miR-424 loaded circulating small extracellular vesicles: Novel biomarkers associated with aggressive prostate cancer D. Albino, Bellinzona (CH)
P0429	Pathological role of the prostaglandin E2-specific type E prostanoid receptors in hormone-sensitive and castration-resistant prostate cancer K. Ohba, Nagasaki (JP)
P0430	Prognostic significance of cell-free DNA and androgen receptor amplification in castration-resistant prostate cancer Y.K. Kubota, Hirosaki (JP)
P0431	Biomarker exploration of neoadjuvant therapy in metastatic/local hormone-sensitive prostate cancer J. Zhuang, Nanjing (CN)
P0432	Heterogenous Genomic Features in Viscerally-Metastatic Prostate Cancer Y. Gong, Shanghai (CN)
P0433	Analysis of BRCA germline mutations in Chinese prostate cancer patients W. Chen, Wenzhou (CN)
18:33 - 18:43	Discussion
18:43 - 18:56	Novel therapies
P0434	Creating a cumulative equivalent thermal isoeffect dosimetry model in several ex vivo tissue models mimicking focal laser ablation treatment of the prostate L.A.M.J.G. Van Riel, Amsterdam (NL)
P0435	Stroma transcriptomic and proteomic profile of prostate cancer metastasis xenograft models reveals prognostic value of stroma signatures S. Karkampouna, Bern (CH)
P0436	Mechanism of CDK1 regulating AR-V7-induced castration resistance in prostate cancer X. Gao, Wuhan (CN)

P0437	Apalutamide and autophagy inhibition in xenograft mouse model of human prostate cancer D. Eberli, Zürich (CH)
P0438	A novel vascular disrupting agent (NOV202) increases the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer cells with BRCA1/2 mutations E. Sereti, Malmö (SE)
P0439	Cisplatin tolerance is elevated in mismatch repair deficient prostate cancer cell lines but independent of acquired resistance to irradiation or docetaxel L. Donix, Dresden (DE)
P0440	The role of nuclear export in primary high-risk prostate cancer: A genomic analysis identifies XPO1 as potential therapeutic agent in high risk prostate cancer L. Moris, Leuven (BE)
P0441	Cabazitaxel efficacy is strongly enhanced by continued Androgen Receptor Targeted Agents (ARTA) in Castration-Resistant Prostate Cancer (CRPC) W.M. Van Weerden, Rotterdam (NL)
18:51 - 18:56	Discussion
18:56 - 19:00	Expert summary A.S. Bjartell, Malmö (SE)

Round table: The Road to successful intervention

Live from the studio: Patient Information Session

Friday 9 July
18:00 - 19:00

Location Virtual Room 2

Chairs H. Van Poppel, Leuven (BE)
E. Rogers, Renmore, Galway (IE)

This round table discussion has been funded by Ferring Pharmaceuticals. The programme of this online activity has been independently developed and approved by the EAU Patient Office.

Learning objectives

The objective of the roundtable is to discuss the shared responsibilities of both the healthcare provider and patient during a patient's care pathway. Do healthcare providers ask the right questions during intake? Do patients provide all the information the healthcare provider needs, such as a detailed medical history and anything that could be relevant to the decision-making process, as to what care pathway to take?

18:00 - 18:02

Welcome and introduction

18:02 - 18:18

Awareness, education and communication

18:02 - 18:04

What did you know about PCa?
S.A. Clark-Wehinger, Meudon (FR)

18:04 - 18:06

Why does our general male population know so little about the prostate and prostate cancer?
M. Rogan, Galway (IE)

18:06 - 18:08

How did you find out about PSA testing?
S.A. Clark-Wehinger, Meudon (FR)

18:08 - 18:10

Do you discuss the possibility of PSA Testing with your patients?
M. Rogan, Galway (IE)

18:10 - 18:12

Tell us more about your communications with your primary physician
S.A. Clark-Wehinger, Meudon (FR)

18:12 - 18:14

How should a patient prepare for intake?
M. Rogan, Galway (IE)

18:14 - 18:18

Discussion

18:18 - 18:32

Early detection

18:18 - 18:20

What is PSA testing and why is it so important?
R.J.A. Van Moorselaar, Amsterdam (NL)

18:20 - 18:22

Would you consider a PSA test, and if so, why? If not, why?
M. McRory, Roscommon (IE)

18:22 - 18:24

Do you know what a digital rectal examination (DRE) is?
M. McRory, Roscommon (IE)

18:24 - 18:26

Why is a DRE important?
R.J.A. Van Moorselaar, Amsterdam (NL)

18:26 - 18:28

What are the financial consequences of early detection vs. late detection?
R.J.A. Van Moorselaar, Amsterdam (NL)

18:28 - 18:32

Discussion

18:32 - 18:44

Active surveillance

18:32 - 18:34	What is active surveillance and when is it recommended as a treatment option? L. Moris, Leuven (BE)
18:34 - 18:36	Did you have a good understanding of what active surveillance entails? C. Pieri, Milan (IT)
18:36 - 18:38	When do you change from AS to active treatment? Triggers? L. Moris, Leuven (BE)
18:38 - 18:40	How did it make you feel when your doctor recommended active surveillance? C. Pieri, Milan (IT)
18:40 - 18:44	Discussion
<hr/>	
18:44 - 18:56	Treatment
18:44 - 18:46	What are the most common side-effects of prostate cancer treatment? R. Wassersug, Vancouver (CA)
18:46 - 18:48	What is ADT and when is it recommended as a treatment option? A.S. Merseburger, Lübeck (DE)
18:48 - 18:50	Do you address ADT-related CV risks and other frequent comorbidities with your patients and if so, to what extent? A.S. Merseburger, Lübeck (DE)
18:50 - 18:52	Were you made aware of the cardiovascular risks? Were you made aware of medical tests that assess one's risk of having or developing cardiovascular disease? R. Wassersug, Vancouver (CA)
18:52 - 18:56	Discussion
<hr/>	
18:56 - 19:00	Closing remarks

Advanced course on urethral stricture surgery

ESU Course 10

Saturday 10 July
08:00 - 10:00

Location Zoom 1

Chair R.D. Inman, Sheffield (GB)

Learning objectives

- To be aware of typical presenting symptoms of male urethral stricture
- To understand the important aspects in clinically and radiologically assessing a male patient with a urethral stricture for treatment
- To know the options and evidence base for choosing the best surgical treatments for treating penile, bulbar and traumatic urethral strictures and the principles of their surgery
- To be aware of the complications and results of stricture surgery and in order to be able to discuss and consent a patient for surgery

08:00 - 10:00

Introduction and explaining principles for interaction

R.D. Inman, Sheffield (GB)

08:00 - 10:00

Investigations and assessment of stricture disease; Possibly touch on non-transecting and ED controversy

P. Nyirády, Budapest (HU)

08:00 - 10:00

Questions/cases

P. Nyirády, Budapest (HU)

08:00 - 10:00

Penile strictures; Lichen sclerosis/hypospadias and techniques and results

R.D. Inman, Sheffield (GB)

08:00 - 10:00

Questions/cases

R.D. Inman, Sheffield (GB)

08:00 - 10:00

Bulbar Strictures; Techniques, grafts, results

R.D. Inman, Sheffield (GB)

08:00 - 08:00

Questions/cases

R.D. Inman, Sheffield (GB)

08:00 - 10:00

Pelvic fracture distraction injuries

L. Martínez Piñeiro, Madrid (ES)

08:00 - 10:00

Cases

L. Martínez Piñeiro, Madrid (ES)

Novel biomarkers, subtypes, and disease models in urothelial cancer

Poster Session 16

Saturday 10 July
10:00 - 11:00

Location Virtual Room 7

Chairs J. Meeks, Chicago (US)
R. Seiler, Liebfeld (CH)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

During this session, most recent findings and newest results on biomarker research in non-muscle and muscle invasive bladder cancer will be presented and discussed. This session contains not only biomarker data on novel predictive biomarkers that are e.g. related to response to BCG. There are several presentations on tumor modeling and culturing techniques that allow an in-vitro measurement of response. Finally, computational approaches for the identification of prognostic biomarkers and treatment options round up this session.

10:00 - 10:01

Introduction

10:01 - 10:18

NMIBC

- P0442** **Transcriptome sequencing of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG failure**
F.C. De Jong, Rotterdam (NL)
- P0443** **A molecular signature determines the prognostic and therapeutic subtype of non-muscle-invasive bladder cancer responsive to intravesical Bacillus Calmette-Guérin therapy**
S.J. Yun, Cheongju - Chungbuk (KR)
- P0444** **Intravesical BCG induces a trained immunity phenotype in patients with non-muscle invasive bladder cancer**
J.H. van Puffelen, Nijmegen (NL)
- P0445** **Somatic features of response and relapse in non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin**
D.C. Müller, Basel (CH)
- P0446** **Results of a phase I/II single arm clinical trial assessing the recombinant Bacillus Calmette-Guérin (rBCG) VPM1002BC in patients with non muscle-invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14**
- P0447** **Safety evaluation of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with high risk non-muscle invasive bladder cancer: MITOBCG study (EUDRACT Number 2017-004540-37) preliminary results**
C. De Nunzio, Rome (IT)

P0448	Tumor budding correlates with discohesive growth pattern, tumor invasiveness and is associated with worse survival of pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC) J. Breyer, Regensburg (DE)
P0449	Assessment of molecular pathways activated by mitomycin C in primary non-muscle invasive bladder tumors B. Oresta, Pieve Emanuele (IT)
P0450	Low expression of mitochondrial complex I correlates with bladder cancer recurrence after intravesical treatment with mitomycin C B. Oresta, Pieve Emanuele (IT)
10:10 - 10:18	Discussion
10:18 - 10:37	Biomarkers for treatment response in MIBC
P0451	Nonsense-mutation in TP53 improves clinical benefits of PD-1/PD-L1 blockade immunotherapy in advanced urothelial carcinoma through up-regulating PD-L1 expression via miR-34a S. Chen, Shanghai (CN)
P0452	Molecular characterization of residual bladder cancer after pembrolizumab J.J. De Jong, Rotterdam (NL)
P0453	Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to Chemoradiotherapy (CRT) in localized Muscle Invasive Bladder Carcinoma (MIBC) B. De Ruiter, Amsterdam (NL)
P0454	Boosting the combination of radiation and anti-pd-l1 with sting agonist in a preclinical muscle invasive bladder cancer murine model G. Marcq, Marcq-en-Baroeul (FR)
P0455	Immune genes expression order model predicted response of immune checkpoint blockade therapy on urothelial carcinoma Y.Q. Zhang, Shanghai (CN)
P0456	FBXW7 loss identifies a subgroup of bladder cancer patients with poor prognosis who benefit from neoadjuvant chemotherapy T. Matsumoto, Fukuoka (JP)
P0457	Splice variant V1 of HYAL4 causes Gemcitabine resistance and predicts Gemcitabine/Cisplatin failure in metastatic bladder cancer M.C. Hupe, Lübeck (DE)
P0458	Isocitrate dehydrogenase 2 regulates intracellular metabolic reprogramming in chemo-resistant urothelial carcinoma K. Shigeta, Tokyo (JP)
P0459	Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in Muscle-Invasive Bladder Cancer (MIBC) patients J.L. Gago Ramos, Badalona (ES)
P0460	Epigenetic priming of Bladder cancer cells improves CAR T-cell cytotoxicity C.M. Grunewald, Düsseldorf (DE)
P0461	The role of angiogenic signatures in advanced urothelial carcinoma (aUC) treated with VEGF-targeted therapy F.E. Jackson-Spence, Birmingham (GB)
10:29 - 10:37	Discussion
10:37 - 10:55	Organoids, subtypes and biomarkers in MIBC
P0462	Bladder cancer: Patient-derived organoids as a tool for precision medicine M. Minoli, Berne (CH)

P0463	A novel patient-derived model of sarcomatoid urothelial bladder cancer M. Garioni, Basel (CH)
P0464	Methodology of drug testing using patient derived organoids of upper tract urothelial carcinoma Y. Wei, Tuebingen (DE)
P0465	Identification and validation of pathomics-based whole slide images signatures for survival and lymphocyte infiltration prediction of patients with bladder cancer using machine learning methods
P0466	Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling M. Eckstein, Erlangen (DE)
P0467	Characterization of the tumor-infiltrating immune repertoire in Muscle Invasive Bladder Cancer R. Benítez Dorta, Madrid (ES)
P0468	The switching phenotype and intratumor plasticity in carcinoma of the bladder: A mono-institutional analysis of 211 muscle-invasive carcinoma patients with clinical considerations for therapy C. De Carlo, Rozzano (IT)
P0469	Using a curated semi-automated algorithm for target identification in muscle-invasive bladder cancer F.A. Krentel, Bern (CH)
P0470	Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders V. Weyerer, Erlangen (DE)
P0471	Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder H. Liu, Beijing (CN)
10:47 - 10:55	Discussion
10:55 - 11:00	Expert summary S. Lerner, Houston (US)

Game changing session 3

Live from the studio: Game changing session

Saturday 10 July
10:30 - 11:15

Location

Virtual room 1

Chairs

M. De Santis, Berlin (DE)
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)

10:30 - 10:45

Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: final results of the CirGuidance study

10:30 - 10:38

Presenter

N. Beije, Rotterdam (NL)

10:38 - 10:45

Discussant

M. Rouprêt, Paris (FR)

10:45 - 11:00

DANUBE post-hoc analysis: Outcomes for durvalumab with or without tremelimumab by cisplatin eligibility and PD-L1 biomarker status in metastatic urothelial carcinoma

10:45 - 10:53

Presenter

T. Powles, London (GB)

10:53 - 11:00

Discussant

M. De Santis, Berlin (DE)

11:00 - 11:15

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

11:00 - 11:08

Presenter

J.E. Gschwend, Munich (DE)

11:08 - 11:15

Discussant

A. Stenzl, Tübingen (DE)

Game changing session 4

Live from the studio: Game changer session

Saturday 10 July 10:45 - 11:00	Location	Virtual Room 3
	Chairs	U. Capitanio, Milan (IT) P.F.A. Mulders, Nijmegen (NL)
10:45 - 11:00	Pembrolizumab (pembro) vs. placebo as post nephrectomy adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study	
10:45 - 10:53	Presenter T. Powles, London (GB)	
10:53 - 11:00	Discussant A. Breda, Barcelona (ES)	

Advanced bladder cancer in 2021: Going forward?

Live from the studio: Plenary Session 03

Saturday 10 July
11:15 - 12:45

Location Virtual room 1

Chairs
M. De Santis, Berlin (DE)
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)

Learning objectives

Scientific efforts of the last decade have yielded several novel diagnostic and therapeutic opportunities for patients suffering from MIBC and metastatic disease. The learning objectives of this session are:

- Go through technical innovations such as next-generation sequencing which have enabled the comprehensive molecular classification of MIBC.
- Improve personalized and targeted therapeutical strategies by administration of highly selective drugs with good tolerability, in neoadjuvant and adjuvant settings.
- Describe technological advances in imaging and in surgery may which improve risk stratification and eventually improve the outcomes of bladder cancer patients.

11:15 - 11:25

State-of-the-art lecture Safe and optimal management of MIBC in the time of SARS-COV-2

J.W.F. Catto, Sheffield (GB)

11:25 - 11:35

Confederación Americana de Urología (CAU) lecture What is the role of TUR in MIBC?

A.R. Rodriguez, Rochester (US)

11:35 - 11:52

Debate

11:35 - 11:40

Pro: Robotic radical cystectomy and neobladder - concrete advantages of the robotic approach

A. Gallina, Milan (IT)

11:40 - 11:45

Con: Open radical cystectomy and neobladder - still the gold standard surgery

O. Rodriguez Faba, Barcelona (ES)

11:45 - 11:52

Discussion

11:52 - 11:57

Is there a role for neoadjuvant immunotherapy in MIBC?

F. Audenet, Paris (FR)

11:57 - 12:02

The role of imaging in the neoadjuvant setting CT, PET/CT or MRI?

A. Messina, Milan (IT)

12:02 - 12:25

Clinical complete response after neoadjuvant chemotherapy for MIBC: Do we always need to perform a cystectomy?

12:02 - 12:07

Clinical case presentation

A. Masson-Lecomte, Paris (FR)

12:07 - 12:12

Oncologist's point of view

M. De Santis, Berlin (DE)

12:12 - 12:17

Urologist's point of view

M.J. Ribal Caparros, Barcelona (ES)

12:17 - 12:25

Discussion

12:25 - 12:35

State-of-the-art lecture Molecular markers in MIBC: Can we use them to decide treatment?

L. Dyrskjød, Aarhus (DK)

12:35 - 12:45

State-of-the-art lecture Does every metastatic patient need immunotherapy in a first-line setting?

E. Grande, Madrid (ES)

Renal cancer: From localised to metastatic disease

Live from the studio: Plenary session 04

Saturday 10 July
11:00 - 12:30

Location Virtual Room 3

Chairs
U. Capitanio, Milan (IT)
M-O. Grimm, Jena (DE)
P.F.A. Mulders, Nijmegen (NL)

Learning objectives

Renal cell cancer (RCC) is evolving rapidly with regard to molecular, diagnostic and treatment research and its implementation in clinical practice. The VHL mechanism in RCC is a good example and all its aspects will be discussed to set the scene of this session. For the small renal mass, an update will be given on different approaches and will help you to make the right decision. In larger tumours there is a shift in surgery towards more nephron sparing. A pro and con discussion on this issue will finetune your clinical practice. In the mRCC setting prospective randomised trials tried to answer the role of nephrectomy in different eras of systemic therapy. The choice can be individualised and is also dependent on new treatment possibilities.

11:00 - 11:10

Society of Urologic Oncology (SUO) lecture The VHL kidney cancer gene: Discovery, oxygen sensing and therapy
W.M. Linehan, Bethesda (US)

11:10 - 11:35

Small renal mass
Moderator A. Volpe, Novara (IT)

11:10 - 11:15

Active surveillance
M.C. Mir Maresma, Valencia (ES)

11:15 - 11:20

Focal treatment
E. Barret, Paris (FR)

11:20 - 11:25

Surgical resection
U. Capitanio, Milan (IT)

11:25 - 11:35

Discussion

11:35 - 12:00

Case-based debate cT2 Renal cancer
Moderator J. Gómez Rivas, Madrid (ES)

11:35 - 11:40

Case presentation
M. Taratkin, Moscow (RU)

11:40 - 11:45

Partial nephrectomy whenever possible
C.K. Bensalah, Rennes (FR)

11:45 - 11:50

Radical nephrectomy remains the gold standard
H. Zargar Shoshtari, Melbourne (AU)

11:50 - 12:00

Panel discussion
Panel
C.K. Bensalah, Rennes (FR)
J. Gómez Rivas, Madrid (ES)
M. Taratkin, Moscow (RU)
H. Zargar Shoshtari, Melbourne (AU)

12:00 - 12:15

Cytoreductive nephrectomy in the management of metastatic clear cell RCC

12:00 - 12:05

The ideal case: Cytoreductive nephrectomy first
G.N. Thalmann, Bern (CH)

Scientific Programme - EAU21 Virtual

12:05 - 12:10	Systemic treatment without or with delayed nephrectomy: When and how? A. Bex, London (GB)
12:10 - 12:15	Discussion
12:15 - 12:25	State-of-the-art lecture Immunotherapy-based management of metastatic clear-cell and variant RCC: What can we achieve? I. Duran, Santander (ES)
12:25 - 12:30	Closing remarks

Male sexual dysfunction

Poster Session 17

Saturday 10 July
11:00 - 12:00

Location Virtual Room 8

Chairs M.M. Fode, Herlev (DK)
I. Moncada Iribarren, Madrid (ES)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

The poster session on male sexual dysfunction represents world-wide state-of-the art research within the area and anyone wishing to keep up with the latest developments within the area should participate. Topics span from basic research over epidemiology and diagnosis to both medical and surgical treatments. Topics include erectile dysfunction, priapism, Peyronie's disease, ejaculatory dysfunctions and more.

11:00 - 11:01

Introduction

To be confirmed
To be confirmed

11:00 - 11:10

Basic research

P0472

Up-regulating the RXFP1 gene of adipose-derived stem cells by CRISPRa and relaxin-2 improved the erectile function of rats with diabetic mellitus

P0473

Long term consequences of bilateral cavernous crush injury in normal and diabetic rats: A functional study

F. Castiglione, London (GB)

P0474

Dipeptidyl peptidase IV inhibition (DPP4i) alleviates diabetic erectile dysfunction via regulating endothelial function, apoptosis and oxidative oxidases

T. Sun, Wuhan (CN)

P0475

Strategy for the restoration of erectile function by a combination of anti-apoptotic effects by a JNK inhibitor and regeneration by hepatocyte growth factor in a rat model of cavernosal nerve injury

J. Lee, Seoul (KR)

11:04 - 11:10

Discussion

11:10 - 11:27

Epidemiology & diagnosis

P0476

Erectile Dysfunction (ED) prevalence, risk factors, comorbid chronic conditions, and quality of life burden in the UK general population

T.A. Maguire, Belfast (IE)

P0477

Medications mostly associated with priapism events: Assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries

N. Schifano, Milan (IT)

P0478	The combination of blood flow velocity and vascular diameter: The Arterial Flow Index is a better parameter in the evaluation of arteriogenic erectile dysfunction W-L. Huang, Taipei (TW)
P0479	The relationship between Gensini's score and erectile dysfunction in patients with chronic coronary syndrome N. Akdoğan, Sarıçam - Adana (TR)
P0480	Positive uroflow stop test with EMG may predict potency recovery after RARP G. Maiolino, Perugia (IT)
P0481	Haemospermia in the real-life setting: Challenging the EAU guidelines E. Pozzi, Milan (IT)
P0482	Ultrasonography and magnetic resonance imaging are accurate for suspected penile fracture A.A. Cayetano Alcaraz, Truro (GB)
P0483	Complete study for Erectile Dysfunction (CompED): Improving diagnosis and treatment decision-making J. Chavarriaga, Bogota (CO)
P0484	Urologists, sex and pandemic. How did we do? M. Capdevila Gonzalo, Barcelona (ES)
P0485	Prevalence and predictors of unrecognized low sexual desire in men with new onset erectile dysfunction – Findings from a cross-sectional, real-life study L. Boeri, Milan (IT)
P0486	Primary organic vs. primary psychogenic erectile dysfunction: A cross-sectional study on patient's characteristics and sexual function from a tertiary referral centre G. Fallara, Meda (IT)
11:21 - 11:27	Discussion
11:27 - 11:38	New therapies
P0487	Hyaluronic acid injection in the glans penis for the treatment of refractory early ejaculation a prospective controlled study S.E. Shebl Zidan, Cairo (EG)
P0488	Prilocaine/lidocaine spray to treat premature ejaculation: A dose and timing finding prospective protocol T. Cai, Trento (IT)
P0489	The effect of a single intracavernous injection of autologous adipose-derived stem cells in patients with erectile dysfunction following radical cystectomy M. Moussa, Beirut (LB)
P0490	Mirabegron for treatment of Erectile Dysfunction (ED) concomitant with Lower Urinary Tract Symptoms (LUTS) in patients with Benign Prostatic Hyperplasia (BPH): A randomized controlled trial To be confirmed
P0491	Intracavernosal aviptadil with phentolamine mesylate should be offered for treatment of refractory erectile dysfunction F. Holden, London (GB)
11:32 - 11:38	Discussion
11:38 - 11:55	Surgical approaches
P0492	The surgical outcome of buried penis surgery M. Megson, London (GB)

P0493	Clinical outcomes for surgical straightening procedures for persistence of penile curvature after a modified CCH treatment protocol: A multicenter experience A. Cocci, Florence (IT)
P0494	Comparison of the surgical outcomes and couples' satisfaction with the type of penile prosthesis; Malleable versus Inflatable penile prosthesis: From 157 patients with erectile dysfunction who underwent penile prosthesis implantation in single center Y.U. Kim, Daegu (KR)
P0495	Are patients really willing to undergo surgery for Peyronie's disease? L. Candela, Milan (IT)
P0496	Prospective evaluation of erectile dysfunction with a validated patient reported outcome measure in patients with Peyronie's disease requiring Nesbit's type surgery M. Skrodzka, London (GB)
P0497	Mid-term outcomes of modified grid plaque incision and sealing with Collagen Fleece for treatment of Peyronie's disease H.S. Lee, Seoul (KR)
P0498	Surgical treatment in ischaemic and non-ischaemic priapism: A systematic review U. Milenkovic, Leuven (BE)
P0499	The process of translation and cross cultural adaptation of the Quality of Life and Sexuality with Penile Prosthesis (QoLSPP) questionnaire, as part of the Phoenix Registry C. Caris, Arnhem (NL)
P0500	To drain or not to drain an inflatable penile prosthesis implantation? A multi-institutional experience tracking scrotal hematoma and infection occurrence A. Ragheb, Giza (EG)
P0501	Current practices in high and low volume centers regarding corporotomy localization during penoscrotal inflatable penile implant surgery B. Jacobs, Hasselt (BE)
P0502	Effects of gender-affirming hormone therapy on sexual function of transgender men and women M. Garcia, San Francisco (US)
11:49 - 11:55	Discussion

11:55 - 11:59	Expert summary J.P. Mulhall, New York (US)
---------------	--

Male infertility and hypogonadism

Poster Session 18

Saturday 10 July
12:00 - 13:00

Location Virtual Room 7

Chairs J. Dupree, Ann Arbor (US)
P. Sangster, London (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

12:00 - 12:01

Introduction

12:00 - 12:11

Infertility diagnosis

- P0503** Identifying a genomic region at Chromosome 11p.14.1 that is associated to FSH serum level in men with unexplained male infertility
M. Schubert, Münster (DE)
- P0504** Which infertile men with normal semen analysis deserve a second semen analysis in the real-life setting?
L. Boeri, Milan (IT)
- P0505** Triglyceride-Glucose index (TyG) is associated with sperm parameters and sperm DNA fragmentation in primary infertile men: a cross-sectional study
L. Boeri, Milan (IT)
- P0506** Male infertility and the effect of seminal and urinary infections on sperm DNA fragmentation, reactive oxygen species and WHO semen parameters
T. Tharakan, London (GB)
- P0507** Sperm content in Y chromosome AZFb microdeletions
J. Vargha, Budapest (HU)
- P0508** Paternal age affects the performance of EAU guidelines for genetic testing in infertile men: Implications for candidate selection
E. Ventimiglia, Milan (IT)

12:06 - 12:11

Discussion

12:11 - 12:22

Assisted reproduction

- P0509** Identifying the differential effects of sperm DNA fragmentation on the reproductive cycle in couples undergoing IVF and ICSI
M.H Abdallah, London (GB)
- P0510** Does intracytoplasmic morphologically selected sperm injection improve live birth rates compared to ICSI in men with infertility and raised sperm DNA fragmentation?
R. Chen, London (GB)
- P0511** Audit of testicular sperm in assisted conception for non-azoospermic infertile couples
C. Merrett, Windsor (AU)

P0512	Microdissection Testicular Sperm Extraction (mTESE) vs. multiple needle-pass percutaneous Testicular Sperm Aspiration (TESA) in men with non-obstructive azoospermia: A randomized clinical trial C.F.S. Jensen, Herlev (DK)
P0513	Single centre retrospective analysis of endocrine stimulation therapy prior to microsurgical Testicular Sperm retrieval (mTESE) in men with hypogonadism and Non-Obstructive Azoospermia (NOA) G. Chiriaco, London (GB)
P0514	Assisted reproductive technology outcome in patients with ejaculatory dysfunction using EEJ or needle-TESE P-H. Pan, Taipei City (TW)
12:17 - 12:22	Discussion
12:22 - 12:34	Varicocele and torsion
P0515	SERPIN may have a potential as biomarker in reflecting the improvement of semen quality in infertile men who underwent varicocele repair K. Teke, Kocaeli (TR)
P0516	Male reproductive function recovery after microsurgical varicocelectomy: Possible clinical and laboratory predictors A.B. Shomaruf, Tashkent (UZ)
P0517	Varicocelectomy improves the sperm capacity to induce optimal embryonic and fetal development post-fertilization in a donor oocyte-surrogacy motherhood program F. Dimitriadis, Kalamaria, Thessaloniki (GR)
P0518	Cutoff time for surgery in spermatic cord torsion: Results of a multicentric retrospective study of 2986 patients over 15 years E. Seizilles de Mazancourt, Lyon (FR)
P0519	Impact of testicular torsion on fertility and erectile dysfunction: A multicenter national retrospective studyTORSAFUF W. Berchiche, Marseille (FR)
P0520	Tight undergarment and tucking impair semen quality: A prospective cohort study in trans women I. de Nie, Amsterdam (NL)
P0521	Effects of platelet-rich plasma on spermatogenesis and hormone production in an experimental testicular torsion model M.A. Kutluhan, Istanbul (TR)
12:29 - 12:34	Discussion
12:34 - 12:46	Hypogonadism diagnosis & COVID
P0522	Men who father children with donated spermatozoa – a high risk group for testosterone deficiency and metabolic syndrome A. Elenkov, Malmö (SE)
P0523	Androgen receptor gene polymorphism modulates symptoms of androgen deficiency and erectile function in men with type 2 diabetes and hypogonadism M.I. Kogan, Rostov On Don (RU)
P0524	Density alteration of penile corpora cavernosa in hypogonadism model. Experimental micro-CT study I. Popov, Rostov On Don (RU)
P0525	Testosterone concentrations in hair and its potential relation with symptoms of testosterone deficiency syndrome H. Da Eun, Seoul (KR)

P0526	Current stepwise EAU recommendations for male hypogonadism screening in erectile dysfunction are not cost-effective in almost any subgroup! A. Morgado, Maia (PT)
P0527	Inverse correlation between central hypogonadism and circulating IL-10 levels in males with severe COVID-19 G. Amodio, Milan (IT)
P0528	Severely low testosterone in men with COVID-19: A case-control study P. Capogrosso, Milano (IT)
12:41 - 12:46	Discussion

12:46 - 12:55	TRT
P0529	A cohort study on thromboembolic risk with the use of testosterone therapy in klinefelter syndrome F. Melling, London (GB)
P0530	Long-term testosterone therapy improves renal function in men with hypogonadism: A real-life prospective controlled registry R. Al-Zoubi, Al Wakrah (QA)
P0531	Improvement of urinary function in men with hypogonadism and obesity receiving long-term treatment with testosterone in comparison to a control group – Experience of 4367 patient-years in a urological office K.S. Haider, Bremerhaven (DE)
P0532	Less mortality and less Major Adverse Cardiovascular Events (MACE) under long-term Testosterone Therapy (TTh): 15-year data from a prospective controlled registry study O.M. Aboumarzouk, Cardiff (GB)
12:49 - 12:54	Discussion

12:55 - 12:59	Expert summary M. Shabbir, London (GB)
---------------	--

Improving outcomes following robotic cystectomy

Video Session 07

Saturday 10 July
12:30 - 13:15

Location Virtual Room 4

Chairs A.E. Canda, Istanbul (TR)

C.J. Wijburg, Arnhem (NL)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

12:30 - 12:32

Introduction

V19

Optimizing totally intracorporeal pure Studer robot-assisted neobladder - Technique and outcomes after initial 13 cases

E.C. Bujoreanu, Cluj Napoca (RO)

V20

Side docking approach for robotic radical cystectomy with simultaneous urethrectomy

G. Rebez, Trieste (IT)

V21

Robotic prostate sparing cystectomy with intracorporeal neobladder - single tertiary care institution experience

J.I. Perez Reggeti, Barcelona (ES)

13:06 - 13:09

Conclusion

Award winning video session

Video Session 08

Saturday 10 July
12:30 - 13:15

Location Virtual Room 5

Chairs Y. Abu-Ghanem, Ramat Gan (IL)
F. Van Der Aa, Leuven (BE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

12:30 - 12:32

Introduction

V22

Robot-assisted partial nephrectomy with 3D preoperative surgical planning: Video presentation of the florentine experience

A.A. Grosso, Florence (IT)

V23

Indocyanine green guidance during 3D augmented reality robot assisted partial nephrectomy: A step towards the “automatic” overlapping

D. Amparore, Turin (IT)

V24

New technologies in robot-assisted kidney transplantation: Improving surgical performances, expanding the indication

A. Piana, Prarostino (IT)

13:07 - 13:10

Conclusion

Challenging retroperitoneal surgery for testicular disease

Video Session 09

Saturday 10 July
12:30 - 13:15

Location Virtual Room 6

Chairs D. Nicol, London (GB)
D. Pfister, Cologne (DE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

12:30 - 12:32

Introduction

V25

Step-by-step robot-assisted retroperitoneal lymph node dissection

I. Bentellis, Nice (FR)

V26

Post chemotherapy robotic retroperitoneal lymph node dissection with IVC repair

V. Agarwal, Mumbai (IN)

V27

False aneurysm of the inferior vena cava secondary to metastatic testicular cancer

F. Pellegrinelli, Jesi (an) (IT)

13:04 - 13:07

Conclusion

Liquid biopsies, biomarkers, and novel therapies in renal tumours

Poster Session 19

Saturday 10 July
13:00 - 14:00

Location Virtual Room 8

Chairs M. Horstmann, Gütersloh (DE)
H-P. Marti, Bergen (NO)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Novel biomarkers

To get an overview of recent developments

- in liquid biopsies (urine/blood) for renal cancer
- in prognostic molecular markers for renal cancer
- in molecular markers for subtype differentiation of renal cancer
- in new molecular treatment targets for renal cancer

13:00 - 13:01

Introduction

M. Horstmann, Krefeld (DE)

13:01 - 13:11

Liquid biopsy, exosomes

P0533

Kidney cancer urine marker

B. Köditz, Köln (DE)

P0534

Role of exosomal antitumor microRNA-1 in renal cell carcinoma

P0535

Expression of PD-L1 on extracellular vesicles in renal cell carcinoma cell lines and patient samples

P. Zeuschner, Homburg (DE)

P0536

Tumor specific exosome-based liquid biopsy biomarkers for kidney cancer

R.C. Zieren, Baltimore (US)

P0537

Organ-specific uptake of extracellular vesicles secreted by urological cancer cells

J. Linxweiler, Homburg/saar (DE)

13:06 - 13:11

Discussion

13:11 - 13:34

Novel biomarkers

P0538

N6-Methyladenosine (m6A) readers are dysregulated in renal cell carcinoma

J. Ellinger, Bonn (DE)

P0539

Ubiquitin modification patterns of clear cell renal cell carcinoma and the ubiquitin score to aid immunotherapy and targeted therapy

P. Zhou, Wuhan (CN)

P0540

Clinicopathological and prognostic significance of TFE3 in papillary renal carcinoma

D. Takamatsu, Fukuoka (JP)

P0541	Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with renal cell carcinoma W. Kong, Shanghai (CN)
P0542	Comprehensive molecular characterization of renal cell carcinoma in the Chinese population W. Kong, Shanghai (CN)
P0543	A multi-omics approach for kidney cancer biomarker discovery R.C. Zieren, Baltimore (US)
P0544	miR-92b-3p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinoma
P0545	DNA Damage Repair (DDR) gene and VHL concurrent alterations in advanced clear cell Renal Cell Carcinoma (ccRCC) are association with good progression free survival with tyrosine kinase inhibitor therapy W. Zhai, Shanghai (CN)
P0546	Development and validation of a nine redox related long noncoding RNA prognostic signature in renal clear cell carcinoma Q-D. Xia, Wuhan (CN)
P0547	PDCD1 methylation predicts response to anti-PD-1 based immunotherapy in advanced and metastatic renal cell carcinoma N. Klümper, Bonn (DE)
P0548	CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma G. Tulchiner, Innsbruck (AT)
P0549	Transcriptome-based estimation of immune cell populations is prognostic for risk of relapse in localized renal cell carcinoma E. Roussel, Brugge (BE)
P0550	Tryptophan 2,3-dioxygenase in tumor cells is associated with kynurenine accumulation and resistance to immunotherapy in renal cell carcinoma M. Sumitomo, Aichi (JP)
13:24 - 13:34	Discussion
13:34 - 13:55	Cell biology and novel therapies
P0551	Comprehensive molecular characterization of TFE3-translocation renal cell carcinoma J. Chen, Chengdu (CN)
P0552	An in vitro comparison between Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma A. Zaccagnino, Homburg (DE)
P0553	KIBRA plays as tumour suppressor via phosphorylation of LATS-2 in conventional renal cell carcinoma tissues K. Mitsunari, Nagasaki (JP)
P0554	Anti-mesothelin human CAR-T cells producing IL-7 and CCL19 enhance antitumor efficacy against solid cancer in orthotopic and PDX mouse models S. Goto, Ube-shi (JP)
P0555	Successful therapy of experimental, orthotopic renal cell carcinoma with two different types of Axl inhibiting agents T.J. Chen, Bergen (NO)
P0556	Combination of mAb cG250 with natural killer cells for RCC treatment J.C. Oosterwijk-Wakka, Nijmegen (NL)

P0557	Cytotoxic T lymphocytes regenerated from iPS cells have therapeutic efficacy in a patient-derived xenograft model of renal cell carcinoma S. Kashima, Akita (JP)
P0558	Deconstruction of metastatic tumor microenvironment reveals a metastatic immunosignature predictive of prognosis and treatment response in ccRCC Y. Xiong, Shang Hai (CN)
P0559	Typical prognostic immune subtypes of clear cell renal cell carcinoma defined by the unique tumor immune microenvironment W-H. Xu, Shanghai (CN)
P0560	Inhibition of autophagy as a therapeutic concept in renal cell carcinoma V. Stuehler, Tuebingen (DE)
P0561	Efficacy and safety of anlotinib in metastatic renal cell carcinoma: A single-center retrospective study H. Zhu, Xuzhou (CN)
P0562	Comprehensive genome-wide profiles reveals prognosis-related alternative splicing events landscape and identifies DDX21 as novel signature in adrenocortical carcinoma W-H. Xu, Shanghai (CN)
13:46 - 13:55	Discussion
13:55 - 14:00	Expert summary To be confirmed

Germline genetic testing and clinical consequences for patients and relatives in onco-urology

Live from the studio: Thematic Session 08

Saturday 10 July
13:15 - 14:15

Location Virtual Room 2

Chairs
P. Albers, Düsseldorf (DE)
R.A. Eeles, London (GB)
B. Faltas, New York (US)
F.C. Hamdy, Oxford (GB)
A. Stenzl, Tübingen (DE)

Learning objectives

Genetic testing is an emerging tool for risk consultations. However, the test reliability and the predicted risks differ tremendously. This session will highlight the newest developments on when and how to integrate genetic tests in clinical routine.

13:15 - 13:35

What urologists need to know about germline mutations and prostate cancer management

13:15 - 13:20

State-of-the-art lecture Germline mutations and prostate cancer management
R.A. Eeles, London (GB)

13:20 - 13:25

Clinical case presentation Germline mutations and prostate cancer management
N. Fossati, Milan (IT)

13:25 - 13:35

Discussion
Moderator F.C. Hamdy, Oxford (GB)
Discussants R.A. Eeles, London (GB)
N. Fossati, Milan (IT)

13:35 - 13:55

What urologists need to know about germline mutations and kidney cancer management

13:35 - 13:40

State-of-the-art lecture Germline mutations and kidney cancer management
U. Capitanio, Milan (IT)

13:40 - 13:45

Clinical case presentation Germline mutations and kidney cancer management
M.C. Mir Maresma, Valencia (ES)

13:45 - 13:55

Discussion
Discussants U. Capitanio, Milan (IT)
M.C. Mir Maresma, Valencia (ES)
Moderator W.M. Linehan, Bethesda (US)

13:55 - 14:15

What urologists need to know about germline mutations and urothelial cancer management

13:55 - 14:00

State-of-the-art lecture Germline mutations and urothelial cancer management
B. Faltas, New York (US)

14:00 - 14:05

Clinical case presentation Germline mutations and urothelial cancer management
G. Niegisch, Düsseldorf (DE)

14:05 - 14:15

Discussion
Moderator P. Black, Vancouver (CA)
Discussants B. Faltas, New York (US)
G. Niegisch, Düsseldorf (DE)

Urinary biomarkers: Are we there yet?

Live from the studio: Thematic Session 09

Saturday 10 July
13:15 - 14:15

Location

Virtual Room 3

Chairs

A. Alcaraz, Barcelona (ES)
L. Dyrskjød, Aarhus (DK)
J.A. Witjes, Nijmegen (NL)
J.A. Schalken, Nijmegen (NL)

Learning objectives

Good biomarkers could make diagnosis, determination of prognosis and follow-up better and easier. Although promising and studied for decades, biomarkers have still not entered urological practice. For urothelial carcinoma this now seems the case, and after this session the audience will have an idea of how to implement current markers depending of the clinical situation and tumour location. For prostate and kidney cancer, markers beyond PSA are also on the horizon. The audience will have an idea what to expect in the very near future with potential onsequences for clinical practice.

13:15 - 13:20

Welcome and introduction

J.A. Witjes, Nijmegen (NL)

13:20 - 13:55

Bladder cancer

13:35 - 13:40

Urine biomarkers for diagnosis and follow-up/recurrence

J.L. Boormans, Rotterdam (NL)

13:40 - 13:45

Urine biomarkers for diagnosis of upper tract urothelial carcinoma (UTUC)

G. Netto, Birmingham (US)

13:45 - 13:50

Prognosis and correlation to plasma biomarkers: Are urinary biomarkers helpful?

E. Christensen, Aarhus (DK)

13:50 - 13:55

Urine biomarkers for treatment response

A.M. Kamat, Houston (US)

13:20 - 13:35

Panel discussion Clinical impact of urinary biomarkers in bladder cancer: Are they here to stay?

Panel

J.L. Boormans, Rotterdam (NL)
E. Christensen, Aarhus (DK)
A.M. Kamat, Houston (US)
G. Netto, Birmingham (US)

13:55 - 14:07

Kidney cancer

13:55 - 14:02

Promising new urinary biomarkers in kidney cancer

K. Junker, Homburg (DE)

14:02 - 14:07

Discussion

14:07 - 14:15

Closing remarks

Nephron-sparing treatment in localised kidney cancer

Poster Session 20

Saturday 10 July
14:00 - 15:00

Location Virtual Room 7
Chairs C.K. Bensalah, Rennes (FR)
A. Volpe, Novara (IT)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

To explore the innovations in localised kidney cancer treatment: outcomes of percutaneous ablation, new technologies, surgical variations & outcomes in minimally-invasive partial nephrectomy

14:00 - 14:01

Introduction

14:01 - 14:21

Perc ablation and minimally-invasive partial nephrectomy

P0563

Percutaneous image guided cryoablation and radio-frequency ablation versus partial nephrectomy for small renal cell carcinomas: A ten-years, single centre observational study
V.W-S. Chan, Leeds (GB)

P0564

Percutaneous ablation versus surgical resection for local recurrence following partial nephrectomy for renal cell cancer: A propensity score analysis (REPART Study – UroCCR 71)
M. Brassier, Angers (FR)

P0565

Comparison of robot-assisted partial nephrectomy and percutaneous ablation for ct1 renal masses: Mid term outcome analysis
U. Carbonara, Triggiano (IT)

P0566

Feasibility of salvage robotic partial nephrectomy after ablative treatment failure (UroCCR- 62 study)
G. Margue, Bordeaux (FR)

P0567

Impact of preexisting opioid-dependence on morbidity, length of stay, and inpatient cost of urologic oncologic surgery
S. Arora, Detroit (US)

P0568

Oncological outcome of neoadjuvant target therapy in patients with localized RCC
S. Semko, Kiev (UA)

P0569

Impact of surgical approach (open vs. minimally invasive) on oncological outcomes after nephrectomy for localized renal cell carcinoma: A RECUR database project
G. Fallara, Meda (IT)

P0570

Partial versus radical nephrectomy for the treatment of T1 renal tumors: A large contemporary matched-cohort study (RECORD2 Project)
R. Tellini, Firenze (IT)

P0571	Life quality among patients with kidney cancer depending on the surgery type S. Semko, Kiev (UA)
P0572	Is whenever feasible-strategy for partial nephrectomy invariably justified? The impact of clinical tumour size on postoperative renal function G. Colandrea, Milano (IT)
P0573	Partial Nephrectomy: Is there substantial overtreatment of patients? L. Gietelink, Amsterdam (NL)
P0574	Imperative versus elective minimally-invasive partial nephrectomy: Results of a multi-institutional collaborative series R.S. Flammia, Rome (IT)
14:13 - 14:21	Discussion
14:21 - 14:37	Partial nephrectomy in specific populations
P0575	Retroperitoneal vs. transperitoneal robotic partial nephrectomy for postero-lateral renal masses: An international multicenter analysis U. Carbonara, Triggiano (IT)
P0576	Perioperative and mid-term oncological and functional outcomes after partial nephrectomy for entirely endophytic renal tumors: A prospective multicenter observational study (the RECORD2 Project) F. Di Maida, Palermo (IT)
P0577	Renal function deterioration assessment in totally endophytic “deep” renal masses treated with robotic partial nephrectomy: Comparison with a whole cohort of cT1-2 renal tumors patients from a multicenter analysis (ROSULA database) G. Tuderti, Roma (IT)
P0578	Is robotic transperitoneal partial nephrectomy safe in the management of cystic renal cell masses? Outcomes of an ERUS multicenter study including 216 patients A.E. Canda, Istanbul (TR)
P0579	Management and outcomes of complicated renal cysts, a single-institute observational study L. Luomala, Helsinki (FI)
P0580	External validation of a novel trifecta system in predicting oncologic and functional outcomes of partial nephrectomy: Results of a multicentric series U. Anceschi, Rome (IT)
P0581	Critical evaluation of the Clavien-Dindo classification for postoperative complications in renal tumor surgery, a national multi-center study from Finland K. Erkkilä, Helsinki (FI)
P0582	Partial nephrectomy in frail patients: Effect of surgical approach on complications and health-care expenditures G. Rosiello, Bacoli (IT)
14:29 - 14:37	Discussion
14:37 - 14:47	Surgical innovations
P0583	Comparison of early surgical outcomes of laparoscopic partial nephrectomy between T1a and T1b renal tumors with the incorporation of EAUiaC in the “trifecta” – a retrospective study reported according to EAU standardized quality criteria S. Kumar, Vellore (IN)
P0584	Transfer trial: Ancillary study within the UroCCR network. Does the transfer of knowledge from the pioneer generation to the second generation accelerate the learning curve of Robot-Assisted Partial Nephrectomies (RAPN)? I. Bentellis, Nice (FR)

P0585	Laparoscopic partial nephrectomy with Thulium Laser enucleation of the tumour: Perioperative and functional outcomes M. Maltagliati, Modena (IT)
P0586	The utilization of intraoperative ultrasound in overcoming adherent perinephric fat In laparoscopic partial nephrectomy M. Gulsen, Samsun (TR)
P0587	Off-clamp versus on-clamp pure laparoscopic partial nephrectomy: Per-protocol analysis from the CLOCK II randomized clinical trial R.G. Bertolo, Torino (IT)
P0588	Better specificity and less ischemia: High-precision three-dimensional Reconstruction is superior to routine CT angiography in navigation of Robot assisted partial nephrectomy with selective clamping C. Wu, Guangzhou (CN)
P0589	Automatic 3D augmented reality RAPN with Indocyanine green guidance: A novel technology for a more precise surgical resection D. Amparore, Turin (IT)
P0590	Avoiding renorrhaphy at the end of off-clamp robotic partial nephrectomy does not jeopardize surgical and functional outcomes: A multicenter analysis A. Brasseti, Rome (IT)
P0591	Super-selective Ischemia in robotic partial nephrectomy does not provide better long-term renal function than renal artery clamping in a randomized controlled trial: Why bother and take risks? J.A. Long, Grenoble (FR)
P0592	Trans-arterial ICG delivery before purely off-clamp robot-assisted partial nephrectomy for totally endophytic renal tumors: Mid-term outcomes G. Tuderti, Roma (IT)

14:47 - 14:55	Discussion
----------------------	-------------------

14:55 - 15:00	Expert summary L-M. Krabbe, Münster (DE)
----------------------	--

Prostate cancer imaging and biopsy

ESU Course 11

Saturday 10 July
10:30 - 12:30

Location Zoom 1

Chair J. Walz, Marseille (FR)

Learning objectives

Recently new imaging technologies have been developed to improve the diagnosis and management of prostate cancer. These are multiparametric MRI, PET and new ultrasound based technologies.

The course's aim is to provide:

- An overview on the currently available imaging tools for prostate cancer
- Practical information about their use and their implementation in prostate biopsy procedures
- A critical assessment of their clinical performance and their limitations

10:30 - 12:30

Introduction and objective of course

J. Walz, Marseille (FR)

-

Diagnosis of prostate cancer

10:30 - 12:30

Standardization, acquisition and reporting and reading of multiparametric MRI

G. Villeirs, Ghent (BE)

10:30 - 12:30

Indications for prostate biopsy

C. Moore, London (GB)

10:30 - 12:30

TRUS and TRUS guided biopsy

P. Hammerer, Braunschweig (DE)

10:30 - 12:30

MRI guided biopsy and image fusion

J. Walz, Marseille (FR)

10:30 - 12:30

Infections, antibiotics and the access: Transrectal vs. transperineal for biopsy

P. Hammerer, Braunschweig (DE)

10:30 - 12:30

MRI in prostate cancer diagnosis: Results and critical assessment

C. Moore, London (GB)

-

Staging of prostate cancer: Initial and at recurrence

10:30 - 12:30

Staging of prostate cancer with conventional imaging

G. Villeirs, Ghent (BE)

10:30 - 12:30

Use of PET imaging in the management of prostate cancer

J. Walz, Marseille (FR)

10:30 - 12:30

Closure and evaluation

J. Walz, Marseille (FR)

Localised renal tumour diagnosis and prognosis in the digitalised era

Poster Session 21

Saturday 10 July
15:00 - 16:00

Location Virtual Room 8

Chairs A. Bex, London (GB)
P.F.A. Mulders, Nijmegen (NL)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

To explore the innovations in localised kidney cancer diagnosis: preoperative tumour characterization, nephrometry score, 3D reconstruction, and prognostic models

15:00 - 15:01

Introduction

15:01 - 15:19

Renal tumour characterisation

P0593

Cumulative obesity exposure on the risk of kidney cancer: A longitudinal nationwide cohort study

P0594

Accurate differentiation of renal tumour pathological subtypes using a machine learning model of epigenetic markers
S. Rossi, Cambridge (GB)

P0595

A pilot study investigating the feasibility of using a fully automatic software to assess the renal and PADUA score
M. Carlier, Valbonne (FR)

P0596

Computer tomography texture analysis: a promising tool aiding in suspecting clear cell renal carcinoma at pre-treatment imaging
V. Forte, Rome (IT)

P0597

Prostate Specific Membrane Antigen (PSMA) PET/CT ligand uptake across histological sub-types of renal tumours
A. Tariq, Windsor (AU)

P0598

Multiparametric prospective contrast enhanced ultrasound evaluation of kidney lesions: Comparison with histological examination
A. Tufano, Rome (IT)

P0599

Utility of ex vivo confocal fluorescence microscopy for renal mass biopsy optimization
A.S. Valiquette, Valencia (ES)

P0600

PERC-score: a nephrometry score for percutaneous tumor ablation of small renal mass
P. Piazza, Bologna (IT)

P0601

Outcomes of 10 years' experience of percutaneous cryoablation for the treatment of cT1 renal tumour presented according to RENAL, PADUA and ABLATE nephrometry systems
A. Piasentin, San Donà di Piave (IT)

P0602	Utility of Bosniak classification version 2019 for Contrast-Enhanced Ultrasound (CEUS) evaluation of cystic renal masses L. Angelini, Voltaggio (AL) (IT)
15:11 - 15:19	Discussion
15:19 - 15:37	Imaging & 3D reconstruction
P0603	Simplified PADUA Renal (SPARE) nephrometry system: French multi-institutional retrospective validation and comparison for Robot-Assisted Partial Nephrectomy (RAPN) C. Klein, MERIGNAC (FR)
P0604	Measuring renal tumor endophycity by tumor center rather than edge J. Schoephoerster, Minneapolis (US)
P0605	Predicting complications after robotic partial nephrectomy: Back to simplicity Z-E. Khene, Rennes (FR)
P0606	Novel volumetric and morphologic parameters derived from 3D virtual modelling to improve comprehension of tumour's anatomy in patients with renal cancer L. Bianchi, Bologna (IT)
P0607	The three-dimensional reconstructed virtual images improve the reliability, accuracy, and efficiency of the R.E.N.A.L. nephrometry score for preoperative assessment K. Yoshitomi, Chiyoda-ku (JP)
P0608	Three-dimensional virtual modelling for anatomical comprehension of renal anatomy: Validation of CSA, RENAL, PADUA, ABC scores before partial nephrectomy A. Mottaran, Bologna (IT)
P0609	Assessment of cortical parenchymal volume of the kidney by 3D processing of contrast-enhanced MSCT data before and after nephron-sparing surgery for kidney malignancy A. Proskura, Moscow (RU)
P0610	Three-dimensional printing soft kidney model for surgical simulation of robot-assisted partial nephrectomy F. Hongo, Kyoto (JP)
P0611	Impact of abdominal aortic atherosclerotic burden in patients submitted to partial nephrectomy: A pilot study on 142 cases M.A. Cerruto, Verona (IT)
P0612	The changing trends of image guided biopsy of small renal masses before intervention - an analysis of European multinational prospective EuRECA registry V.W-S. Chan, Leeds (GB)
15:29 - 15:37	Discussion
15:37 - 15:55	Prognostic models
P0613	Neutrophil-to-lymphocyte ratio in unclassified renal cell carcinoma is associated with clinical outcome and varies between genomic subgroups J. Marcon, Munich (DE)
P0614	Construction and validation of a standardized paraneoplastic syndrome for renal cell carcinoma S. Soliman, San Diego (US)
P0615	Correlation between remaining functioning parenchyma volume and kidney function in patients with RCC S. Semko, Kiev (UA)

P0616	Assessing predictors of chronic kidney disease progression in patients receiving minimally-invasive partial nephrectomy: Results of a multi-institutional collaborative series U. Anceschi, Rome (IT)
P0617	A nomogram for the prediction of significant long-term renal function loss after robot-assisted partial nephrectomy for localized renal tumors: A prospective multicenter observational study (RECORD2 project) A. Mari, Florence (IT)
P0618	External validation and head-to-head comparison of all the prognostic models recommended by the European Association of Urology guidelines to predict oncologic outcomes in patients with renal cell carcinoma G. Rosiello, Bacoli (IT)
P0619	European Association of Urology COVID intermediate prioritisation group is poorly predictive of pathological high-risk among patients with renal tumours P. Satish, Swindon (GB)
P0620	External validation of the VENUSS prognostic model to predict disease recurrence after surgery for non-metastatic papillary renal cell carcinoma: An analysis of a multi-institutional European cohort S. Erdem, Istanbul (TR)
P0621	Major Adverse Cardiovascular Events (MACE) following partial nephrectomy: PN-A4CH a novel risk index N. Abou Heidar, Riad El Solh - Beirut (LB)
P0622	Impact of post-operative proteinuria on development of CKD: Analysis of functional outcomes post nephrectomy M.F. Meagher, La Jolla (US)
15:47 - 15:55	Discussion
15:55 - 16:00	Expert summary M.C. Mir Maresma, Valencia (ES)

Immunotherapy in urothelial cancer

Live from the studio: Thematic Session 10

Saturday 10 July
15:15 - 16:15

Location

Virtual Room 2

Chairs

J.W.F. Catto, Sheffield (GB)
Y. Loriot, Villejuif (FR)
M.J. Ribal Caparros, Barcelona (ES)
J.A. Witjes, Nijmegen (NL)

Learning objectives

This session examines the current state of immunotherapy in urothelial cancer, divided into lectures on muscle and non-muscle invasive bladder cancer, metastatic urothelial cancer and a live discussion. The session will then cover predictive markers, both in their current state and their potential. We conclude with a "look into the future" that suggests some ideal combination therapies for urothelial cancer patients.

15:15 - 15:23

Immunotherapy in non-muscle invasive urothelial cancer of the bladder
J.A. Witjes, Nijmegen (NL)

15:23 - 15:31

Perioperative immunotherapy in muscle-invasive bladder cancer
M.S. Van Der Heijden, Amsterdam (NL)

15:31 - 15:39

Immunotherapy for metastatic urothelial cancer (including upper tract)
U. Vogl, Bellinzona (CH)

15:39 - 15:49

Discussion

15:49 - 15:57

Predictive markers for response in urothelial cancer: Are we there yet?
T. Powles, London (GB)

15:57 - 16:05

Look in the future: Ideal combination therapies
M. Galsky, New York (US)

16:05 - 16:15

Discussion

Testis Cancer: Innovations by biomarkers and surgery

Live from the studio: Thematic Session 11

Saturday 10 July
15:15 - 16:15

Location Virtual Room 3

Chairs
C.D. Fankhauser, Lucerne (CH)
K. Fizazi, Villejuif (FR)
H.S. Haugnes, Tromsø (NO)
A. Hiester, Duesseldorf (DE)

Learning objectives

This session on testis cancer looks at both surgical solutions and the role of biomarkers in treatment options. Apart from an overview on current and upcoming developments in the treatment of testis cancer, the session features a case-based debate on the role of surgery for metastatic seminoma, offering different options based in daily practice.

15:15 - 15:20

Ongoing trials and outlook on miRNA

M. Murray, Cambridge (GB)

15:20 - 15:25

The role of MRI and FDG-PET-CT for tailored treatment

T. Zuiverloon, Rotterdam (NL)

15:25 - 15:30

Long-term toxicity and secondary cancers in testis cancer survivors

H.S. Haugnes, Tromsø (NO)

15:30 - 15:35

Discussion

15:35 - 15:55

Case-based debate Surgery for metastatic seminoma

Moderator J.L. Boormans, Rotterdam (NL)

15:35 - 15:37

Case presentation Stage IIA seminoma patient

J. Mayor De Castro, Madrid (ES)

15:37 - 15:41

Flash presentation Yes! SEMS or PRIMETEST - which is the best concept?

S. Daneshmand, Los Angeles (US)

15:41 - 15:45

Flash presentation No! At least Carbo is necessary!

R.A. Huddart, London (GB)

15:45 - 15:55

Discussion

15:55 - 16:00

RPLND for chemoresistant disease including salvage/desperation surgery

A. Heidenreich, Cologne (DE)

16:00 - 16:05

New drug developments for chemoresistant disease and molecular developments

D. Nettersheim, Düsseldorf (DE)

16:05 - 16:10

Expert centers & eUROGEN in testicular cancer: One for all or all for one?

D. Nicol, London (GB)

16:10 - 16:15

Discussion

Emerging threats by infectious diseases

Thematic Session 12

Saturday 10 July
15:15 - 16:15

Location Virtual Room 5

Chairs G. Bonkat, Basel (CH)
F.M.E. Wagenlehner, Giessen (DE)

Learning objectives

In this thematic session we discuss emerging infectious diseases relevant for urology. Given the large influence of the COVID-19 pandemic on our daily work and activities, we target this topic also in the light of other possible future challenges of emerging infectious diseases. As the importance of vaccines has been re-evaluated throughout the Covid-19 pandemic, we will cover vaccines that are of relevance for the practicing urologist. Another topic is urosepsis and how to best manage patients. Antimicrobial resistance is directly related to the outcome in the treatment of uroseptic patients and is a pandemic by its own. Lastly we discuss about one of the largest killers in the world, which is tuberculosis.

15:15 - 15:20

Welcome and introduction

15:20 - 15:30

Urosepsis: When does treatment make a difference?
Z. Tandođdu, London (GB)

15:30 - 15:40

What vaccines are important for urologists?
S. Schubert, Munich (DE)

15:40 - 15:50

Antimicrobial resistance: How to deal with this pandemic
J. Medina-Polo, Madrid (ES)

15:50 - 16:00

Tuberculosis, the leading infectious killer
E. Kulchavenya, Novosibirsk (RU)

16:00 - 16:15

Discussion

YUORDay21: EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU)

EAU Specialty Session

Saturday 10 July
15:15 - 17:15

Location Virtual Room 6

Chairs F. Esperto, Rome (IT)
J.P.M. Sedelaar, Nijmegen (NL)

Format 10 minutes lectures: 7 min. presentation + 3 min. live discussion/Q&A

Learning objectives

In this session we introduce the European Society of Residents in Urology (ESRU) and the Young Urology Office (YUO). The main aim of this session is to offer talks tailored to residents' educational needs. We present the traditional surgical tips and tricks with all you need to know about certain surgical procedures. Furthermore, we show what residents need to know on the most recent oncological studies. Modern surgical practice requires technical and non-technical skills. As a consolidated feature, we present also this year a session together with the Young Endourological society. We will finish with the great finale of the EAU Guidelines Cup, a competition between the three finalists of the Cup and also the audience.

15:15 - 15:25

Welcome and introduction

F. Esperto, Rome (IT)
J.P.M. Sedelaar, Nijmegen (NL)

15:25 - 15:35

European Urology Scholarship Programme (EUSP)

Moderator D.M. Carrión Monsalve, Madrid (ES)
V.G. Mirone, Naples (IT)
A.S. Merseburger, Lübeck (DE)

15:35 - 15:55

Research: Tips and tricks

Moderators S. Nikles, Zagreb (HR)
K.H. Pang, Leeds (GB)

15:35 - 15:45

How to conduct prospective collaborative research

V. Kasivisvanathan, London (GB)

15:45 - 15:55

How to get a grant for a research study

M.G.K. Cumberbatch, Sheffield (GB)

15:55 - 16:35

Surgery: Tips and tricks

Moderators G. Mantica, Genoa (IT)
T. Ucar, Istanbul (TR)

15:55 - 16:05

How to manage priapism? Clinical and surgical management

G.I. Russo, Catania (IT)

16:05 - 16:15

TURP: How to begin?

N.I. Osman, Sheffield (GB)

16:15 - 16:25

How to avoid complications during URS

E. Emiliani, Barcelona (ES)

16:25 - 16:35

Scrotal surgery

L.A. Kluth, Frankfurt (DE)

16:35 - 16:45

The European School of Urology (ESU)

J. Gómez Rivas, Madrid (ES)

16:45 - 17:05

Lectures for residents

Scientific Programme - EAU21 Virtual

Moderators

D. Karsza, Budapest (HU)

A. Mattigk, Ulm (DE)

16:45 - 16:55

Benefits of ejaculation in urology

M. Gül, Konya (TR)

16:55 - 17:05

Antibiotic resistance: The new issue!

Z. Tandoğdu, London (GB)

17:05 - 17:15

Winners Guidelines cup

J.L. Vásquez, Roskilde (DK)

Urinary tract and genital trauma

ESU Course 13

Saturday 10 July
15:30 - 17:30

Location Zoom 1

Chair N. Kitrey, Ramat Gan (IL)

Learning objectives

Trauma is a leading cause of morbidity and death. Most urologists are involved in the management of trauma patients, therefore need to understand and follow the basic principles.

The ESU urological trauma course details the epidemiology, mechanism of action, diagnosis, and management of urogenital trauma – renal, ureteric, bladder, urethra, and external genitalia. The course is based on the peer-reviewed yearly-updated EAU guidelines on urological trauma. Interactive case-based discussion will highlight the key points of trauma management.

15:30 - 17:30

Introduction and general trauma considerations
N. Kitrey, Ramat Gan (IL)

15:30 - 17:30

Renal trauma
D.M. Sharma, London (GB)

15:30 - 17:30

Ureteral Trauma
N. Kitrey, Ramat Gan (IL)

15:30 - 17:30

Bladder Trauma
N. Kitrey, Ramat Gan (IL)

15:30 - 17:30

Urethral Trauma
D.M. Sharma, London (GB)

15:30 - 17:30

Genital Trauma
N. Kitrey, Ramat Gan (IL)

Best of EAU21 abstracts

Abstract session

Saturday 10 July
16:00 - 17:00

Location Virtual Room 7

Chairs P. Albers, Düsseldorf (DE)
J-N.L. Cornu, Rouen (FR)

Learning objectives

This session will present the best poster abstracts of the EAU selected and presented by the track leaders and tracks of the Scientific Congress Office of the EAU. Viewing this session will give you an update of cutting-edge knowledge presented at EAU 21!

16:00 - 16:02

Introduction

16:02 - 16:07

Prostate cancer

A. Briganti, Milan (IT)

16:07 - 16:12

Imaging

J. Walz, Marseille (FR)

16:12 - 16:17

BPH/LUTS

J-N.L. Cornu, Rouen (FR)

16:17 - 16:22

Functional urology

J.P.F.A. Heesakkers, Maastricht (NL)

16:22 - 16:27

Renal cancer

A. Breda, Barcelona (ES)

16:27 - 16:32

Bladder cancer

M. Rouprêt, Paris (FR)

16:32 - 16:37

Upper Tract TCC

M. Rouprêt, Paris (FR)

16:37 - 16:42

Paediatric urology

M.S. Silay, Istanbul (TR)

16:42 - 16:47

Stones

T. Knoll, Sindelfingen (DE)

16:47 - 16:52

Andrology

M. Albersen, Leuven (BE)

16:52 - 16:57

Testis/Penile cancer

M. Albersen, Leuven (BE)

16:57 - 17:00

Closing remarks

Controversies in Bladder Cancer 2021: Rapid-fire debates

Live from the studio: Special Session

Saturday 10 July
16:45 - 18:15

Location Virtual room 1

Chairs
A.M. Kamat, Houston (US)
J. Palou, Barcelona (ES)
A. Stenzl, Tübingen (DE)

Learning objectives

- With case based discussions, multiple presenters have the opportunity to discuss nuances of common dilemmas facing urologic oncology patients and providers
- Use these evidence based debates to provide clear, rationale guidance on the timely management of difficult situations in bladder cancer

16:45 - 16:48

Session introduction

A.M. Kamat, Houston (US)

16:48 - 17:04

Rapid-fire debate Elderly patient with recurrent TaLG tumors, small size, negative cytology

16:48 - 16:49

Case presenter

M. Babjuk, Prague (CZ)

16:49 - 16:52

Discussant: TURBT + Intravesical therapy

M. Rouprêt, Paris (FR)

16:52 - 16:55

Discussant: Active surveillance + Fulguration

W. Kassouf, Montreal (CA)

16:55 - 16:57

Rebuttal

W. Kassouf, Montreal (CA)

M. Rouprêt, Paris (FR)

16:57 - 17:04

Summary and Q&A

M. Babjuk, Prague (CZ)

A.M. Kamat, Houston (US)

J. Palou, Barcelona (ES)

A. Stenzl, Tübingen (DE)

17:04 - 17:20

Rapid-fire debate Ileal conduit or continent diversion; which is a better choice for patient with GFR ~ 60

17:04 - 17:05

Case presenter

P. Black, Vancouver (CA)

17:05 - 17:08

Discussant: Conduit

H. Mostafid, Guildford (GB)

17:08 - 17:11

Discussant: Neobladder

J. Bedke, Tübingen (DE)

17:11 - 17:13

Rebuttal

J. Bedke, Tübingen (DE)

H. Mostafid, Guildford (GB)

17:13 - 17:20

Summary and Q&A

P. Black, Vancouver (CA)

A.M. Kamat, Houston (US)

J. Palou, Barcelona (ES)

A. Stenzl, Tübingen (DE)

17:20 - 17:36	Rapid-fire debate Otherwise healthy patient with T1HG disease plus CIS; what is the best treatment?
17:20 - 17:21	Case presenter R. Sanchez-Salas, Paris (FR)
17:21 - 17:24	Discussant: Intravesical therapy J. Palou, Barcelona (ES)
17:24 - 17:27	Discussant: Upfront radical cystectomy J.A. Witjes, Nijmegen (NL)
17:27 - 17:29	Rebuttal J. Palou, Barcelona (ES) J.A. Witjes, Nijmegen (NL)
17:29 - 17:36	Summary and Q&A A.M. Kamat, Houston (US) J. Palou, Barcelona (ES) R. Sanchez-Salas, Paris (FR) A. Stenzl, Tübingen (DE)
17:36 - 17:56	Rapid-fire debate Optimal therapy for patient with T0 after neoadjuvant chemotherapy
17:36 - 17:37	Case presenter S. Porten, San Francisco (US)
17:37 - 17:40	Discussant: Radical cystectomy K. Pohar, Columbus, Ohio (US)
17:40 - 17:43	Discussant: ChemoXRT A. Choudhury, Manchester (GB)
17:43 - 17:46	Discussant: Observation/Active Surveillance P. Gontero, Turin (IT)
17:46 - 17:49	Rebuttal A. Choudhury, Manchester (GB) P. Gontero, Turin (IT) K. Pohar, Columbus, Ohio (US)
17:49 - 17:56	Summary and Q&A A.M. Kamat, Houston (US) J. Palou, Barcelona (ES) S. Porten, San Francisco (US) A. Stenzl, Tübingen (DE)
17:56 - 18:12	Rapid-fire debate 52 yr old female patient, with partial response in retroperitoneal lymph nodes after 6 cycles of platinum based chemotherapy
17:56 - 17:57	Case presenter M.S. Van Der Heijden, Amsterdam (NL)
17:57 - 18:00	Discussant: Cystectomy plus RPLND S. Lerner, Houston (US)
18:00 - 18:03	Discussant: Alternative systemic therapy T. Powles, London (GB)
18:03 - 18:05	Rebuttal S. Lerner, Houston (US) T. Powles, London (GB)
18:05 - 18:12	Summary and Q&A A.M. Kamat, Houston (US) J. Palou, Barcelona (ES)

A. Stenzl, Tübingen (DE)
M.S. Van Der Heijden, Amsterdam (NL)

18:12 - 18:15

Closing remarks
A. Stenzl, Tübingen (DE)

Telemedicine in urology

Thematic Session 13

Saturday 10 July
16:30 - 17:30

Location Virtual Room 4

Chairs F. Dimitriadis, Kalamaria, Thessaloniki (GR)
S.M. Haensel, Rotterdam (NL)

Learning objectives

During the COVID-19 pandemic, telemedicine offered both outpatient and clinical urologists the ability to continue care for their patients. E-health benefits include reduced costs for patients and health systems, increased ease of accessing treatment, and better long-term results. Telemedicine is rapidly evolving, and new applications are coming to light, though not without producing skepticism concerning their acceptance. Furthermore, the advanced deployment of novel services created ethical and legal questions related to the European Data Protection law. This session explores the emerging chances of telemedicine and e-health in everyday clinical practice of outpatient and clinic urologists, highlighting the pros and cons.

16:30 - 16:35

Introduction: How COVID changed our everyday practice

F. Dimitriadis, Kalamaria, Thessaloniki (GR)

16:35 - 16:42

“The Virtual Urologist”: Applications and acceptance of telemedicine in outpatient and office urology

H. Brenneis, Pirmasens (DE)

16:42 - 16:45

Discussion

16:45 - 16:52

Utilisation of telemedicine in the pre- and postoperative course for in-hospital patients

H. Borgmann, Mainz (DE)

16:52 - 16:55

Discussion

16:55 - 17:02

Technical aspects of telemedicine: Making the pieces work together

D. Veneziano, Reggio Calabria (IT)

17:02 - 17:05

Discussion

17:05 - 17:12

Ethical and legal aspects of telemedicine

L.P. Zapala, Warsaw (PL)

17:12 - 17:15

Discussion

17:15 - 17:22

Financial aspects of telemedicine: Practical considerations

A. Zachariou, Volos (GR)

17:22 - 17:25

Discussion

17:25 - 17:30

Closing remarks: Telemedicine and e-health - the road ahead

S.M. Haensel, Rotterdam (NL)

Renal tumours: Locally advanced and metastatic disease

Poster Session 22

Saturday 10 July
17:00 - 18:00

Location Virtual Room 8

Chairs L. Albiges, Villejuif (FR)
M. Oya, Tokyo (JP)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Learning cutting edges of the subjects below:

- Surgeries for RCC with IVC thrombus
- Variant histology of RCC and angiomyolipoma including sarcomatoid variant and epithelioid angiomyolipoma
- Genetic testing of RCC and TSC
- Managing adverse events for patients treated with targeted agents or immune-checkpoint inhibitors
- Novel biomarkers for metastatic RCC
- Role of cytoreductive nephrectomy in the era of targeted agents and immunotherapy.

17:00 - 17:01

Introduction

17:01 - 17:15

Surgical aspects of advanced kidney tumors

P0623

Renal functional outcomes at 5 years from radical and partial nephrectomies in normal renal function patients: An untold story of hyperfiltrations
F. Trevisani, Milan (IT)

P0624

Prostate Specific Membrane Antigen (PSMA) PET/CT compared to standard of care imaging in the assessment of renal cancers: A multi-institutional series
A. Tariq, Windsor (AU)

P0625

Robot-assisted radical nephrectomy and inferior vena cava level I-III thrombectomy: An update on perioperative and mid-term oncologic outcomes from a tertiary-referral centre
U. Anceschi, Rome (IT)

P0626

Survival analysis of Renal Cell Carcinoma with venous tumor thrombus: A single centre 20-yr experience
M.L. Righetto, Padova (IT)

P0627

Predictive factors of recurrence after surgery in patients with non-metastatic renal cell carcinoma with venous tumor thrombus (uroccr-56 study) and the impact of adjuvant treatment
M. Baboudjian, Marseille (FR)

P0628

Radical nephrectomy and caval thrombectomy with heart beating technique for renal cell cancer with tumor thrombus extension into inferior vena cava and right atrium: A less invasive multidisciplinary approach
S. Guzzo, Vanzago (IT)

17:07 - 17:15	Discussion
17:15 - 17:31	Impact of variant histology
P0629	Cognitive function after cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of renal cell carcinoma with IVC tumor thrombus J. Huang, Shanghai (CN)
P0630	The natural history of sarcomatoid renal-cell carcinoma, a stage-by-stage analysis K.H. Tully, Herne (DE)
P0631	Methylthioadenosine Phosphorylase (MTAP) deletion is more common in Sarcomatoid (srcRCC) than in clear cell Renal Cell Carcinoma (ccRCC) A. Necchi, Milan (IT)
P0632	Construction and validation of a robust genomic classifier for high-risk sporadic type 2 papillary renal cell carcinoma: support more accurate utilization of mTOR inhibitors X. Tian, Shanghai (CN)
P0633	Papillary renal cell carcinoma type I and II: Two distinct diseases with different clinical and therapeutical implications G. Rosiello, Bacoli (IT)
P0634	Evaluation of clinicopathological profiles and development of a risk model in epithelioid angiomyolipoma patients: A large-scale Chinese retrospective study A. Anwaier, Shanghai (CN)
P0635	A familial TSC1 exon 5 microdeletion associated with angioliomas and renal-cell carcinoma: A mTORopathy Tunisian familial pedigree B. Abdelmoula, Sfax (TN)
P0636	External validation of the VHL alliance guidelines for VHL genetic testing in patients diagnosed with renal cell carcinoma A. Larcher, Milan (IT)
17:23 - 17:31	Discussion
17:31 - 17:55	Metastatic disease, role of cytoreductive nephrectomy
P0637	Does the time before starting first-line treatment influences the survival of patients with metastatic renal cell cancer in favorable-risk groups? C. Rolley, Angers (FR)
P0638	Overall Adverse events of drugs for metastatic renal cell carcinoma: Real world reporting patterns from eudra vigilance database C. De Nunzio, Rome (IT)
P0639	Severe immune-related adverse events in nivolumab-treated patients with metastatic RCC are associated to PDCD1 polymorphism K. Numakura, Akita (JP)
P0640	Renal mass size and presence of synchronous lung metastasis at time of diagnosis: Implications for chest imaging M. Jamil, Detroit (US)
P0641	Evaluation of a panel of preoperative blood-based systemic inflammatory response biomarkers for outcome prediction in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma E. Laukhtina, Moscow (RU)
P0642	Prognostic significance of radiologic infiltrative feature of primary renal tumor in metastatic renal cell carcinoma H. Tanaka, Tokyo (JP)

P0643	Is presence of vena caval thrombosis in primary tumor associated with worsened outcomes in metastatic renal cell carcinoma: Analysis of the REMARCC registry M.F. Meagher, La Jolla (US)
P0644	Optimizing patient selection for deferred cytoreductive nephrectomy in the contemporary era of targeted therapy J. Choy, London (GB)
P0645	The role of cytoreductive nephrectomy for metastatic renal cell carcinoma in National Health Insurance Service J. Gook, Seoul (KR)
P0646	Cytoreductive nephrectomy in patients receiving TKI therapy versus immune checkpoint inhibitor therapy: Comparative outcome analysis of the REMARCC registry M.F. Meagher, La Jolla (US)
P0647	Nephrectomy after complete response to immune checkpoint inhibitors for Metastatic Renal Cell Carcinoma (mRCC): A surgical challenge allowing favorable oncological outcomes G. Pignot, Marseille (FR)
P0648	Predictors of complications after cytoreductive nephrectomy in the immunotherapy era: Results from a multicenter international study M. Marchioni, Cantalice (RI) (IT)
P0649	Surgical safety of Cytoreductive Nephrectomy (CN) following pretreatment with Immune Checkpoint Inhibition (ICI) combination therapy in primary metastatic clear-cell Renal Carcinoma (mccRCC) N.M. Graafland, Amsterdam (NL)
P0650	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma E. Laukhtina, Moscow (RU)
P0651	Management of local recurrence after radical nephrectomy: Surgical removal is still the gold standard. Results from a multicenter international cohort M. Marchioni, Cantalice (RI) (IT)
P0652	Urine free glycosaminoglycans as monitoring biomarkers in confined renal cell carcinoma - A prospective observational study F. Gatto, Solna (SE)
17:47 - 17:55	Discussion
17:55 - 18:00	Expert summary U. Capitanio, Milan (IT)

Prostate cancer screening and active surveillance – Where are we now?

ESU Course 12

Saturday 10 July
13:00 - 15:00

Location Zoom 1

Chair A.R. Zlotta, Toronto (CA)

Learning objectives

- Prostate cancer is a global public health concern. While large randomized trials have shown a reduction in prostate cancer mortality with regular prostate-specific antigen (PSA) screening, there is potential for negative effects from over-diagnosis and treatment, making screening a controversial topic. This course will provide an overview of the evidence of both benefits and harm from the randomized trials as well as data from epidemiological studies illustrating the global incidence and mortality trends.
- Today's challenges include the age when to start screening, screening intervals and the optimal use of "smarter screening". This course will cover the EAU-ESTRO-SIOG guidelines and other risk-stratified approaches to screening based on age, health and PSA-values, family history, ethnicity and genetic risk.
- Magnetic resonance imaging (MRI) offers improved visualization of potentially significant prostate cancers and thus has shown advantages as a means by which to select patients for biopsy and facilitate direct targeting of lesions during biopsy. MRI is now also studied as a screening tool and its current status in screening studies, alone or in combination with other parameters will be discussed.
- Active surveillance (AS) is now widely accepted as a management strategy for low risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Several AS studies have consistently shown a low rate of progression to metastatic disease or death from prostate cancer with AS, with the majority of patients remaining free from definitive therapy for many years.
- AS is also an accepted and safe management strategy in select patients with favorable intermediate risk PCa, at least in the short term. However intermediate-risk PCa consists of a highly heterogeneous group of patients and eligibility criteria for suitable AS candidates differ. The course will address this important issue.
- Clinical, genetic (such as BRCA2 germline mutations) and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under AS will be discussed, together with surveillance strategies, the role of repeat biopsy, timing and interval for repeat biopsy, inclusion criteria, and the use of MRI.
- The course will be interactive and include illustrative and practical clinical case discussions.

13:00 - 15:00

Case discussion

A.R. Zlotta, Toronto (CA)

13:00 - 15:00

Screening: • Who, when and how often to screen • “Smart screening” • MRI, genetics and biomarkers

S. Carlsson, New York (US)

M. Eklund, Stockholm (SE)

13:00 - 15:00

Case discussion

A.R. Zlotta, Toronto (CA)

13:00 - 15:00

Active surveillance: • Clinical, pathological and genetic factors influencing the risk of disease progression • Favourable intermediate risk amenable to AS • MRI and repeat biopsy • International guidelines, recent changes in management and controversies • What lies in the future

A.R. Zlotta, Toronto (CA)

M. Eklund, Stockholm (SE)

New perspectives in inguinal and pelvic lymph node dissection

Video Session 10

Saturday 10 July
17:45 - 18:30

Location Virtual Room 2

Chairs M. Falcone, Torino (IT)
A. Muneer, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:45 - 17:47

Introduction

V28

Saphenous sparing ascending video-endoscopic inguinal lymph node dissection (VEILND-AS+) using a leg approach: Surgical technique, perioperative and pathological outcomes
C.D. Fankhauser, Lucerne (CH)

V29

Video endoscopic inguinal lymphadenectomy: Step-by-step technique and mid-term oncological outcomes
A. Gallioli, Barcelona (ES)

V30

ICG guided laparoscopic pelvic lymph node dissection for prostate cancer
A. Civitella, Rome (IT)

18:23 - 18:26

Conclusion

A tale of three kidneys: Complex and salvage robotic kidney surgery

Video Session 11

Saturday 10 July
17:45 - 18:30

Location Virtual Room 3

Chairs C.K. Bensalah, Rennes (FR)
M.C. Mir Maresma, Valencia (ES)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:45 - 17:47

Introduction

V31

Salvage robot-assisted renal surgery for local recurrence after surgical resection or renal mass ablation: Classification, techniques and clinical outcomes
A. Martini, Milan (IT)

V32

Monocentric experience of Robot-assisted radical nephrectomy with vena cava thrombectomy: Technique and results
L. Gobinet, Bordeaux (FR)

V33

Robotic nephrectomy with inferior vena cava thrombectomy: A good indication also in case of haemodynamic instability
A. Caviglia, Genova (IT)

18:22 - 18:25

Conclusion

Robotic partial nephrectomy - get your clamp off!

Video Session 12

Saturday 10 July
17:45 - 18:30

Location Virtual Room 5

Chairs U. Capitanio, Milan (IT)
A. Antonelli, Verona (IT)

All presentations have a maximum length of 8 minutes. First 2 presentations and last 2 presentations are followed by 5 minutes of discussion.

17:45 - 17:47

Introduction

V34

Sutureless purely off-clamp robotic partial nephrectomy: Surgical technique and outcomes

A. Brasseti, Rome (IT)

V35

Purely off-clamp robot-assisted partial nephrectomy for totally endophytic renal tumors: Surgical technique and mid-term outcomes of a single center series

G. Tuderti, Roma (IT)

18:00 - 18:05

Discussion

V36

Robot-assisted partial nephrectomy for ruptured angiomyolipomas: A multi institutional series

A. Uleri, Pieve Emanuele (IT)

V37

Robot Assisted Partial Nephrectomy using Intra-Arterial Renal Hypothermia for Highly Complex Endophytic or Hilar Tumors: Case series and Description of Surgical Technique

P. De Backer, Erembodegem (BE)

18:21 - 18:26

Discussion

18:26 - 18:29

Conclusion

Penile and testis cancer

Poster Session 24

Saturday 10 July
18:15 - 19:15

Location Virtual Room 6

Chairs O.R. Brouwer, Amsterdam (NL)
N.W. Clarke, Manchester (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Novel insights and developments in penile and testicular cancer

18:15 - 18:16

Introduction

18:16 - 18:31

Testis localised and biomarkers

P0653

Anxiety and depressive symptom prevalence in testicular cancer patients: A systematic review

A.N. Dincer, London (GB)

P0654

Management of indeterminate Small Testis Masses (STMs): A 10-year single centre experience

S.W. Wardak, London (GB)

P0655

Development of a predictive model utilising lesion size as a cutoff to predict testicular cancer in patients with small testicular masses

S.W. Wardak, London (GB)

P0656

Analysis of clinical characteristics, treatment patterns, and outcome of patients with bilateral testicular germ cell tumors

A. Hoffman, Kfar Yehoshua (IL)

P0657

Oncological and functional outcomes after testis sparing surgery in men with germ cell tumors: A systematic review and individual patient meta-analysis of 285 men

J.B. Grogg, Zurich (CH)

P0658

The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens

T. Nestler, Cologne (DE)

P0659

The new tumor biomarker miRNA-371-3p is involved in mediating cisplatin resistance in testicular germ cell tumor cell lines

T. Engler, Bonn (DE)

P0660

The new tumor biomarker miRNA-371a-3p in testicular germ cell tumours: First insights into the molecular function in vitro

R. Weiten, Bonn (DE)

P0661

Corona, higher risk for testicular cancer development?

M. von Brandenstein, Köln (DE)

18:25 - 18:31	Discussion
18:31 - 18:42	Testis post-chemo dilemma
P0662	Post-chemotherapy residual tumor resection in patients with elevated tumor markers Y. Che, Düsseldorf (DE)
P0663	Perioperative safety and short-term oncological outcomes of minimally invasive retroperitoneal lymph node dissection C.D. Fankhauser, Lucerne (CH)
P0664	Retroperitoneal lymphadenectomy after chemotherapy in seminoma – an update on feasibility P. Paffenholz, Cologne (DE)
P0665	Discordant histology of abdominal and thoracic post chemotherapy residual tumor resection in patients with metastatic germ cell tumor C. Buddensieck, Düsseldorf (DE)
P0666	Targeted therapy in patients with chemorefractory, progressing testicular germ cell tumors A. Heidenreich, Cologne (DE)
18:36 - 18:42	Discussion
18:42 - 18:57	Penile localised and staging
P0667	Long term outcomes of Dynamic Sentinel Lymph Node Biopsy (DSNB) for clinically impalpable (cN0) penile cancer patients- an eUROGEN study E. Pozzi, Milan (IT)
P0668	c-MET receptor-targeted fluorescence on the road to image-guided surgery in penile squamous cell carcinoma patients H.M. De Vries, Leiden (NL)
P0669	Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer: Evaluation at a single high-volume center L. Wever, Amsterdam (NL)
P0670	Penile preserving Surgery vs. partial amputation of penis: Functional assessment of sexual and urinary function using patient reported outcomes measures P. Gordon, Leeds (GB)
P0671	Oncoplastic penile surgery: Patients' perceptions of form and function S.M. Croghan, Sutton (IE)
P0672	Outcomes in men undergoing complex circumcision: An aid to consent and litigation A. Issa, Manchester (GB)
P0673	Treatment options and outcomes of men with Penile Intraepithelial Neoplasia (PeIN): A systematic review A. Issa, Manchester (GB)
P0674	Clinical analysis of urethral stricture with urethral squamous cell carcinoma caused by lichen sclerosing in male genitalia Q. Fu, Shanghai (CN)
P0675	Long term functional and oncological outcomes of urethral reconstruction for invasive and non-invasive squamous carcinoma of the male urethra M. Skrodzka, London (GB)
18:51 - 18:57	Discussion
18:57 - 19:10	Penil metastatic

P0676	miRNA expression characterizes histological subtypes and metastasis in penile squamous cell carcinoma A. Hires, Homburg (DE)
P0677	Clinically advanced pelvic Squamous Cell Carcinomas (pSCC) in men and women: A Comprehensive Genomic Profiling (CGP) study A. Necchi, Milan (IT)
P0678	Elements of Wnt/β-catenin signaling pathway as prognostic biomarkers and therapeutic targets in penile squamous cell carcinoma A. Thomas, Mainz (DE)
P0679	Patterns and mechanisms of resistance to cisplatin and osimertinib in penile squamous cell carcinoma A. Thomas, Mainz (DE)
P0680	A phase II study to evaluate safety and efficacy of PD-1 blockade plus anti-EGFR target therapy plus chemotherapy in patients with advanced penile squamous cell carcinoma Y. Shi, Guangzhou (CN)
P0681	Factors associated with additional tumour-bearing lymph nodes at completion ILND after positive DSNB for penile cancer staging: A European multicentre evaluation H.M. De Vries, Leiden (NL)
P0682	Long-term outcomes of Penile Squamous Cell Carcinoma (SCC) patients with sarcomatoid variant compared to non-sarcomatoid group - An eUROGEN study H.M. Alnajjar, London (GB)
19:04 - 19:10	Discussion
19:10 - 19:15	Expert summary R. Hamilton, Toronto (CA)

Miscellaneous: Rare and complex urology and all about adrenals

Poster Session 23

**Saturday 10 July
18:15 - 19:15**

Location Virtual Room 7

Chairs S. Mourad, New Cairo (EG)
P.D. Violette, Woodstock (CA)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

18:15 - 18:16

Introduction

P0683	Identifying changes in the zona glomerulosa of adrenals in patients below the age of 40 years A.H. Chaman Baz, Nijmegen (NL)
P0684	Unilateral adrenalectomy in bilateral adrenal hyperplasia with primary aldosteronism Y-C. Lu , Taipei (TW)
P0685	Surgical quality, antihypertensive therapy and electrolyte balance: A novel trifecta for evaluating outcomes of unilateral primary aldosteronism U. Anceschi, Rome (IT)
P0686	The TIS score for the prediction of long-term clinical outcomes after minimally-invasive partial and total adrenalectomy for unilateral primary aldosteronism: Results of a multicentric series U. Anceschi, Rome (IT)
P0687	Comparative study of Adrenal Fast Track and Enhanced Recovery (AFTER) protocol for retroperitoneoscopy in patients with primary aldosteronism E. Van de Wiel, Nijmegen (NL)
P0688	Partial versus total adrenalectomy for the treatment of unilateral primary aldosteronism: A systematic review and meta-analysis T. Wu, Nanchong (CN)
P0689	Preoperative factors associated with intraoperative maximum arterial pressures in patients with pheochromocytoma and paraganglioma H. Ohsugi, Hirakata (JP)
P0690	Adrenalectomy for pheochromocytoma: Complications and predictive factors of intraoperative hemodynamic instability F. Taniel, Rennes (FR)
P0691	Laparoscopic treatment of adrenocortical carcinoma: Single center experience L. Penezić, Zagreb (HR)

P0692	Adrenocortical Carcinoma with venous tumor invasion. Is there a role for mini-invasive surgery? A. Olivero, Torino (IT)
P0693	Laparoscopic retroperitoneal adrenalectomy for large adrenal tumors: Is there any limit? Y-C. Hsieh, Tainan (TW)
P0694	Minimally invasive retroperitoneal adrenalectomy in oligometastatic disease recurrence post nephrectomy – a safe and feasible approach D. Sri, Morden (GB)
P0695	Perioperative outcomes of open, laparoscopic and robotic adrenalectomy: A multicenter experience N. Selvaraj, Erode (IN)
P0696	Development and validation of a new nomogram for predicting surgical outcome in posterior retroperitoneoscopic adrenalectomy based on preoperative patient characteristics A. Van Uitert, Nijmegen (NL)
P0697	Chronic pain and localized hypoesthesia following minimally invasive adrenalectomy: Prevalence and impact on quality of life A. Van Uitert, Nijmegen (NL)
18:31 - 18:42	Discussion
18:42 - 18:47	Malignant lower urinary tract, cystectomy
P0698	The diagnostic value of [18F]-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET/CT) for urachal cancer L.E. Stokkel, Amsterdam (NL)
P0699	Urological outcomes after total pelvic exenteration – Ten-year experience at a single institution K. Rajan, Swansea (GB)
P0700	Supratrigonal cystectomy as a last line treatment for radiation-induced hemorrhagic cystitis J.A. Pereira, Barcelos (PT)
P0701	Prospective detailed analysis of the outcomes of patients with malignant ureteral obstruction referred to urology as an emergency R. Hawthorne, Bristol (GB)
P0702	Is partial cystectomy safe for non-urologic malignant tumors invading bladder wall? A ten year follow-up report G. dos Anjos Silva, Sao paulo (BR)
18:47 - 18:51	Urodynamics, neurogenic, functional, vesical varices
P0703	The Postural Tachycardia Syndrome (PoTS) bladder - urodynamic findings N.A. Faure Walker, London (GB)
P0704	Evaluation of PTEN inhibitor following spinal cord injury on recovery of voiding efficiency and motor function observed by regeneration in spinal cord
P0705	Urodynamics in the evaluation of lower urinary tract symptoms in young adult males: A systematic review G. Singh, Hoshiarpur (IN)
P0706	Cystic papillary adenoma of the seminal vesicle – A distinct histological entity B. Heijkoop, Unley Park (AU)

18:51 - 18:55	Retroperitoneal fibrosis, pregnancy, SWL, horseshoe
P0707	Drugs associated the most with retroperitoneal fibrosis: Assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database N. Schifano, Milan (IT)
P0710	The model for predicting a complicated course of supravescical obstruction during pregnancy M. Khasanov, Tashkent (UZ)
P0709	Outcomes of a modified Shock Wave Lithotripsy (SWL) service offering multiple sessions and including patients with poor prognostic factors during the Coronavirus pandemic C. Ross, Manchester (GB)
P0708	Is robotic surgery safe and feasible for horseshoe kidneys? A multicentre case series A. Ng, London (GB)
18:55 - 19:10	RCC, COVID and cell biology/basic science
P0711	Extracorporeal partial nephrectomy with orthotopic autotransplantation in conditions of pharmaco-cold ischemia for renal cell carcinoma: A single center experience T.P. Baitman, Moscow (RU)
P0712	Mutation associated with Fanconi anemia pathway may increase patients' second primary malignancy risk: Results from somatic and germline testing of clear cell papillary renal cell carcinoma X. Tian, Shanghai (CN)
P0713	Urological emergency care for patients with covid-19: Practical experience of specialized department S.O. Sukhikh, Moscow (RU)
P0714	Long-lasting ex-4-Loaded carbohydrate Polymeric PLGA NPs ameliorate cerebral ischemia/reperfusion injury through efficiently inhibiting oxidative stress, endoplasmic reticulum stress, apoptosis, autophagy and pyroptosis signaling in diabetic rats C.Y. Chang, New Taipei City (TW)
P0715	TP53-dependent release of Extracellular Vesicles (EVs) from urological malignancies affects functional status of tumor associated macrophages and therapy response B. Köditz, Köln (DE)
19:00 - 19:10	Discussion
19:10 - 19:15	Conclusion P.D. Violette, Woodstock (CA)

Practical management of non-muscle-invasive bladder cancer (NMIBC)

ESU Course 15

**Sunday 11 July
08:00 - 10:00**

Location Zoom 1

Chair J.A. Witjes, Nijmegen (NL)

Learning objectives

This course starts with addressing the initial diagnosis of NMIBC with innovations. Then, the mainstay of NMIBC treatment, the TUR, will be extensively discussed and demonstrated with video's, including TUR techniques such as en bloc resection, TUR in difficult places such as a diverticulum, the use of enhanced imaging such as PDD and NBI.

After that trouble shooting during TUR will be discussed and what to do or how to avoid complications.

After discussing the TUR, we will also discuss additional treatment: as well the guideline recommendations as when there might be exceptions to the rule or innovations. As we discussed problems with TUR, we will also address complications of instillation therapy and how to treat/avoid.

Finally a topic that remains a clinical problem remains on the program: How to deal with abnormal cytology including locations outside the bladder.

We will try to keep the course as practical as possible, even in the virtual world, and we certainly reserve time for interaction and questions.

The final goal is that attendees will have updated their TUR skills and guideline knowledge, but also know what (not) to do in exceptional or complicated cases, and what alternatives could be.

08:00 - 10:00

Introduction

J.A. Witjes, Nijmegen (NL)

08:00 - 10:00

Diagnosis NMIBC, including markers and innovations

J. Palou, Barcelona (ES)

08:00 - 10:00

TUR technique (tips and tricks; problems; en bloc, TUR and the location, diverticula, ureteral meatus; Re-TUR; PDD, SPIES, NBI)

M. Babjuk, Prague (CZ)

08:00 - 10:00

Complications during surgery and what to do: Obturator nerve contraction, intra and extraperitoneal perforation, bleeding etc.

J. Palou, Barcelona (ES)

08:00 - 10:00

Risk groups and guideline treatment and follow up: What it is clearly established, including markers for follow up

J.A. Witjes, Nijmegen (NL)

08:00 - 10:00

Comment on guideline treatment including BCG shortage and new treatment modalities

M. Babjuk, Prague (CZ)

08:00 - 10:00

Complications of intravesical therapy, including case

J.A. Witjes, Nijmegen (NL)

Scientific Programme - EAU21 Virtual

08:00 - 10:00

How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations
J. Palou, Barcelona (ES)

08:00 - 10:00

Closure
J.A. Witjes, Nijmegen (NL)

Robot-assisted laparoscopic radical cystectomy: Intracorporeal urinary diversions and nerve-sparing techniques. Surgical tricks and management of complications

ESU Course 14

Saturday 10 July
18:00 - 20:00

Location Zoom 1

Chair P. Wiklund, Stockholm (SE)

Learning objectives

The course is video based. The steps in the surgical treatment of muscle invasive bladder cancer by conventional laparoscopy and robot-assisted technique will be described. The surgical technique to perform Male and female cystectomy, lymph node dissection, urinary diversion with extracorporeal and intracorporeal technique, conduits as well as orthotopic neobladders, will be shown. Indications, contraindications, outcomes and handling of complications will be discussed.

- The surgical steps in nerve sparing and non-nerve sparing male cystectomy.
- The surgical steps in female cystectomy with and without organ sparing technique.
- The surgical steps in lymph node dissection during cystectomy.
- The technique in urinary diversion, conduit and neobladder, with intra and extracorporeal technique.
- Indications, outcomes and complications after minimally invasive cystectomy.
- The handling of the most common complications after minimally invasive cystectomy.

18:00 - 18:03

Introduction

P. Wiklund, Stockholm (SE)

18:03 - 18:13

Port placement and pre op considerations

C.J. Wijburg, Arnhem (NL)

18:13 - 18:18

Questions and answers

C.J. Wijburg, Arnhem (NL)

18:18 - 18:33

Male cystectomy

A. Minervini, Florence (IT)

18:33 - 18:38

Questions and answers

A. Minervini, Florence (IT)

18:38 - 18:53

Female cystectomy, exenteration and organ-sparing

P. Wiklund, Stockholm (SE)

18:53 - 18:58

Questions and answers

P. Wiklund, Stockholm (SE)

18:58 - 19:03

Urinary diversion Bricker

C.J. Wijburg, Arnhem (NL)

19:03 - 19:08

Questions and answers

C.J. Wijburg, Arnhem (NL)

19:08 - 19:23

Urinary diversion neobladder

A. Minervini, Florence (IT)

Scientific Programme - EAU21 Virtual

19:23 - 19:28

Questions and answers

A. Minervini, Florence (IT)

19:28 - 19:43

Outcomes

P. Wiklund, Stockholm (SE)

19:43 - 19:48

Questions and answers

P. Wiklund, Stockholm (SE)

Game changing session 5

Live from the studio: Game changer session

Sunday 11 July
11:15 - 11:45

Location

Virtual room 1

Chairs

A. Briganti, Milan (IT)
K. Fizazi, Villejuif (FR)
S. Gillessen Sommer, Bellinzona (CH)
A. Villers, Lille (FR)

11:15 - 11:25

Phase 3 study of ^{177}Lu -PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)
J. De Bono, London (GB)

11:25 - 11:35

TheraP Phase 2 trial of Lu-PSMA-617 versus cabazitaxel: Results and contrasts to VISION
M. Hofman, Melbourne (AU)

11:35 - 11:45

Discussant
S. Gillessen Sommer, Bellinzona (CH)

Game changing session 6

Live from the studio: Game changing session

Sunday 11 July 11:30 - 11:45	Location	Virtual Room 3
	Chairs	M. Albersen, Leuven (BE) A. Motttrie, Aalst (BE) T.S. O'Brien, London (GB)
11:30 - 11:45	To transect or not - a randomized Scandinavian study of sexual dysfunction after urethroplasty	
11:30 - 11:38	Presenter	O.J. Nilsen, Oslo (NO)
11:38 - 11:45	Discussant	A. Mundy, London (GB)

Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)

ESU Course 16

Sunday 11 July
10:30 - 12:30

Location

Zoom 1

Chair

S. Shariat, Vienna (AT)

Learning objectives

Upper tract urothelial carcinoma (UTUC) is an uncommon disease with little evidence-based data to guide clinical decision-making. Recently, the tools available for the diagnosis and management of UTUC have improved significantly, complementing a growing understanding of the biology of this disease. UTUC requires appropriate management at all stages, since both the cure rate and morbidity are very sensitive to nuances of treatment. Yet proper risk stratification remains a challenge owing to the difficulty of clinical staging. This course will address contemporary concepts and controversies, including the timely and accurate diagnosis of UTUC, emphasizing the integration of pathologic and radiographic variables for appropriate risk stratification. Important features regarding the natural history of UTUC will also be emphasized; the role of imaging and endoscopy in clinical decision making, diagnosis, staging and follow-up; and, common pathways of metastatic spread. Up-to-date information regarding boundaries of surgical resection, indication and extent of lymphadenectomy, clinical staging of UTUC, and the role of perioperative chemotherapy in patients with high risk UTUC will be detailed. Patient selection and treatment options for patients with UTUC such as endoscopic management, distal ureterectomy, radical nephroureterectomy and chemotherapy will be discussed.

Objectives: After attending this course, participants should be able to:

- Identify problems associated with clinical staging of UTUC
- Illustrate importance of accurate staging techniques and their role in clinical decision making maximize ureteroscopic diagnostic biopsy and tumor resection
- Be aware of newer modalities such as optical coherence tomography and other novel staging methods
- Cite current concepts and controversies in the management of low-stage and high-stage UTUC
- Discuss and compare the risk, benefit, and side effects of laparoscopic and open radical nephroureterectomy
- Understand the management of the bladder cuff
- Understand the current role of multimodal therapy for high risk patients- integration of systemic therapy – neo-adjuvant vs. adjuvant treatment
- Discuss the need and boundaries of the recommended lymph node dissection know the current management of metastatic UTUC.

10:30 - 10:45

Epidemiology, genetics, imaging, diagnosis

M. Rouprêt, Paris (FR)

10:45 - 10:50

Questions and answers

M. Rouprêt, Paris (FR)

10:50 - 11:10

Accurate risk stratification and pathology (with video)

S. Shariat, Vienna (AT)

11:10 - 11:15

Questions and answers

S. Shariat, Vienna (AT)

Scientific Programme - EAU21 Virtual

11:15 - 11:35	Treatment of low risk cancer (with video) M. Rouprêt, Paris (FR)
11:35 - 11:40	Questions and answers M. Rouprêt, Paris (FR)
11:40 - 12:00	Treatment of localized high risk (invasive) (with video) P. Gontero, Turin (IT)
12:00 - 12:05	Questions and answers P. Gontero, Turin (IT)
12:05 - 12:20	Treatment of metastatic disease S. Shariat, Vienna (AT)
12:20 - 12:25	Questions and answers S. Shariat, Vienna (AT)

Treatment for metastatic hormone-sensitive prostate cancer

Live from the studio: Plenary session 05

Sunday 11 July
11:45 - 13:15

Location Virtual room 1

Chairs
A. Briganti, Milan (IT)
K. Fizazi, Villejuif (FR)
S. Gillessen Sommer, Bellinzona (CH)
A. Villers, Lille (FR)

Learning objectives

Metastatic hormone-sensitive prostate cancer can be approached with a variety of treatment options. This session examines the options for treatment of both de-novo and recurrent mHSPCa. Case discussion place the lessons in a "daily practice" scenario, so that participants see the practical implications of their choice of treatment.

11:45 - 11:53	State-of-the-art lecture De novo versus recurrent metastatic mHSPC: What is the role of modern imaging? D. Murphy, Melbourne (AU)
11:53 - 12:36	Treatment options for de-novo mHSPCa
11:53 - 12:01	Systemic treatments: How to choose the right treatment for the right patient N.W. Clarke, Manchester (GB)
12:01 - 12:06	Local treatment: Radiation therapy (primary +/- lymph nodes) P. Ost, Ghent (BE)
12:06 - 12:11	Local treatment: Surgery (primary +/- lymph nodes) A. Briganti, Milan (IT)
12:11 - 12:19	Future: Personalised medicine for mHSPCa? K. Fizazi, Villejuif (FR)
12:19 - 12:36	Case discussion Patient with high volume disease <i>Case presenter</i> M. Heck, Munich (DE) <i>Panel</i> N.W. Clarke, Manchester (GB) A. Briganti, Milan (IT) K. Fizazi, Villejuif (FR) P. Ost, Ghent (BE)
12:36 - 13:10	Treatment options for recurrent mHSPCa
12:36 - 12:44	Systemic treatments: When and how? C. Sweeney, Boston (US)
12:44 - 12:49	The role of imaging-guided treatments: Radiotherapy P. Blanchard, Villejuif (FR)
12:49 - 12:54	The role of imaging-guided treatments: Surgery T. Maurer, Hamburg (DE)
12:54 - 13:10	Case discussion Patient with oligometastatic disease <i>Case presenter</i> R.C.N. Van Den Bergh, Nieuwegein (NL) <i>Panel</i> P. Blanchard, Villejuif (FR) T. Maurer, Hamburg (DE) C. Sweeney, Boston (US)
13:10 - 13:15	Closing remarks

Reconstructive surgery: Did the robot take over?

Live from the studio: Plenary Session 06

Sunday 11 July
11:45 - 13:15

Location Virtual Room 3

Chairs M. Albersen, Leuven (BE)
A. Motttrie, Aalst (BE)
T.S. O'Brien, London (GB)

Learning objectives

With ever-increasing applications for robot-assisted surgery in urology, in this session we examine the role of the robot in reconstructive surgery. This session covers kidney transplantation, ureteral injuries, paediatric urology, the intracorporeal neobladder and finally using reconstruction techniques during robotic prostatectomies in order to improve continence. A quick succession of video-based flash presentations will demonstrate different techniques for creating a neobladder.

11:45 - 12:20

Robotic reconstruction in urological surgery

11:45 - 11:55

American Urological Association (AUA) lecture Robotic management of Uretero-Pelvic Junction obstruction in conjunction with calculi management

R. Thomas, New Orleans (US)

11:55 - 12:00

Robotic kidney transplantation: Not fiction anymore

A. Breda, Barcelona (ES)

12:00 - 12:05

Robotic management of iatrogenic ureteral injuries

J. Rassweiler, Heilbronn (DE)

12:05 - 12:10

Robotic surgery in paediatric urology: Big tech for small bellies?

A-F. Spinoit, Ghent (BE)

12:10 - 12:20

Discussion

12:20 - 12:45

Intracorporeal Neobladder: Functionally as good as open?

Moderator J. Palou, Barcelona (ES)

12:20 - 12:25

Case presentation

J. Palou, Barcelona (ES)

12:25 - 12:30

Video-based presentation Studer neobladder

P. Wiklund, Stockholm (SE)

12:30 - 12:35

Video-based presentation VIP neobladder

F. Dal Moro, Padova (IT)

12:35 - 12:40

Video-based presentation Florence neobladder

A. Minervini, Florence (IT)

12:40 - 12:45

Video-based presentation Y neobladder

R. Gaston, Bordeaux (FR)

12:45 - 12:55

Panel discussion on intracorporeal neobladder

Challenger: Are functional outcomes good enough?

J.P.F.A. Heesakkers, Maastricht (NL)

12:45 - 12:55

Panel

F. Dal Moro, Padova (IT)
R. Gaston, Bordeaux (FR)
A. Minervini, Florence (IT)
J. Palou, Barcelona (ES)
P. Wiklund, Stockholm (SE)

12:55 - 13:15	Debate Should we use reconstruction techniques to improve continence during robotic prostatectomy?
12:55 - 13:00	Yes A. Tewari, New York (US)
13:00 - 13:05	No M. Graefen, Hamburg (DE)
13:05 - 13:15	Discussion

NMIBC: New insights for the diagnosis, management and follow-up

Poster Session 25

Sunday 11 July
12:00 - 13:00

Location Virtual Room 6

Chairs A.M. Kamat, Houston (US)
B. Pradere, Toulouse (FR)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Through nearly 30 posters presentations, attendees will have the opportunity to update their knowledge regarding the diagnosis and follow-up of NMIBC. Tremendous presentations from all over the world will provide the most recent advances especially in imaging and urinary biomarker test.

All the session will be alternatively posters presentations and discussions to allow you to exchange and ask your questions.

Attending this session will allow you to clarify the most exciting upcoming challenges in the field of NMIBC diagnosis

12:00 - 12:01

Introduction

P0716	Early PDD cystoscopy after BCG induction for high-risk non-muscle invasive bladder cancer significantly increased the detection of BCG-refractory tumors M. Morelli, Milan (IT)
P0717	Time to turn on the blue lights: A systematic review and meta-analysis of photodynamic diagnosis for bladder cancer P. Gravestock, Newcastle upon Tyne (GB)
P0718	Impact of clinical and pathological subtypes of Carcinoma In Situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG J.D. Subiela Henríquez, Barcelona (ES)
P0719	Does anticoagulant drug use affect the diagnosis and staging of bladder cancer? C. Ozcan, Ankara (TR)
P0720	All HG NMIBC is high risk: BCG response in HG Ta lesions K.K. Bree, Houston (US)
P0721	Natural course of low-risk Non-Muscle-Invasive Bladder Cancers (NMIBC): A 10 year follow-up and comparative study to European Association of Urology (EAU) A. Sultana, REDDITCH (GB)

P0722	Xpert® bladder cancer monitor and bladder epicheck® in the follow up of patients affected by intermediate risk non muscle invasive bladder cancer (nmibc): Preliminary data C. D'Elia, Bolzano (IT)
P0723	Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck in NMIBC surveillance J.A. Witjes, Nijmegen (NL)
P0724	Anticipatory effects of ADXBLADDER test results in the follow up of cystoscopy negative non muscle invasive bladder cancer patients in a large multicentric European cohort M. Rouprêt, Paris (FR)
P0725	Reducing the frequency of follow up cystoscopies for recurrence through the utilization of the urinary biomarker test ADXBLADDER in patients with Low grade, Low stage non-muscle invasive bladder cancer R.J. Sylvester, Brussels (BE)
12:11 - 12:23	Discussion
P0726	Role of urinary cotinine level in the recurrence of non-muscle invasive bladder cancer M. Abdessater, Paris (FR)
P0727	Head-to-head comparison between high-resolution microultrasound imaging and multiparametric MRI in detecting and local staging of bladder cancer: The bus-miss protocol P. Diana, Rozzano, Milan (IT)
P0728	Risk of genitourinary malignancies in Lynch syndrome patients with DNA mismatch repair gene mutations in a large Canadian Familial Registry K. Rebullar, Toronto (CA)
P0729	The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis M. Kardoust Parizi, Tehran (IR)
P0730	Is metabolic syndrome associated with high tumor grade and stage of bladder cancer and prognosis of non-muscle invasive bladder cancer: Pooled analysis of eleven observational studies F. Dechao, Chengdu (CN)
P0731	Skeletal muscle loss predicts oncological outcomes in T1HG patients treated with adjuvant intravesical BCG: Implications for decision-making? F. Soria, Torino (IT)
P0732	Diagnostic performance of vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical setting: Comparison to diagnostic cystoscopy K. Shigeta, Tokyo (JP)
P0733	A randomized trial regarding Antimicrobial Prophylaxis (AMP) in Transurethral Resection of Bladder tumor (TURB) in support of antimicrobial stewardship E. Baten, Leuven (BE)

P0734	Influence of the virtual reality devices on pain and anxiety in patients undergoing cystoscopy performed under local anesthesia W. Krajewski, Wrocław (PL)
P0735	Survival outcomes of urothelial carcinoma with squamous differentiation versus pure squamous cell carcinoma C. Lonati, Brescia (IT)
P0736	Very low risk of severe complications after a single, post-operative instillation of intravesical chemotherapy in patients with low- or intermediate risk urothelial carcinoma of the bladder L.M.C. van Hoogstraten, Nijmegen (NL)
P0737	Association of sex with oncologic outcomes in pTa bladder cancer I. Lysenko, Vienna (AT)
P0738	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer M. Van Hemelrijck, London (GB)
P0739	Day-case transurethral resection of bladder tumour (TURBT): A feasible approach in selected patients S. Ippoliti, King's Lynn (GB)
P0740	SERS spectroscopy to discriminate between bladder cancer tissue and urothelium G. Platkevicius, Vilnius (LT)
P0741	Potential role of micro-ultrasound in the differentiation between muscle-invasive and non-muscle invasive bladder cancer: A prospective analysis P. Diana, Rozzano, Milan (IT)
P0742	The influence of the COVID-19 pandemic on haematuria diagnostic services: Are we adapting to a new era? A. Rowell, Torbay (GB)
P0743	Deep learning system for automatic detection of bladder tumors in cystoscopic images J. Mutaguchi, Fukuoka (JP)
P0744	Youtube clips to select low-grade low-stage recurrent Non-Muscle-Invasive Bladder Cancers (NMIBC) for office fulguration, a multinational multi institutional study T. Minvielle-Moncla, Toulouse (FR)
12:42 - 12:54	Discussion
12:54 - 12:59	Expert summary J.L. Boormans, Rotterdam (NL)

NMIBC: Treatment and prognosis

Poster Session 26

Sunday 11 July
13:00 - 14:00

Location Virtual Room 7

Chairs A. Gallina, Lugano (CH)
G. Pignot, Marseille (FR)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Provide an overview of new insights in NMIBC treatment and prognosis

13:00 - 13:01

Introduction

P0745

Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
V. Narayan, Atlanta Georgia (US)

P0746

Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
V. Narayan, Atlanta Georgia (US)

P0747

Survival outcomes after radical cystectomy versus conservative management for clinical T1 high grade non-muscle invasive squamous bladder cancer: A multicenter collaboration by the European Association of Urology–Young Academic Urologists
C. Lonati, Brescia (IT)

13:04 - 13:08

Discussion

P0748

Recurrence-free survival following resection of low-grade, Non-Muscle-Invasive Urothelial Cancer (NMIBC): A Southwest Oncology Group (SWOG) S0337 post-hoc analysis
N. Corsi, Detroit (US)

P0749

Prognostic value of T1a/T1b-subclassification in bladder cancer in Denmark - a national cohort study
E. Hansen, Aarhus C (DK)

P0750

Survival outcomes after radical cystectomy versus conservative management for clinical T1 high grade non-muscle invasive micropapillary bladder cancer: A multicenter collaboration by the European Association of Urology–Young Academic Urologists
C. Lonati, Brescia (IT)

P0751	<p>Oncological long-term outcomes of patients under active surveillance for low-grade bladder tumors: An update from the Bladder Cancer Italian Active Surveillance (BIAS) project</p> <p>R. Contieri, Pieve Emanuele (IT)</p>
P0752	<p>Xpert bladder monitor: Longitudinal clinical performance for avoiding unnecessary cystoscopies in patients under active surveillance for recurrent bladder cancer (BIAS project)</p> <p>V. Fasulo, Milano (IT)</p>
P0754	<p>The impact of the presence of Squamous Cell Carcinoma (SCC) variant at Trans-Urethral Resection of the Bladder (TURB) on pathological and follow-up outcomes in patients affected by Non Muscle-Invasive Bladder Cancer (NMIBC)</p> <p>F. Chierigo, Genova (IT)</p>
13:15 - 13:19	Discussion
P0755	<p>Estimating recurrence free survivability of Non-Muscle Invasive Bladder Cancer (NMIBC) after intravesical therapy: A clinical-based recursive partition analysis</p> <p>N. Corsi, Detroit (US)</p>
P0756	<p>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder carcinoma</p> <p>S. Katayama, Okayama (JP)</p>
P0757	<p>The effect of a neoadjuvant instillation of chemotherapy in the prevention of recurrences of non-muscle invasive bladder cancer. Preliminary results of the PRECAVE prospective, controlled, randomized clinical trial</p> <p>D.M. Carrión Monsalve, Madrid (ES)</p>
P0758	<p>Laser versus Electrical En-Bloc resection of bladder tumors for treatment of non-muscle invasive bladder cancer; critical appraisal through a randomized trial</p> <p>M. Bahy, Mansoura (EG)</p>
P0759	<p>En-bloc versus conventional transurethral resection of bladder tumors: Interim analysis of a single-center prospective randomized trial</p> <p>P. Diana, Rozzano, Milan (IT)</p>
P0760	<p>Higher detection of bladder tumor urothelial variants by using plasma kinetic bipolar resection than monopolar resection</p> <p>A. Abdel Latif, Beni Suef (EG)</p>
13:25 - 13:29	Discussion
P0761	<p>Primary complete transurethral resection of bladder tumor using photodynamic diagnosis for high-risk non-muscle invasive bladder cancer: Is second-look TURBT mandatory?</p> <p>A. Tadrist, Marseille (FR)</p>
P0763	<p>Is it safe to replace ReTUR in high grade T1 non-muscle invasive bladder cancer patients with urine cytology and in-office cystoscopy? Preliminary results from an ongoing prospective multicenter trial</p> <p>R. Contieri, Pieve Emanuele (IT)</p>
13:32 - 13:36	Discussion

P0764	Oncological long-term benefit of re-resection in T1 bladder cancer: A population-based cohort study from Ontario M.S. Wettstein, Zurich (CH)
P0765	Implications of guideline-based, risk-stratified restaging transurethral resection of HG Ta urothelial carcinoma on BCG therapy outcomes P.J. Hensley, Houston (US)
P0766	A randomized clinical trial of intravesical instillation of MMC and combination of MMC and Ara-C in non-muscle invasive bladder cancer Y. Miyata, Nagasaki (JP)
P0767	Evaluation for efficacy of repeat transurethral resection of bladder tumor at Ta high grade bladder cancer S.H. Yoo, Seoul (KR)
P0768	Time interval from transurethral resection of bladder tumor to onset of BCG induction does not impact therapeutic response P.J. Hensley, Houston (US)
13:41 - 13:45	Discussion
P0769	Can we predict of the response of high risk non muscle invasive bladder cancer patients to intravesical bacillus calmette-guerin? The role of immunological markers A. Elbatta, Mansoura (EG)
P0770	Prediction of response to BCG in patients with non-muscle invasive bladder cancer of high risk using molecular profile M. Elbaset, Mansoura (EG)
P0771	Long-term oncological outcomes of bladder Carcinoma In Situ (CIS) treated with BCG immunotherapy: Prognostic implications of 6-month pathological response assessed by a propensity score matching analysis J.D. Subiela Henríquez, Barcelona (ES)
P0772	Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis Q-D. Xia, Wuhan (CN)
P0773	Intravesical chemohyperthermia versus bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis H. Zhao, Hongkong (HK)
13:50 - 13:54	Discussion
13:54 - 13:59	Summary A. Gallina, Lugano (CH) G. Pignot, Marseille (FR)

Salvage robotic pelvic surgery

Video Session 14

Sunday 11 July
13:15 - 14:00

Location Virtual Room 2

Chairs A. Messas, Paris (FR)
P. Wiklund, Stockholm (SE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

13:15 - 13:17

Introduction

V41

Intense androgen receptor inhibition with neoadjuvant apalutamide does not complicate robotic prostatectomy outcomes
X.Y. Yang, Singapore (SG)

V42

Tips and tricks in salvage rarp post focal therapy failure for prostate cancer
K.R. Bhat, Celebration (US)

V43

The impact of previous prostate surgery on surgical outcomes in patients treated with robot-assisted radical cystectomy for bladder cancer
G. Rosiello, Bacoli (IT)

13:50 - 13:53

Conclusion

Interesting techniques in urethral stricture management

Video Session 13

Sunday 11 July
13:15 - 14:00

Location Virtual Room 4

Chairs T.J. Greenwell, London (GB)
M. Waterloos, Ghent (BE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

13:15 - 13:17

Introduction

V38

Penile skin flap dorsal onlay urethroplasty for reconstruction of penile urethral strictures

B.T. Enganti, Hyderabad (IN)

V39

Self-expandable covered metallic urethral stent for bulbar urethral stricture

F. Bagheri, Dubai (AE)

V40

Penis and glans reconstruction with buccal mucosa graft in a multi-operated, failed hypospadias repair

W. Claeys, Gent (BE)

13:51 - 13:54

Conclusion

Pushing the boundaries in female reconstructive surgery

Video Session 15

Sunday 11 July
13:15 - 14:00

Location Virtual Room 5

Chairs F.J. Burgos Revilla, Madrid (ES)
N. Gibbons, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

13:15 - 13:17

Introduction

V44

Uterine transplantation: First case
L. Peri Cusi, Barcelona (ES)

V45

Urethral duplication as cause of incontinence in a 5-year-old female: Treatment of a rare congenital condition
C. Sinatti, Gent (BE)

V46

Female genital sparing robotic radical cystectomy with robotic intracorporeal karolinska neobladder
V. Agarwal, Mumbai (IN)

13:50 - 13:53

Conclusion

UTUC: Molecular characterisation and modern management

Poster Session 27

Sunday 11 July
14:00 - 15:00

Location Virtual Room 6

Chairs H. Mostafid, Guildford (GB)
T. Seisen, Paris (FR)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

- Identify new developments in the molecular characterisation of UTUC including those specifically used in new urine-based diagnostic tests
- Compare the role of different surgical approaches including ureteroscopy in the management of UTUC
- Evaluate the relationship between UTUC and bladder UC, adjuvant oncological therapies and follow-up

14:00 - 14:01

Introduction

P0774	The germline mutation landscape of cancer susceptibility genes in Chinese patients with upper tract urothelial carcinoma J. Shengming, Shanghai (CN)
P0775	Genomic profile - possible prognostic marker in upper tract urothelial carcinoma A. Grahm, Stockholm (SE)
P0776	DNA methylation urine biomarkers test (EpiCheck® assay) in the diagnosis of upper tract urothelial carcinoma: Results from a single-center prospective study A. Gallioi, Barcelona (ES)
P0777	Xpert® BC detection as a diagnostic tool in upper urinary tract urothelial carcinoma: Preliminary results C. D'Elia, Bolzano (IT)
P0778	Ten-year oncological outcomes of diagnostic ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma R. Veeratterapillay, Newcastle upon Tyne (GB)
P0779	Should the follow-up schedule after radical nephroureterectomy be revised? An analysis on the timing and location of recurrences A. Martini, Milan (IT)
P0780	Clinicopathological characteristics of upper tract urothelial cancer with loss of immunohistochemical expression of mismatch repair proteins T. Hayashi, Vancouver (CA)

P0781	Upper tract urothelial malignancy in adults less than 50 years of age with visible haematuria: A 5-year review of CT urography S. Watson, Bristol (GB)
P0782	Is prior or concomitant bladder urothelium carcinoma a significant prognostic factor of survival in patients with upper tract urothelium carcinoma T-E. Tai, Taipei (TW)
P0783	Comparison of clinicopathological characteristics between primary muscle-invasive bladder cancer and secondary muscle invasive bladder recurrence subsequent to upper tract urothelial carcinoma K. Shigeta, Tokyo (JP)
14:11 - 14:23	Discussion
P0784	Accuracy and clinical utility of the tumor grade- and stage-centered predictive model in upper tract urothelial carcinoma S. Katayama, Okayama (JP)
P0785	Novel classification for upper tract urothelial carcinoma to better risk-stratify patients eligible for kidney sparing strategies: an international collaborative study G. Marcq, Marcq-en-Baroeul (FR)
P0786	Pathological significance and prognostic utility of KIBRA in upper urinary tract urothelial cancer T. Kondo, Nagasaki (JP)
P0787	Influence of neoadjuvant chemotherapy on surgical complexity reduction in invasive UTUC M. Pikul, Kyiv (UA)
P0788	PURE-02: An open-label, single-arm, feasibility study of neoadjuvant pembrolizumab before Radical Nephroureterectomy (RNU) in patients with high-risk, Upper-Tract Urothelial Carcinoma (UTUC) A. Necchi, Milan (IT)
P0789	GFR fluctuation induced by neoadjuvant chemotherapy correlates with pathologic stage of upper tract urothelial carcinoma P.J. Hensley, Houston (US)
P0790	Outcomes of lymph node dissection in nephroureterectomy in treatment of upper tract urothelial carcinoma: Analysis of the robuust registry K. Hakimi, Encino (US)
P0791	The role of prior bladder cancer on any recurrence and distant metastasis in patients treated with radical nephroureterectomy A. Martini, Milan (IT)
P0792	Prognostic impact of secondary bladder cancer following radical nephroureterectomy on organ confined upper urothelial carcinoma patients: A propensity score matching analysis S. Lai, Beijing (CN)
P0793	Radical nephroureterectomy pentapecta: A proposal for standardisation of oncologic outcomes reporting following open, laparoscopic or robot-assisted radical nephroureterectomy F. Soria, Torino (IT)

P0794	Assessment of the lower ureteric excision technique associated oncological outcomes for upper urinary tract urothelial carcinoma: Retrospective, updated interim analysis from the Scottish Renal Cancer Network J.P. Blackmur, Edinburgh (GB)
P0795	The protective effect of metformin in upper tract urothelial carcinoma patients with type 2 diabetes C-W. Chang, Kaohsiung (TW)
P0796	Discrepancy between clinical and nephroureterectomy tumors stage as well as grade in upper tract urothelial carcinoma K. Mori, Tokyo (JP)
P0797	Open vs. robot-assisted radical nephroureterectomy: Perioperative and oncological outcomes P. Zeuschner, Homburg (DE)
P0798	Endoscopic exploration directly impacts clinical decision making in the management of patients with suspected upper tract urothelial carcinoma following radical cystectomy J. Aumatell Ovide, Barcelona (ES)
P0799	Oncologic surveillance for surgically-treated high risk upper tract urothelial carcinoma A. Martini, Milan (IT)
P0800	What part does ureteroscopy play in the diagnostic pathway of upper tract urothelial carcinoma? A two-year review in a high volume institution R. Sehgal, London (GB)
P0801	High volume robotic assisted nephro-ureterectomy allows improved perioperative outcomes N. Campaign, Exeter (GB)
P0802	Clinicopathological features, oncological and functional outcomes in patients who underwent simultaneous radical cystectomy and nephroureterectomy in panurothelial carcinoma context J.D. Subiela Henríquez, Barcelona (ES)
P0803	Propensity score based comparison of nephroureterectomy versus segmental ureterectomy for ureteral tumors M. Paciotti, Rozzano, Milan (IT)
14:43 - 14:55	Discussion
14:55 - 15:00	Expert summary S. Shariat, Vienna (AT)

Management of invasive and locally or metastatic bladder cancer: From bladder sparing to cystectomy and systemic treatment

ESU Course 17

Sunday 11 July
13:00 - 15:00

Location Zoom 1

Chair B. Malavaud, Toulouse (FR)

Learning objectives

From non-muscle invasive to muscle invasive and metastatic cancer, recent evidence is promoting the personalization of the care of transitional cell carcinoma of the bladder at all moments of its natural history TCC of the bladder now epitomizes to the urology & oncology specialist the challenges and benefits of multidisciplinary approach.

Perioperative management and expert surgical skills are the domains of the trained urologist oncologist, while leveraging the recent advances, in imaging, molecular biology and conservative management of MIBC, medical oncology and radiotherapy, requires multidisciplinary environment.

1. One size does not fit all; urologists are at the core of the development of personalized treatment in NMIBC and MIBC
2. Patients' selection is based on advances in imaging, surgical expertise and pathology
3. Controlling the burden of non-muscle invasive bladder cancer to the patient and the healthcare system requires from the urologist a multidimensional expertise in biology, endoscopy, endosurgery and adjuvant treatments
4. Expert perioperative care, surgical skills and use of chemotherapy are crucial to optimize the outcomes of aggressive MIBC
5. Organ preservation is feasible in a select minority of muscle invasive bladder cancer patients
6. Checkpoint inhibitors are changing the landscape of metastatic bladder cancer

13:00 - 15:00

Transitional cell carcinoma of the bladder, one multifaceted challenge to the urology & oncology specialist

B. Malavaud, Toulouse (FR)

13:00 - 15:00

Non-muscle invasive bladder cancer; Focal disease or local evidence of diffuse abnormalities? Organizing the medical armamentarium - biomarkers, optics, imaging, and pathology - to the best of risk stratification and treatment

B. Malavaud, Toulouse (FR)

13:00 - 15:00

How expert endoscopic surgery and intra-vesical treatments are crucial to optimizing the outcome(s) of NMIBC?

M. Burger, Regensburg (DE)

13:00 - 15:00

Bladder-sparing approaches to muscle invasive bladder cancer

M. Burger, Regensburg (DE)

13:00 - 15:00

Cystectomy in the management of bladder invasive and locally advanced bladder cancer

J.E. Gschwend, Munich (DE)

13:00 - 15:00

Update on the systemic treatments of metastatic bladder cancer

J.E. Gschwend, Munich (DE)

Guideline Session II: Prostate cancer - cN+ in newly diagnosed patients

Live from the studio: Thematic Session 14

Sunday 11 July
15:00 - 16:00

Location Virtual Room 2

Chairs
A. Breda, Barcelona (ES)
P. Cornford, Liverpool (GB)
N. Mottet, Saint-Étienne (FR)

Learning objectives

In a newly diagnosed M0 prostate cancer, finding suspicious nodes on imaging leads to the optimal treatment sequence. Recently conventional imaging has been surpassed by newer imaging modalities. However what is the clinical meaning of such findings and to what extent is this associated with a treatment change? If the optimal treatment usually includes a local therapy, the optimal combined systemic therapy needs clarification, especially regarding adding something on top of ADT: what is the real benefit of drug combination, if any?

15:00 - 15:05

Introduction cN+: What does it mean?
N. Mottet, Saint-Étienne (FR)

15:05 - 15:24

cN+ and imaging

15:05 - 15:12

What are we talking about?
W.J.G. Oyen, Arnhem (NL)

15:12 - 15:19

Guidelines Point of view cN+ = pN+?
J. Grummet, Melbourne (AU)

15:19 - 15:24

Discussion

15:24 - 15:43

cN+ and systemic treatment

15:24 - 15:31

More than ADT is needed as systemic TTT: Yes!
M. De Santis, Berlin (DE)

15:31 - 15:38

Guidelines Point of view More than ADT is needed as systemic TTT: No!
G. Ploussard, Toulouse (FR)

15:38 - 15:43

Discussion

15:43 - 15:55

cN+ and local treatment

15:43 - 15:50

Guidelines Point of view
T. Wiegel, Ulm (DE)

15:50 - 15:55

Discussion

15:55 - 16:00

Closing remarks
P. Cornford, Liverpool (GB)

Complications/solutions of robot-assisted urologic surgery: Quick answers

Live from the studio: Thematic Session 15

Sunday 11 July
15:00 - 16:00

Location Virtual Room 4

Chairs
X. Cathelineau, Paris (FR)
J. Rassweiler, Heilbronn (DE)
J. Witt, Gronau (DE)

Learning objectives

Understanding of mechanisms for complications, strategies for prevention and actions to deal with these complications.

15:00 - 15:10

Video-assisted PowerPoint presentation Complications of robot-assisted aquablation of the prostate
M. Rieken, Zürich (CH)

15:10 - 15:20

Video-assisted PowerPoint presentation Complications of robot-assisted laparoscopic radical prostatectomy (RALP)
F. Montorsi, Milan (IT)

15:20 - 15:30

Video-assisted PowerPoint presentation Complications of robot-assisted laparoscopic radical cystectomy (RARC)
J. Palou, Barcelona (ES)

15:30 - 15:40

Video-assisted PowerPoint presentation Complications of robot-assisted sacrocolpopexy
H. John, Winterthur (CH)

15:40 - 15:50

Video-assisted PowerPoint presentation Complications of robotic kidney surgery
B.J. Challacombe, London (GB)

15:50 - 16:00

Discussion

How machine learning is transforming diagnostics

Thematic Session 16

Sunday 11 July
15:00 - 16:00

Location Virtual Room 5

Chairs G. Salomon, Hamburg (DE)
K.A.O. Tikkinen, Helsinki (FI)

Learning objectives

Machine learning is a rapidly developing field with the potential of transforming diagnostics in urology. This session, with pre-recorded lectures from experts and live moderation and discussion, will give an overview of the medical applications of AI and machine learning, the latest breakthroughs, and what they can mean for urologists in the near future. This session also features an update on the PIONEER project and a live debate on radiomics.

15:00 - 15:05

Introduction: AI in urological imaging
G. Salomon, Hamburg (DE)

15:05 - 15:10

The beginning of a new area: Principal basics of AI
D. Bonekamp, Heidelberg (DE)

15:10 - 15:15

Early MRI-based detection of prostate cancer: Will AI play a role?
M. De Rooij, Nijmegen (NL)

15:15 - 15:20

Discussion

15:20 - 15:25

AI and the 3D multiparametric ultrasound
M. Mischi, Eindhoven (NL)

15:25 - 15:30

mpMRI in recurrent prostate cancer following radiotherapy
U. Van der Heide, Amsterdam (NL)

15:30 - 15:35

Discussion

15:35 - 15:40

AI in uro-pathology
T. Mirtti, Helsinki (FI)

15:40 - 15:45

PIONEER update Advanced analytics and incorporation of AI models
B. De Meulder, Lyon (FR)

15:45 - 15:50

Discussion

15:50 - 15:55

State-of-the-art lecture Radiomics simplified: False discovery or genuine insight?
A. Hung, Los Angeles (US)

15:55 - 16:00

Discussion

MIBC: Evolution of surgical management and morbidity

Poster Session 28

Sunday 11 July
15:00 - 16:00

Location Virtual Room 7

Chairs A. Masson-Lecomte, Paris (FR)
J.A. Witjes, Nijmegen (NL)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Several posters deal with robotic and open surgery, both bladder and nodes, including for example the value of a sentinel node technique and ERAS. Postop. complications (wound infections, strictures) are discussed, also how to prevent them, for example by surgical volume. Pt selection based on imaging (MRI, PET) and frailty and QOL are important issues. Periop. systemic therapy and complications and impact on QOL are also presented. Finally the impact of no treatment is shown. In all the audience will get an update of surgical care of MIBC, including perioperative systemic therapy. There will be some tips how to avoid complications and improve care, QOL and outcome. At the end of the session Prof Black will give his expert summary.

15:00 - 15:01

Introduction

P0804	Nephrostomy in advanced cancer: Sometimes a step too far? A. Dosanjh, Birmingham (GB)
P0805	Wound dehiscence after radical cystectomy: A novel risk-prediction model M. Mansour, Riad El Solh - Beirut (LB)
P0806	A comparison of Charlson comorbidity index and cardiopulmonary exercise testing in predicting outcomes after Robotic Assisted Radical Cystectomy (RARC) and intracorporeal reconstruction for bladder cancer A. McPhee, Glasgow (GB)
P0807	Selecting the best candidates for platinum-based adjuvant chemotherapy after radical cystectomy in pN+ bladder cancer patients L. Afferi, Lucerne (CH)
P0808	Diagnostic value of sentinel lymph node technique in patient with invasive bladder cancer – Results from a prospective study B. Małkiewicz, Wrocław (PL)
P0809	Real life applicability of VI-RADS score for bladder cancer staging: Challenges of cut-offs definition and MRI sequences weighting R. Clery, Paris (FR)

P0810	Examining the association between operative time and radical cystectomy complications L. Haeuser, Herne (DE)
P0811	Reduced local recurrence with en bloc radical cystectomy E. Kjøbli, Trondheim (NO)
15:09 - 15:16	Discussion
P0812	Open vs. robot-assisted radical cystectomy with totally intracorporeal urinary diversion: 30-day and 90-day complication rates comparison from a single centre randomised controlled trial R. Mastroianni, Rome (IT)
P0813	Robot-assisted laparoscopic radical cystectomy with intracorporeal ileal conduit diversion versus open radical cystectomy with ileal conduit in an ERAS setup (BORARC): A double-blinded, randomised feasibility study U.N. Joensen, Copenhagen (DK)
P0814	Robot-assisted versus open radical cystectomy: A cohort study on perioperative outcomes accounting for stage selection bias and surgical experience P. Zeuschner, Homburg (DE)
P0815	Pentafecta achievement comparison between open and robot-assisted radical cystectomy with totally intracorporeal urinary diversion: Results from a randomized controlled trial R. Mastroianni, Rome (IT)
P0816	Validation of comprehensive pentafecta criteria after open radical cystectomy in bladder cancer patients with long-term oncological follow-up M.W. Vetterlein, Hamburg (DE)
P0817	Two-yr oncologic outcomes of ORC vs. RARC: Focus on recurrence sites from a prospective-randomized study M.C. Ferriero, Rome (IT)
P0818	Peak incidence of ureteroenteric anastomotic strictures after introduction of robot-assisted radical cystectomy with intracorporeal urinary diversion D.J. Reesink, Nieuwegein (NL)
P0819	Would you choose a neobladder again? Impact of clinicopathological parameters on long-term decision regret regarding ileal neobladder reconstruction after radical cystectomy G.B. Schulz, Munich (DE)
P0820	The effects of Robotic surgery, Urinary diversion and early recovery protocol on costs of Radical cystectomy – a complete cost effectiveness analysis M. Haifler, Ramat Gan (IL)
15:25 - 15:32	Discussion
P0821	Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial J.E. Gschwend, Munich (DE)

P0822	Survival after neoadjuvant/induction combination immunotherapy versus combination platinum-based chemotherapy for stage III urothelial cancer S. Einerhand, Amsterdam (NL)
P0823	Intermediate-term overall survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non muscle-invasive bladder cancer in the Netherlands S.C. Van Beek, Rotterdam (NL)
P0824	Real time urethral and ureteral assessment during radical cystectomy using ex vivo optical imaging F. Prata, Rome (IT)
P0825	Fear of cancer recurrence in bladder cancer patients undergoing radical cystectomy with urinary diversion - Preliminary results from a prospective study (NCT04535921) J. Troost, München (DE)
P0826	Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2018: Increasing case numbers facilitate more high-volume centers L. Flegar, Dresden (DE)
P0827	Defining factors associated with high-quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit W.S. Tan, London (GB)
P0828	Adjuvant vs. progression-triggered treatment with gemcitabine after radical cystectomy in platinum-ineligible patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (AUO-AB 22-00): Long-term follow-up of a randomized multicenter phase 3 trial N. Spieler, Homburg/Saar (DE)
P0829	Prospective study on fdg-pet/ct for on-treatment assessment of response to neoadjuvant or induction chemotherapy in invasive bladder cancer S. Einerhand, Amsterdam (NL)
P0830	Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy J.L. Boormans, Rotterdam (NL)
P0831	Ureteral stenting does not increase the risk of metachronous upper tract urothelial carcinoma in patients with bladder cancer presenting with hydronephrosis in comparison with percutaneous nephrostomy: A multicenter analysis L. Afferi, Lucerne (CH)
P0832	Multi-omics prognosis predictive model of metastatic urothelial carcinoma (mUCs) with immunotherapy H. Ning, Shanghai (CN)
P0833	First-line treatments for cisplatin-eligible patients with metastatic urothelial carcinoma: A meta-analysis K. Mori, Tokyo (JP)
P0834	Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials E. Laukhtina, Moscow (RU)

P0835

Characteristics and survival of untreated versus treated patients with non-metastatic muscle invasive bladder cancer
L.M.C. van Hoogstraten, Nijmegen (NL)

15:47 - 15:54

Discussion

15:54 - 15:59

Expert summary
P. Black, Vancouver (CA)

Percutaneous nephrolithotripsy (PCNL)

ESU Course 18

Sunday 11 July
15:30 - 17:30

Location Zoom 1

Chair E. Liatsikos, Patras (GR)

Learning objectives

Aim of this course is to describe in detail the surgical techniques of all available treatment options in percutaneous surgery of renal stones. In addition, to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on their prevention and proper management.

Objectives

- Describe the basic percutaneous nephrolithotripsy techniques
- Provide tips to improve the efficacy of the operation
- Provide evidence on the comparison of percutaneous with ureteroscopic and extracorporeal treatment options; Which approach for which stone
- Describe associate complications including their management

15:30 - 17:30

Guidelines on stone treatment

T. Knoll, Sindelfingen (DE)

15:30 - 17:30

ECIRS: Indications, equipment and technique

C.M. Scoffone, Turin (IT)

15:30 - 17:30

Supine PNL

G.M. Kamphuis, Amsterdam (NL)

15:30 - 17:30

Prone PNL

T. Knoll, Sindelfingen (DE)

15:30 - 17:30

Tips & tricks in PNL

E. Liatsikos, Patras (GR)

15:30 - 17:30

Round table: Complications of PCNL: Diagnosis, management, prevention

E. Liatsikos, Patras (GR)

T. Knoll, Sindelfingen (DE)

C.M. Scoffone, Turin (IT)

G.M. Kamphuis, Amsterdam (NL)

Metastatic prostate cancer

Poster Session 29

Sunday 11 July
16:00 - 17:00

Location Virtual Room 6

Chairs N. Fossati, Milan (IT)
B. Tombal, Brussels (BE)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

16:00 - 16:01

Introduction
B. Tombal, Brussels (BE)

16:01 - 16:15

Lymphnode metastases

P0836 **External validation of a nomogram for predicting 68Ga-PSMA PET/CT detection rate in patients with prostate cancer recurrence. A clinical tool to guide physicians before suggesting 68Ga-PSMA PET/CT**
L. Bianchi, Bologna (IT)

P0837 **Diagnostic accuracy of PSMA-PET-CT for pelvic lymph node staging in men with prostate cancer undergoing radical prostatectomy and pelvic lymph node dissection**
J.B. Grogg, Zurich (CH)

P0838 **Lymph node staging with 18F-PSMA-1007 PET/CT in newly diagnosed prostate cancer using histopathological evaluation as a reference**
To be confirmed

P0839 **Salvage Therapies for PSMA PET/CT-positive nodal-only recurrent prostate cancer: Impact on survival, functional outcomes and health-related quality of life**
A. Kretschmer, Munich (DE)

P0840 **Preoperative prediction of lymph node invasion in prostate cancer: Ga-68 PSMA PET or nomograms?**
Y. Kordan, Istanbul (TR)

P0841 **Postoperative complications and functional outcome parameters in patients undergoing salvage lymph-node dissection due to nodal-recurrent prostate cancer**
M.T. Grabbert, Freiburg (DE)

16:07 - 16:15

Discussion

16:15 - 16:24

Metastatic hormone-sensitive disease

P0842 **Metastasis-directed therapy for oligorecurrent prostate cancer: A pooled analysis of prospective trials**
P. Ost, Ghent (BE)

P0843 **Predictors of recurrence after metastasis-directed therapy in metachronous, castrate-sensitive oligometastatic prostate cancer**
U. Milenkovic, Leuven (BE)

P0844	Which patients with Oligometastatic Prostate Cancer should be considered for Cytoreductive Radical Prostatectomy as part of a multimodal treatment? Results from a large, multi-institutional collaboration S. Scuderi, Catania (IT)
P0845	Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa) S. Chowdhury, London (GB)
P0846	Prognostic importance of concomitant non-regional lymph node and bone metastases in men with de novo metastatic prostate cancer B.L. Heesterma, Utrecht (NL)
P0847	Androgen deprivation therapy and excess mortality during the COVID-19 pandemic P. Stattin, Uppsala (SE)
P0848	Severity of COVID-19 infection in prostate cancer patients and effect of ADT on disease presentation C. García Fuentes, Alcorcón (ES)
P0849	Adjuvant Metformin use in advanced hormone sensitive prostate cancer; Clinical assessment through a randomized trial
P0850	Type of androgen deprivation therapy and the risk of cardiovascular diseases in patients with prostate cancer with or without pre-existing cardiovascular risk N. Touma, Laval (CA)
P0851	Diabetes control in men with type 2 diabetes mellitus and prostate cancer treated with GnRH Agonists: A nationwide, population-based cohort study E. Lin, London (GB)

16:24 - 16:32

Discussion

16:32 - 16:52

Castration resistant disease

P0852	Fatigue, quality-of-life and metabolic changes in men treated with enzalutamide versus abiraterone plus prednisone for metastatic castration-resistant prostate cancer (HEAT): A randomised trial K. Kvorning Ternov, Hellerup (DK)
P0853	Geriatric nutritional risk index as a prognostic marker for patients with metastatic castration-resistant prostate cancer receiving docetaxel H. Hsieh, Taichung (TW)
P0854	Distinct response to platinum-based chemotherapy among patients with metastatic castration-resistant prostate cancer harboring alterations in genes involved in homologous recombination L. Fan, Shanghai (CN)
P0855	The obesity paradox in metastatic castration resistant prostate cancer G.O. Cirulli, Roma (IT)
P0856	Prospective study of the relationship between clinical outcomes of enzalutamide and serum androgen levels measured by LC-MS/MS in CRPC patients Y. Miyazawa, Maebashi, Gunma (JP)
P0857	A drug comorbidity index to predict all-cause mortality in men with castration resistant prostate cancer G. Fallara, Meda (IT)
P0858	Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer Y.G. Tan, Singapore (SG)

P0859	Clinical study of VERU-111, an oral cytoskeletal disruptor in men with metastatic Castration Resistant Prostate Cancer (mCRPC) who failed an androgen receptor targeting agent R. Getzenberg, Memphis, Tn (US)
P0860	Balancing efficacy and toxicity of docetaxel in patients with metastatic castration-resistant prostate cancer. Results from a pooled analysis of three prospective randomized trials G.O. Cirulli, Roma (IT)
P0861	A multi-trial based external validation of the Halabi nomogram in predicting the overall survival of metastatic castration-resistant prostate cancer patients D. Modonutti, Pagnacco (IT)
P0862	Impact of Prior Local Trecepherapy (PLT) on survival in metastatic castration resistant prostate cancer (mCRPC). Results from COU-AA-302 trial M. Rodrigo-Aliaga, Benicàssim (ES)
P0863	Time on treatment with abiraterone and enzalutamide in the patient-overview prostate cancer in the national prostate cancer register of Sweden G. Fallara, Meda (IT)
16:44 - 16:52	Discussion
16:52 - 16:57	Expert summary C. Ryan, Minneapolis (US)

Treatment sequencing in metastatic prostate cancer

Live from the studio: Thematic Session 17

Sunday 11 July
16:30 - 17:30

Location Virtual room 1

Chairs S. Gillessen Sommer, Bellinzona (CH)
K. Fizazi, Villejuif (FR)
G. Niegisch, Düsseldorf (DE)
C. Gratzke, Freiburg (DE)

Learning objectives

Apart from individual treatment options, a suitable sequencing of these options can have a big impact on patients. This session presents a variety of considerations that urologists face, as well as a twenty-minute, five-way live case discussion on a patient on ADT and Abiraterone.

16:30 - 16:40

Monitoring and when to change treatment in mHSPC

G. Ploussard, Toulouse (FR)

16:40 - 16:50

Systemic treatment options for mCRPC: An overview

G. Kramer, Vienna (AT)

16:50 - 17:00

Tumour molecular testing: For whom and when is it clinically useful?

J. De Bono, London (GB)

17:00 - 17:10

PSMA in diagnostics and treatment

K. Fizazi, Villejuif (FR)

17:10 - 17:30

Case discussion: Patient progressing on ADT plus Abi

Case presenter N. Grivas, Ioannina (GR)

Discussants J. De Bono, London (GB)

K. Fizazi, Villejuif (FR)

G. Kramer, Vienna (AT)

G. Ploussard, Toulouse (FR)

Semi-Live III: Laparoscopic and robotic surgery for malignant diseases

Thematic Session 18

Sunday 11 July
16:15 - 17:15

Location

Virtual Room 3

Chairs

R. Bollens, Lomme (FR)

A. De La Taille, Créteil (FR)

D. Nikoleishvili, Tbilisi (GE)

Learning objectives

In the era of Robotic surgery, we remain conventional Laparoscopic technique for urological diseases. It is always interesting to look through the innovations of approach and technique improvements.

16:15 - 16:25

Latest news Comparison of laparoscopic and robotic assisted surgery - 1 year outcomes from the first multicentre randomised patient blinded controlled trial in radical prostatectomy (LAP-01)

J-U. Stolzenburg, Leipzig (DE)

16:25 - 16:30

Discussion

16:30 - 16:40

Video: Robotic lymph node dissection during radical nephro-ureterectomy

To be confirmed

16:40 - 16:45

Discussion

16:45 - 16:55

Video: Laparoscopic retroperitoneal partial nephrectomy: Lessons learned from robotics

J.M. Gaya Sopena, Barcelona (ES)

16:55 - 17:00

Discussion

17:00 - 17:10

Video: Robotic radical nephrectomy with vena caval thrombectomy

M. Gallucci, Rome (IT)

17:10 - 17:15

Discussion

Clinical trials

Poster Session 30

Sunday 11 July
17:00 - 17:30

Location Virtual Room 7

Chairs S. Aufderklamm, Tübingen (DE)
J. N'Dow, Aberdeen (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This sessions will give an overview of upcoming or actively recruiting trials in urology.

17:00 - 17:01

Introduction

P0864	Frequency and risk factors for acute kidney injury in patients with coronavirus infection V. Pavlov, Ufa (RU)
P0865	Final results of a prospective, randomized controlled trial assessing the impact of early Dorsal Venous Complex (eDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy F. Montorsi, Milan (IT)
P0866	Impact of peri-operative testosterone levels on oncological and functional outcomes in radical prostatectomy (ENFORCE trial) D.J.H. Baas, Utrecht (NL)
P0867	Optimizing the number of systematic cores during an MRI target biopsy: Preliminary results from the prospective, single center SCOT Trial (NCT 04183699) A. Stabile, Milan (IT)
P0868	Randomized controlled trial comparing holmium laser en-bloc resection with monopolar transurethral resection in patients with large bladder tumors A. Iscaife, São Paulo (BR)
P0869	Metastatic prostate cancer patients' Attitudes towards Treatment of the local Tumour and metastasis Evaluative Research (IP5-MATTER): A multicentre, discrete choice experiment trial-in-progress M.J. Connor, London (GB)
P0870	The impact of COVID-19 on the medium-term outcomes of urological cancer - International prospective 3 year follow up study C. Gao, Ashford (GB)
P0871	NeuroSAFE PROOF. Update on a multi-centre, pragmatic, RCT for men undergoing robot-assisted radical prostatectomy: Trial in progress E. Dinneen, London (GB)

P0872	STONE (STent Or NEphrostomy) study N. Hendriks, Den Haag (NL)
P0873	Triple AiM1: A prospective observational study of treatment options in men with metastatic hormone sensitive prostate cancer T. van Elst, Nijmegen (NL)
P0874	Prostate pathway embedded comparative trial: The ip3-prospect study E.J. Bass, London (GB)
P0875	Improving the inclusion rate in clinical trials of bladder cancer patients by mapping the quality process of the multidisciplinary team J. Gómez Rivas, Madrid (ES)
17:13 - 17:25	Discussion
17:25 - 17:30	Conclusion

Metastatic prostate cancer: Systemic treatments and options of local treatment in case of oligometastatic disease

ESU Course 19

Sunday 11 July 18:00 - 20:00	Location	Zoom 1
	Chair	S. Joniau, Leuven (BE)
18:00 - 18:05	Introduction S. Joniau, Leuven (BE)	
18:05 - 18:15	An overview of the metastatic PCa landscape S. Joniau, Leuven (BE)	
18:15 - 18:20	Questions and answers S. Joniau, Leuven (BE)	
18:20 - 18:30	Oligometastatic PCa, a family of different disease stages with different biology G. De Meerleer, Leuven (BE)	
18:30 - 18:35	Questions and answers G. De Meerleer, Leuven (BE)	
18:35 - 18:45	How to best diagnose oligometastatic PCa T. Maurer, Hamburg (DE)	
18:45 - 18:50	Questions and answers T. Maurer, Hamburg (DE)	
18:50 - 19:00	Treating the primary tumour in de novo oligometastatic PCa: Rationale and outcomes G. De Meerleer, Leuven (BE)	
19:00 - 19:05	Questions and answers G. De Meerleer, Leuven (BE)	
19:05 - 19:15	Systemic treatment in oligometastatic PCa S. Joniau, Leuven (BE)	
19:15 - 19:20	Questions and answers S. Joniau, Leuven (BE)	
19:20 - 19:50	Interactive case discussions with MCQ's (including radical prostatectomy for de novo oligometastatic PCa, metastasis-directed treatment, radioguided surgery, combination treatment, ongoing trials) S. Joniau, Leuven (BE) T. Maurer, Hamburg (DE) G. De Meerleer, Leuven (BE)	
19:50 - 20:00	Wrap-up T. Maurer, Hamburg (DE)	

Augmented reality in robotic urological surgery

Video Session 17

Sunday 11 July
17:15 - 18:00

Location Virtual Room 2

Chairs A. Haese, Hamburg (DE)
I.M. Van Oort, Nijmegen (NL)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:15 - 17:17

Introduction

V50

The use of augmented reality to guide intraoperative frozen section during robot-assisted radical prostatectomy

R. Schiavina, Bologna (IT)

V51

Artificial intelligence 3D augmented reality guided biopsy during robotic prostatectomy: A new way to reduce the positive surgical margin rate

E. Checcucci, Venaria Reale (IT)

V52

Bench surgery and kidney auto-transplantation in rescue of germ-cell residual mass. 3D models utility in surgical planning

F.J. Burgos Revilla, Madrid (ES)

17:53 - 17:56

Conclusion

Robotic reconstructions

Video Session 16

Sunday 11 July
17:15 - 18:00

Location Virtual Room 4

Chairs F. Gómez Veiga, Salamanca (ES)
B. Peyronnet, Rennes (FR)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:15 - 17:17

Introduction

V47

Robot-assisted bladder neck reconstruction Y-V plasty
M. Arndt, Homburg/Saar (DE)

V48

Robot assisted ileal interposition
T. Ajami Fardoun, Barcelona (ES)

V49

Robot-assisted buccal mucosa graft ureteroplasty: Single surgeon experience
P. Emiliozzi, Rome (IT)

17:49 - 17:52

Conclusion

Interesting techniques for management of upper tract obstruction

Video Session 18

**Sunday 11 July
17:15 - 18:00**

Location Virtual Room 5

Chairs S. Nathan, London (GB)

O. Traxer, Paris (FR)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

17:15 - 17:17

Introduction

V53

Extra anatomical ureteral bypass for the definitive treatment of complex ureteral stenosis: Description of a modified technique in the supine position in 27 cases
I. Kartalas-Goumas, Vigevano (IT)

V54

Buccal mucosa graft repair of proximal ureteral lesion
F. Proietti, Rome (IT)

17:40 - 17:43

Conclusion

Robotic surgery and ablative treatment of renal tumours

ESU Course 20

Monday 12 July
08:00 - 10:00

Location Zoom 1

Chair A. Mottrie, Aalst (BE)

Learning objectives

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained on a video- based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well. Don't miss this course, a must for all robotic surgeons!

- Video-based step-by-step approach
- Standard techniques
- Complex cases
- Troubleshooting and complication management
- Technical innovations: What's new in robotics?

08:00 - 10:00

Introduction

A. Mottrie, Aalst (BE)

08:00 - 10:00

How, who & why trans- and retroperitoneal access

N. Buffi, Milan (IT)

-

Questions and answers

08:00 - 10:00

Partial nephrectomy: Different ways to skin the cat. - Different tumour resection techniques - Different renorrhaphy techniques

Moderator A. Mottrie, Aalst (BE)

Expert panel N. Buffi, Milan (IT)

B.J. Challacombe, London (GB)

F. Keeley, Bristol (GB)

08:00 - 10:00

Technical innovations in RAPN

A. Mottrie, Aalst (BE)

08:00 - 10:00

Focal therapy in renal tumour treatment: An update

F. Keeley, Bristol (GB)

08:00 - 10:00

Wrap up and conclusions

B.J. Challacombe, London (GB)

Affordable urology, instruments and disposables and trauma

Poster Session 31

**Sunday 11 July
18:00 - 19:00**

Location Virtual Room 6

Chairs M. Lezrek, Meknes (MA)
A.R. Rodriguez, Rochester (US)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session presents new technology and interesting ideas to solve common problems. New technology may not always be more expensive. The session covers many fields of urology while focussing on cost-effectiveness.

18:00 - 18:01

Introduction

18:01 - 18:19

Urological trauma

P0876

Control imaging after blunt renal trauma in the adult patient - A single level 1 trauma center experience
S. Deininger, Freilassing (DE)

P0877

Renal trauma: Risk factors associated with nephrectomy; proposal of a 3-point score to aid surgical decision making
R. Pallares-Mendez, Monterrey Nuevo Leon (MX)

P0878

Who is at risk of death after renal trauma? An analysis of thirty-day mortality after 1799 renal trauma
M. Baboudjian, Marseille (FR)

P0879

Conservative management of grade 4 and 5 renal injuries
I. Glykas, Athens (GR)

P0880

Initial radiological findings associated with active bleeding control necessity and long term functional outcomes after isolated high grade blunt renal trauma
To be confirmed

P0881

Review of iatrogenic ureteric injuries management in a tertiary centre
G. Kyriazis, Hull (GB)

P0882

Validation of the TORSAFUF score in diagnosis of spermatic cord torsion: A French multicenter study
C. Plassais, paris (FR)

P0883

Porous Se@SiO₂ nanosphere-coated catheter accelerates prostatic urethra wound healing by modulating macrophage polarization
Y. Boyu, Beijing (CN)

P0884

Ex-vivo evaluation of intraurethral catheter balloon inflation pressures, urethral diametric strain and rupture thresholds in porcine and human specimens
S.M. Croghan, Sutton (IE)

P0885	Gross hematuria and anticoagulation - Critical evaluation of clinical outcome predictors and underlying urological pathology in hospitalized patients L. Lawaczek, Tübingen (DE)
18:11 - 18:19	Discussion
18:19 - 18:37	Affordable urology: New technology may be also cost-effective
P0886	Human volatilome analysis of patients with prostate cancer: prospective, two-arm non-randomized monocentric study A. Filianoti, Rome (IT)
P0887	Comparative analysis of surgical outcomes and cost effectiveness of a novel 3-instrument technique for Robotic Assisted Radical Prostatectomy (RARP) with the standard 5-instrument technique U.B. Mufti, Leeds (GB)
P0888	Switching from sedation to local anaesthetic transperineal prostate biopsies: A cost-benefit analysis U. Walters, London (GB)
P0889	Global cost assessment of robot-assisted versus open radical cystectomy: Results of a prospective randomized controlled trial R. Mastroianni, Rome (IT)
P0890	The senhance robotic system is feasible in oncologic and non-oncologic urologic surgeries: Initial experiences and troubleshooting of new system S-W. Wu, Yunlin County (TW)
P0891	Use of ureteric stent related mobile phone application UROSTENTZ App (free of cost) in COVID-19 for improving patient communication and safety: A prospective pilot study from a university hospital To be confirmed
P0892	Comparing the ability of wearable devices and CPET to predict major complications following radical cystectomy P. Khetrapal, London (GB)
P0893	Results of percutaneous diathermocoagulation of spermatocele I.V. Dovzhanskii, Saint-Petersburg (RU)
P0894	The cancer immunohistogram, a functional status of tumor-infiltrating cells evaluated by immunohistochemistry, predicts the efficacy of immune checkpoint inhibitors in urological cancer patients T. Kijima, Tokyo (JP)
P0895	Ice slush in surgical glove: An innovative device to keep the graft cool during renal transplantation H.S. Talwar, Rishikesh (IN)
18:29 - 18:37	Discussion
18:37 - 18:49	Instruments and disposables
P0896	Repair rate and associated cost of reusable flexible ureteroscopes: A systematic review and meta-analysis B. Somani, Southampton (GB)
P0897	Safety and tolerability of disposable endosheath use in flexible cystoscopy: A prospective evaluation of over 1,000 cases L. Ratcliffe, Stoke Row (GB)
P0898	A novel vacuum-based tissue holding device for laparoscopic and robotic partial nephrectomy: The development process and in vitro evaluation in human cadaveric and porcine models L. Hefermehl, Baden (CH)

P0899	The use of allium metal ureteric stents in the treatment of ureteric obstruction or injury A. Rogers, Newcastle upon Tyne (GB)
18:41 - 18:49	Discussion

18:49 - 18:54	Can micro-ultrasound be an alternative for MRI in prostate cancer detection and staging? G. Karazanashvili, Tbilisi (GE)
----------------------	--

Stones: Keeping with tradition or time for new concepts?

Live from the studio: Plenary Session 07

Monday 12 July
08:00 - 09:30

Location Virtual room 1

Chairs
J. Denstedt, London (CA)
T. Knoll, Sindelfingen (DE)
E. Liatsikos, Patras (GR)
M.S. Silay, Istanbul (TR)

Learning objectives

Today, stone treatment means endourology in most cases. New endoscopes, new lasers, new disposables promise better efficacy, lower morbidity and shorter hospital stays. Is this all true or are there potential drawbacks to be considered? Which protocols and treatment algorithms lead to the best treatment results? This plenary will give the answers.

08:00 - 08:14

Part I: Prevention of stones

Moderator J. Denstedt, London (CA)

08:00 - 08:03

Flash presentation Dietary modifications

C.A. Wagner, Zurich (CH)

08:03 - 08:06

Flash presentation Medication to prevent stones

P.M. Ferraro, Rome (IT)

08:06 - 08:14

Discussion

08:14 - 08:28

Debate Do we always need a stone analysis in the lab?

08:14 - 08:17

Flash presentation No – endoscopic evaluation is sufficient

G. Giusti, Milan (IT)

08:17 - 08:20

Flash presentation Yes – laboratory stone analysis should stay

A. Miernik, Freiburg (DE)

08:20 - 08:28

Discussion

08:28 - 08:43

Crossfire Part II: The 1.5 cm pelvic stone in a 5 year-old boy

Moderator S. Tekgül, Ankara (TR)

08:28 - 08:29

Case presentation

S. Tekgül, Ankara (TR)

08:29 - 08:31

Flash presentation ESWL

B. Önal, Istanbul (TR)

08:31 - 08:33

Flash presentation PNL

B. Geavlete, Bucharest (RO)

08:33 - 08:35

Flash presentation Flexible URS

B. Somani, Southampton (GB)

08:35 - 08:43

Discussion

08:43 - 09:06

Part III: Update on technique and training

Moderators T. Knoll, Sindelfingen (DE)
E. Liatsikos, Patras (GR)

08:43 - 08:48

Lasers: Not all that glitters is gold

P. Kallidonis, Patras (GR)

Scientific Programme - EAU21 Virtual

08:48 - 08:53	Personalised virtual training: Can proctoring be remote, virtual and effective? O. Traxer, Paris (FR)
08:53 - 08:58	What do we really need from a single-use ureteroscope? M. Brehmer, Stockholm (SE)
08:58 - 09:06	Discussion
09:06 - 09:30	Crossfire Part IV: The 1.5 cm renal stone in a 49 year-old lady <i>Moderators</i> T. Knoll, Sindelfingen (DE) E. Liatsikos, Patras (GR)
09:06 - 09:07	Case presentation K. Thomas, London (GB)
09:07 - 09:12	PNL A. Papatsoris, Athens (GR)
09:12 - 09:17	Flexible URS J. Baard, Amsterdam (NL)
09:17 - 09:22	ESWL M-C. Rassweiler-Seyfried, Mannheim (DE)
09:22 - 09:30	Discussion

Controversies on EAU Guidelines - Session I

Live from the studio: EAU Specialty Session

Monday 12 July
09:45 - 10:45

Location Virtual Room 2

Chairs
M. Babjuk, Prague (CZ)
A. Breda, Barcelona (ES)
C. Türk, Vienna (AT)
R. Zigeuner, Graz (AT)

Learning objectives

Recurrences of papillary NMIC are common, and some patients suffer from frequent transurethral resection. Office fulguration or even active surveillance may offer attractive alternatives for selected patients with less morbidity and without the need for a hospital stay. Another difficult location of urothelial cancer is the upper urinary tract. While local treatment of low-grade tumours as an alternative to radical nephroureterectomy is now considered an established treatment, follow-up is not yet standardised. Repeated endoscopy of the upper tract has more risks than cystoscopy, requires anesthesia, and commonly stents. Modern imaging modalities may reduce the need for invasive follow-up. Finally, follow-up is essential not only in malignancies but also for recurrent urinary calculi. Or might this be questioned? The three debates in this session will try to enlighten these controversies.

09:45 - 10:07

Debate Standard TURB or office fulguration or active surveillance for small papillary recurrence in the bladder? Are hospital urologists really necessary?
Moderator M. Babjuk, Prague (CZ)

09:45 - 09:46

Introduction
M. Babjuk, Prague (CZ)

09:46 - 09:50

TURB is necessary, anything else is insufficient therapy!
M. Burger, Regensburg (DE)

09:50 - 09:54

Office fulguration is safe, the patient will be spared from unnecessary anesthesia!
J. Palou, Barcelona (ES)

09:54 - 09:58

Active surveillance is the best choice, patients can enjoy life before treatment!
S. Shariat, Vienna (AT)

09:58 - 10:07

Discussion
A.M. Kamat, Houston (US)

10:07 - 10:26

Debate Flexible ureterorenoscopy or imaging for upper tract urothelial cancer?
Moderator R. Zigeuner, Graz (AT)

10:07 - 10:08

Introduction
R. Zigeuner, Graz (AT)

10:08 - 10:13

Flexible ureterorenoscopy
A. Breda, Barcelona (ES)

10:13 - 10:18

Imaging
M. Rouprêt, Paris (FR)

10:18 - 10:26

Discussion
O. Traxer, Paris (FR)

10:26 - 10:37

Debate Follow-up of stone formers is important
Moderator C. Türk, Vienna (AT)

10:26 - 10:27

Introduction
C. Türk, Vienna (AT)

10:27 - 10:32

Follow-up of stone formers is important: Yes!

K. Thomas, London (GB)

10:32 - 10:37

Follow-up of stone formers is important: No!

N.D. Davis, Dublin (IE)

10:37 - 10:45

Discussion

Moderators

A. Skolarikos, Athens (GR)

C. Türk, Vienna (AT)

K. Thomas, London (GB)

N.D. Davis, Dublin (IE)

Prostate cancer detection by MR, PET and Micro-US imaging

Poster Session 32

Monday 12 July
09:30 - 10:30

Location Virtual Room 9

Chairs S. Joniau, Leuven (BE)
I.G. Schoots, Rotterdam (NL)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session highlights the latest developments on MRI, PET and Micro-US for localized or locally advanced prostate cancer detection and their role in diagnostic pathways.

09:30 - 09:31

Introduction

09:31 - 09:52

MRI and PET for detection and diagnostic pathway

P0900

Ultra-fast biparametric MRI for prostate cancer detection
G. Brembilla, Milan (IT)

P0901

Is fast-MRI as accurate as multi-parametric MRI in the detection of clinically significant prostate cancer in biopsy naïve men? A prospective, single centre, non-inferiority randomized trial
M. Manfredi, Torino (IT)

P0902

Real-time clinical impact of an MRI-influenced diagnostic pathway in prostate cancer
N. Nørgaard, Virum (DK)

P0903

Which prostate cancers are undetected by multiparametric magnetic resonance imaging in men with previous prostate biopsy? An analysis from the PICTURE study
J.M. Norris, London (GB)

P0904

How to follow patients with negative targeted prostate biopsy but positive multi-parametric MRI? Results from a large, single institution series
A. Stabile, Milan (IT)

P0905

A 2-arm pseudo-randomized multicenter (MR PROPER) trial: MRI-directed pathway outperforms TRUS-directed pathway in prostate cancer diagnosis following upfront risk stratification
I.M. Wagenveld, Rotterdam (NL)

P0906

A predictive tool for clinically significant prostate cancer detection in men with prostate cancer suspicion
M. Triquell Llauro, Barcelona (ES)

P0907	Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography–fusion biopsy: A prospective, randomized comparison to conventional target biopsy Y. Saner, Essen (DE)
P0908	What is the definition of misclassification in patients with grade group 2 prostate cancer eligible for active surveillance and diagnosed with MRI targeted biopsy? A multi-institutional analysis with pathological confirmation G. Gandaglia, Milan (IT)
P0909	Prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: A systematic review and meta-analysis P. Satish, Swindon (GB)
P0910	Preliminary results from the PEDAL trial: A prospective single arm paired comparison of ability to diagnose and locate prostate cancer between multiparametric MRI and 18F-PSMA-PET/CT V. Tran, Melbourne (AU)
P0911	A prospective multi-centre study of the additive diagnostic value of 68Ga-PSMA-11 PET/CT to multiparametric MRI in the diagnosis of prostate cancer (PRIMARY Trial)
P0912	68Ga-PSMA-PET/CT in newly diagnosed patients on active surveillance (PASPoRT study) P.D. Polm, Amsterdam (NL)
P0913	Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy? H. Yin, Nanjing (CN)
P0914	Predicting early biochemical progression in prostate cancer patients staged with PSMA PET and multiparametric magnetic resonance imaging D. Meijer, Amsterdam (NL)
09:46 - 09:52	Discussion
09:52 - 10:02	MRI interpretation
P0915	Are urologists ready for interpretation of multiparametric MRI findings? A prospective multicentric evaluation G. Mantica, Genoa (IT)
P0916	Interobserver reproducibility of the Prostate Imaging Quality (PI-QUAL) score for prostate MRI quality F. Giganti, London (GB)
P0917	Should we routinely recommend a central review of magnetic resonance imaging of the prostate in men with positive mp-MRI? Implication for targeted biopsies F. Barletta, Milan (IT)
P0918	Positive predictive value of mpMRI in men under active surveillance: Can the biopsy history influence radiological assessment? L. Nocera, Milan (IT)
09:56 - 10:02	Discussion
10:02 - 10:15	MRI and PET for staging and follow-up
P0919	Added value of radiological tumor stage in predicting early oncological outcomes in prostate cancer patients undergoing radical prostatectomy within clinical stage: A stage-by-stage analysis G. Gandaglia, Milan (IT)

P0920	Identifying the optimal clinical setting for the use of multiparametric magnetic resonance imaging of the prostate as local staging tool in men candidate to radical prostatectomy. Results from a multi-institutional series F. Barletta, Milan (IT)
P0921	Detection of lymph node metastases using pooling method by One-Step Nucleic Acid Amplification (OSNA) assay in prostate cancer patients: Preliminary results M. Cuadras Sole, Barcelona (ES)
P0922	Standardized uptake values as determined on PSMA PET/CT are associated with higher Gleason grade and lower biochemical-free recurrence rates in patients with prostate cancer Y.J.L. Bodar, Amsterdam (NL)
P0923	Diagnostic value, oncological outcomes and safety profile of image-guided surgery technologies during robot-assisted lymph node dissection with sentinel node biopsy for prostate cancer P. Dell'Oglio, Milan (IT)
P0924	PET/CT allows for a reliable assessment of the real nodal burden in clinically node-positive prostate cancer patients candidate for radical prostatectomy: Results from a multi-institutional series G. Gandaglia, Milan (IT)
P0925	Radio-guided lymph node dissection in primary oligometastatic prostate cancer patients M.G.M. Schilham, Nijmegen (NL)
10:09 - 10:15	Discussion
10:15 - 10:26	Micro-US and mpUS for detection and diagnostic pathway
P0926	The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer A.D.R. Grey, London (GB)
P0927	Diagnostic accuracy of mpMRI-US fusion and micro-ultrasound guided biopsies for clinically significant prostate cancer detection D. Maffei, Villa Lagarina (IT)
P0928	Comparison of the accuracy of 29 MHz micro-ultrasound versus multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer D. Robin, Reims (FR)
P0929	High-resolution micro-ultrasound for local staging of prostate cancer: A prospective single-center experience V. Fasulo, Milano (IT)
P0930	Assessing the relationship between micro-ultrasound results and pathology at radical prostatectomy P.P. Avolio, Pieve Emanuele (IT)
10:20 - 10:26	Discussion
10:26 - 10:30	Expert summary G. Salomon, Hamburg (DE)

Kidney transplantation in 2021

Thematic Session 19

Monday 12 July
10:00 - 11:00

Location Virtual Room 3

Chairs A. Alcaraz, Barcelona (ES)
J.D. Olsburgh, London (GB)

Learning objectives

To provide the general urologist and specialist transplant urologist 'State of the Art' information about current challenges and opportunities in Transplant Surgery.

Specifically the role of:

- Robot-assisted surgery in kidney transplantation
- The urologist in management of transplant ureteric complications
- Orthotopic kidney transplantation including indications & outcomes
- Safe kidney transplant surgery in Jehovah's Witness patients
- Radical prostate surgery in kidney transplant patients

10:00 - 10:10

Robotic kidney transplantation: The global experience
R.K. Ahlawat, New Delhi (IN)

10:10 - 10:17

The challenge of training in robotic kidney transplantation
K. Decaestecker, Ghent (BE)

10:17 - 10:22

Discussion

10:22 - 10:27

Management of early and late graft ureteral complications
V. Hevia Palacios, Madrid (ES)

10:27 - 10:32

Discussion

10:32 - 10:37

Orthotopic kidney transplantation
M. Musquera Felip, Barcelona (ES)

10:37 - 10:42

Discussion

10:42 - 10:47

Kidney transplantation in Jehova's witnesses
G. Guerra, Miami (US)

10:47 - 10:52

Radical prostatectomy in kidney transplant patients
A.J. Figueiredo, Coimbra (PT)

10:52 - 11:00

Discussion

Semi-Live IV: New standards in endourology

Thematic Session 20

Monday 12 July
10:00 - 11:00

Location Virtual Room 5

Chairs M. Fernández, Santiago (CL)
P. Krombach, Luxembourg (LU)
P.J.S. Osther, Fredericia (DK)

Learning objectives

Viewers are presented with new endourological concepts with their respective advantages and disadvantages. The session has the aim to allow them an objective judgement.

10:00 - 10:10

Video: Totally-en-bloc low-power TFL enucleation of the prostate
C.M. Cracco, Turin (IT)

10:10 - 10:15

Discussion

10:15 - 10:25

Video: High-power laser ureteroscopic lithotripsy
K. Ghani, Ann Arbor (US)

10:25 - 10:30

Discussion

10:30 - 10:40

Video: Flexible ureterorenoscopy with thulium fiber laser
P.M. Kronenberg, Amadora (PT)

10:40 - 10:45

Discussion

10:45 - 10:55

Video: Upper tract urinary cancer (UTUC): Kidney preserving management
A. Gallioli, Barcelona (ES)

10:55 - 11:00

Discussion

Latest developments in paediatric urology

Thematic Session 21

Monday 12 July
10:00 - 11:00

Location Virtual Room 7

Chairs W.F.J. Feitz, Nijmegen (NL)
D.N. Wood, London (GB)

Learning objectives

This session will present to you the latest developments in paediatric urology. State-of-the-art lectures will cover several new insights and practical applications in your daily urological practice. We expect attendance of residents interested in the field of paediatric urology, fellows, urologists, paediatric urologists and nurse specialists for exchange of the latest knowledge and experiences.

10:00 - 10:02

Quality improvement in paediatric urology: A historical perspective
F. O'Kelly, Dublin (IE)

10:02 - 10:04

Video counseling in paediatric urology: What is here to stay after the pandemic?
A. Radford, Womersley (GB)

10:04 - 10:11

Primary monosymptomatic nocturnal enuresis in children and adolescents
E. Merlini, Torino (IT)

10:11 - 10:18

Distal hypospadias repair: Tips and tricks for a successful repair
R. Subramaniam, Leeds (GB)

10:18 - 10:25

Modern management of vesicoureteral reflux in 2021
C. Radmayr, Innsbruck (AT)

10:25 - 10:35

Discussion

10:35 - 11:00

Debate 10mm lower pole kidney stone in 5 year old girl: What is the best approach?
Moderator M.S. Silay, Istanbul (TR)

10:35 - 10:36

Introduction
M.S. Silay, Istanbul (TR)

10:36 - 10:41

SWL
B. Haid, Linz (AT)

10:41 - 10:46

PNL
A. Bujons Tur, Barcelona (ES)

10:46 - 10:51

RIRS
H.S. Dogan, Ankara (TR)

10:51 - 11:00

Discussion

Prostate cancer biopsy protocols and methods of targeting

Poster Session 33

Monday 12 July
10:30 - 11:30

Location Virtual Room 10

Chairs J.M. Norris, London (GB)
G. Ploussard, Toulouse (FR)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session highlights the latest developments of MRI role before biopsies, role of systematic biopsies along with targeted biopsies and methods of targeting

10:30 - 10:31

Introduction

10:31 - 10:48

MRI role before biopsies

- P0931** **Improving intermediate risk classification of prostate cancer with radiomics features**
R. Thenault, Rennes (FR)
- P0932** **The detection of a PI-RADS 4-5 lesion at multiparametric MRI before confirmatory biopsy. Is the strongest predictor of disease progression among men with low-risk prostate cancer included in an active surveillance prospective protocol**
L. Nocera, Milan (IT)
- P0933** **The potential prognostic role of pre-biopsy MRI: An example with PIRADS 5 lesions**
G. Fiard, Grenoble (FR)
- P0934** **Evaluation of radiomics in the prediction of the stage and grade of localized prostate cancer: What benefits are expected?**
R. Thenault, Rennes (FR)
- P0935** **One day prostate cancer screening and diagnosis using Magnetic Resonance imaging and Digital Prostate Biopsy with fluorescence confocal microscopy**
U.G. Falagario, Bari (IT)
- P0936** **A nomogram to predict absence of clinically significant prostate cancer in men with negative MRI**
M. Kaneko, Glendale (US)
- P0937** **Putting clinical assessment and patient experience at the centre of prostate cancer diagnostics: The superior prostate experience and efficient diagnostics (SPEED) pathway**
J. Withington, London (GB)
- P0938** **Prospective analysis of prostate cancer local staging with [18f] psma pet/mri combined with multiparametric mri – a comparison to histopathology in the radical prostatectomy specimen**
Y.J.L. Bodar, Amsterdam (NL)

P0939	The role of psa density in decision making to perform transperineal prostate biopsy in men with multi-parametric MRI Likert 2 or 3 scores: A retrospective analysis from a multi-centre cancer network study J. Fanshawe, London (GB)
10:40 - 10:48	Discussion
10:48 - 11:06	Role of systematic biopsies along with targeted biopsies
P0940	Is it safe to omit systematic biopsies in addition to targeted MRI-ultrasound fusion biopsies in biopsy naïve men suspected for prostate cancer? N.G. Alkema, Zwolle (NL)
P0941	The learning curve of mpMRI targeted biopsy for the detection of clinically significant prostate cancer is related to the characteristics of the index lesion A. Stabile, Milan (IT)
P0942	Comparative analysis of a novel target saturation biopsy approach in Magnetic Resonance Imaging (MRI) TransRectal UltraSound (TRUS) fusion biopsy versus transperineal template saturation biopsy for the detection of significant prostate cancer J.P. Radtke, Essen (DE)
P0943	Transrectal and transperineal MRI-guided prostate cancer pathways in biopsy-naïve men B. Israël, Nijmegen (NL)
P0944	Prostate Mapping: The Madrid protocol (Transperineal prostate biopsies combining Micro-ultrasound and mpMRI fusion biopsy) concordance with robotic radical prostatectomy specimens M.E. Rodríguez Socarrás, Madrid (ES)
P0945	Artificial intelligence with fuzzy logic algorithms approach for target prostate biopsy outcomes prediction E. Checcucci, Venaria Reale (IT)
P0946	Beware excluding systematic biopsy in patients undergoing radical prostatectomy: A five year follow up study of biochemical recurrence free survival J. James, Edinburgh (GB)
P0947	Analysis of the detection rate of target only vs. target plus standard biopsy in naïve patients based on radical prostatectomy specimens M. Manfredi, Torino (IT)
P0948	The added value of systematic sampling in in-bore magnetic resonance imaging guided prostate biopsy B. Rosenzweig, Ramat Gan (IL)
P0949	Additional value of systematic biopsies for preoperative assessment in MRI-detected prostate cancer E. Axén, Göteborg (SE)
10:58 - 11:06	Discussion
11:06 - 11:25	Methods of biopsy for targeting
P0950	Diagnostic performance of fusion (US/MRI guided) prostate biopsy: Propensity score matched comparison of elastic versus rigid fusion system M.C. Ferriero, Rome (IT)
P0951	Tranperineal vs. transrectal micro-ultrasound and mpMRI targeted prostate biopsies: propensity score-matched study A. Rakauskas, Lausanne (CH)
P0952	Head-to-head comparison of orostate cancer detection rate at MRI-targeted FUSION biopsy between hub and spoke mpMRI Italian centers M. Droghetti, Ferrara (IT)

P0953	Free-hand MRI-TRUS transperineal prostate fusion biopsy under local anesthesia: A multicentre analysis of the learning curve G. Callaris, Cuneo (IT)
P0954	Performance comparison between computer-software-based fusion versus cognitive fusion technique in biopsy-naïve patients: A single-center analysis R.G. Bertolo, Torino (IT)
P0955	Added value of randomized biopsy to mpMRI-targeted biopsy of the prostate: 5-year experience from a community-based urologic outpatient clinic M. Chaloupka, München (DE)
P0956	Cognitive fusion-guided prostate biopsy with multiparametric magnetic resonance imaging versus high-resolution microultrasound-guided biopsy in prostate cancer diagnosis M. Beltrán, VALENCIA (ES)
P0957	A new horizon-electromagnetic (EM) needle tip tracking to support mpMRI/US fusion transperineal prostate biopsies under local anaesthesia C. Kastner, Cambridge (GB)
P0958	Transperineal vs. transrectal MRI-targeted prostate biopsy: Evaluation of cancer detection risk and biopsy accuracy for clinical significant prostate cancer F. Zattoni, Verona (IT)
P0959	Accuracy of Koelis fusion biopsy: Improved cancer detection with targeted biopsies only M. Oderda, Bra (CN) (IT)
P0960	The learning curve of prostate MRI/TRUS target fusion biopsy after more than 1000 procedures: Residents' experience F. Piramide, Torino (IT)
11:17 - 11:25	Discussion
11:25 - 11:30	Expert summary J. Barentsz, Nijmegen (NL)

Controversies on EAU Guidelines - Session II

Live from the studio: EAU Specialty Session

Monday 12 July
11:00 - 12:00

Location Virtual room 1

Chairs
M.P. Laguna Pes , İstanbul (TR)
T. Knoll, Sindelfingen (DE)
B. Ljungberg, Umeå (SE)
S. Minhas, London (GB)

Learning objectives

This session addresses certain controversies that arise in the latest version of the EAU's Guidelines. Three topics will be addressed in the form of moderated debates, with plenty of time reserved for discussion between the speakers.

This session will first cover small renal masses and whether to treat or observe them. RCT's are still missing and treatment options have also recently changed to (robot-assisted) laparoscopic, and from radical nephrectomy to partial nephrectomy, each raising new questions on optimal treatment of small renal masses.

The second debate deals with high-risk non-seminoma CS1, and the merits of chemotherapy and surgical treatment options. The objective of this debate is to discuss specific indications, toxicity and outcomes of chemotherapy and NS-RPLND emphasising the capital concept of shared decision-making.

The third and final debate concerns the best surgical technique for delayed or refractory ischaemic priapism. In 2021, the EAU guideline panel on male sexual and reproductive Health published contemporary guidance in this controversial and challenging area. Internationally recognised experts will focus on the management of ischaemic priapism and the potential pitfalls in diagnosis and treatment.

11:00 - 11:19

Debate Small renal mass: Treat or observe?

Moderator B. Ljungberg, Umeå (SE)

11:00 - 11:03

Introduction

B. Ljungberg, Umeå (SE)

11:03 - 11:06

Surveillance

A. Volpe, Novara (IT)

11:06 - 11:09

Active treatment

C.K. Bensalah, Rennes (FR)

11:09 - 11:19

Discussion

A. Bex, London (GB)

11:19 - 11:38

Debate High-risk non-seminoma CS1: 1x BEP or surgery

Moderator M.P. Laguna Pes , İstanbul (TR)

11:19 - 11:22

Introduction

M.P. Laguna Pes , İstanbul (TR)

11:22 - 11:25

BEP

T. Tandstad, Trondheim (NO)

11:25 - 11:28

Surgery

N. Nicolai, Milan (IT)

11:28 - 11:38

Discussion

A. Heidenreich, Cologne (DE)

11:38 - 12:00	Debate What is the best surgical technique for delayed or refractory ischaemic priapism? <i>Moderator</i> S. Minhas, London (GB)
11:38 - 11:41	Introduction S. Minhas, London (GB)
11:41 - 11:44	Conventional shunts? A. Kadioglu, Istanbul (TR)
11:44 - 11:47	Novel shunts and penile decompression? C. Bettocchi, Bari (IT)
11:47 - 11:50	Penile prosthesis? J.I. Martínez Salamanca, Majadahonda (ES)
11:50 - 12:00	Discussion A. Salonia, Milan (IT)

The threat of urogenital infections

Meeting of the EAU Section of Infections in Urology (ESIU)

Monday 12 July
11:00 - 12:00

Location Virtual Room 4

Chairs T.E. Bjerklund Johansen, Oslo (NO)
F.M.E. Wagenlehner, Giessen (DE)

Learning objectives

Infections have always been a threat to mankind. In this session we discuss the impact of various infections involving the urogenital tract on urologic health. Antibiotics have been magic drugs fighting bacterial infections, however their effectivity is melting away, due to resistance or because side effects have led regulatory agencies to withdraw indication, such as prophylaxis in prostate biopsy. Prudent use of antibiotics is therefore of paramount importance to keep this weapon sharp.

11:00 - 11:02

Introduction

F.M.E. Wagenlehner, Giessen (DE)

11:02 - 11:09

The standpoint of the European Medicines Agency (EMA) regarding the use of fluoroquinolones

G. Bonkat, Basel (CH)

11:09 - 11:14

Case report prostate biopsy

J. Medina-Polo, Madrid (ES)

11:14 - 11:21

Legal consequences on the use of fluoroquinolones

B. Leigh, London (GB)

11:21 - 11:28

(Antibiotic) prophylaxis in prostate biopsy in 2021

A. Pilatz, Giessen (DE)

11:28 - 11:33

Discussion

11:33 - 11:40

Reduction of inappropriate use of catheters

S.E. Geerlings, Amsterdam (NL)

11:40 - 11:47

How to prevent surgical site infections and postoperative infections?

F. Bruyere, Tours (FR)

11:47 - 11:54

Bacteriophages: Non antibiotic treatment of urinary tract infections

T. Perepanova, Moscow (RU)

11:54 - 11:59

Discussion

11:59 - 12:00

Closing remarks

T.E. Bjerklund Johansen, Oslo (NO)

History of urology at a glance

EAU Specialty Session

Monday 12 July
11:00 - 12:00

Location

Virtual Room 6

Chairs

R. Jungano, Naples (IT)
P. Van Kerrebroeck, Berchem- Antwerp (BE)

Learning objectives

This specialty session is organised by the EAU History Office and covers a variety of interesting topics related to the History of Urology. In addition to the biography of a notable pioneer in the field of Urology, this session features a topic close to everyone's current daily practice: Urology and pandemics. Specific attention is paid to urological surgery in ancient Roman times. After this session, participants will have gained a wider perspective of current urological issues and have learned from the experiences of their predecessors.

11:00 - 11:05

Welcome and introduction

P. Van Kerrebroeck, Berchem- Antwerp (BE)

11:05 - 11:15

Prof. Enrico Dormia: The man, the urologist and his basket

E. Montanari, Milan (IT)

11:15 - 11:20

Discussion

11:20 - 11:30

COVID-19 and urologists: Nihil novi sub sole?

M.S. Rahnama'i, Aachen (DE)

11:30 - 11:35

Discussion

11:35 - 11:45

Urological surgery in ancient Roman times

J.C. Goddard, Leicester (GB)

11:45 - 11:50

Discussion

11:50 - 12:00

General discussion & closing remarks

R. Jungano, Naples (IT)
P. Van Kerrebroeck, Berchem- Antwerp (BE)

Education and training models in urology and E-health

Poster Session 34

Monday 12 July
11:00 - 12:00

Location Virtual Room 8

Chairs J.M. Nijman, Groningen (NL)
A. Pietropaolo, Southampton (GB)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Urology education, training models, simulation models, gender equity in urology will be discussed with the audience.

11:00 - 11:01

Introduction

P0961 **Simulation in urological training and Education (SIMULATE): A randomised controlled clinical and educational trial to determine the effect of simulation-based surgical training**
A. Aydin, London (GB)

P0962 **The role of simulation in endourology training: development and validation of a 3D-printed model**
S. Chiva San Roman, Pamplona (ES)

P0963 **Risks and benefits of live surgery: A systematic review**
U. Carbonara, Triggiano (IT)

P0964 **The webin-era of urologic education during COVID-19**
G.E. Cacciamani, Los Angeles (US)

P0965 **Climate change impact of virtual urology meetings**
S. Patel, San Diego (US)

11:06 - 11:12

Discussion

P0966 **Nephrotoxicity in immune checkpoint inhibitor therapy: A pharmacovigilance study**
L. Haeuser, Herne (DE)

P0967 **Dreaming of gender equity in urology: An analysis of urological congresses**
T. Hüscher, Mainz (DE)

P0968 **Women in urology: Spanish national survey**
E. Seguí Moya, Elche (ES)

Scientific Programme - EAU21 Virtual

P0969	Lessons learnt from 1010 consecutive robot assisted radical prostatectomies: Safe fellowship training S. Folkard, London (GB)
P0970	The reliability, sensitivity, and specificity of Global Evaluative Assessment of Robotic Skills (GEARS) and binary scoring metrics of robotic suturing and knot tying skills in a Vesico Urethral Anastomosis (VUA) task A. Gallagher, Melle (BE)
P0971	Proficiency based progression training versus the Halsted's model for learning to perform a robotic vesico-urethral anastomosis on an avian tissue model: A prospective, randomized, multicenter, cross-specialty and blinded clinical trial R. De Groote, Denderhoutem (BE)
11:18 - 11:24	Discussion
P0972	Defining the ideal urology training programme from the trainee's and professor's perspective: Is there a concordance in their idea of good training? G. Mantica, Genoa (IT)
P0973	Validation of 3D printed models of the upper urinary tract for high fidelity simulation of Retrograde Intrarenal Surgery (RIRS) L. Orecchia, Roma (IT)
P0974	Three-dimensional printing technology to create a high-fidelity ureteroscopy simulator: Development and evaluation A. de Hauteclocque, Neuilly sur Seine (FR)
P0975	Application of Artificial Intelligence-based classifiers to predict the outcome measures and stone-free status following percutaneous nephrolithotomy for staghorn calculi: Cross-validation of data and estimation of accuracy
P0976	The association between Dietary Inflammatory Index and sex hormones among men in the United States C. Zhang, ChengDu (CN)
P0977	Assessing online crowdfunding for urologic cancer care using automated data extraction P. Rajwa, Zabrze (PL)
P0978	Urology at your fingertips: Medical students reception of a newly developed urology m-learning app K.G. Keane, Dublin (IE)
P0979	Are virtual clinics the new normal? A single-institution comparative analysis of outcomes and cost-effectiveness of virtual and face-to-face clinics I. Khawaja, Colchester (GB)
P0980	Is Movember an effective prostate cancer awareness campaign in Spanish? Insights from Google trends D.A. González-Padilla, Madrid (ES)
P0981	Does quality assured eLearning provide adequate preparation for robotic surgical skills; A prospective, randomized and multi-center study S. Puliatti, Modena (IT)

P0982	Virtual interactive surgical skills classroom – a single-blinded, randomised control trial (VIRTUAL) A. Nathan, London (GB)
11:35 - 11:41	Discussion
-	E-Health
P0983	Using a remote monitoring kit to predict re-admissions for patients discharged following radical cystectomy P. Khetrapal, London (GB)
P0984	Comparing patient experience between telemedicine and traditional urology visits during the COVID-19 pandemic E. Lim, Singapore (SG)
P0985	Positive environmental impact of remote teleconsultation in urology during the COVID-19 pandemic in a highly populated area U. Pinar, Paris (FR)
P0986	Emerging role of Telemedicine in urology: COVID brought the opportunity for the future! R. Ranjan, Rishikesh (IN)
P0987	The role of a digital psychological support for prostate cancer patients managed by a multidisciplinary disease unit: Initial experience from a referral center M. Sironi, Milan (IT)
P0988	Podcasts in urology: A growing tendency? M.P. Moreno-Fontela, Madrid (ES)
P0989	Assessment of physicians' satisfaction with a virtual tumour board in a French academic centre during the COVID-19 pandemic U. Pinar, Paris (FR)
11:48 - 11:54	Discussion
11:54 - 11:59	Expert summary D. Veneziano, Reggio Calabria (IT)

Prosthetic surgery in urology

ESU Course 22

Monday 12 July
14:15 - 16:15

Location Zoom 1

Chair A. Muneer, London (GB)

Learning objectives

An increasing number of urological surgeons are developing a surgical practice which involves prosthetic surgery. This course will aim to cover the key areas of prosthetic surgery in urology with the aid of a video based platform. The course is aimed at urological trainees as well as established urologists wishing to develop a practice or gain an update and surgical tips in this area.

Surgical techniques with the aid of semi-live surgery will be a key focus of this course. At the end of the course participants should have a good understanding of:

- Minimising the risk of prosthesis infection and understand the role of biofilms
- Theatre preparation and set up for prosthetic surgery
- Patient selection and prosthetic surgery for male and female urinary incontinence including artificial urinary sphincters and sacral neuromodulation
- Penile prosthesis surgery – surgical techniques, avoiding complications and revision surgery

14:15 - 16:15

Introduction to prosthetic surgery, theatre set up and patient selection
A. Muneer, London (GB)

14:15 - 16:15

Primary penile prosthesis surgery – surgical technique and avoiding complications
A. Muneer, London (GB)

14:15 - 16:15

Penile prosthesis surgery - Managing intraoperative complications and navigating difficult cases
D.J. Ralph, London (GB)

14:15 - 16:15

Penile prosthesis revision surgery
D.J. Ralph, London (GB)

14:15 - 16:15

Prosthetic surgery for male urinary incontinence - Male slings and AUS
R. Dahlem, Hamburg (DE)

14:15 - 16:15

Prosthetic surgery for female urinary incontinence
R. Dahlem, Hamburg (DE)

-

Discussion and conclusion

Laparoscopy for beginners

ESU Course 21

Monday 12 July
11:00 - 13:00

Location Zoom 1

Chair X. Cathelineau, Paris (FR)

Learning objectives

Considering the large widespread of mini-invasive surgery in Urology, improving knowledge of practical aspects of laparoscopy is mandatory.

The aim of this interactive course (with several experts) is to give you bases, tips and tricks about:

- . Indications and contra indications of laparoscopic approach
- . How to choose and use the best instrumentation
- . Managing air parameters and optimal access
- . How to prevent and manage complications

Through a practical and interactive way (video, open discussions), the objective is to assist beginners in laparoscopy shortening their learning curve and optimizing success of their laparoscopic procedures

11:00 - 13:00

Introduction

X. Cathelineau, Paris (FR)

11:00 - 13:00

Devices in laparoscopy: Optimal instrumentation

P.J. Zondervan, Amsterdam (NL)

-

Questions and answers

11:00 - 13:00

Main procedures in laparoscopy: Video clips

T.M. Ribeiro De Oliveira, Lisbon (PT)

-

Questions and answers

11:00 - 13:00

How to prevent and manage complications

X. Cathelineau, Paris (FR)

-

Questions and answers

Prostate cancer screening, biopsy indication protocols and markers

Poster Session 35

Monday 12 July
11:30 - 12:30

Location Virtual Room 9

Chairs H.U. Ahmed, London (GB)
G. Gandaglia, Milan (IT)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session highlights the latest developments for localized prostate cancer on screening, biopsy safety, route and detection rate. Place of biomarkers and risk calculators in the diagnostic pathway will also be discussed.

11:30 - 11:31

Introduction

11:31 - 11:43

Screening and pathology

P0990 **Prostate cancer specific mortality in the ERSPC trial: What is the role of screening result and adherence**
L.W. Prause, Aarau (CH)

P0991 **Visioning - Evaluation of a solely MRI-based, PSA-free prostate cancer screening program**
M.O. Matthias, Basel (CH)

P0993 **Long-term predictive value of serum PSA values obtained in clinical practice – Results from the Norwegian Prostate Cancer Consortium (NPCC)**
S. Carlsson, New York (US)

P0994 **CD8-positive T cells and CD204-positive M2 macrophages predict postoperative prognosis of very high-risk prostate cancer**
Y. Yanai, Tokyo (JP)

P0995 **Significant inter- and intra-laboratory variation in Gleason grading of prostate cancer: A nationwide study of 35,258 patients in The Netherlands**
R.N. Flach, Utrecht (NL)

P0996 **Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer**
F. Preisser, Frankfurt (DE)

11:37 - 11:43

Discussion

P0992 **The PROFILE study. Targeted screening using germline genetics in men with a family history of prostate cancer**
H. Ni Raghallaigh, London (GB)

11:43 - 11:55

Safety, antibiotic prophylaxis

P0997	Transrectal ultrasound guided prostate needle biopsy is still a standard of care for prostate cancer diagnosis – A multicentre Australian analysis of infection rates C.J. Parkin, Sydney (AU)
P0998	Effectiveness of trans-perineal prostate biopsy without antibiotic prophylaxis. A prospective bicentric trial P. Giacomo Maria, Arezzo (IT)
P0999	Prostate cancer detection, tolerability and safety of transperineal prostate biopsy under local-anaesthesia versus standard transrectal biopsy in biopsy-naïve men: A pragmatic, parallel group, randomized-controlled study W. Lam, Hong Kong (HK)
P1000	Antibiotic prophylaxis is not necessary before local anaesthetic transperineal prostate biopsies - an institution's experience of 443 consecutive cases J.B. John, Exeter (GB)
P1001	Monoprophylaxis with cephalosporins for transrectal prostate biopsy after the fluoroquinolone-era: A multi-institutional comparison of infectious complications M. Wenzel, Frankfurt (DE)
P1002	Safety and side effects after perineal prostate biopsy without antibiotic prophylaxis: Results of a multicenter trial with 30 days follow-up A. Sigle, Freiburg (DE)
11:49 - 11:55	Discussion
11:55 - 12:06	Biopsy protocol and detection
P1007	The urologist's learning curve of in-bore magnetic resonance-guided prostate biopsy B. Rosenzweig, Ramat Gan (IL)
P1004	Impact of non-targeted prostate sampling histology on the probability of receiving invasive local treatment in an mpMRI-targeted pathway – analysis of 1,719 men M.J. Connor, London (GB)
12:00 - 12:06	Discussion
P1003	Saturation of the mpMRI lesion is not necessary to minimize the risk of missing clinically significant prostate cancer at targeted biopsy. Analysis of a large, multi-institutional series A. Stabile, Milan (IT)
P1005	Assessing the need for systematic biopsies in addition to targeted biopsies according to the volume of the index lesion diagnosed at mpMRI. Results from a large multi-institutional database F. Pellegrino, Milan (IT)
P1006	Site-specific concordance of targeted and systematic biopsy cores at the index lesion on mpMRI: Can we spare the double-tap? M. Droghetti, Ferrara (IT)
12:06 - 12:25	Biomarkers and risk calculators
P1009	Impact of decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative R. Vince, Ann Arbor (US)
P1010	Exosome-based testing enhances shared decision-making and improves patient risk stratification R.F. Tutrone Jr., Baltimore, Maryland (US)
P1011	Retrospective evaluation of Proclarix as a companion to mpMRI for the detection of clinically significant prostate cancer M. Campistol Torres, Barcelona (ES)

P1012	Clinical utility of ExosomeDx with or without multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer V. Fasulo, Milano (IT)
P1013	Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy G.M. Busetto, Rome (IT)
P1015	MRI-targeted or systematic biopsies in prostate cancer screening: The STHLM3MRI trial T. Nordström, Stockholm (SE)
P1014	Prostate cancer screening using prostate-specific antigen, a multiplex blood-test, magnetic resonance imaging and targeted prostate biopsies: The STHLM3MRI trial T. Nordström, Stockholm (SE)
P1017	Retrospective evaluation of Proclarix for the detection of clinically significant prostate cancer together with mpMRI M. Campistol Torres, Barcelona (ES)
P1019	The genomic landscape of unsuspected, incidentally detected Gleason 7 prostate cancer found on autopsy A.R. Zlotta, Toronto (CA)
P1020	Association between Oncotype DX Genomic Prostate Score (GPS) and adverse tumor pathology after radical prostatectomy M. Covas Moschovas, Celebration (US)
P1018	The Biopsy Prevention Calculator (BioPrev C): A novel prediction tool to avoid unnecessary prostate biopsies C. Poyet, Zürich (CH)
P1008	Reducing biopsies and mris in the diagnostic pathway of prostate cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION trial data S. Remmers, Rotterdam (NL)
P1016	Prediction of prostate cancer in biopsy-naïve men: Diagnostic accuracy and external validation of current prostate cancer risk calculators B. Israël, Nijmegen (NL)
12:19 - 12:25	Discussion
12:25 - 12:29	Expert summary C.L. Dickinson, London (GB)

Contemporary urogenital reconstruction and continence restoration: A practical guide

Meeting of the EAU Section of Genitourinary Reconstructive Surgeons (ESGURS)

Monday 12 July
12:00 - 13:00

Location Virtual Room 2

Chair D.J. Ralph, London (GB)

Learning objectives

This year there will be various interesting topics for all on reconstructive surgery with the introduction of new and young speakers. The main topics covered will include urethral surgery with exciting sessions on male and female urethroplasty as well as a session on male incontinence surgery and the use of slings.

12:00 - 12:01

Welcome

D.J. Ralph, London (GB)

12:01 - 12:16

Failed hypospadias repair

Moderator W. Verla, Ghent (BE)

12:01 - 12:06

When and how to do one-stage urethroplasty in failed hypospadias repair

R. Dahlem, Hamburg (DE)

12:06 - 12:11

When and how to do two-stage urethroplasty in failed hypospadias repair

P. Anderson, Dudley (GB)

12:11 - 12:16

Discussion

12:16 - 12:31

The nearly-obliterative bulbar stricture

Moderator L.A. Kluth, Frankfurt (DE)

12:16 - 12:21

Double grafting technique and outcomes

E. Palminteri, Arezzo (IT)

12:21 - 12:26

Non-transecting anastomotic repair

F. Campos Juanatey, Santander (ES)

12:26 - 12:31

Discussion

12:31 - 12:46

Female urethroplasty

Moderator J. Ockrim, London (GB)

12:31 - 12:36

Ventral onlay urethroplasty

T.J. Greenwell, London (GB)

12:36 - 12:41

Dorsal onlay urethroplasty

M. Waterloos, Ghent (BE)

12:41 - 12:46

Discussion

12:46 - 13:00

New techniques in male incontinence

Moderator R. Dahlem, Hamburg (DE)

12:46 - 12:51

Adjustable fascia sling in the male

E. Kocjancic, Chicago (US)

12:51 - 12:56

Implantation of adjustable sling ATOMS

S. Foley, Reading (GB)

12:56 - 13:00

Discussion

Andrological tips and tricks for outpatient and office urologists

Meeting of the EAU Section of Outpatient and Office Urology (ESUO)

Monday 12 July
12:00 - 13:00

Location Virtual Room 3

Chairs F. Dimitriadis, Kalamaria, Thessaloniki (GR)
A. Zachariou, Volos (GR)

Learning objectives

ESUO, following its commitment to upgrade the skills of outpatient and office urologists, aims by the end of the session to introduce the audience to the following topics:

- Both oxidative stress and reductive stress threaten male fertility. The use of simple interventions can re-establish redox balance, and therefore reduce the incidence of idiopathic male infertility.
- COVID-19 and other viruses affect the male reproductive system with detrimental effects on male fertility. Adequate investigation and interventions can optimize the male biological material aiming to increase the fertilization potential of the sperm.
- Our understanding of the genetic causes of male infertility remains limited. The aetiology of male infertility remains unknown in about 40% of patients. The outpatient and office urologist should be familiar with the novel genetic factors leading to idiopathic infertility. This knowledge in the field of androgenetics will make the urologist able to furnish adequate genetic consultation to the couple.
- Premature ejaculation can have a significant adverse impact on the quality of life for the patient and his sexual partners. In this session the audience will be introduced to the psychological effect, effect of anxiety as an extra stress factor in couples who seek help for infertility.

12:00 - 12:02

Welcome and introduction

F. Dimitriadis, Kalamaria, Thessaloniki (GR)

12:02 - 12:12

Oxidative and reductive stress in male infertility: Two sides of the same coin

M. Benyó, Debrecen (HU)

12:12 - 12:14

Discussion

12:14 - 12:24

Viral menace to male fertility

G. Semini, Ioannina (GR)

12:24 - 12:26

Discussion

12:26 - 12:36

Genetics of male infertility

A. Khelaia, Tbilisi (GE)

12:36 - 12:38

Discussion

12:38 - 12:48

Premature ejaculation in its broader context

S.M. Haensel, Rotterdam (NL)

12:48 - 12:50

Discussion

12:50 - 12:58

Debate: How the pandemic changed andrological care in outpatients

Scientific Programme - EAU21 Virtual

Panel

M. Benyó, Debrecen (HU)
S.M. Haensel, Rotterdam (NL)
A. Khelaia, Tbilisi (GE)
G. Semini, Ioannina (GR)

12:58 - 13:00

Closing remarks

A. Zachariou, Volos (GR)

Joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC)

EAU Specialty Session

Monday 12 July
12:00 - 13:00

Location Virtual Room 5

Chairs S. Gillessen Sommer, Bellinzona (CH)
N. Mottet, Saint-Étienne (FR)

Learning objectives

Learn about current gaps on evidence in several situations in prostate cancer management; Learn about controversies and state of the art of cN1M0 disease; Pro's and Con's on adjuvant versus early salvage RT in advanced prostate cancer.

12:00 - 12:03

Welcome and introduction

S. Gillessen Sommer, Bellinzona (CH)

12:03 - 12:34

cN1 patients

Moderator

N. Mottet, Saint-Étienne (FR)

12:03 - 12:07

Case presentation

R. Pereira Mestre, Bellinzona (CH)

12:07 - 12:12

Surgical treatment

A. Briganti, Milan (IT)

12:12 - 12:17

Radiotherapy treatment

P. Ost, Ghent (BE)

12:17 - 12:22

Systemic treatment

K. Fizazi, Villejuif (FR)

12:22 - 12:27

Summary: Optimal treatment for cN1 disease

P. Albers, Düsseldorf (DE)

12:27 - 12:34

Questions and answers

12:34 - 13:00

Adjuvant vs. early salvage RT

Moderator

N. Mottet, Saint-Étienne (FR)

12:34 - 12:38

Case presentation

D. Tilki, Hamburg (DE)

12:38 - 12:43

Arguments for adjuvant

G. De Meerleer, Leuven (BE)

12:43 - 12:48

Arguments for early salvage

A. Bossi, Villejuif (FR)

12:48 - 12:53

Summary

A. Stenzl, Tübingen (DE)

12:53 - 13:00

Questions and answers

History and histories

Poster Session 36

Monday 12 July
12:00 - 12:30

Location Virtual Room 7

Chairs M.S. Rahnama'i, Aachen (DE)
P. Van Kerrebroeck, Berchem- Antwerp (BE)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

In this poster session several aspects of the history of Urology are discussed. The content is interesting for those interested in the history of our specialty but also includes relevant information for all involved in actual daily practice. Furthermore this session will reveal some intriguing facts that you cannot find published anywhere.

12:00 - 12:01

Introduction

P1021	The man in the red coat – Samuel Pozzi (1846-1918): French pioneer of gynecology in the belle époque D. Schultheiss, Giessen (DE)
P1022	Alfonso Dehesa Bailo (1895-1953) and the studies on the development of the human prostate L.A. Fariña-Pérez, Vigo (ES)
P1023	The phallus in the corbels of Romanesque churches in Castilla as the source of generation: A protection from the devil and an invitation to repopulate the Muslim medieval frontier J. Angulo Cuesta, Getafe (ES)
P1024	Bolesław Wojciech Motz (1865-1935): Social activist, chef de la consultation and academic mentor for visiting monitors in Clinique des Maladies des Voies Urinaires in Necker J. Angulo Cuesta, Getafe (ES)
P1025	Early Vienna sources on the history of urology, sexual medicine and sexology F. Moll, Cologne (DE)
P1026	Ignacio Purpón (1913-2006), author of "Prostatectomia transurethral endoscópica" (1979), one of the first Spanish monographic treatises on transurethral resection of the prostate L.A. Fariña-Pérez, Vigo (ES)
P1027	An ancient plant with aphrodisiac effect for males and contraceptive effect for females E. Guner, Istanbul (TR)

Scientific Programme - EAU21 Virtual

12:08 - 12:23

Discussion

12:23 - 12:28

Expert summary

J.C. Goddard, Leicester (GB)

Meeting of the Young Academic Urologists (YAU)

EAU Specialty Session

Monday 12 July
12:30 - 13:30

Location Virtual Room 8

Chair J. Gómez Rivas, Madrid (ES)

Learning objectives

The Young Academic Urologists (YAU) is a group of talented and already renowned European young urologists. We aim to promote high-quality studies in order to provide strong evidence for the best urological practice. In this session both scientific and educational context will be discussed among the members of YAU and the leaders of European Urology.

12:30 - 12:38

EAU Young Academic Urologists (YAU) & awards

Moderators J. Gómez Rivas, Madrid (ES)
J.P.M. Sedelaar, Nijmegen (NL)

12:30 - 12:34

Overview of the Young Academic Urologists

J. Gómez Rivas, Madrid (ES)

12:34 - 12:38

YAU Awards

G. Gandaglia, Milan (IT)

12:38 - 13:00

Challenge the expert

Moderators P. Kallidonis, Patras (GR)
L.A. Kluth, Frankfurt (DE)
A. Larcher, Milan (IT)

12:38 - 12:48

Adjuvant chemotherapy beneficial in upper tract urothelial carcinoma

Pro A. Aziz, Munich (DE)
Con E. Xylinas, Paris (FR)

12:48 - 12:58

The MRI-directed biopsy: The end of systematic biopsies for diagnosis and prognostic assessment

Pro V. Kasivisvanathan, London (GB)
Con G. Marra, Turin (IT)

12:58 - 13:00

Discussion

13:00 - 13:25

Key research studies of the year

Moderators R. Campi, Florence (IT)
B. Haid, Linz (AT)
A. Pietropaolo, Southampton (GB)

13:00 - 13:05

Facing guidelines on Sexual medicine: Where we are on priapism topic?

Speaker G.I. Russo, Catania (IT)
Discussant M.M. Fode, Herlev (DK)

13:05 - 13:10

The impact of AI in urology: A journey from concepts to clinical applications

Speaker G.E. Cacciamani, Los Angeles (US)
Discussant F. Porpiglia, Turin (IT)

13:10 - 13:15

Thulium fiber laser, burst wave lithotripsy, disposable scopes and stone dust suction devices: What's the future in endourology?

Speaker E.X. Keller, Zürich (CH)
Discussant D. Enikeev, Moscow (RU)

13:15 - 13:20

Improving management of rare genitourinary syndromes: Focus on Lynch syndrome and VHL-related disease

Speaker M. Moschini, Lucerne (CH)
Discussant A. Necchi, Milan (IT)

Scientific Programme - EAU21 Virtual

13:20 - 13:25

Discussion

13:25 - 13:30

How to establish a professional career at a European level: Motivational talk from Crystal Matula award winner
M.S. Silay, Istanbul (TR)

Active surveillance and focal therapy: Evolving concepts and long term outcome

Poster Session 37

Monday 12 July
12:30 - 13:30

Location Virtual Room 10

Chairs A.S. Rannikko, Helsinki (FI)
R. Sanchez-Salas, Paris (FR)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

This session highlights the latest developments in the management of localized prostate cancer within active surveillance and focal therapy programs.

12:30 - 12:31

Introduction

A.S. Rannikko, Helsinki (FI)
R. Sanchez-Salas, Paris (FR)

12:31 - 12:42

Selection for AS

P1028

Clinical impact of the predict prostate risk communication tool in men newly diagnosed with non-metastatic prostate cancer: A multi-centre randomised controlled trial

D. Thurtle, Whittlesford (GB)

P1029

The development of a dynamic prediction model using MRI predicting Gleason upgrading on prostate biopsy in patients on active surveillance

D. Nieboer, Rotterdam (NL)

P1030

Development of novel criteria to identify the optimal candidates for active surveillance among men with low-risk prostate cancer and a positive family history. Results from a large, single institution series

R. Leni, San Donato Milanese (IT)

P1031

A machine learning approach to predicting progression on active surveillance for prostate cancer

M. Nayan, Brampton (CA)

P1032

Active surveillance for prostate cancer: Comparison between incidental tumors vs. tumors diagnosed at prostate biopsies

M.L. Piccinelli, Milan (IT)

12:36 - 12:42

Discussion

12:42 - 12:59

Imaging, biomarkers and biopsy

P1033

The secondary evaluation of biopsy tissue for initial prostate cancer diagnosis: does a dedicated uro-pathologist change therapy recommendation in active surveillance patients?

S. Knipper, Hamburg (DE)

P1034	Upfront MRI is the new standard, have confirmatory biopsies become obsolete? H.B. Luiting, Rotterdam (NL)
P1035	Low risk prostate cancer patients with negative confirmatory biopsies during active surveillance are at low risk of being treated for their disease J. Abi Chebel, Achrafieh - Beirut (LB)
P1036	Association between previous negative biopsies and lower rates of disease progression during active surveillance for prostate cancer M.L. Piccinelli, Milan (IT)
P1037	Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: Results from a prospective cohort in the PRIAS-JAPAN study Y. Tohi, Kagawa (JP)
P1038	Existing urine exosome gene expression signature to assess upgrade risk on radical prostatectomy A. Kretschmer, Munich (DE)
P1039	%p2PSA and phi predict the pathological reclassification of first-year protocol biopsy during Active surveillance for early prostate cancer patients: From the PRIAS-JAPAN study K. Takuma, Kagawa (JP)
P1040	PSA density and clinical outcome in MRI-based active surveillance for prostate cancer: A joint longitudinal-survival analysis V. Stavriniades, London (GB)
P1041	An MRI guided active surveillance strategy. Can the PRECISE score exclude reclassification? R. Hogenhout, Rotterdam (NL)
P1042	Unchanged negative prostate mpMRI during active surveillance, is it still necessary to biopsy and follow-up? H.B. Luiting, Rotterdam (NL)
P1043	Outcomes of serial multiparametric magnetic resonance imaging in patients managed with active surveillance for prostate cancer M.L. Piccinelli, Milan (IT)
12:53 - 12:59	Discussion
12:59 - 13:08	Outcome of AS
P1044	Development of the STRATified CANcer Surveillance protocol for men with favourable-risk prostate cancer A. Light, Southwark (GB)
P1045	Anxiety in men on active surveillance: A longitudinal comparison between Italian and Dutch PRIAS patients L.D.F. Venderbos, Rotterdam (NL)
P1046	Adverse pathological findings in deferred radical prostatectomy in men under active surveillance for very low and low risk prostate cancers: Results from GAP3 active surveillance cohorts C. Marengi, Milan (IT)
P1047	Secondary treatment for men with localized prostate cancer: A pooled analysis of PRIAS and ERSPC-Rotterdam datasets within the PIONEER data platform K. Beyer, London (GB)
P1048	Very long term outcomes of active surveillance for prostate cancer: Population-based state transition estimates E. Ventimiglia, Milan (IT)

P1049	Sexual function of men undergoing invasive prostate cancer treatment versus active surveillance – Results of the EUPROMS study L.D.F. Venderbos, Rotterdam (NL)
P1050	Holmium Laser Enucleation of the Prostate (HoLEP) in patients on active surveillance for low risk prostate cancer: an analysis on oncological and functional outcomes L.J. Tay, London (GB)
13:02 - 13:07	Discussion
13:08 - 13:23	Focal therapy and tissue ablation
P1051	Magnetic Resonance guided adaptive Radiotherapy (MRgRT) for localised prostate cancer: The first result from a prospective international registry for the evidence-based Introduction of MRgRT F.R. Teunissen, Utrecht (NL)
P1052	Eligibility for focal treatment of ISUP grade 2 single lesion on MRI-targeted biopsies A-S. Bajeot, Thonon (FR)
P1053	High Intensity Focused Ultrasound (HIFU) vs. Radical Prostatectomy (RP) in the curative treatment of ISUP 1-2 localized prostate cancer: Safety results of the HIFI study P. Rischmann, Toulouse (FR)
P1054	Cancer control outcomes following focal therapy using HIFU in 1,829 men with non-metastatic prostate cancer treated over 15 years D.T. Reddy, London (GB)
P1055	Focal HIFU treatment of Apical lesion: Safety and oncological results S. Crouzet, St Didier au Mt d'Or (FR)
P1056	The percentage of prostate-specific antigen reduction after high-intensity focused ultrasound for primary localized prostate cancer as a predictive parameter for treatment failure: A validation study A. Mattlet, Brussels (BE)
P1057	Preliminary results of in vivo focal transperineal laser ablation treatment of the prostate: Correlation of mpMRI and CEUS imaging to histology in radical prostatectomy specimen L.A.M.J.G. Van Riel, Amsterdam (NL)
P1058	A matched analysis of salvage robot assisted radical prostatectomy following focal ablation vs. radical robotic assisted radical prostatectomy K.R. Bhat, Celebration (US)
P1059	Patients report satisfaction/regret following focal therapy for localized prostate cancer: A prospective multicenter evaluation A.G. Ghoreifi, Tehran (IR)
13:17 - 13:23	Discussion
13:23 - 13:27	Expert summary L.H. Klotz, Toronto (CA)

Minimally invasive techniques in adrenal surgery

Video Session 19

Monday 12 July
13:00 - 13:30

Location Virtual room 1

Chairs J.F. Langenhuijsen, Nijmegen (NL)

M. Musquera Felip, Barcelona (ES)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

13:00 - 13:02

Introduction

V55

The effectiveness of robotic-assisted adrenalectomy under the guidance of Indocyanine Green (ICG) fluorescence

P.-C. Liu, Taichung (TW)

V56

Step-wise tutorial for laparoscopic left adrenalectomy

H-C. Yang, Taichung (TW)

13:24 - 13:27

Conclusion

Pathophysiology and management of urolithiasis: New perspectives and approaches in 2021

Meeting of the EAU Section of Urolithiasis (EULIS)

Monday 12 July
13:30 - 14:30

Location Virtual Room 2

Chairs K. Sarica, Istanbul (TR)
C.C. Seitz, Vienna (AT)

Learning objectives

As the programme is somewhat condensed for the purposes of the EAU21 Virtual Congress, EULIS is focussing on its core competence: Stone pathophysiology and perspectives in the minimal invasive endourologic stone management with an update in the light of recent advances. Presented are Randall's plaques and its role in recurrence prediction, emerging knowledge of microbiomics in urolithiasis as well as endourologic exit strategies and imaging followed by drug based stone prevention strategies.

Each recorded presentation is discussed live by a panel of nephrologists and urologists answering questions.

13:30 - 13:33

Introduction

K. Sarica, Istanbul (TR)
C.C. Seitz, Vienna (AT)

13:33 - 14:26

Stone pathophysiology and perspectives in the minimal invasive endourologic management of stones: An update in the light of recent advances

Moderators P.M. Ferraro, Rome (IT)
I. Saltirov, Sofia (BG)
M. Straub, Munich (DE)
R.J. Unwin, London (GB)

13:33 - 13:36

Introduction by moderators

13:36 - 13:43

Randall's plaques, endoscopic evaluation and metabolic risk status: How could we combine them for recurrence prediction?

B. Somani, Southampton (GB)

13:43 - 13:46

Discussion

13:46 - 13:53

Microbiomics and urolithiasis

J.A. Galán-Llopis, Alicante (ES)

13:53 - 13:56

Discussion

13:56 - 14:03

Exit strategy in endourology: Do we have an agreement?

E. Montanari, Milan (IT)

14:03 - 14:06

Discussion

14:06 - 14:13

An evidence-based follow-up recommendation including when and how and how often to perform imaging after active stone treatment

L.B. Dragoş, Timișoara (RO)

14:13 - 14:16

Discussion

14:16 - 14:23

Drug-based therapy to prevent stone recurrence

C.A. Wagner, Zurich (CH)

14:23 - 14:26

Discussion

14:26 - 14:30

Closing remarks

K. Sarica, Istanbul (TR)
C.C. Seitz, Vienna (AT)

Unanswered questions in andrology

Meeting of the EAU Section of Andrological Urology (ESAU)

Monday 12 July
13:30 - 14:30

Location Virtual Room 4

Chair N. Sofikitis, Ioannina (GR)

Learning objectives

The main objective of the Meeting of the EAU Section of the European Section of Andrological Urology is to provide the latest information on several controversial issues and unanswered questions in the fields of male infertility, male endocrinology, and sexual medicine. Video presentations will assist the participants to pick up the tips and tricks of several surgical procedures in the male genital tract as take home messages. Emphasis will be given to the effects of SARS-CoV-2 virus on the testicular endocrine and exocrine function, the hypothalamo-pituitary testicular axis, and the pituitary-adrenal axis. In addition the influence of the Leydig cellular secretory function on the morbidity and mortality induced by SARS-CoV-2 virus will be discussed extensively. Surgical techniques concerning placement of penile prosthesis in selected difficult cases, removal of infected penile prosthesis, and management of penile shortening and curvature in Peyronie's disease will be presented and extensively discussed. Efforts will be done to clarify one of the most perplexing problems in testicular sperm recovery programs that is whether there is evidence-based medicine to support the pre-operative employment of assays that have a high overall diagnostic accuracy to predict the outcome of therapeutic testicular testicular biopsy.

13:30 - 13:46

SARS-COV-2: A new and urgent challenge in andrology?

Moderators A. Giwercman, Malmö (SE)
N. Sofikitis, Ioannina (GR)

13:30 - 13:36

Impact of SARS-CoV-2 virus on male reproductive organs

S. Minhas, London (GB)

13:36 - 13:42

SARS-COV-2: Is an acute or chronic hypogonadal state associated with morbidity and mortality?

A. Salonia, Milan (IT)

13:42 - 13:46

Discussion

13:46 - 14:05

Surgery in motion: When the urologist has hard time in penile surgery

Moderators C. Bettocchi, Bari (IT)
F. Fusco, Naples (IT)

13:46 - 13:51

When the urologist has hard time to place penile prosthesis

D.J. Ralph, London (GB)

13:51 - 13:56

When the urologist has hard time to manage infected penile prosthesis

E. Ruiz-Castañé, Barcelona (ES)

13:56 - 14:01

When the urologist has hard time to manage penile shortening and curvature in Peyronie's disease

A. Kadioglu, Istanbul (TR)

14:01 - 14:05

Discussion

14:05 - 14:25

Debate Are there any assays parameters predicting the TESE outcome with high overall diagnostic accuracy in non-obstructed azoospermic males?

Moderators M. Dinkelmann-Smit, Rotterdam (NL)
G.I. Russo, Catania (IT)

14:05 - 14:11

Pro

T. Diemer, Giessen (DE)

Scientific Programme - EAU21 Virtual

14:11 - 14:17

Con

Z. Kopa, Budapest (HU)

14:17 - 14:25

Discussion

14:25 - 14:30

Closing remarks

N. Sofikitis, Ioannina (GR)

7th ESO Prostate Cancer observatory: Innovations and care in the next 12 months

Special Session



Monday 12 July
13:30 - 14:30

Location Virtual Room 6

Chairs S. Gillesen Sommer, Bellinzona (CH)
R. Millman, Stockton-on-Tees (GB)

Learning objectives

ESO Observatories are high-level sessions organised during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory lasts about one hour and concentrates on a forecast given by panel of experts of what it is expected to happen in their own field in the coming 12 months. The Panel includes distinguished clinicians and/or scientists and a patient advocate. The forecast by each Panel Member is given in the form of concise take-home messages with a 3-4 minute slide presentation followed by a 1-2 minute discussion for each topic.

13:30 - 13:35

Welcome and introduction

13:35 - 13:40

The urologist's perspective on surgery
S. Joniau, Leuven (BE)

13:40 - 13:45

The urologist's perspective on active surveillance
P. Cornford, Liverpool (GB)

13:45 - 13:50

The radiation oncologist's perspective
G. De Meerleer, Leuven (BE)

13:50 - 13:55

The medical oncologist's perspective
U. Vogl, Bellinzona (CH)

13:55 - 14:00

The pathologist's perspective
E. Comp  rat, Paris (FR)

14:00 - 14:05

The geneticist's perspective
E. Castro, Madrid (ES)

14:05 - 14:10

The imaging specialist's perspective on PSMA-PET/CT
S. Fanti, Bologna (IT)

14:10 - 14:15

The imaging specialist's perspective on MRI
J. Barentsz, Nijmegen (NL)

14:15 - 14:20

The urologist's perspective on focal therapy
R. Sanchez-Salas, Paris (FR)

14:20 - 14:25

The nurse's perspective
C.N. Tillier, Amsterdam (NL)

14:25 - 14:30

The patient's perspective
R. Millman, Stockton-on-Tees (GB)

Paediatric urology

Poster Session 38

Monday 12 July
13:30 - 14:30

Location Virtual Room 7

Chairs L.A. 't Hoen, Rotterdam (NL)
C. Radmayr, Innsbruck (AT)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Gaining insights of the latest developments in pediatric urology.
Specific topics including neurogenic bladder, stone disease, hypospadias and circumcision will be discussed with the participants.

13:30 - 13:31

Introduction

P1061	Evaluation of the efficacies of methylphenidate and biofeedback treatments in giggle incontinence: One-year follow-up study M. Ekşi, Istanbul (TR)
P1062	Add-on therapy with mirabegron in children with refractory neurogenic bladder dysfunction: Effective in low-compliance bladders F.E.E. van Veen, Rotterdam (NL)
P1063	Long-term safety and tolerability of repeated treatments with onabotulinumtoxinA in children with neurogenic detrusor overactivity E. Dobremez, Bordeaux CEDEX (FR)
P1064	Factors predicting the success of intradetrusor onabotulinum toxin-a treatment in children with neurogenic bladders due to myelomeningocele: The outcomes of a large cohort M.S. Silay, Istanbul (TR)
P1065	How can bladder augmentation surgery change the life of patients with spina bifida? A report of 26 years of clinical experience B. Bañuelos Marco, Berlin (DE)
P1066	Auto-augmentation: A feasible option before ileal augmentation in selected cases M. Altan, Ankara (TR)
P1067	Ileocystoplasty in pediatric population: Long-term outcome and factors affecting the reoperation rates M. Altan, Ankara (TR)

13:40 - 13:48

Discussion

P1069	Is Triple D Score effective to predict the stone-free rate after shockwave lithotripsy in pediatric population? O. Telli, Istanbul (TR)
P1070	Ureteral wall thickness at the stone site: A critical predictor of success and complications in children undergoing semi-rigid ureteroscopy E. Bülbul, Istanbul (TR)
P1071	Safety and outcomes of using ureteral access sheaths for treatment of paediatric renal stones: A review of 48 patients across 2 large European endourology centres A.E. Brewin, Southampton (GB)
P1072	Is flexible ureteroscopy and laser lithotripsy (FURLS) the new gold standard for paediatric lower pole stones: Outcomes from 2 large European tertiary paediatric endourology centres L. Mosquera Seoane, A Coruña (ES)
P1073	Role of mini-percutaneous nephrolithotomy in the management of pediatric stone disease: A systematic review of literature C.P.W. Jones, Bergen (NO)
P1074	Treatment of ureteropelvic junction obstruction and urolithiasis in children with minimally invasive surgery S. Sforza, Florence (IT)
P1075	Autologous tunica albuginea cells in fibrin scaffold for correction of penile chordee: An experimental study in rabbits M. Abdullateef, Mansoura (EG)
P1076	Protective effect of oltpiraz in testicular ischemia/reperfusion injury: An experimental study
P1077	Albugineotomy with tunica vaginalis flap coverage in acute testicular torsion: A prospective randomized study R. Zanotti, Sao Paulo (BR)
P1078	Laparoscopic staged management of high Intrabdominal testis: A prospective randomized study A. Fahmy, Alexandria (EG)
P1079	Undescended testicles: Is there really no role for ultrasound? S. Dunk, Shrewsbury (GB)
P1080	Testicular torsion serious incidents: Lessons from England to improve outcomes R. Menzies-Wilson, Portsmouth (GB)
P1081	Testicular torsion: A modified surgical technique for immediate intravaginal testicular prosthesis implant L.A. Favorito, Rio de Janeiro (BR)
P1082	A systematic review and meta-analysis highlighting the adjunctive role of tissue sealant application in the prevention of complications following urethroplasty in children with hypospadias A. Singh, New Delhi (IN)
14:02 - 14:10	Discussion

P1083	Circumcision and risk of HIV among males from Ontario, Canada M. Nayan, Brampton (CA)
P1084	Listening to the parents as key to early infant male circumcision efforts in fight against HIV: Perspectives of a contemporary cohort of legal adult representatives of infants enrolled in the ShangRing vs. mogen clamp trial Q. Nang, NYC (US)
P1085	Treatment modalities for urethral strictures in pediatric population V. Kojovic, Belgrade (RS)
P1086	Which patients with posterior urethral valves end with chronic renal disease? Follow up of 107 patients S. Tekgül, Ankara (TR)
P1087	Early warning parameters for the development of chronic kidney disease in children with posterior urethral valves R. Banthia, Lucknow (IN)
P1088	Renal growth in children with vesicoureteral reflux, is it a significant clinical indicator? A. El Helaly, Riyadh (SA)
P1089	Telocytes and Cajal cells deficiency in the distal ureteric segment of pediatric patients with congenital Primary Obstructed Megaureter (POM) causing massive ureterohydronephrosis is an indication for early surgery M. Wishahi, Cairo (EG)
14:17 - 14:25	Discussion
14:25 - 14:30	Expert summary F. O'Kelly, Dublin (IE)

Radical prostatectomy: Long-term outcome and how we can do better

Poster Session 39

Monday 12 July
13:30 - 14:30

Location Virtual Room 9

Chairs A. De La Taille, Créteil (FR)
S. Loeb, New York (US)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Radical prostatectomy remains a challenging procedure. New technologies and tools are developed with the aim to facilitate the management and to improve the outcome. Can they have an effect on long term outcome?

13:30 - 13:31

Introduction

13:31 - 13:39

Outcome and outcome predictions

P1090

National Cancer Database analysis assessing the impact of treatment modalities on survival outcomes in localized neuroendocrine prostate adenocarcinoma
C. Bronkema, Detroit (US)

P1091

Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center
C. Würrnschimmel, Hamburg (DE)

P1092

Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data
C. Würrnschimmel, Hamburg (DE)

13:34 - 13:39

Discussion

P1093

Individualized risk stratification of patients candidate to radical prostatectomy based on clinical and multi-parametric MRI parameters: Beyond the conventional clinical risk models
E. Mazzone, Milan (IT)

P1094

Prognostic impact of different Gleason patterns within grade group 4 prostate cancer in radical prostatectomy specimens
K. Mori, Tokyo (JP)

P1095

A multi-surgeon learning curve analysis of overall and site-specific positive surgical margins after RARP
C. Gandi, Rome (IT)

13:42 - 13:53

New technologies 1

P1096	Neurovascular Structure-Adjacent Frozen-section Examination (NeuroSAFE) Robotic Radical Prostatectomy: Functional outcomes from the first 500 consecutive cases J.P. Noël, Celebration (US)
P1097	Outcomes after introducing intraoperative NeuroSAFE technique in robot-assisted radical prostatectomy M.A. van der Slot, Rotterdam (NL)
P1098	The applicability of patient-Specific 3D models in the planning of nerve-sparing robot-assisted radical prostatectomy H. Veerman, Volendam (NL)
P1099	Intraoperative 3D elastic fusion imaging guided robotic radical prostatectomy: A pilot study M. Oderda, Bra (CN) (IT)
P1100	Artificial intelligence guided 3D automatic augmented-reality images allow to identify the extracapsular extension on neurovascular bundles during robotic prostatectomy E. Checcucci, Venaria Reale (IT)
P1101	3D models' use during robotic prostatectomy allows to reduce positive surgical margins rate E. Checcucci, Venaria Reale (IT)
13:48 - 13:53	Discussion
13:53 - 14:04	Retzius sparing RP
P1102	Retzius-sparing vs. conventional robotic assisted radical prostatectomy in a prospective, randomised trial – early functional outcome and quality of life V.S. Schütz, Heidelberg (DE)
P1103	Retzius-sparing robot assisted radical prostatectomy has similar 1-year functional and oncological outcomes as standard robot-assisted radical prostatectomy: Results from a high volume UK centre P. Umari, Duino-Aurisina (TS) (IT)
P1104	Learning curve for Retzius-Sparing Robot-Assisted Radical Prostatectomy (RS-RARP): Experience of two high volume UK surgeons T.A. Narain, Patna (IN)
P1105	Retzius-sparing robot-assisted radical prostatectomy in high-risk prostate cancer patients: Results from a large single institution series P. Dell'Oglio, Milan (IT)
P1106	Multicentric experience in Retzius-sparing robot assisted radical prostatectomy performed by expert surgeons for high risk prostate cancer A. Galfano, Milano (IT)
P1107	Challenging cases in high-risk prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy P. Dell'Oglio, Milan (IT)
13:59 - 14:04	Discussion
14:04 - 14:17	New technologies 2
P1108	Evaluation of radio-guided pelvic lymph node dissection in patients with intermediate or high-risk prostate cancer. A French, multicenter, prospective study F. Lannes, Marseille (FR)
P1109	Intraoperative strategies to reduce catheter-related bladder discomfort in the early postoperative period after robot-assisted radical prostatectomy H. Veerman, Volendam (NL)

P1110	Very early catheter removal on postoperative day 2 after robot-assisted radical prostatectomy: reporting on early complications and functional results D. Develtere, Aalst (BE)
P1111	Is postoperative pelvic pain after robot-assisted radical prostatectomy associated with suture material used for sewing the anastomosis? A prospective randomized trial B. Breu, Winterthur (CH)
P1112	Impact of robotic technologies on prostate cancer patient's choice for radical treatment P. Tuzzolo, Rome (IT)
P1113	Extraperitoneal robotic radical prostatectomy with Senhance®, first 77 cases T. Kuliš, Zagreb (HR)
P1114	Comparing the approach to radical prostatectomy using the Da Vinci Xi and Da Vinci Single Port: A propensity score analysis M. Covas Moschovas, Celebration (US)
P1115	Patient surgical satisfaction following da vinci single port and multi port robotic-assisted radical prostatectomy: A propensity score matched analysis J.P. Noël, Celebration (US)
14:12 - 14:17	Discussion
V65	Technical details comparing the da Vinci SP and da Vinci Xi approach to radical prostatectomy M. Covas Moschovas, Celebration (US)
14:25 - 14:30	Expert summary A. Govorov, Moscow (RU)

State of the art in robotic surgery: ERUS 2021

Meeting of the EAU Robotic Urology Section (ERUS)

Monday 12 July
14:30 - 15:30

Location Virtual room 1

Chair A. Breda, Barcelona (ES)

Learning objectives

To give a comprehensive summary of the latest advances in robotic surgery in 2021 including the new robots coming in the market as well as the next generation machines.

14:30 - 14:31

Welcome and introduction

A. Breda, Barcelona (ES)

14:31 - 14:51

The technology corner

Moderators

P. Dasgupta, London (GB)

D. Tilki, Hamburg (DE)

C. Wagner, Gronau (DE)

14:31 - 14:36

Update: New kids on the block

A. Motttrie, Aalst (BE)

14:36 - 14:41

Augmented reality: Engineers meet urology

F. Porpiglia, Turin (IT)

14:41 - 14:46

Proficiency training in robotic surgery at its best

H.G. Van Der Poel, Amsterdam (NL)

14:46 - 14:51

Discussion

14:51 - 15:11

Kidney/Bladder/Prostate at its best

Moderators

B.J. Challacombe, London (GB)

M. Rouprêt, Paris (FR)

B.M.C. Rocco, Modena (IT)

14:51 - 14:56

Robotic partial nephrectomy

A. Minervini, Florence (IT)

14:56 - 15:01

Robotic radical prostatectomy

M. Graefen, Hamburg (DE)

15:01 - 15:06

Robotic radical cystectomy

P. Wiklund, Stockholm (SE)

15:06 - 15:11

Discussion

15:11 - 15:30

Not only oncology

Moderators

A.E. Canda, Istanbul (TR)

K. Decaestecker, Ghent (BE)

C.J. Wijnburg, Arnhem (NL)

15:11 - 15:16

Robotic LDN in testis cancer: When and how?

P. Albers, Düsseldorf (DE)

15:16 - 15:21

RAKT: What's new?

A. Breda, Barcelona (ES)

15:21 - 15:26

Paediatric robotic surgery

A. Bujons Tur, Barcelona (ES)

15:26 - 15:30

Discussion

Surgical matters in kidney transplantation

Meeting of the EAU Section of Transplantation Urology (ESTU)

Monday 12 July
14:30 - 15:30

Location Virtual Room 3

Chairs
F.J. Burgos Revilla, Madrid (ES)
A.J. Figueiredo, Coimbra (PT)
E. Lledó García, Madrid (ES)

Learning objectives

To understand and learn different surgical issues important in kidney transplant patients.

14:30 - 14:32

Introduction

E. Lledó García, Madrid (ES)

14:32 - 14:50

Moderator J.D. Olsburgh, London (GB)

14:32 - 14:40

COVID and Kidney Transplant: How manage the coexistence?

J. Pascual, Madrid (ES)

14:40 - 14:48

Prostate cancer in the KT patient: What is the best treatment?

M. Musquera Felip, Barcelona (ES)

14:48 - 14:50

Discussion

14:50 - 14:59

Moderator K. Decaestecker, Ghent (BE)

14:50 - 14:58

Robotic kidney transplant: The current situation and future options

F. Vignes Julia, Barcelona (ES)

14:58 - 14:59

Discussion

14:59 - 15:08

Moderator E. Lledó García, Madrid (ES)

14:59 - 15:07

Deceased donor kidney transplant in Jehovah's witnesses: A special population of patients to take decisions

G. Guerra, Miami (US)

15:07 - 15:08

Discussion

15:08 - 15:17

Moderator F.J. González García, Madrid (ES)

15:08 - 15:16

The teaching of kidney transplantation: What I consider the most important

G. Ciancio, Miami (US)

15:16 - 15:17

Discussion

15:17 - 15:27

Possibilities of joined actions USTRS-ESTU: A future global overview after COVID

A. Sener, London (CA)

15:27 - 15:30

Closing remarks

E. Lledó García, Madrid (ES)

PIONEER prostate cancer platform

EAU Specialty Session

Monday 12 July
14:30 - 15:30

Location Virtual Room 5

Chairs M.J. Ribal Caparros, Barcelona (ES)
J. N'Dow, Aberdeen (GB)

Learning objectives

Greater understanding of the European policy and programme landscape for fighting Cancer (the EU Beating Cancer Plan and the EU research mission on cancer) and the EU's digital health agenda.

14:30 - 14:40

Community driven partnership academia and industry working together for the advancement of prostate cancer
A. Asiimwe, Berlin (DE)

14:40 - 14:50

The PIONEER Big Data platform: How does it apply to prostate cancer?
S. Evans Axelsson, Malmo (SE)

14:50 - 15:00

Live demonstration of the potential of the EAU PIONEER platform How Big Data analysis connects with real practice to become clinically useful
B. De Meulder, Lyon (FR)

15:00 - 15:10

The patient voice in research: For patients with patients
AH Achtman, Melbourne (AU)

15:10 - 15:15

Discussion

15:15 - 15:25

EU Cancer Research Mission and Cancer Plan: Seizing the opportunities at EU level
J.W. Van de Loo, Brussels (BE)

15:25 - 15:30

EAU Prostate cancer initiatives at EU level: Can we do more?
H. Van Poppel, Leuven (BE)

Transgender and adult and paediatric genital surgery

Poster Session 40

Monday 12 July
14:30 - 15:30

Location Virtual Room 8

Chairs D. Batura, London (GB)
E. Kocjancic, Chicago (US)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

At the conclusion of this session, participants will be able to identify and synthesise key elements in the assessment, treatment and outcomes of a relatively new kid on the urology block: transgender surgery. Participants will also learn to recognise and interpret aspects of genital surgery for conditions like penile fractures and surgery of scrotal anomalies. Finally, the session will provide comprehension on pediatric scrotal surgery, including testicular torsion.

14:30 - 14:31

Introduction

P1116	Surgical and functional outcomes of anterolateral thigh flap phalloplasty for genital gender affirmation surgery K.O. Adasonla, London (GB)
P1117	Early surgical outcomes following 400 feminising genital reconstructive surgeries performed by a single urological surgeon U. Walters, London (GB)
P1118	PROGRESS (Patient Reported Outcomes in Genital Reconstructive Surgeries): A validated patient reported outcome measure questionnaire to assess post-operative functional improvement following feminising genital reconstructive surgery A. Kanthabalan, London (GB)
P1119	Patient-reported outcomes after genital gender-affirming surgery with versus without urethral lengthening in transgender men F.P.W. de Rooij, Amsterdam (NL)
P1120	Determining the outcomes of urethral reconstruction in phalloplasty L. Paganelli, Les Eparres (FR)
P1121	Neourethroplasty in phalloplasty for transmen B. Stojanovic, Belgrade (RS)
P1122	Novel classification of urethral complications in female to male gender affirmation surgery W.G. Lee, LONDON (GB)

P1123	Suprapubic phalloplasty in transmen: Surgical results and critical review M. Terrier, Lyon (FR)
P1124	Flap phalloplasty outcomes in female to male gender affirming surgery: A systematic review J. Ridgley, London (GB)
P1125	Maleable and inflatable penile prosthesis insertion after musculocutaneous latissimus dorsi total phalloplasty: Outcomes and complications B. Stojanovic, Belgrade (RS)
P1126	Outcomes after surgical treatment for urethral strictures in transgender men after genital gender-affirming surgery with urethral lengthening F.P.W. de Rooij, Amsterdam (NL)
P1127	Surgical outcomes after treatment of urethral complications following metoidioplasty in transgender men F.P.W. de Rooij, Amsterdam (NL)
P1128	Planning prostate cancer radiotherapy following male to female gender affirming surgery N. Bedi, Uxbridge (GB)
14:44 - 14:52	Discussion
14:52 - 14:54	Expert summary R. Djinnovic, Belgrade (RS)
P1129	Final validation of a Patient Reported Outcome Measure (PROM) for penile curvature surgery M.U.V. Natarajan, Guildford (GB)
P1130	Ventral corporoplasty in hypospadias with severe curvature - tunical attenuation by multiple transversal corporotomies B. Spiridonescu, Bucuresti (RO)
P1131	Does tunical defect length affect functional outcomes in penile fracture surgery? A.T. Albayrak, Istanbul (TR)
P1132	Assessing the value of a novel MRI protocol in patients undergoing posterior urethroplasty for Pelvic Fracture Urethral Distraction Defect (PFUDD) M. Bandini, Milan (IT)
P1133	Assessment of erectile function in pelvic fracture urethral injury following progressive perineal urethroplasty K. Parmar, Chandigarh (IN)
P1134	Surgical urinary continence outcomes in female exstrophy-epispadias patients M.Y. Schechter, West Hempstead (US)
P1135	Risk factors of erectile dysfunction, painful erection and morphological complications after the penile fracture A. Chaachou, Tunis (TN)
P1136	Our experience in the treatment of penile amputation injury B. Stojanovic, Belgrade (RS)

P1137	The effects of primary realignment or suprapubic cystostomy on prostatic displacement in patients with pelvic fracture urethral injury: A clinical study based on MR urethrography W. Zeyu, Shanghai (CN)
P1138	What constitutes complexity rather than difficulty in the surgical reconstruction of pelvic fracture-related urethral injuries? J. Olphert, London (GB)
P1139	Contralateral orchiopexy at the time of urgent scrotal exploration: is it safe? A propensity score matched analysis from the TORSAFUF cohort I. Duquesne, Paris (FR)
P1140	Double-face augmentation ureteroplasty with buccal mucosal graft: A novel surgical technique for reconstruction of complex ureteral strictures and injuries M. Nafie, Sharkia (EG)
P1141	Practice variation in the management of adult hydroceles: A multinational survey K. Bolsunovskyi, Tammisaari (FI)
15:07 - 15:15	Discussion
P1142	Acute scrotum in children: Management and costs at the emergency room A. Bernal Gomez, Valencia (ES)
P1143	Testicular salvage: Using machine learning algorithm to develop a more predictive model in testicular torsion M. Ekşi, Istanbul (TR)
P1144	The use of doppler ultrasound for suspected testicular torsion: Lessons learned from a 15-year multicentre retrospective study of 2922 patients U. Pinar, Paris (FR)
P1145	Using the TWIST scoring system to evaluate for testicular torsion safely reduces unnecessary ultrasound and surgical exploration T.M.M. Clarkson, Dunedin (NZ)
P1146	Is there bacterial growth inside the tunica vaginalis cavity in patients with unsalvageable testicular torsion? L.A. Favorito, Rio de Janeiro (BR)
15:20 - 15:28	Discussion
15:28 - 15:30	Expert summary A-F. Spinoit, Ghent (BE)

Functional outcome of radical prostatectomy and how we can do better

Poster Session 41

Monday 12 July
14:30 - 15:30

Location Virtual Room 10
Chairs G. Marra, Turin (IT)
K. Touijer, New York (US)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Good functional outcome after radical prostatectomy remains a challenge. This session shows factors influencing the results and how we can improve the outcome for our patients.

14:30 - 14:31

Introduction

14:31 - 14:34

COVID-19

P1147

Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU prostate cancer working group multi-institutional study
F. Zattoni, Verona (IT)

14:32 - 14:34

Discussion

14:34 - 14:43

PROMS

P1148

Match of Patient Reported Outcome Measures (PROMs) and the urologists' assessment in non-metastatic prostate cancer: Results from a randomized controlled trial
J. Huber, Dresden (DE)

P1149

Functional outcomes rather than complications affect quality of life at 6 months after robot-assisted radical prostatectomy
M.J. Hagens, Amsterdam (NL)

P1150

The effect of different post-prostatectomy incontinence definitions on outcomes reporting: a prospective review of a contemporary series of 1000 consecutive Robot-assisted Radical Prostatectomy
M. Abuelnaga, Bedford (GB)

P1151

Pad number and pad weight and its correlation with Patient Reported Outcome Measures (PROM): Insights from a prospective single centre comparison study of LRP
D.W. Good, Edinburgh (GB)

14:38 - 14:43

Discussion

14:43 - 14:47

Continence predictions

P1152

Individual risk prediction of urinary incontinence after prostatectomy and impact on treatment choice in patients with localized prostate cancer
C.N. Tillier, Amsterdam (NL)

P1153	Does age affect continence outcomes following robot-assisted radical prostatectomy? Results from an Australian multi-institutional study W. Gondoputro, Sydney (AU)
P1154	Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men 75 years or older S. Hatakeyama, Hiroasaki (JP)
P1155	Patient-specific risk factors and post-operative complications have a significant impact on long term functional outcomes following minimally invasive N. Raison, London (GB)
14:47 - 14:52	Discussion
14:52 - 15:04	Urinary outcome
P1156	Marked clinical improvement of lower urinary tract symptom burden due to robot-assisted radical prostatectomy: Results of a large high-volume center cohort M.A. Mendrek, Gronau (DE)
P1157	The change of pressure-flow study parameters in patients before and after robot-assisted laparoscopic radical prostatectomy P-H. Yu, Taipei (TW)
P1158	A randomised controlled trial to assess the benefit of posterior rhabdosphincter reconstruction in early urinary continence recovery after robot assisted radical prostatectomy O. Moreno, Barcelona (ES)
P1159	Improved early continence following robotic-assisted radical prostatectomy with a concurrent retropubic vascularised fascia sling (RoboSling) J. Fallot, marseille (FR)
P1160	A biofeedback guided program or pelvic floor muscle electric stimulation for early recovery of urinary continence after radical prostatectomy: A single-center study and a meta-analysis of the literature M. Maggi, Rome (IT)
P1161	Comparing robotic prostatectomy and male continence procedure trends: A medicare Australia analysis L. Qu, Melbourne (AU)
P1162	The key role of levator ani thickness for early urinary continence recovery in patients undergoing robot-assisted radical prostatectomy: A multi-institutional study M. Tutolo, Milano (IT)
14:59 - 15:04	Discussion
15:04 - 15:15	Sexual outcome
P1163	Orgasmic dysfunction after robot-assisted radical prostatectomy: Rates of occurrence and predictors M. Honda, Yonago (JP)
P1164	Full neurovascular sparing extraperitoneal robotic radical prostatectomy: A single center experience with PERUSIA technique G. Cochetti, Terni (IT)
P1165	Effect of prostate biopsy technique on nerve sparing during radical prostatectomy: Do transperineal template mapping biopsies in combination with mpMRI translate into more nerve sparing? M.S. Wettstein, Zurich (CH)

P1166	Prediction of post-operative outcomes by analyses of video-recorded surgery in patients submitted to robotic-assisted radical prostatectomy N.R. Suardi, Genoa (IT)
P1167	Long-term evaluation of functional results after 3D laparoscopic prostatectomy using visual analog scale H. Haapiainen, Seinäjoki (FI)
P1168	Be-RALP study: The effect of adjuvant treatment on quality of life, erectile function and continence W. Devlies, Kessel-Lo (BE)
15:10 - 15:15	Discussion
V50	The use of augmented reality to guide intraoperative frozen section during robot-assisted radical prostatectomy R. Schiavina, Bologna (IT)
15:25 - 15:30	Expert summary A. Mattei, Luzern (CH)

Focal diagnosis and treatment

Video Session 20

Monday 12 July
15:30 - 16:00

Location Virtual Room 2

Chairs J. Gómez Rivas, Madrid (ES)
C. Moore, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

15:30 - 15:32

Introduction

V57

Key steps in the evaluation and treatment planning for successful Prostate Focal Cryotherapy

Y.G. Tan, Singapore (SG)

V58

3d Cognitive targeted prostate biopsy

M. Zingarelli, Bari (IT)

V59

Transperineal Targeted Microwave Ablation (TMA) of anterior midline prostate cancer using minigrid and Organ Based Tracking (OBT)

P.K-F. Chiu, Hong Kong (HK)

16:01 - 16:04

Conclusion

Mini-PCNL for paediatric stones

Video Session 21

Monday 12 July
15:30 - 16:00

Location Virtual Room 4

Chairs J-T. Klein, Ulm (DE)
S. Proietti, Milan (IT)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

15:30 - 15:32

Introduction

V60

Tubeless mini percutaneous nephrolithotomy with antegrade stent tether in preschool children

A. Tursunkulov, Tashkent (UZ)

V61

Semi-closed-circuit vacuum-assisted Mini-PCNL system for renal stones in pediatric patients: The experience by a tertiary referral center

G. Sampogna, Varese (IT)

15:51 - 15:54

Conclusion

Contemporary robotic kidney transplantation

Video Session 22

Monday 12 July
15:30 - 16:15

Location Virtual Room 6

Chairs F. D'Ancona, Nijmegen (NL)
E. Lledó García, Madrid (ES)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion

15:30 - 15:32

Introduction

V62

Orthotopic robot-assisted kidney transplantation

F. Vignes Julia, Barcelona (ES)

V63

Robot-assisted laparoscopic living donor nephrectomy: The university of Florence technique

R. Campi, Florence (IT)

V64

The use of 3D augmented reality during Robot-assisted living donor nephrectomy (RALDN): A case report technical overview

R. Schiavina, Bologna (IT)

16:06 - 16:09

Conclusion

Surgery-in-Motion session

European Urology

Monday 12 July
15:30 - 16:30

Location Virtual Room 7

Chair G. Giusti, Milan (IT)

Learning objectives

The Surgery-in-Motion session is dedicated to treatment single renal stone. Experts in the field will provide explanations and video demonstrations of various surgical techniques and discuss why they do it “their way”.

15:30 - 16:30

Different ways to skin the cat: 2 cm single renal stone

15:30 - 15:45

Video presentation RIRS with TFL laser

O. Traxer, Paris (FR)

15:45 - 16:00

Video presentation MINIPERC with holmium laser

T. Knoll, Sindelfingen (DE)

16:00 - 16:15

Video presentation Standard supine PCNL with standard combined lithotripter

H. Eisner, Boston (US)

16:15 - 16:30

Discussion

Detection of recurrence and salvage treatment options after primary treatment for prostate cancer

Poster Session 42

Monday 12 July
15:30 - 16:30

Location Virtual Room 9

Chairs B.A. Hadaschik, Essen (DE)
R.C.N. Van Den Bergh, Nieuwegein (NL)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Recurrent disease after initial local treatment with curative intent is a frequent clinical issue. This session shows the salvage treatment options for recurrent prostate cancer and gives information on how to select the best treatment.

15:30 - 15:31

Introduction

15:31 - 15:45

Recurrence, risk estimation and imaging

P1169

Identifying the most informative cut-off of psa to define biochemical recurrence after radical prostatectomy: A stage-by-stage analysis
L. Nocera, Milan (IT)

P1170

Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study
V.H. Meissner, Munich (DE)

P1171

Machine learning algorithms can more efficiently predict biochemical recurrence after robot assisted radical prostatectomy
O. Ozdemir, Istanbul (TR)

P1172

A prospective study assessing the post-prostatectomy detection rate of a presumed local failure at mpMR with 18F-choline, 64Cu-CI2 or 64Cu-PSMA PET/CT
M.C. Ferriero, Rome (IT)

P1173

68Ga-PSMA PET/CT for Recurrent Prostate Cancer after Radical Prostatectomy: What's next? Analysis from a single, high volume tertiary referral center
D. Robesti, Milan (IT)

P1174

Identification of the best candidates for PSMA PET/CT among patients experiencing biochemical recurrence after radical prostatectomy. A new tool to optimize of Patient Selection
G. Gandaglia, Milan (IT)

P1175

Long-term validation on the impact of PSMA-PET on metastasis-free survival in a large salvage radiotherapy cohort
C. Würnschimmel, Hamburg (DE)

P1176

Intraprostatic recurrences on PSMA PET/CT after prostate whole gland radiotherapy. Is histological confirmation necessary?
H.B. Luiting, Rotterdam (NL)

15:39 - 15:45	Discussion
15:45 - 16:03	Salvage radiotherapy
P1177	EAU BCR risk classification as decision tool for salvage radiotherapy? A multicenter study F. Preisser, Frankfurt (DE)
P1178	Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treated with post-prostatectomy radiation therapy: Results from a large, multi-institutional study D. Robesti, Milan (IT)
P1179	Comparison of salvage radiation therapy delivered for PSA persistence versus PSA relapse after radical prostatectomy: How is the outcome changing? D. Robesti, Milan (IT)
P1180	Finding ideal timing of radiotherapy after radical prostatectomy – the impact on health-related quality of life T. Westhofen, München (DE)
P1181	There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent Prostate Cancer after Radical Prostatectomy. A retrospective, multi-centre analyses on oncological and toxicity outcomes E. Mazzone, Milan (IT)
P1182	Anti-androgen therapy overcomes the time-delay in initiation of salvage radiation therapy and rescues the oncological outcomes in men with recurrent prostate cancer after radical prostatectomy: A post-hoc analysis of the RTOG 9601 trial data A. Sood, Detroit (US)
P1183	The key role of PSA doubling time in patients treated with salvage radiation therapy after radical prostatectomy: Implications for the extent of radiation and the concomitant use of hormonal therapy N. Fossati, Milan (IT)
P1184	Independent role of dose-escalation and prophylactic lymph-nodal irradiation in salvage radiotherapy after prostatectomy. A retrospective, multi-institute analysis on 725 men treated with high-dose radiotherapy and eight years follow-up C. Cozzarini, Milan (IT)
P1185	Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study M.G. Parry, London (GB)
P1186	A novel prognostic model for patients undergoing salvage radiotherapy for biochemical recurrence after radical prostatectomy T. Van Den Broeck, Leuven (BE)
P1187	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy P. Rajwa, Zabrze (PL)
P1188	Very long-term outcomes, time patterns of recurrence and other-cause mortality in patients treated with salvage radiation therapy for recurrent prostate cancer after radical prostatectomy: Implications for risk tailored follow-up strategies E. Mazzone, Milan (IT)
15:57 - 16:03	Discussion
16:03 - 16:13	Salvage lymph node dissection

P1189	Salvage pelvic lymph node dissection of locally recurrent prostate cancer after radical prostatectomy can delay the need for systemic interventions T. Ahlering, Orange (US)
P1190	Assessing the association between the template of pelvic salvage lymph node dissection for node-only recurrent prostate cancer and oncological outcomes. Results of a multi-institutional series C.A. Bravi, Milan (IT)
P1191	Definition and impact on oncologic outcomes of persistently elevated PSA after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: Clinical Implications for multi-modal therapy C.A. Bravi, Milan (IT)
P1192	Identifying the optimal candidates for radiation therapy after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: Results from a multi-institutional collaboration C.A. Bravi, Milan (IT)
16:07 - 16:13	Discussion
16:13 - 16:25	Salvage treatment after radiotherapy
P1193	Validation of EAU recommendation for salvage radical prostatectomy candidates F. Preisser, Frankfurt (DE)
P1194	Robot-assisted cystectomy with intracorporeal urinary diversion after pelvic irradiation for prostate cancer: Technique and results from a single high-volume center P. Piazza, Bologna (IT)
P1195	MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial T.T. Shah, London (GB)
P1196	Focal HIFU treatment of radiorecurrent localized prostate cancer: Long term results S. Crouzet, St Didier au Mt d'Or (FR)
P1197	Focal ablative salvage therapy for radio-recurrent prostate cancer: 6 year oncological and safety outcomes D.T. Reddy, London (GB)
P1198	Salvage versus primary robot-assisted radical prostatectomy: A propensity-matched comparative effectiveness study from a high-volume tertiary center A. Nathan, London (GB)
16:19 - 16:25	Discussion
16:25 - 16:30	Expert summary N.R. Suardi, Genoa (IT)

Controversies in onco-urology

Joint meeting of the EAU Section of Oncological Urology (ESOU) and the EAU Robotic Urology Section (ERUS) in conjunction with ESMO and ESTRO

Monday 12 July
16:00 - 17:30

Location Virtual room 1

Chairs G. Giannarini, Udine (IT)
M. Rouprêt, Paris (FR)

Learning objectives

To reinforce the leading role of European urologists in providing care to patients with genitourinary malignancies. To implement personalized pathways of care across the wide spectrum of genitourinary malignancies. To promote strategic alliance between EAU sections and other scientific societies with the aim of strengthening multidisciplinary collaborations where there are no boundaries among urologists, medical oncologists and radiation oncologists.

16:00 - 16:05

Welcome and introduction

G. Giannarini, Udine (IT)
M. Rouprêt, Paris (FR)

16:05 - 16:15

European Society for Radiotherapy and Oncology (ESTRO)

16:05 - 16:10

Radiotherapy after radical prostatectomy in the PSMA-PET era

A. Bossi, Villejuif (FR)

16:10 - 16:15

Discussion

16:15 - 16:25

European Society for Medical Oncology (ESMO)

16:15 - 16:20

Evolving landscape of first-line systemic treatment in metastatic renal cell carcinoma

L. Albiges, Villejuif (FR)

16:20 - 16:25

Discussion

Common problems in onco-urology

Moderators A.E. Canda, Istanbul (TR)
A. Mottrie, Aalst (BE)
M. Rouprêt, Paris (FR)

16:25 - 16:45

Should we perform PSMA PET/TC in the initial staging of prostate cancer?

D. Murphy, Melbourne (AU)
A. Briganti, Milan (IT)
To be confirmed

16:45 - 17:05

There is no role for radical cystectomy in cT0 after neoadjuvant chemotherapy

Case presenter B. Pradere, Toulouse (FR)

16:50 - 16:55

Yes

A. Masson-Lecomte, Paris (FR)

16:55 - 17:00

No

J.A. Witjes, Nijmegen (NL)

17:00 - 17:05

Discussion

17:05 - 17:25

Optimal timing of perioperative systemic therapy for high-risk upper urinary tract cancer

Case presenter C. Poyet, Zürich (CH)

Scientific Programme - EAU21 Virtual

17:10 - 17:15

Neoadjuvant

A. Breda, Barcelona (ES)

17:15 - 17:20

Adjuvant

N. Houede, Bordeaux (FR)

17:20 - 17:25

Discussion

17:25 - 17:30

Closing remarks

M. Rouprêt, Paris (FR)

G. Giannarini, Udine (IT)

Ready for take-off: Molecular markers for clinical management of urological malignancies

Joint meeting of the EAU Section of Urological Imaging (ESUI), the EAU Section of Uropathology (ESUP) and the EAU Section of Urological Research (ESUR)

Monday 12 July
16:00 - 17:30

Location Virtual Room 3

Chairs
K. Junker, Homburg (DE)
R. Montironi, Ancona (IT)
G. Salomon, Hamburg (DE)

Learning objectives

The first part of the session is focused on DNA damage repair (DDR) defects that are playing an important role in tumour development and progression as well as for therapy response. Somatic and germline mutations in DDR genes such as BRCA1 and BRCA2 have been found in prostate cancer. Their value for cancer risk prediction, prognosis and therapy response will be discussed. In this regard, the rationale of germline testing has to be defined considering the experience in breast cancer patients. PARP inhibitors represent new targeted therapeutic options not only in prostate but also in bladder cancer, especially in patients with DDR defects. In the second part, we will discuss progress in the field of molecular markers and their clinical relevance focusing on liquid biopsy and molecular imaging for precision medicine in urological cancers.

16:00 - 16:01

Welcome and introduction
K. Junker, Homburg (DE)

16:01 - 16:40

BRCA1, BRCA2 and beyond: Important for clinical management in urological tumours?

Moderators
I. Heidegger, Innsbruck (AT)
H.Y. Leung, Glasgow (GB)
R. Montironi, Ancona (IT)

16:01 - 16:11

DNA damage repair defects: An overview
R.G. Bristow, Manchester (GB)

16:11 - 16:21

DNA repair gene mutations in prostate cancer: Effects on outcome after primary and systemic therapy
E. Castro, Madrid (ES)

16:21 - 16:40

Panel discussion: To test BRCA: Who should be tested: when, what, by whom?

Panel
R.G. Bristow, Manchester (GB)
E. Castro, Madrid (ES)
M. Eckstein, Erlangen (DE)
M. Wunderle, Erlangen (DE)

16:40 - 17:29

Liquid biopsy and molecular imaging for precision medicine in urological cancers

Moderators
M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)
G. Salomon, Hamburg (DE)

16:40 - 16:50

Liquid biopsy: Current status and clinical perspectives
K. Pantel, Hamburg (DE)

16:50 - 17:00

cfDNA for metastasis detection and therapy monitoring in bladder cancer
L. Dyrskjød, Aarhus (DK)

17:00 - 17:05

Discussion

Scientific Programme - EAU21 Virtual

17:05 - 17:15	Monitor the disease: Which imaging modality to follow-up drug response F. Sanguedolce, Barcelona (ES)
17:15 - 17:25	PSMA PET Tracers: Different tracers for different urological cancers To be confirmed
17:25 - 17:29	Discussion

17:29 - 17:30	Closing remarks R. Montironi, Ancona (IT)
---------------	---

Functional urology in 2021: What did we miss at EAU20 and what is essential?

Meeting of the EAU Section of Female and Functional Urology (ESFFU)

Monday 12 July
16:15 - 17:15

Location Virtual Room 5

Chairs F. Cruz, Porto (PT)
E. Costantini, Perugia (IT)

Learning objectives

The meeting will address several hot topics in functional urology: Surgical treatment of male and female incontinence, bladder pain syndrome and OAB.

16:15 - 16:20

Introduction

F. Cruz, Porto (PT)

16:20 - 16:30

Male incontinence: How the MASTER trial will help urologists to choose between AUS or sling

16:20 - 16:25

MASTER trial summary
J-N.L. Cornu, Rouen (FR)

16:25 - 16:30

Discussion

16:30 - 16:45

Female stress urinary incontinence

16:30 - 16:33

Synthetic mid urethral slings and Burch colposuspension are not free of complications. How to inform patients?
A. Tubaro, Rome (IT)

16:33 - 16:40

My patient has SUI again! What can I offer her to treat the recurrence?
A.K. Nambiar, Newcastle upon Tyne (GB)

16:40 - 16:45

Discussion

16:45 - 16:59

ESFFU meets with other societies

16:45 - 16:52

ICS lecture Is the paradigm of Botulinum Toxin A injection in the bladder wall for OAB maintained in real life?
M.A. Averbeck, Porto Alegre (BR)

16:52 - 16:59

SUFU lecture Interstitial cystitis: What are the hot findings we learned so far from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) research network?
J.Q. Clemens, Ann Arbor (US)

16:59 - 17:14

OAB treatment

16:59 - 17:06

Drug interactions a functional urologist must know
M.C. Michel, Mainz (DE)

17:06 - 17:10

PTNS for OAB patients. Which are the main developments in 2021 in 3 slides?
B.Y. Padilla Fernandez, San Cristóbal De La Laguna (ES)

17:10 - 17:14

Discussion

17:14 - 17:15

Closing remarks
F. Cruz, Porto (PT)

ERN eUROGEN 2021: Update on rare and complex urology

Special Session

Monday 12 July
16:30 - 17:30

Location Virtual Room 8

Chairs M. Battye, Nijmegen (NL)
W.F.J. Feitz, Nijmegen (NL)

Learning objectives

The ERN eUROGEN session will update you on the European Reference Networks (ERNs): The recent largest health care innovation in Europe involving 30 million patients with a rare disease or complex condition. This program on uro-recto-genital rare diseases and complex conditions involves the whole spectrum from congenital anomalies to lifelong care and complex functional and rare urogenital tumours. ERN eUROGEN now delivers virtual highly specialised advice to health care professionals across Europe using innovative IT provided by the European Commission. The network also collaborates on clinical guidelines, training and education and research - all aimed at improving care for your patients. Information is available: www.eurogen-ern.eu

16:30 - 16:35

Welcome and introduction
W.F.J. Feitz, Nijmegen (NL)

16:35 - 16:40

ERN eUROGEN Update, expansion and disease coverage
M. Battye, Nijmegen (NL)

16:40 - 16:45

ERN eUROGEN Registry, data and future perspectives
L.F.M. Van Der Zanden, Nijmegen (NL)

16:45 - 16:50

Questions and answers on ERN eUROGEN developments

16:50 - 16:55

Workstream 1: Cross ERN activities for spina bifida and progress
G. Mosiello, Rome (IT)

16:55 - 17:00

Workstream 2: Adult urogenital reconstructive surgery (transition)
D.N. Wood, London (GB)

17:00 - 17:05

Workstream 3: Rare oncological urology and metrics: Our road to success
V. Sangar, Manchester (GB)

17:05 - 17:10

Questions and answers on ERN eUROGEN workstream and specific diseases

17:10 - 17:20

European Patient Advocacy Groups (ePAGs): Patient perspectives of transition
M. Haanen, München (DE)
N. Schwarzer, Munich (DE)

17:20 - 17:30

Questions and answers on ERN eUROGEN patients and future perspectives

How to manage high risk and advanced prostate cancer?

Poster Session 43

Monday 12 July
16:30 - 17:30

Location Virtual Room 10

Chairs M. Alvarez-Maestro, Madrid (ES)
T. Steuber, Hamburg (DE)

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives

Advanced prostate cancer is one of the most challenging tumor entities. This session gives in depth information on how this disease stage should be best managed today.

16:30 - 16:31

Introduction

16:31 - 16:41

Trends and EBRT

P1199

Comparison of relative survival and cause-specific survival in men with prostate cancer according to age and risk category. Nationwide, population-based study
A.W. Orrason, Uppsala (SE)

P1200

Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England
M.G. Parry, London (GB)

P1201

High-dose-rate brachytherapy and hypo-fractionated external beam radiation combined with long-term androgen deprivation for very-high-risk prostate cancer
K. Mori, Tokyo (JP)

P1202

Impact of modern radiotherapy on second primary cancer risk in prostate cancer survivors: A nationwide cohort study
M-C. Jahreis, Rotterdam (NL)

16:35 - 16:41

Discussion

16:41 - 16:53

Treatment planning and predictions

P1203

Regional lymph node metastasis on PSMA-PET correlates with decreased BCR-free and therapy-free survival after radical prostatectomy
T. Amiel, Munich (DE)

P1204

Preoperative PSMA PET/CT as a predictor of biochemical persistence and early biochemical recurrence
D.J.H. Baas, Utrecht (NL)

P1205

Neo-adjuvant ¹⁷⁷Lu-PSMA-I&T radionuclide in high-risk prostate cancer before radical prostatectomy: A feasibility trial
M. Frumer, Haifa (IL)

P1206

An algorithm to personalize nerve sparing in men with unilateral high-risk prostate cancer
A. Martini, Milan (IT)

P1207	Validation and survival of biopsy Gleason Grade Group V patients treated with radical prostatectomy or external beam radiation therapy: 4+5 vs. 5+4 vs. 5+5 M. Wenzel, Frankfurt (DE)
P1208	The 17-gene Genomic Prostate Score® assay as a predictor of biochemical recurrence in men with intermediate- and high-risk prostate cancer T. Aboushwareb, Redwood City (US)
16:47 - 16:53	Discussion
P1209	Biological significance of cribriform pattern in radical prostatectomy specimens: Study of its prognostic significance in biochemical recurrence F. Gómez Palomo, Valencia (ES)
P1210	The comparative advantage of supervised machine learning algorithms over nomograms in predicting biochemical failure after radical prostatectomy Y.G. Tan, Singapore (SG)
P1211	Which surgical margins truly matter? Identifying clinically relevant positive surgical margins after robot-assisted radical prostatectomy H. Veerman, Volendam (NL)
16:56 - 17:11	Lymph node management
P1212	Development and external validation of a novel tool predicting lymph node invasion in patients with prostate cancer detected at targeted-biopsies A. Stabile, Milan (IT)
P1213	Novel nomogram to identify patients candidate for extended pelvic lymph-node dissection during radical prostatectomy based on target biopsy findings only C. Fiori, Orbassano (IT)
P1214	Reimagining pelvic lymph node dissection during radical prostatectomy: Insights from a large series of fluorescence-guided procedures F. Claps, Trieste (IT)
P1215	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients M. Wenzel, Frankfurt (DE)
P1216	Prognostic variability among high-risk prostate cancer patients with pN1 disease according to the primary tumour pathologic features after radical prostatectomy L. Tosco, Leuven (BE)
P1217	Evaluation of the utility of lymphovascular invasion as a complementary or independent prognostic predictor of overall survival after radical prostatectomy N. Rakic, Detroit (US)
P1218	Lymph vessel invasion as negative predictor in pN0 prostate cancer patients after radical prostatectomy R.M. Pose, Hamburg (DE)
P1219	The prognostic value of histopathological nodal features in patients with pelvic lymph node metastases of prostate cancer after extended pelvic lymph node dissection D. Meijer, Amsterdam (NL)
P1220	What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 Prostate Cancer? Results form a large Multi-Institutional series N. Fossati, Milan (IT)
17:05 - 17:11	Discussion
17:11 - 17:25	Advanced and systemic disease

P1221	Post radical prostatectomy radiation therapy with androgen deprivation therapy does not improve 10-Year overall and prostate cancer specific mortality compared to androgen deprivation therapy alone T. Ahlering, Orange (US)
P1222	Impact of late dosing on testosterone suppression with two different leuprolide acetate formulations: In situ gel and microsphere – an analysis of US clinical data N. Shore, Myrtle Beach (US)
P1223	The efficacy and safety of relugolix compared to degarelix in advanced prostate cancer patients: A network meta-analysis of randomized trials R. Sari Motlagh, Vienna (AT)
P1224	Androgen deprivation therapy in patients with prostate cancer is associated with the risk of subsequent Alzheimer's disease but not with vascular dementia J.W. Kim, Seoul (KR)
P1225	Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER M-O. Grimm, Jena (DE)
P1226	Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study K. Fizazi, Villejuif (FR)
P1227	Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study S. Feyerabend, Nürtingen (DE)
P1228	The insignificant effect of the androgen deprivation therapy on the incidence of dementia in a retrospective population-based prostate cancer study using the extension of Cox proportional hazard model with time-dependent survival S.H. Kim, Goyang (KR)
17:19 - 17:25	Discussion
17:25 - 17:30	Expert summary P. Hoskin, Northwood (GB)

Best of EAU21 session

EAU Specialty Session

Monday 12 July 17:30 - 19:30	Location	Virtual Room 2
	Chairs	P. Albers, Düsseldorf (DE) A. Stenzl, Tübingen (DE)
17:30 - 17:35	Welcome and introduction	
17:35 - 17:45	Prostate cancer A. Villers, Lille (FR)	
17:45 - 17:55	Imaging J. Walz, Marseille (FR)	
17:55 - 18:05	BPH/LUTS J-N.L. Cornu, Rouen (FR)	
18:05 - 18:15	Functional urology J.P.F.A. Heesakkers, Maastricht (NL)	
18:15 - 18:25	Renal cancer M-O. Grimm, Jena (DE)	
18:25 - 18:35	Bladder cancer M. Rouprêt, Paris (FR)	
18:35 - 18:45	Upper Tract TCC M. Rouprêt, Paris (FR)	
18:45 - 18:55	Paediatric urology M.S. Silay, Istanbul (TR)	
18:55 - 19:05	Stones T. Knoll, Sindelfingen (DE)	
19:05 - 19:15	Andrology M. Albersen, Leuven (BE)	
19:15 - 19:25	Testis/Penile cancer M. Albersen, Leuven (BE)	
19:25 - 19:30	Closing remarks by the EAU Scientific Congress Committee Chair P. Albers, Düsseldorf (DE)	

Recent advances in robotic urology of the prostate

ESU Course 23

Monday 12 July
17:30 - 19:30

Location Zoom 1

Chair P. Dasgupta, London (GB)

Learning objectives

This new course will familiarise attendees with the principles of robotic surgery for prostate cancer and bring them up to date with the latest techniques and outcomes of the commonest robotic procedure in the world.

The course is a must for residents and established surgeons wishing to get up to date with a constantly evolving field.

17:30 - 19:30

Anatomical principles, patient positioning, safe training

P. Dasgupta, London (GB)

17:30 - 19:30

How I do it – step by step

B.M.C. Rocco, Modena (IT)

17:30 - 19:30

The NeuroSafe approach to RARP

M. Graefen, Hamburg (DE)

17:30 - 19:30

Retzius sparing RARP

B.M.C. Rocco, Modena (IT)

-

Questions and answers

17:30 - 19:30

Is there a role for RARP in oligometastasis?

M. Graefen, Hamburg (DE)

17:30 - 19:30

Complications of RARP

P. Dasgupta, London (GB)

17:30 - 19:30

Oncological and functional outcomes and the role of nomograms

B.M.C. Rocco, Modena (IT)

-

Questions and answers

17:30 - 19:30

Future developments and summary

P. Dasgupta, London (GB)

EAU General Assembly

General Assembly

Monday 12 July 19:30 - 20:30	Location Virtual room 1
19:30 - 20:30	Welcome by the EAU Secretary General
19:30 - 20:30	Approval minutes General Assembly of 16 March 2019, Barcelona, Spain
19:30 - 20:30	General report by the EAU Secretary General C.R. Chapple, Sheffield (GB)
19:30 - 20:30	Report by the EAU Treasurer M. Wirth, Dresden (DE)
20:30 - 20:30	Specific reports on the EAU Offices by the EAU Executive
20:30 - 20:30	EAU Communication M. Wirth, Dresden (DE)
20:30 - 20:30	EAU Science A. Stenzl, Tübingen (DE)
20:30 - 20:30	EAU Education H. Van Poppel, Leuven (BE)
19:30 - 20:30	EAU Clinical Practice J.O.R. Sønksen, Herlev (DK)
20:30 - 20:30	Elections and Nominations for EAU Executive and EAU Office Chair positions
20:30 - 20:30	Election of the Adjunct Secretary General – Education
20:30 - 20:30	Election of the EAU Treasurer
20:30 - 20:30	Approval Nomination Chair Scientific Congress Office
20:30 - 20:30	Approval Nomination Chair Education Office
20:30 - 20:30	Approval Nomination Chair EUSP Office
20:30 - 20:30	Approval Nomination Chair EU-ACME Office
20:30 - 20:30	Approval Nomination Chair Guidelines Office
20:30 - 20:30	Approval Nomination Chair Patient Office
20:30 - 20:30	Approval Nomination Chair EU Policy Office
-	Report by the Secretary General on the EAU Membership
-	Approval new EAU members
-	Approval new Honorary members
-	Other business
-	Report of the Chairman of the EAU Research Foundation (EAURF)
19:30 - 20:30	Announcement of the 37th Annual EAU Congress

